<SEC-DOCUMENT>0001213900-25-021251.txt : 20250306
<SEC-HEADER>0001213900-25-021251.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306171756
ACCESSION NUMBER:		0001213900-25-021251
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		101
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283212
		FILM NUMBER:		25716364

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>ea0233170-posam1_oruka.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:orka="http://www.orukatx.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>As filed with the Securities and Exchange Commission
on March 6, 2025 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-283212</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="-sec-ix-hidden: hidden-fact-0">POST-EFFECTIVE AMENDMENT</span> NO. 1 TO </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM S-1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>UNDER</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>THE SECURITIES ACT OF 1933</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-69"><b>Oruka Therapeutics, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-87"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><span style="font-size: 10pt"><b>36-3855489</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of<br/>
incorporation or organization)</b></span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer<br/>
Identification No.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>855 Oak Grove Avenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Suite 100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Menlo Park, CA 94025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(650) 606-7910</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Address, including zip code, and telephone
number, including area code, of registrant&#8217;s principal executive offices)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Paul Quinlan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>General Counsel and Corporate Secretary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Oruka Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>855 Oak Grove Avenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Suite 100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Menlo Park, CA 94025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(650) 606-7910</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ryan A. Murr </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Branden C. Berns </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gibson, Dunn &amp; Crutcher LLP </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>One Embarcadero Center, Suite 2600 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>San Francisco, CA 94111 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(415) 393-8373</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approximate date of commencement of proposed sale to the public</b>:
From time to time after the effective date of this Registration Statement.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth
company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="text-align: center; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="text-align: center; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">Non-accelerated filer</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-231"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 7(a)(2)(B) of the Securities Act.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states
that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended,
or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may
determine. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>EXPLANATORY NOTE </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription" id="ixv-269"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc., a Delaware corporation, filed a Registration
Statement on Form S-1 on November 14,2024, which was declared effective on November 26, 2024 (the &#8220;registration statement&#8221;).
This Post-Effective Amendment No. 1 to Form S-1 (the &#8220;Post-Effective Amendment&#8221;) is being provided to include the fiscal year
ended December 31, 2024 financial statements, contained in the Form 10-K for the year-ended December 31, 2024 filed on March 6, 2025,
as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K and updated selling stockholder
information.</p></ix:nonNumeric><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AmendmentDescription-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this filing amends the registration statement
and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective
Amendment. All applicable registration fees were paid at the time of the original filing of the registration statement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Red"><b>The information in this prospectus is
not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration
statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This prospectus is not an offer to
sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not
permitted. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Red"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="color: Red"><b>SUBJECT TO COMPLETION,
DATED MARCH 6, 2025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PRELIMINARY PROSPECTUS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Oruka Therapeutics, Inc.<span style="font-size: 24pt">&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>8,719,000 Shares</b><span style="font-size: 18pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Common Stock </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Offered by the Selling Stockholders </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the proposed resale or other disposition
by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;) of up to (i) 5,600,000 shares (the &#8220;Private
Placement Common Shares&#8221;) of our common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), (ii) 2,439,000 shares of
Common Stock (the &#8220;Private Placement Conversion Shares&#8221;) issued upon the conversion of 2,439 shares (the &#8220;Private Placement
Preferred Shares&#8221;) of Series A preferred stock, par value $0.001 (the &#8220;Series A Preferred Stock&#8221;) in November 2024 and
(iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;). The shares
of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Private Placement Common Shares, Private Placement Preferred Shares
and Pre-Funded Warrants were issued and sold to accredited investors in a private placement (the &#8220;September 2024 PIPE&#8221;), which
closed on September 13, 2024. We are not selling any Resale Shares under this prospectus and will not receive any of the proceeds from
the sale or other disposition of Resale Shares by the Selling Stockholders. Upon any exercise of the Pre-Funded Warrants by payment of
cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those
proceeds, if any, for general corporate purposes.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Selling Stockholders may sell the Resale Shares on any national
securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter
market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using
a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale, or at negotiated prices. See the disclosure under the heading &#8220;Plan of Distribution&#8221; elsewhere in this
prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Selling Stockholders may sell any, all or none of the securities
offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following
the effective date of the registration statement of which this prospectus forms a part. Discounts, concessions, commissions and similar
selling expenses attributable to the sale of the Resale Shares will be borne by the Selling Stockholder. We will pay certain fees and
expenses (other than discounts, concessions, commissions and similar selling expenses) incident to the registration of the Resale Shares
with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should carefully read this prospectus and any applicable prospectus
supplement before you invest in any of the securities being offered.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Common Stock is traded on The Nasdaq Global Market under the symbol
&#8220;ORKA.&#8221; On [March 5], 2025, the last reported sale price for our Common Stock was $[&#9679;]
per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>An investment in our securities involves a high degree of risk.
You should carefully consider the information under the heading &#8220;Risk Factors&#8221; beginning on page 6
of this prospectus and any applicable prospectus supplement. </b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>We are a &#8220;smaller reporting company&#8221; as defined by Rule
12b-2 of the Exchange Act and are subject to reduced public company reporting requirements. </b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Neither the SEC nor any state securities commission has approved
or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal
offense. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_001"><span style="font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_002"><span style="font-size: 10pt">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_003"><span style="font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_004"><span style="font-size: 10pt">RISK FACTOR SUMMARY</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_005"><span style="font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_006"><span style="font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">34</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_007"><span style="font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">35</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_008"><span style="font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_009"><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_010"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_011"><span style="font-size: 10pt">MANAGEMENT</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_012"><span style="font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_013"><span style="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_014"><span style="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_015"><span style="font-size: 10pt">SELLING STOCKHOLDERS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_016"><span style="font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_017"><span style="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">119</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_018"><span style="font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">123</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_019"><span style="font-size: 10pt">EXPERTS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_020"><span style="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10.25pt; text-indent: -10pt"><a href="#a_021"><span style="font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is part of the registration statement
that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders
may, from time to time, sell the securities described in this prospectus in one or more offerings.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus contains information that you should
consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized anyone to give any information
or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking
offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different
information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer
to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation
of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information
appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective
dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In this prospectus, unless the context otherwise
requires, the terms &#8220;Oruka,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to
Oruka Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus contains trade names, trademarks
and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred
to in this prospectus may appear without the &#174; or TM symbols.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All references to &#8220;our product candidates,&#8221;
&#8220;our programs,&#8221; &#8220;our portfolio&#8221; and &#8220;our pipeline&#8221; in this prospectus refer to the research programs
with respect to which we have exercised the option to acquire intellectual property license rights to or have the option to acquire intellectual
property license rights to pursuant to those certain antibody discovery and option agreements, each dated March 6, 2024 and subsequently
amended and restated on March 28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC
(&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus contains &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and
Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements involve
a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and
that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current
expectations of future events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All statements, other than statements of historical
facts contained in this prospectus, including, without limitation, statements regarding: our future results of operations and financial
position, business strategy, the length of time that we believe our existing cash resources will fund our operations, our market size,
our competition, our potential growth opportunities, our clinical development activities and timeline, the efficacy and safety profile
of our product candidates, the potential therapeutic benefits and economic value of our product candidates, the timing and results of
preclinical studies and clinical trials, the expected impact of macroeconomic conditions, including inflation, increasing interest rates
and volatile market conditions, current or potential bank failures, as well as global events, including military conflicts and geopolitical
tensions on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product
candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking
statements generally relate to future events or our future financial or operating performance. The words &#8220;believe,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221;
&#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221;
&#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These forward-looking statements are subject to
a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new
risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed in the sections titled
&#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;
You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. We caution
you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties and
other factors that may affect our future results and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, statements that &#8220;we believe&#8221;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to
us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information
may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review
of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All subsequent written or oral forward-looking
statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements
contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking
statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events,
except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference
should be drawn that we will make additional updates with respect to those or other forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="padding: 4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<a id="a_003"></a><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>PROSPECTUS SUMMARY </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><i>&#160;</i></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>This summary may not contain all the information
that you should consider before investing in securities. You should read the entire prospectus carefully, including the sections titled
&#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221;
and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.
</i></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><b>&#160;</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Company Overview </b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.3pt; text-indent: 0.25in">We are a clinical-stage biopharmaceutical
company focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;) and other inflammatory and immunology
(&#8220;I&amp;I&#8221;) indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>, for &#8220;restoration,&#8221;
and reflects our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition.
Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to
improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological
risk. Our programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease
pathology and the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;).</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-indent: 35.7pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our lead program, ORKA-001, is designed to target
the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other
conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the
aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise
position us to set a new treatment standard in large I&amp;I markets with continued unmet need.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our principal executive offices are located at
855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Our website address is www.orukatx.com.
Information contained on, or accessible through, our website is not incorporated by reference in this prospectus. We make our periodic
and current reports available on our website, free of charge, as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. No portion of our website is incorporated by reference into this prospectus. We file our annual,
quarterly and special reports, proxy statements and other information with the SEC. Our filings with the SEC are also available to the
public on the SEC&#8217;s website at http://www.sec.gov. Our Common Stock is traded on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><b>&#160;</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Combination of ARCA and Pre-Merger Oruka and Pre-Closing
Financing</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 3, 2024, we (formerly known as ARCA biopharma,
Inc.) (prior to the Closing Date, unless context otherwise requires, &#8220;ARCA&#8221; and, after the Closing Date, the &#8220;Company&#8221;
or &#8220;Oruka&#8221;) entered into the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), by and
among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas
Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (&#8220;Second Merger Sub&#8221;), and Oruka
Therapeutics, a private Delaware corporation (&#8220;Pre-Merger Oruka&#8221;) prior to the consummation of the Merger (as defined below).</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 29, 2024 (the &#8220;Closing Date&#8221;),
we consummated that previously announced business combination (the &#8220;Closing&#8221;) pursuant to the Merger Agreement to create a
new public company focused on advancing Pre-Merger Oruka&#8217;s pipeline of antibody therapies. On the Closing Date, First Merger Sub
merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the
&#8220;First Merger&#8221;), and Oruka merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the
merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the completion
of the Merger, we changed our name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Immediately prior to the execution and delivery
of the Merger Agreement, certain new and existing investors of Oruka (the &#8220;Financing Investors&#8221;) entered into a subscription
agreement with Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the terms and subject to the conditions of
which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208
Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares
of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date),
immediately prior to the Closing and before the effect of the Reverse Stock Split (as defined below) (the &#8220;Pre-Closing Financing&#8221;).
At the Closing, the shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants issued in the Pre-Closing Financing
were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein).</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the consummation of the Merger,
on the Closing Date (prior to the Reverse Stock Split (as defined below)):</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka issued to the Financing Investors an aggregate of 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka
pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares of Pre-Merger
Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date); and</span></td>
</tr></table>

<p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">all
of the then-outstanding (i) 9,460,019 shares of Pre-Merger Oruka common stock, (ii) 20,000,000 shares of Series A convertible preferred
stock of Pre-Merger Oruka (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), (iii) 2,063,669 options exercisable for shares of
Pre-Merger Oruka common stock, (iv) 5,345,336 Pre-Merger Oruka employee warrants and (v) the Pre-Closing Financing Pre-Merger Oruka common
stock and pre-funded warrants were automatically converted into the right to receive the number of Common Stock, Series B Preferred Stock
or warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;),
except for the preferred stock, which was converted at the Exchange Ratio divided by 1,000.</span></td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Following the consummation of the Merger, we effected
a 1-for-12 reverse stock split of our Common Stock (the &#8220;Reverse Stock Split&#8221;), which became effective on September 3, 2024.
Our Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the open of trading on September 3, 2024.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><b>&#160;</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Private Placement of Common Stock, Preferred Stock and Pre-Funded
Warrants </b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 13, 2024, we completed the Private
Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants pursuant to the Securities Purchase
Agreement dated September 11, 2024 (the &#8220;SPA&#8221;) with the Selling Stockholders. The Selling Stockholders purchased (i) an aggregate
of 5,600,000 shares of the Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock,
at a price per share of $23,000.00, and (iii) Pre-Funded Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase
price of $22.999 per Pre-Funded Warrant, which represents the per share purchase price of the Private Placement Common Shares less the
$0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate purchase price of approximately $200.5 million.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Following stockholder approval, in November 2024,
the 2,439 shares of Series A Preferred Stock were converted to 2,439,000 shares of Common Stock. The Pre-Funded Warrants will be exercisable
at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its
affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect
to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by
providing at least 61 days&#8217; prior notice to us.</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The sale of Private Placement Common Shares, Private
Placement Conversion Shares and Pre-Funded Warrants was not registered under the Securities Act, and such sale was intended to be exempt
from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporation Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 29, 2024, we completed the Merger, in
connection with which Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA
changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; Our principal executive offices are located at 855 Oak Grove Ave., Suite 100,
Menlo Park, CA 94025, and our telephone number is (650) 606-7910.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="padding: 4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Shares Offered by the Selling Securityholders </span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Up to (i) 5,600,000 shares of Common Stock, (ii) 2,439,000 shares of Common Stock issued upon the conversion of 2,439 shares of Series A Preferred Stock in November 2024 and (iii) 680,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; width: 25%; font-size: 10pt"><span style="font-size: 10pt">Terms of the Offering </span></td>
    <td style="text-align: left; width: 75%; font-size: 10pt"><span style="font-size: 10pt">The selling securityholders will determine when and how they will dispose of the shares of Common Stock, shares of Common Stock issued upon conversion of Series A Preferred Stock and shares of Common Stock issuable upon the exercise of Pre-Funded Warrants registered under this prospectus for resale. </span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Shares Outstanding </span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">As of December 31, 2024, there were 37,440,510 of our Common Stock and 137,138 shares of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (&#8220;Series B Preferred Stock&#8221;), outstanding.</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Use of Proceeds </span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. See the section titled &#8220;Use of Proceeds.&#8221; </span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Risk Factors </span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">See the section titled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. </span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Trading Markets and Ticker<br/>
 Symbols </span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Our Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The number of issued and outstanding shares of
Common Stock does not include the following, as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: left">11,428,149 shares of Common Stock issuable upon the conversion of 137,138 shares of Series B Preferred Stock;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                              </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: left">5,522,207 shares of Common Stock issuable upon the exercise of 5,522,207 pre-funded warrants to acquire shares of Common Stock with
an exercise price of $0.01 per share;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                               </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: left">680,000 shares of Common Stock issuable upon the exercise of 680,000 pre-funded warrants to acquire shares of Common Stock with an
exercise price of $0.001 per share;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                             </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>1,567,760 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2024 Equity Incentive Plan and
the 2024 Stock Incentive Plan with a weighted-average exercise price of $11.39 per share;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                   </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>3,054,358 shares of Common Stock issuable upon the exercise of 3,054,358 warrants issued to employees, directors and service providers
to acquire shares of Common Stock with a weighted-average exercise price of $7.80 per share;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                      </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>4,246,324 shares of Common Stock reserved for issuance under our 2024 Stock Incentive Plan; and</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                </table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>460,529 shares of Common Stock reserved for issuance under our 2024 Employee Stock Purchase Plan (&#8220;ESPP&#8221;).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">For additional information concerning the offering, see the section
titled &#8220;<i>Plan of Distribution</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>RISK FACTOR SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following summarizes the principal factors
that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below.
This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the
material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations
and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made
in this prospectus and those we may make from time to time. You should consider all the risk factors described in our public filings when
evaluating our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Risks Related to Drug Development and Regulatory
Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002. Our projected development
goals, including our clinical trials, may not be successful or we may fail to achieve our projected development goals in the time frames
we announce and expect.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory approval processes are lengthy and time
consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates. Moreover, even
if we obtain regulatory approval, we will be subject to ongoing regulatory obligations.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We are a clinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not completed
any clinical trials, and have no products approved for commercial sale.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We have never generated revenue from product sales and may never be profitable.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may not be able to raise the capital that we need to support our business plans.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our ability to obtain and protect our patents and other proprietary rights is uncertain and we may fail in obtaining or maintaining
necessary rights to our programs.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may become subject to claims challenging the inventorship or ownership of our intellectual property and may be subject to patent
infringement claims or may need to file such claims.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our patents and our ability to protect our products may be impaired by changes to patent laws, and our patent protection could be
reduced or eliminated for non-compliance with legal requirements.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may fail to identify or interpret relevant third-party patents.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Patent terms may be inadequate to protect our competitive position of our programs.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our technology licensed from third parties may be subject to retained rights.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Risks Related to Our Reliance on Third Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations
or licensing arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Third parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or
we may need to switch or create third-party manufacturer redundancies.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Other Risk Factors - Risks Related to Employee
Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we
compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our business is dependent on key personnel, and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully
implement our business strategy.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience
difficulties in managing this growth.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely
affect our business, operations and consolidated financial performance.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Our business could be adversely affected by macroeconomic or geopolitical conditions.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>We do not anticipate paying any dividends in the foreseeable future.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Future sales of shares by existing stockholders could cause our stock price to decline.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Future sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price
to decline.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Our Financial Condition
and Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We are a clinical stage biopharmaceutical
company with a limited operating history on which to assess our business; we have not completed any clinical trials, have no products
approved for commercial sale, have historically incurred losses, and we anticipate that we will continue to incur significant losses for
the foreseeable future. Moreover, we have never generated revenue from product sales and may never be profitable.</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are a clinical stage biopharmaceutical company
with a limited operating history. We will need to raise substantial additional capital to continue to fund our operations in the future.
We have based our estimates on assumptions that may prove to be wrong, and could exhaust our available financial resources sooner than
we currently anticipate. We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates,
organizing and staffing our company, and providing general and administrative support for our operations.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter advanced
clinical trials. It may be several&#160;years, if ever, before we complete pivotal clinical trials or have a product candidate approved
for commercialization. We expect to invest significant funds into the research and development of our programs to determine the potential
to advance product candidates to regulatory approval. If we obtain regulatory approval to market a product candidate, our future revenue
will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market
acceptance, pricing, coverage and adequate reimbursement from third-party&#160;payors, and adequate market share for our product candidates
in those markets. Even if we obtain adequate market share for our product candidates, we may never become profitable despite obtaining
such market share and acceptance of our products.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expect to continue to incur significant expenses
and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">continue the clinical development of our product candidates, including advancing our product candidates into larger, more expensive
trials;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">continue efforts to discover and develop new product candidates, including initiating preclinical studies or clinical trials;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">progress our chemistry, manufacturing and control development, registration, and validation, including the manufacture of our product
candidates by third parties, including increasing volumes manufactured by third parties;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">seek regulatory and marketing approvals and reimbursement for our product candidates;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval
and market for ourselves;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">make milestone, royalty, or other payments under third-party license agreements;</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">seek to maintain, protect, and expand our intellectual property portfolio; and</td></tr></table><div>

</div><p style="text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">experience any delays or encounter issues with the development and potential regulatory approval of our product candidates such as
safety issues, manufacturing delays, clinical trial delays, longer follow-up for planned studies or trials, additional major studies or
trials, or supportive trials necessary to support marketing approval.</td></tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">If we are unable to raise additional capital when
required or on acceptable terms, we may be required to curtail our product development activities and other activities commensurate with
the magnitude of the shortfall and our product development activities may cease altogether, which could materially harm our business,
financial condition, and results of operations. To the extent that the costs of our activities exceed our current estimates and we are
unable to raise sufficient additional capital to cover such costs, we will need to reduce operating expenses, sell assets, enter into
strategic transactions, or effect a combination of the above. No assurance can be given that we will be able to enter into any of such
transactions on acceptable terms, if at all. Any of the following events could have a material adverse effect on our business, operating
results, and prospects:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">a delay, scaling back, or discontinuation of the development or commercialization of our product candidates;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">seeking strategic partnerships, or amending existing partnerships, for research and development programs at an earlier stage than
otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than
might otherwise be available in the future;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>disposal of technology assets, or the relinquishing or licensing of assets on unfavorable terms, of our rights to technologies or
any of our product candidates that we otherwise would seek to develop or commercialize ourselves;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>pursuing the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>filing for bankruptcy or cease operations altogether.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Even if we are successful in raising new capital,
we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise, or
other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Raising additional capital may cause dilution
to our stockholders, restrict our operations, or require us to relinquish rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">To the extent that we raise additional capital
through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and
the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock.
Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our
ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. For example,
in September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the
investors purchased an aggregate of 5,600,000 shares of common stock, 2,439 shares of Series A Preferred Stock and pre-funded warrants
to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of approximately $200.5 million. Each share
of Series A Preferred Stock is convertible into 1,000 shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If we raise additional funds through collaborations,
strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable
rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. Debt financing, if available,
would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Clinical Development, Regulatory
Approval and Commercialization&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We face competition from entities that have
developed or may develop programs for the diseases addressed by our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The development and commercialization of drugs
is highly competitive. Product candidates developed by us, if approved, will face significant competition and our failure to effectively
compete may prevent us from achieving significant market penetration. We compete with a variety of biopharmaceutical companies as well
as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with
which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing than we do. Mergers
and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage&#160;companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in establishing clinical trial sites, recruiting
participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our competitors have developed, are developing
or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that
have already been approved and accepted by the medical community and any new treatments. Our success will depend partially on our ability
to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity
and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation
or are less expensive than the products we develop, or if biosimilars enter the market and are able to gain market acceptance more quickly
than we do or at wider scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our product candidates may fail in development
or suffer delays. We depend on the successful initiation and completion of clinical trials for our product candidates to advance our product
development plans.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We have no products on the market, and all of
our programs are in preclinical or clinical stages of development. As a result, we expect it will be many&#160;years before we can obtain
regulatory approval for and commercialize any product candidate, if ever. Clinical testing is expensive, difficult to design and implement,
and can take years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage
of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials,
and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible
to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval for their products. It may be difficult for us to raise
additional capital if we experience any issues that delay or prevent the regulatory approval or the ability to commercialize our product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">We may experience a number of unforeseen events
affecting our product development timeline, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>our clinical trials may fail to show safety or efficacy, produce negative or inconclusive results, or our product candidates may have
undesirable side effects or unexpected characteristics, and we may decide, or regulators may require that we conduct additional preclinical
studies or clinical trials or we may decide to abandon product development programs;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates
may be insufficient or inadequate;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                            </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>regulators or IRBs, the FDA, or ethics committees may not authorize us or our investigators to commence or conduct a clinical trial
at one or more prospective trial sites; or may require that we or our investigators materially modify, suspend or terminate clinical research
or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are
being exposed to unacceptable health risks;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                     </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data as well as data
emerging from other therapies in the same class as our product candidates;</td></tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory
bodies require completion of non-inferiority or superiority trials; enrollment in these clinical trials may be slower than we anticipate
or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>trial conduct or data analysis errors may occur, including, but not limited to, failure by investigators or participants to adhere
to the study protocol or data entry and/or labeling errors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract
research organizations (&#8220;CROs&#8221;);</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>our third-party contractors or clinical trial sites may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that
we add new clinical trial sites or investigators and could potentially complicate the analysis of data;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the cost of clinical trials of any of our programs may be greater than we anticipate;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the FDA or other regulatory authorities may require us to submit additional data or impose other requirements and our product development
timeline may be adversely affected.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If our clinical trials do not produce favorable
results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. Moreover, the combined data
from our trials may be inconclusive or may not be sufficient to ultimately gain marketing approval from the FDA or other regulatory authorities.
There are equivalent processes and risks applicable to clinical trial applications in other countries outside of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, because of the competitive landscape
for&#160;immunology and inflammation (commonly referred to as &#8220;I&amp;I&#8221;) indications, we may also face competition for clinical
trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to
undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development
for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our
programs may further exacerbate this competition. Our inability to enroll a sufficient number of participants could, among other things,
delay our development timeline, which may further harm our competitive position and have an adverse effect on our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We are substantially dependent on the success
of our two most advanced programs, ORKA-001 and ORKA-002, and our clinical trials of such programs may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our future success is substantially dependent
on our ability to develop and timely obtain marketing approval for, and then successfully commercialize, our two most advanced programs,
ORKA-001&#160;and ORKA-002. We are investing a majority of our efforts and financial resources into the research and development of these
programs. We have initiated a Phase&#160;1 clinical trial of ORKA-001 in healthy volunteers and anticipate initiating a Phase 1 clinical
trial of ORKA-002 in healthy volunteers&#160;in the second half of 2025, subject to the filing of an IND or foreign equivalent and regulatory
approval. Currently, we believe that the success of our programs is dependent on observing a longer half-life&#160;of our product candidates
in humans than monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as we believe this longer half-life&#160;has
the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully complete clinical development
and obtain marketing approval. This is based in part on the assumption that the longer half-life&#160;we have observed in&#160;NHPs will
translate into an extended half-life&#160;of our product candidates in humans. To the extent we do not observe this extended half-life&#160;in
humans, it would significantly and adversely affect the clinical and commercial potential of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>If we do not achieve our projected development
goals in the time frames we announce and expect, the development and potential commercialization of our product candidates may be delayed
and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From time to time, we estimate the timing of the
anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to
as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected
timing of our clinical trials in our target indications, anticipated data analysis and results from our clinical trials, as well as the
submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of
these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to
our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the
development and potential commercialization of our product candidates may be delayed or never achieved and, as a result, our business
may be materially harmed and our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause
overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development
milestones.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Any drug delivery device that we may use
to deliver our product candidates may have its own regulatory, development, supply and other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expect to deliver our product candidates via
a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development
activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. If our
product candidates are intended to be used with drug delivery devices, we expect to utilize drug delivery devices authorized for marketing
under clearances of approvals held by third parties. Our product candidates may not be approved or may be substantially delayed in receiving
approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval
of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval.
In addition, some drug delivery devices are provided by single-source&#160;third-party&#160;companies. We may be dependent on the sustained
cooperation and effort of those third-party&#160;companies both to supply the devices and, in some cases, to conduct the studies required
for approval or other regulatory clearance of the devices. Even if approval is obtained for our products, we may also be dependent on
those third-party&#160;companies continuing to maintain such approvals or clearances, if required, for their drug delivery devices once
they have been received. Failure of third-party&#160;companies to supply the devices on time and in accordance with the agreed-upon specifications,
to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices
could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our approach to the discovery and development
of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our approach to the discovery and development
of the research programs with respect to which we have signed a license agreement, exercised the Option to acquire intellectual property
license rights to or have the Option to acquire intellectual property license rights to pursuant to the Option Agreements, leverages clinically
validated mechanisms of action and incorporates advanced antibody engineering to optimize half-life&#160;and other properties designed
to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and
products while maintaining the same, well-established&#160;mechanisms of action. However, the scientific research that forms the basis
of our efforts to develop programs using half-life&#160;extension technologies is ongoing and may not result in viable programs. There
is limited clinical data available on product candidates utilizing half-life&#160;extension technologies, especially in&#160;I&amp;I indications,
demonstrating whether they are safe or effective for long-term&#160;treatment in humans. The long-term&#160;safety and efficacy of these
technologies and the extended half-lives&#160;and exposure profiles of our programs compared to currently approved products are unknown.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may ultimately discover that utilizing half-life&#160;extension
technologies for our specific targets and indications and any programs resulting therefrom does not possess certain properties required
for therapeutic effectiveness. In addition, programs using half-life&#160;extension technologies may demonstrate different chemical and
pharmacological properties in human participants than they do in laboratory studies or preclinical studies. This technology and any programs
resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological
systems in unforeseen, ineffective or harmful ways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, we may in the future seek to discover
and develop programs that are based on novel targets and technologies that are unproven. If our discovery activities fail to identify
novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, we may not be able
to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize
any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets,
disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant
use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which we have
signed license agreements with Paragon, exercised the Option to acquire intellectual property license rights to or have the Option to
acquire intellectual property license rights to pursuant to the Option Agreements prove to be ineffective, unsafe or commercially unviable,
such programs would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results
of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Preclinical and clinical development involves
a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be
predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval
of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete,
the development of such product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Before obtaining marketing approval from regulatory
authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to
demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials may not be conducted as planned or completed
on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Furthermore, a failure of one or more clinical
trials can occur at any stage of testing. Clinical data is often susceptible to varying interpretations and analyses, and in addition,
we expect to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently
difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from&#160;day-to-day&#160;for
a particular participant, and from participant to participant and from site to site within a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We cannot be sure that the FDA, or comparable
foreign regulatory authority, as applicable, will agree with our clinical development plan. We plan to use the data from our Phase&#160;1
trials of our ORKA-001&#160;and ORKA-002&#160;programs in healthy volunteers to support Phase&#160;2 trials in PsO and potentially other&#160;I&amp;I
indications. If the FDA and/or comparable foreign regulatory authority requires us to materially modify our proposed trial designs, conduct
additional trials or enroll additional participants, our development timelines may be delayed. We cannot be sure that submission of an
IND, Clinical Trial Application or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable,
allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend
or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability
to generate sufficient preclinical, toxicology or other&#160;in vivo&#160;or&#160;in vitro&#160;data to support the initiation or continuation
of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials;
delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective
CROs and clinical trial sites; recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each
clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our
product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or
us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s
current GCP requirements or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites
deviating from trial protocol or dropping out of a trial; delays or failure by our third party vendors or us in the manufacturing, packaging,
labeling and proper delivery of clinical trial materials; and third parties being unwilling or unable to satisfy their contractual obligations
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We could also encounter delays if a clinical trial
is required to be materially modified or suspended or terminated by us, the IRBs, by the Data Safety Monitoring Board, if any, or by the
FDA or comparable foreign regulatory authorities. Such authorities may suspend, put on clinical hold or terminate a clinical trial due
to a number of factors, including not aligning with or supporting our clinical trial designs or our failure to conduct the clinical trial
in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site
by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse
side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack
of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product
candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates,
if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results
of operations may be adversely affected and we may need to adjust or abandon our business plans and we may incur significant additional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>If we encounter difficulties enrolling participants
in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.&#160;We
depend on the successful completion of clinical trials for our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may experience difficulties in patient participant
enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols
depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until conclusion. The
enrollment of participants in future trials for any of our programs will depend on many factors, including if participants choose to enroll
in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for programs that are under
development for the same indications as our programs, and participants instead enroll in such clinical trials. Even if we are able to
enroll a sufficient number of participants for our clinical trials, it may have difficulty maintaining participants in our clinical trials.
Our inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials
and increased development costs or may require us to abandon one or more clinical trials altogether.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Preliminary, &#8220;topline&#8221; or interim
data from our clinical trials may change as more participant data becomes available and are subject to audit and verification procedures,
and should be viewed with caution until the final data are available.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From time to time, we may publicly disclose preliminary
or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available&#160;data,
and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also
make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and
carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the
same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated
or subsequently made subject to audit and verification procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From time to time, we may also disclose interim
data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes
may materially change as participant enrollment continues and more participant data become available or as participants from our clinical
trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the
particular product candidate, the approvability or commercialization of the particular product candidate and our company in general. In
addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is
typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information
to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including
regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates
may be harmed, which could harm our business, operating results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our clinical trials may reveal significant
adverse events, undesirable side effects or patient intolerance not seen in our preclinical studies or earlier clinical trials, and may
result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance
of any of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Results of our clinical trials could reveal a
high and unacceptable severity and prevalence of side effects or patient intolerance, adverse events or unexpected characteristics, and
any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. If significant
adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting participants to such
trials, participants may drop out of the trials, or we may have to suspend, materially modify or abandon the trials or our development
efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend or require
the material modification of any clinical trials of any program at any time for various reasons, including a belief that participants
in such trials are being exposed to unacceptable health risks or adverse side effects. Moreover, negative or inconclusive results could
cause the FDA or other regulatory agencies to require that we repeat or conduct additional clinical trials. If our clinical trials do
not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Even if side effects do not preclude the product
candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product
due to their tolerability versus other therapies. In addition, an extended half-life&#160;could prolong the duration of undesirable side
effects, which could also affect our clinical trials or inhibit market acceptance. Potential side effects associated with our product
candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates
may not be normally encountered in the general patient population and by medical personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, even if we successfully advance our
product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure
to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when
a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not
be sufficient to determine the effect and safety consequences of using our product candidates over a multi-year&#160;period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If any of the foregoing events occur or if one
or more of the research programs with respect to which we have signed a licensed agreement for or exercised the Option to acquire intellectual
property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Option Agreements prove
to be unsafe, our pipeline could be affected, which would have a material adverse effect on our business, financial condition, results
of operations and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may expend our limited resources to pursue
a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are initially focused on our most advanced
programs, ORKA-001&#160;and ORKA-002, and as a result, we may forgo or delay pursuit of opportunities with other programs that later prove
to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs for specific indications may
not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a
particular product candidate, we may be in a position where we may have to relinquish valuable rights to that product candidate through
collaboration, licensing or other arrangements in cases in which we would have been more advantageous for us to retain sole development
and commercialization rights to such product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Any approved products resulting from our
programs may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical
community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Even if regulatory approval is obtained for a
product candidate resulting from one of our current or future programs, it may not gain market acceptance among physicians, patients,
healthcare payors or the medical community. Market acceptance of our product candidates will depend on many factors, including factors
that are not within our control. While there are several approved products and product candidates in later stages of development for the
treatment of PsO, our programs incorporate advanced antibody engineering to optimize the half-life&#160;and formulation of antibodies,
and to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with influence over acceptance
of new treatments, such as clinicians and third-party&#160;payors, may not adopt a biologic that incorporates half-life&#160;extension
for our targeted indications, and we may not be able to convince the medical community and third-party&#160;payors to accept and use,
or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. Moreover, an extended
half-life&#160;may make it more difficult for patients to change treatments and there may be a perception that half-life&#160;extension
could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Sales of medical products also depend on the willingness
of healthcare providers to prescribe the treatment, and if any of our product candidates is approved but does not achieve an adequate
level of acceptance, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Certain of our programs may compete with
our other programs, which could negatively impact our business and reduce our future revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are developing product candidates for the same
indication, PsO, and may in the future develop our programs for other&#160;I&amp;I indications. Each such program targets a different
mechanism of action. However, developing multiple programs for a single indication may negatively impact our business if the programs
compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the
enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market
share, which could limit our future revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may conduct clinical trials for programs
at sites outside the United&#160;States, and the FDA may not accept data from trials conducted in such locations. Moreover, conducting
clinical trials outside of the U.S. presents additional risks that may delay our clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may choose to conduct one or more of our future
clinical trials outside the United&#160;States. Although the FDA may accept data from clinical trials conducted outside the United&#160;States,
acceptance of this data is subject to conditions imposed by the FDA. If the FDA does not accept the data from any trial that we conduct
outside the United&#160;States, it would likely result in the need for additional trials, which would be costly and time-consuming&#160;and
would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could impose
additional conditions, such as requiring us to modify our planned clinical trials to receive clearance to initiate such trials in the
United&#160;States or to continue such trials once initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Further, conducting clinical trials outside of
the U.S. presents additional risks that may delay completion of our clinical trials. These risks include the failure of investigators
or enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural
customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials
under multiple sets of foreign regulations, potential restrictions, such as local privacy restrictions, on data generated from the clinical
trial, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>The regulatory approval processes of the
FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable. If we are not able to obtain, or
if there are delays in obtaining, required regulatory approvals for our product candidates, we may not be able to commercialize, or may
be delayed in commercializing, our product candidates, and our ability to generate revenue may be materially impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The lengthy regulatory approval process as well
as the unpredictability of clinical trial results may result in our failing to obtain or be delayed in obtaining approval to market our
product candidates, which would significantly harm our business, results of operations and prospects. Of the large number of drugs in
development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The
process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes
many&#160;years following commencement of clinical trials. Approval may never be obtained and the approval process can vary substantially
based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory
approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies
and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval
also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the
relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to
have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The
FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application
or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates
could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the failure to demonstrate that a
product candidate&#8217;s benefits outweigh safety risks; regulatory authorities may disagree with our interpretation of clinical data
or the data collected may not be acceptable or sufficient to support submission; or the results may not meet the level of statistical
significance required for approval by the relevant regulatory authorities or otherwise considered insufficient by the FDA or comparable
foreign regulatory authorities. Regulatory authorities may require the addition of labeling statements, such as black box or other warnings
or contraindications that could diminish the usage of the product or otherwise limit the commercial success of the affected product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Moreover, regulatory authorities may approve any
of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising
indications, may grant approval contingent on the performance of costly post-marketing&#160;clinical trials, or may approve a product
candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product
candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates,
we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue
will be materially impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may not be able to meet requirements
for the chemistry, manufacturing and control of our programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In order to receive approval of our products by
the FDA and comparable foreign regulatory authorities, we must show that we and our CMO partners are able to characterize, control and
manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient,
developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product,
documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. As noted above,
we may deliver our product candidates via a drug delivery device, which also requires us to meet certain chemistry, manufacturing and
control requirements set forth by the FDA and other foreign regulatory authorities. Meeting these chemistry, manufacturing and control
requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control
requirements, we may not be successful in getting our products approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our product candidates for which we intend
to seek approval as biologics may face competition sooner than anticipated.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Patient Protection and Affordable Care Act,
as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the BPCIA, which created
an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA-licensed&#160;reference
biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the
FDA until four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval
of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first
approved. During this&#160;12-year&#160;period of exclusivity, another company may still market a competing version of the reference product
if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and
well-controlled&#160;clinical trials to demonstrate the safety, purity and potency of their product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We believe that any of our product candidates
approved as biologics under a BLA should qualify for the&#160;12-year&#160;period of exclusivity. However, there is a risk that this exclusivity
could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA,
some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which
a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution
for&#160;non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still
developing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review and may result
in restrictions on the use of the product, which may result in significant additional expense and we may be subject to penalties if we
fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Any regulatory approvals that we may receive for
our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy
of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions
or contraindications, and may include burdensome post-approval&#160;study or risk management requirements. For example, the FDA may require
a REMS in order to approve our product candidates. In addition, even if our product candidates receive approval, our product candidates
and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy,
recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive
regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These
requirements include submissions of safety and other post-marketing&#160;information and reports, registration, as well as&#160;on-going&#160;compliance
with current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and
their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for
compliance with CGMPs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If we or a regulatory authority discover previously
unknown problems with a product or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions
on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension
of manufacturing, restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned
trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures,
detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly
new manufacturing requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Disruptions at the FDA, the SEC and
other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability
to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely
manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely,
which could negatively impact our business.</i></b></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The ability of the FDA to review regulatory filings
and our ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels,
ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review
times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies
on which our operations may rely, including those that fund research and development activities is subject to the political process, which
is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Disruptions at the FDA and other agencies or comparable
foreign regulatory authorities, may also slow the time necessary for the review and approval of applications for clinical trial or marketing
authorization, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government
shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical
activities. Additionally, action by the new Trump Administration to limit federal agency budgets or personnel may result in reductions
to the FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting
our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. If a prolonged
government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions,
which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the
public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If a prolonged government shutdown occurs, or
if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other
regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process
our regulatory submissions, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may face difficulties from legislative
or regulatory reform measures.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may be faced with additional or changing regulatory
and governmental regulations that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the
United&#160;States or abroad. For example, the Trump Administration has discussed several changes to the reach and oversight of the FDA,
which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability
of prescription drugs. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The price of pharmaceuticals has been a topic
of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect
of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Many
federal and state legislatures have considered, and adopted, healthcare policies intended to curb rising healthcare costs, such as the
IRA. These cost-containment measures may include, among other measures: requirements for pharmaceutical companies to negotiate prescription
drug prices with government healthcare programs; controls on government-funded reimbursement for drugs; new or increased requirements
to pay prescription drug rebates to government healthcare programs, including if drug prices increase at a higher rate than inflation;
controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing controls or limits or prohibitions
on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive
branded product; and public funding for cost effectiveness research, which may be used by government and private third-party payors to
make coverage and payment decisions. Political, economic and regulatory developments may further complicate developments in healthcare
systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as commercial
and collaborative partners may also consider the impact of these pressures on their licensing strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Any new laws or regulations that have the effect
of imposing additional costs or regulatory burden on pharmaceutical manufacturers, or otherwise negatively affect the industry, could
adversely affect our ability to successfully commercialize our product candidates. The implementation of any price controls, caps on prescription
drugs or price transparency requirements could adversely affect our business, operating results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our business operations and current and
future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers
will be subject to applicable healthcare regulatory laws, including conflicts of interest rules, which could expose us to penalties.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our business operations and current and future
arrangements with investigators, healthcare professionals, consultants, third-party&#160;payors, patient organizations and customers may
expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial
arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product
candidates, if approved. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us or may
be affiliated with our other service providers, including CROs or site management organizations, and from time to time may receive cash
compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts
of interest, the integrity of the data generated at the applicable clinical trial site or in the applicable trial may be questioned or
jeopardized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Ensuring that our internal operations and future
business arrangements with third parties comply with applicable healthcare laws and regulations will involve costs and management attention.
If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it,
we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded&#160;healthcare
programs, integrity oversight and reporting obligations to resolve allegations of&#160;non-compliance,&#160;disgorgement, individual imprisonment,
contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending
against any such actions can be costly and time-consuming&#160;and may require significant personnel resources. Therefore, even if we
are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Even if we are able to commercialize any
product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able
to offer such product candidates at competitive prices, which would seriously harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We intend to seek approval to market our product
candidates in the United&#160;States and in selected foreign jurisdictions, and we will be subject to rules and regulations in those jurisdictions
where we obtain approval. Our ability to successfully commercialize any product candidates that we may develop will depend in part on
the extent to which reimbursement for these product candidates and related treatments will be available from government health administration
authorities, private health insurers and other organizations. In some jurisdictions, government authorities and other third-party&#160;payors
decide which medications they will pay for and establish reimbursement levels, and have attempted to control costs by limiting coverage
and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s
product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our
commercial opportunity. Additionally, if any of our product candidates are approved and we are found to have improperly promoted off-label&#160;uses
of those product candidates, we may become subject to significant liability, which would materially adversely affect our business and
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We are subject to U.S.&#160;and certain
foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can
face criminal liability and other serious consequences for violations, which can harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are subject to export control and import laws
and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade
sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign
Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel
Act, the USA PATRIOT Act, the U.S. Physician Payments Sunshine Act and other state and national anti-bribery&#160;and anti-money&#160;laundering
laws in the countries in which we conduct activities. Anti-corruption&#160;laws are interpreted broadly and prohibit companies and their
employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper
payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products
outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other
regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated&#160;hospitals,
universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors,
and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws
and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Governments outside the United&#160;States
tend to impose strict price controls, which may adversely affect our revenue, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In some countries, particularly member states
of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries,
pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In
addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part
of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing
negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution,
or arbitrage between&#160;low-priced&#160;and high-priced&#160;EU Member States, can further reduce prices. To obtain coverage and reimbursement
or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies
that compare the cost-effectiveness&#160;of our product candidates to other available therapies in order to obtain or maintain reimbursement
or pricing approval. Publication of discounts by third-party&#160;payors or authorities may lead to further pressure on the prices or
reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing
is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results
of operations or prospects could be materially and adversely affected. If the UK or EU Member States were to significantly alter their
regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our ability to obtain and protect our patents
and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We rely upon a combination of patents, trademarks,
trade secret protection, confidentiality agreements and the Option and License Agreements to protect the intellectual property related
to our programs and technologies and to prevent third parties from competing unfairly with it. Our success depends in large part on our
ability to obtain and maintain patent protection for our programs and our product candidates and their uses, as well as our ability to
operate without infringing on or violating the proprietary rights of others. Paragon has filed, on our behalf, provisional patent applications
and we have filed non-provisional patent applications directed to antibodies that target IL-23, including applications covering composition
of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001. In addition, Paragon has filed, on our
behalf, provisional patent applications and we intend to file one or more additional provisional patent applications directed to antibodies
that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies,
including ORKA-002. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems
in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting
and defending patents on programs worldwide is expensive and our intellectual property rights in some foreign jurisdictions can be less
extensive than those in the United&#160;States; the reverse may also occur. As such, we may not have patents in all countries or all major
markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries
where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies
and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our pending and future patent applications may
not result in patents being issued. Any issued patents may not afford sufficient protection of our programs or their intended uses against
competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties,
or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted,
they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found
invalid or unenforceable if challenged in court or before administrative bodies in the United&#160;States or abroad, including the United&#160;States
Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory
approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents
that we may own and license may not afford us any meaningful competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition to seeking patents for some of our
technology and programs, we may also rely on trade secrets, including unpatented&#160;know-how,&#160;technology and other proprietary
information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the personnel
of third parties with whom we share our facilities or third-party&#160;consultants and vendors that we engage to perform research, clinical
trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets
or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive
position in our market. In order to protect our proprietary technology and processes, we rely in part on agreements, such as confidentiality
agreements, with our vendors, collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other
advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in
the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets,
with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets,
including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition,
while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover
trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party.
Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and the outcome is unpredictable. In addition,
courts outside of the U.S. may be less willing to protect trade secrets. Costly and time-consuming&#160;litigation could be necessary
to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely
affect our competitive business position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Lastly, if our trademarks and trade names are
not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business
may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may not be successful in obtaining or
maintaining necessary rights to our programs through acquisitions and&#160;in-licenses.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Because our development programs currently do
and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our
ability to acquire,&#160;in-license,&#160;or use these third-party&#160;proprietary rights. It is possible that we may be unable to obtain
licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby
giving our competitors access to the same technologies licensed to us. We may be unable to acquire or&#160;in-license&#160;any compositions,
methods of use, processes or other third-party&#160;intellectual property rights from third parties that we identify as necessary for
our programs. The licensing and acquisition of third-party&#160;intellectual property rights is a competitive area, and a number of more
established companies may pursue strategies to license or acquire third-party&#160;intellectual property rights that we may consider attractive
or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign
or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual property rights on terms that would
allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party&#160;intellectual
property rights or maintain the existing intellectual property rights we do obtain, we may have to abandon development of the relevant
program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">While we plan to obtain the right to control prosecution,
maintenance and enforcement of the patents relating to our programs, there may be times when the filing and prosecution activities for
patents and patent applications relating to our programs are controlled by our current and future licensors or collaboration partners.
If any of our current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications
in a manner consistent with the best interests of our business, we could lose our rights to the intellectual property or our exclusivity
with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not
be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control
patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or
prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date upon which
we assumed control over patent prosecution. Moreover, if other third parties have ownership rights to our future in-licensed patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Failure to obtain licenses at a reasonable cost
or terms may require us to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing
them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable
to do so, we may be unable to develop or commercialize the affected product candidates. This could have a material adverse effect on our
competitive position, business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Disputes may arise between us and our future licensors
regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and
other interpretation-related&#160;issues; whether and the extent to which our technology and processes infringe on intellectual property
of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our
right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know-how&#160;resulting from the joint
creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may be subject to patent infringement
claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent
us from commercializing our potential products.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Because the intellectual property landscape in
the biopharmaceutical industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate
and guarantee that we can operate without infringing on or violating third-party&#160;rights. Third party patent rights, if found to be
valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings
a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license
from the patent holder. Any intellectual property claims brought against us, whether or not successful, may cause us to incur significant
legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents
owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the
costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition,
any litigation could have a material adverse effect on our business and operations, including our ability to raise funds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Competitors may infringe or otherwise violate
our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to
file claims, which can be expensive and time-consuming, and any such claims could provoke these parties to assert counterclaims against
us. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert
is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from
using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement
claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced
to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other
remedy we receive may not be commercially valuable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Further, we may be required to protect our patents
through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse determination in any such submission or proceeding
could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.
Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary
to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold
a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, if our programs are found to infringe
the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and
other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as
a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other
parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties
or may be required to obtain licenses for the products they use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property
rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or
other proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may be subject to claims that we have
wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed
confidential information of third parties.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As is common in the biopharmaceutical industry,
in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these consultants,
and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services
to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject
to claims that we, our employees or our consultants have inadvertently or otherwise used or disclosed alleged intellectual property, such
as trade secrets, or other confidential information of former employers or competitors. Although we try to ensure that our employees and
consultants do not use the intellectual property, proprietary information,&#160;know-how&#160;or trade secrets of others in their work
for us, we may become subject to claims that we caused an individual to breach the terms of his or her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement,
or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information
of a former employer or competitor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">While we may litigate to defend ourselves against
these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our
defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies
or features that are essential to our programs, if such technologies or features are found to incorporate or be derived from the trade
secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect
our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or
hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Changes to patent laws in the United&#160;States
and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Changes in either the patent laws or interpretation
of patent laws in the United&#160;States and foreign jurisdictions could increase the uncertainties and costs surrounding the prosecution
of our owned and&#160;in-licensed&#160;patent applications and the maintenance, enforcement or defense of our owned and&#160;in-licensed&#160;issued
patents. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that,
if adopted, could impact our ability to enforce our proprietary technology. This combination of events has created uncertainty with respect
to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, the
USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable
ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in
the future. In addition, geopolitical instability could increase the uncertainties and costs surrounding the prosecution or maintenance
of patent applications and the maintenance, enforcement or defense of issued patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The patent positions of companies in the development
and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals
for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights
of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States Supreme Court in&#160;Amgen,
Inc. v. Sanofi&#160;(Amgen) stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification
must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will
be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a
particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge
our patents, when issued, relying on the reasoning in&#160;Amgen&#160;or other recent precedential court decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, a European Unified Patent Court (&#8220;UPC&#8221;)
entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective
for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather
than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Although we do not currently own any European
patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could
have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the
controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity
of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file
and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications
could be challenged for&#160;non-compliance&#160;and brought under the jurisdiction of the UPC.&#160;We cannot be certain that future
European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Periodic maintenance fees, renewal fees, annuities
fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies
in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies
also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application
process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable
rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events that could result in abandonment
or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time
limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents
and patent applications covering our programs, our competitive position would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may not identify relevant third-party
patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability
to develop and market our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We cannot guarantee that any of our patent searches
or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete
or thorough, nor can we be certain that we have identified each and every third-party&#160;patent and pending application in the United&#160;States
and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent
claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our
interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine
that our products are not covered by a third-party&#160;patent or may incorrectly predict whether a third-party&#8217;s pending application
will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United&#160;States or abroad that
we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability
to develop and market our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, because some patent applications
in the United&#160;States may be maintained in secrecy until the patents are issued, patent applications in the United&#160;States and
many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature
often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our
issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may
in the future file, patent applications covering products or technology similar to ours. Any such patent application may have priority
over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may become subject to claims challenging
the inventorship or ownership of our patents and other intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or&#160;co-inventor.&#160;The
failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship
disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign
laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties
involved in developing our programs or as a result of questions regarding&#160;co-ownership&#160;of potential joint inventions. Litigation
may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter
into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Patent terms may be inadequate to protect
the competitive position of our product candidates for an adequate amount of time.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Patents have a limited lifespan. In the United&#160;States,
if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United&#160;States&#160;non-provisional&#160;filing
date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering
our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including
generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result,
our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our technology licensed from various third
parties may be subject to retained rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our future licensors may retain certain rights
under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use,
to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures
of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these
uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, our future licensors may rely on
third-party&#160;consultants or collaborators or on funds from third parties, such as the U.S.&#160;government, such that our licensors
would not be the sole and exclusive owners of any patents we&#160;in-license.&#160;If other third parties have ownership rights or other
rights to our&#160;in-licensed&#160;patents, they may be able to license such patents to our competitors, and our competitors could market
competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Our Reliance on Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We currently rely on licensing arrangements
with Paragon through the License Agreements. If we are unable to maintain collaborations or licensing arrangements, or if our collaborations
or licensing arrangements are not successful, our business could be negatively impacted.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We currently rely on our licensing arrangements
with Paragon through the License Agreements for a substantial portion of our in-licenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Collaborations or licensing arrangements that
we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors.
If any of our current or future collaborators or licensors experience delays in performance of, or fails to perform our obligations under
their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, the research
programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option Agreements,
the licensing agreements we have pursuant to the License Agreements and our development timeline could be adversely affected. If we fail
to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our
collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and
may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements.
Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if
required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of
our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming&#160;and expensive and could
harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third
parties, products that compete directly or indirectly with our programs and products if the collaborators believe that the competitive
products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than
ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As part of our strategy, we plan to evaluate additional
opportunities to enhance our capabilities and expand our development pipeline or provide development or commercialization capabilities
that complement ours. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships
may require us to incur&#160;non-recurring&#160;and other charges, increase our near and long-term&#160;expenditures, issue securities
that dilute our existing stockholders or disrupt our management and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may face significant competition in attracting
appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party&#160;intellectual
property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources
and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be
unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend upon, among other
things, our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and
the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming&#160;to negotiate,
document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential
future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms or at all. If we fail to enter
into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities,
we may not be able to further develop our product candidates or bring them to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We currently rely, and plan to rely in the
future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and
successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize
our product candidates.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We have utilized and plan to continue to utilize
and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs, CMOs and strategic
partners, to supply, conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on
these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities.
As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials
and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely
upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with
the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our
regulatory responsibilities. We and our third-party&#160;contractors and CROs are required to comply with GCP regulations, which are regulations
and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we
or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be
deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications or refuse to approve our marketing applications. We cannot assure you that upon inspection by a given
regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition,
our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may
require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any
of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security
laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Any third parties conducting our clinical trials
will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether
they devote sufficient time and resources to our programs. These third parties may have relationships with other commercial entities,
including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively
affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our
product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We currently rely and expect to rely in
the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and
we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable
to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We do not currently own any facility that may
be used as our clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture our product
candidates. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any
of our product candidates, if approved. We currently have a sole source relationship for our supply of the ORKA-001&#160;and ORKA-002&#160;programs.
If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, it could have
a negative effect on the clinical development of our programs and other operations while we work to identify and qualify an alternate
supply source. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners
for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for
the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate
quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these
facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative
manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect
our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, our failure, or the failure
of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil
penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating
restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs
and harm our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Moreover, our CMOs may experience manufacturing
difficulties due to resource constraints, supply chain issues, proposed or actual legislative changes or requirements, or as a result
of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product
candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost
that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In
addition, our CMOs are responsible for transporting&#160;temperature-controlled&#160;materials that can be inadvertently degraded during
transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity
and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export
of products. Our business could be materially adversely affected by business disruptions to our third-party&#160;providers that could
materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses.
Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our
product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Foreign CMOs may be subject to U.S.&#160;legislation,
including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory requirements, which could increase the cost or
reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability
to secure significant commitments from governments to purchase our potential therapies. We currently rely on foreign CROs and CMOs, including
WuXi Biologics (Hong&#160;Kong) Limited and its affiliates (&#8220;WuXi Biologics&#8221;) and will likely continue to rely on foreign
CROs and CMOs in the future. WuXi Biologics is identified in the U.S. legislation known as the BIOSECURE Act, which was proposed in the
118<sup>th</sup> Congress, as a &#8220;biotechnology company of concern.&#8221; The version of the BIOSECURE Act introduced in the U.S.
House of Representatives during the 118<sup>th</sup> Congress would prohibit federal agencies from entering into procurement contracts
with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of
concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named &#8220;biotechnology
companies of concern&#8221; under a contract or agreement entered into before the effective date until January 1, 2032. The pathway and
timing for the BIOSECURE Act or its provisions to become law are uncertain. Depending on whether the BIOSECURE Act becomes law, what the
final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted
from pursuing U.S. federal government business or grants in the future if we continue to use WuXi or other parties identified as &#8220;biotechnology
companies of concern&#8221; beyond the grandfathering period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Furthermore, our operations and financial condition
may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory
requirements affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving
to those suppliers in the event of geopolitical instability affecting our collaborators in China could introduce delays into the development
program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Employee Matters, Managing
Growth and Other Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>In order to successfully implement our plans
and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expect to experience significant growth in
the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical drug development, technical
operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we
must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and continue
to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management
team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We are highly dependent on our key personnel
and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be
able to successfully implement our business strategy.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our ability to pursue our growth strategy will
be limited if we are unable to continue to attract and retain high quality personnel. We have been and will continue to be highly dependent
on the research and development, clinical and business development expertise of our executive officers, as well as the other principal
members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at
any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Attracting and retaining qualified personnel will
also be critical to our success, including with respect to any strategic transaction that we may pursue. The loss of our executive officers
or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our
ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult
and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience
required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this
limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition
among numerous pharmaceutical and biotechnology companies for similar personnel, as well as from universities and research institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In addition, we rely on consultants and advisors
to assist us in formulating our discovery and nonclinical and clinical development and commercialization strategy. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities
that may limit their availability to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our future growth may depend, in part, on
our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our future growth may depend, in part, on our
ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties.
If we fail to comply with the regulatory requirements in foreign markets and receive applicable marketing approvals, our target market
will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be
adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates
in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign
regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our estimates of market opportunity and
forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our
business may not grow at similar rates, or at all.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our market opportunity estimates and growth forecasts
are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Even if the markets
in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our revenue will be dependent, in part, upon the
size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain
coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not
as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population
is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products,
even if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our employees, independent contractors,
consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are exposed to the risk that our employees,
independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for
or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct and ethics, but it is not always
possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to comply with these laws or regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our internal information technology systems,
or those of any of our third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches
or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal
data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our
operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In the ordinary course of our business, we and
the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure,
dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual
property, trade secrets, and other sensitive data (collectively, sensitive information). If we (or a third party upon whom we rely) experience
a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. While we have implemented
security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Further,
cybersecurity breaches or other cybersecurity incidents may allow hackers access to our preclinical compounds, strategies, discoveries,
trade secrets, and/or other confidential information. Additionally, sensitive data could be leaked, disclosed, or revealed as a result
of or in connection with our employees&#8217;, personnel&#8217;s, vendors&#8217; or partners&#8217; use of generative AI technologies.
Our ability to monitor third parties&#8217; information security practices is limited, and these third parties may not have adequate security
measures in place. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats
and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred.
Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.
Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures
are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Moreover, while we
may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any
award may be insufficient or we may be unable to recover such award. Security incidents and attendant consequences may negatively impact
our ability to grow and operate our business. The risk of a cybersecurity incident or other informational technology disruption, particularly
through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around
the world have increased.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">To the extent that any disruption or security
breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data (including clinical
trial data) or applications, or for it to be believed or reported that any of these occurred, we could incur liability, including under
laws and regulations governing the protection of protected health information and other personal data, and reputational damage and the
development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate
us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party&#160;systems
where information important to our business operations or commercial development is stored.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Despite the implementation of security measures
in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information
maintained on our internal information technology systems and those of our third-party&#160;CROs, contractors (including sites performing
our clinical trials), third-party&#160;service providers and supply chain companies, and consultants, these systems are potentially vulnerable
to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication
and electrical failures, as well as security breaches from inadvertent or intentional actions or from cyber-attacks&#160;by malicious
third parties, or ransomware attacks, which, in each case, may compromise our system infrastructure or lead to the loss, destruction,
alteration or dissemination of, or damage to, our data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our hybrid-remote&#160;workforce may create additional
risks for our information technology systems and data because our employees work remotely and utilize network connections, computers,
and devices working at home, while in transit and in public locations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our contracts may not contain limitations of liability,
and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities,
damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate
or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will
continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We are subject to stringent and changing
laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived
failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties),
fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We and third parties who we work with are or may
become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, data transfer,
and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among
countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data
protection and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or
third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs,
expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation
and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are subject to numerous environmental, health
and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal
of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological
and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health
and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization
efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may be subject to adverse legislative
or regulatory tax changes that could negatively impact our financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The rules dealing with U.S.&#160;federal, state
and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service
and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect our stockholders
or us. We continue to assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions
where we have operations or employees to determine the potential effect on our business and any assumptions we make about our future taxable
income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such
proposals would have on our business if they were to be enacted. For example, the United&#160;States enacted the IRA, which implements,
among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated
the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over
five&#160;years for research activities conducted in the United&#160;States and over 15&#160;years for research activities conducted outside
the United&#160;States. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may acquire businesses or products, or
form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may acquire additional businesses or products,
form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business.
If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses
if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties
in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that
delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition,
we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We maintain our cash at financial institutions,
often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay
our operational expenses or make other payments.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our cash held in&#160;non-interest-bearing&#160;and
interest-bearing&#160;accounts exceeds the Federal Deposit Insurance Corporation insurance limits. If such banking institutions were to
fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. In addition, even if account holders
are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their
accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period
to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments,
which could adversely affect our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>General Risk Factors&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our estimates&#160;of market&#160;opportunity&#160;and
forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which we compete&#160;achieve&#160;the
forecasted&#160;growth, our business&#160;may&#160;not grow at similar&#160;rates, or at all.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our market opportunity estimates and growth forecasts
are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Even if the markets
in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is
subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our revenue will be dependent, in part, upon the
size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain
coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not
as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population
is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products,
even if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We may become exposed to costly and damaging
liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our insurance may not cover
all damages from such claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are exposed to potential product liability
and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products.
The use of a product candidate in clinical trials and the sale of any approved products in the future may expose us to liability claims.
An individual or group of individuals may bring a liability claim against us if one of our product candidates causes, or merely appears
to have caused, an injury. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially
and adversely affect our business. While we carry product liability insurance for our clinical trials, it is possible that any liabilities
could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain
insurance coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class
action or individual lawsuits. A successful product liability claim or series of claims brought against us could cause our stock price
to decline and, if judgments exceed our insurance coverage, could decrease our cash and our business operations could be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Litigation costs and the outcome of litigation
could have a material adverse effect on our business.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From time to time&#160;we&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims
through the ordinary course of our business operations regarding, but not limited to, employment matters, security of patient and employee
personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend ourselves against
claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result
in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of
operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our business could be adversely affected
by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical
events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The global economy, including credit and financial
markets, has experienced and may experience in the future extreme volatility and disruptions, including, among other things, diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, new or increased
tariffs and other barriers to trade, trade and other international disputes, increases in inflation rates, fluctuation in interest rates,
slower growth or recession, tighter credit, volatility in financial markets, high unemployment, labor availability constraints, public
health crises, significant natural disasters, including as a result of climate change, changes to fiscal and monetary policy or government
budget dynamics (particularly in the pharmaceutical and biotech areas), particularly in the pharmaceutical and biotech areas, political
and military conflict, and uncertainty about economic stability. Fluctuation in interest rates, coupled with reduced government spending
and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict
between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital
markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions
may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result
of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain
in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including
materials, operational, labor and employee benefit costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We may in the future experience disruptions as
a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing
sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of
operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Geopolitical events and global economic conditions
may also affect the ability of the FDA and other regulatory authorities to perform routine functions. If such concerns prevent the FDA
or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly
impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have
a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b>Risks Related to Owning Our Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0pt 0pt -0.25in"><b><i>The market price of our common stock has been, and
may continue to be volatile.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The market price of our common stock has been
and is likely to be highly volatile and is subject to significant fluctuations. Some of the factors that may cause the market price of
our common stock to fluctuate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>timing and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing
or future collaborators;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>failure to meet or exceed financial and development projections that we may provide to the public;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>announcements of significant or potential equity or debt sales by us;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and
marketing terms;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>failure to meet or exceed the financial and development projections of the investment community or if securities or industry analysts
do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>general market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent
protection for our technologies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>additions or departures of key personnel, including scientific or management personnel;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>significant lawsuits, including patent or stockholder litigation;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>changes in the market valuations of similar companies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>sales of securities by us or our securityholders in the future;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>trading volume of our common stock;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>announcements by competitors of new products, clinical progress or lack thereof, significant contracts, commercial relationships or
capital commitments;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the introduction of technological innovations or new therapies that compete with our products; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>period-to-period fluctuations in our financial results.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Moreover, the stock markets in general have experienced
substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations
may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market
event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility
in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such
companies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Furthermore, market volatility may lead to securities
litigation or increased stockholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic
value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors
could have an adverse effect on our operating results, financial condition and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our certificate of incorporation and bylaws,
as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders
to replace or remove management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Provisions in our certificate of incorporation
and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the company that stockholders may consider
favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions
could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the
market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management
team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove current management by making it
more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>establish a classified board of directors such that all members of the board are not elected at one time;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>allow the authorized number of our directors to be changed only by resolution of our board of directors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>limit the manner in which stockholders can remove directors from the board;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be
acted on at stockholder meetings;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by
written consent;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>limit who may call a special meeting of stockholders;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison
pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have
not been approved by our board of directors; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>require the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal
certain provisions of our charter or bylaws.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Moreover, because we are incorporated in Delaware,
we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which prohibits stockholders
owning more than 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively
will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they
would apply even if the offer may be considered beneficial by some stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our governing documents provide that, unless
we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain
legal actions between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum
for disputes with us or our directors, officers, employees or agents. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our governing documents provide that, unless we
consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law
claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of or based on a breach of
a fiduciary duty owed by any of our current or former directors, officers, or other employees or our stockholders, (iii) any action asserting
a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws, (iv) any action to interpret, apply,
enforce or determine the validity of the certificate of incorporation or bylaws, or (v) any action asserting a claim that is governed
by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties
named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; Our
governing documents further provide that, unless we consent in writing to an alternative forum, the federal district courts of the United
States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for
purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; Neither the Delaware Forum Provision nor the
Federal Forum Provision will apply to any causes of action arising under the Exchange Act. In addition, any person or entity purchasing
or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and consented to the foregoing Delaware
Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance
with the U.S. federal securities laws and the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Delaware Forum Provision and the Federal Forum
Provision may impose additional litigation costs on our stockholders in pursuing any such claims, particularly if such stockholders do
not reside in or near the State of Delaware. Additionally, these forum selection clauses may limit our stockholders&#8217; ability to
bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage
such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Future sales of shares by existing stockholders
could cause our stock price to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">If our stockholders sell, or indicate an intention
to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our
common stock could decline. In addition, shares of our common stock that are subject to our outstanding options will become eligible for
sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>We do not anticipate that we will pay any
cash dividends in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We do not anticipate that we will pay any cash
dividends in the foreseeable future. The current expectation is that we will retain our future earnings, if any, to fund the development
and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for
the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>Our executive officers, directors and principal
stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our executive officers, directors and principal
stockholders beneficially own a significant percentage of our outstanding common stock. As a result, if these stockholders were to choose
to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well
as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence
the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration
of voting power could delay or prevent our acquisition on terms that other stockholders may desire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><b><i>If equity research analysts do not publish
research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume
could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The trading market for our common stock will be
influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect
to not provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our
common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions
included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or
issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports
on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are not selling any securities under this prospectus
and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares
offered by this prospectus will be received by the Selling Stockholders. Some of the shares of Common Stock offered hereby are issuable
upon the exercise of the Pre-Funded Warrants. Upon exercise of such Pre-Funded Warrants for cash, we will receive the nominal cash exercise
price paid by the holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to limited exceptions, the Selling Stockholders
will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or
legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs,
fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and
filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>You should read the following discussion of
our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes thereto
and other financial information included elsewhere in this prospectus. This discussion contains forward-looking statements based upon
current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties
and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements as a result of various
factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere
in this prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary
Statement Concerning Forward-Looking Statements.&#8221; As used in this prospectus, unless the context suggests otherwise, &#8220;we&#8221;,
&#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221;, or &#8220;Oruka&#8221; refers to Oruka Therapeutics, Inc. and its subsidiaries,
including Oruka Therapeutics Operating Company, LLC. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We are a clinical-stage biotechnology company
focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;)
indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>, for &#8220;restoration,&#8221;&#160;and reflects
our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy
is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully
upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs
aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and
the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Our lead program, ORKA-001, is designed to target
the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other
conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the
aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise
position us to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Since our inception in February&#160;2024, we
have devoted substantially all of our resources to raising capital, organizing and staffing the company, business and scientific planning,
conducting discovery and research activities, establishing arrangements with third parties for the manufacture of our programs and component
materials, and providing general and administrative support for these operations. We do not have any programs approved for sale and have
not generated any revenue from product sales. To date, we have funded our operations primarily with proceeds from the issuance of convertible
preferred stock, common stock, a convertible note, pre-funded warrants, and the proceeds from the reverse recapitalization and merger
with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing (as defined and further described in &#8220;Recent
developments&#8221; below).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Since our inception, we have incurred significant
losses and negative cash flows from our operations. Our ability to generate product revenue sufficient to achieve profitability will depend
heavily on the successful development and eventual commercialization of any programs we may develop. We generated net losses of $83.7
million for the period from February&#160;6, 2024 (inception) to December 31, 2024. For the period from February 6 (inception) to December
31, 2024, we have used net cash of $57.8 million for our operating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We had cash, cash equivalents, and marketable
securities of $393.7 million as of December 31, 2024. We expect that our existing cash, cash equivalents, and marketable securities will
be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We expect to continue
to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development, approval
and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-001</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">ORKA-001 is a high affinity, extended half-life
monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in
the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory
disorders, including PsO.&#160;IL-23 is composed of two subunits: a p40 subunit that is shared with IL-12 and a p19 subunit that is specific
to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23 signaling, while more recent IL-23 antibodies
targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, we believe that ORKA-001 could achieve
higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile
of therapies targeting IL-23p19.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">ORKA-001 is engineered with YTE half-life extension
technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH-dependent binding
to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection
as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of
PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics of
ORKA-001 increase its potential to deliver these disease-modifying benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We initiated the dosing of healthy volunteers
in a Phase 1 trial of ORKA-001 in the fourth quarter of 2024. We expect to share interim data from the first-in-human trial in healthy
volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in the second
half of 2026.&#160;Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human to biologics
license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved
medicines. However, we have no control over the length of time needed for United States Food and Drug Administration (&#8220;FDA&#8221;)
review, and this timeline could vary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-002</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">ORKA-002 is a high affinity, extended half-life
mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;).&#160;IL-17 inhibition has become central to the treatment of psoriatic
diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa and axial
spondyloarthritis.&#160;More recently, the importance of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual
blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL-17A
alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates
half-life extension technology that could enable more convenient dosing intervals. We plan to initiate the dosing of healthy volunteers
in a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human trial in healthy
volunteers, including initial pharmacokinetic data, in the first half of 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We view ORKA-002 and ORKA-001 as highly complementary.
Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high
efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL-17
inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors are often used
in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL-23 inhibitor. Furthermore,
we have the potential opportunity to administer ORKA-002 and ORKA-001 sequentially, called ORKA-021, to combine two features of each program:
the rapid response of an IL-17 inhibitor with the ideal maintenance profile of an IL-23 inhibitor. We believe that ORKA-001 and ORKA-002
provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to
address additional I&amp;I indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional Pipeline Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We have a third mAb program, ORKA-003, designed
to target an undisclosed pathway. Our strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on
inflammatory dermatology conditions. Our third program provides the potential for indication expansion beyond PsO and may create combination
opportunities with our more advanced programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>Acquisition of Pre-Merger Oruka</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">On August 29, 2024 (the &#8220;Merger Closing&#8221;),
we completed our acquisition (the &#8220;Merger&#8221;) of Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) pursuant to an Agreement
and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following the transactions contemplated
by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc.
(&#8220;ARCA&#8221;) and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;),
with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating
Company, LLC.&#8221; Pre-Merger Oruka was a pre-clinical stage biotechnology company that was incorporated on February 6, 2024 under the
direction of Peter Harwin, a Managing Member of Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), for the purposes of holding
rights to certain intellectual property being developed by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). On August 29, 2024, we
changed our name from &#8220;ARCA biopharma, Inc.&#8221; (&#8220;ARCA&#8221;) to &#8220;Oruka Therapeutics, Inc.&#8221; and our Nasdaq
ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>Pre-Closing Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Immediately prior to the execution and delivery
of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka entered into a subscription agreement
with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the terms and subject to the conditions of
which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger Oruka (&#8220;Pre-Merger Oruka
Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes $25.0
million of proceeds previously received from the issuance of the Convertible Note (refer to Note 7 in our consolidated financial statements
included in this prospectus for additional details) and accrued interest on such note which converted to shares of Pre-Merger Oruka Common
Stock) (the &#8220;Pre-Closing Financing&#8221;). We incurred transaction costs of $20.5 million, which was recorded as a reduction to
additional paid-in capital in the consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger
Oruka pre-funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded
warrants of Company Common Stock in accordance with the Exchange Ratio (defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company Common Stock (the &#8220;Exchange Ratio&#8221;),
which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series
A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior
to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred
stock, par value $0.001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83.3332:1
after the reverse stock split discussed below, (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into
an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock
was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding
at the First Effective Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the
merger, the common stock shares were then, subject to a reverse stock split of 1-for-12 effected on September 3, 2024 (&#8220;Reverse
Stock Split&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As part of the Pre-Closing Financing and the Closing,
the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common Stock in exchange for 39,873,706 shares of Pre-Merger
Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company Common Stock in exchange for 4,764,032 shares of Pre-Merger
Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5,522,207 Company
pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka&#8217;s largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA; (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger Oruka;
and (iii) Pre-Merger Oruka was not a variable interest entity as it had sufficient equity at risk in order to fund its next development
milestones at the time of the reverse recapitalization. Additional information regarding the Merger is included in Note 3 to the consolidated
financial statements included in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>Reverse Stock Split</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">On September 3, 2024, we effected the Reverse
Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were
not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock
warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately
increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase
common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the consolidated
financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented, unless
otherwise specifically indicated or the context otherwise requires.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><b><i>PIPE Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">On September 11, 2024, we entered into a Securities
Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors. The
closing of the PIPE Financing occurred on September 13, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Pursuant to the Securities Purchase Agreement,
the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate
of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $0.001 per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.9 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Components of Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">To date, we have not generated revenue from any
sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our
development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future
from product sales or payments from future collaboration or license agreements that we may enter into with third parties, or any combination
thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates.
We may never succeed in obtaining regulatory approval for any of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><i>Research and Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Research and development expenses consist primarily
of costs incurred in connection with the development and research of our programs. These expenses include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>costs of funding research performed by third parties, including Paragon, that conduct research and development activities on our behalf;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>costs incurred, and milestone payments under license and option agreements;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>expenses incurred in connection with continuing our current research programs and discovery-phase development of any programs we may
identify, including under future agreements with third parties, such as consultants and contractors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations
(&#8220;CMOs&#8221;), and with clinical trial sites that conduct research and development activities on our behalf;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the cost of development and validating our manufacturing process for use in our preclinical studies and current and future clinical
trials;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>personnel-related expenses, including salaries, bonuses, employee benefits, travel, and stock-based compensation expense, including
stock-based compensation related to the Paruka warrant; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities,
and depreciation for our leased office space.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expense research and development costs as incurred.
Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities
are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or
when it is no longer expected that the goods will be delivered or the services rendered. Our primary focus since inception has been the
identification and development of our pipeline programs. Our research and development expenses primarily consist of external costs, such
as fees paid to Paragon under the Option Agreements. See &#8220;&#8212;Contractual Obligations and Commitments&#8221; below for further
details on the Option Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expect our research and development expenses
will increase substantially for the foreseeable future as we continue to invest in research and development activities related to the
continued development of our programs, developing any future programs, including investments in manufacturing, as we advance any program
we may identify and continue to conduct clinical trials. The success of programs we may identify and develop will depend on many factors,
including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>timely and successful completion of preclinical studies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>effective investigational new drug (&#8220;IND&#8221;) or comparable foreign applications that allow commencement of our planned clinical
trials or future clinical trials for any programs we may develop;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>successful enrollment and completion of clinical trials;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>positive results from our future clinical trials that support a finding of safety and effectiveness, acceptable pharmacokinetics profile,
and an acceptable risk-benefit profile in the intended populations;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>receipt of marketing approvals from applicable regulatory authorities;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable,
commercial manufacturing capabilities; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>maintenance of a continued acceptable safety, tolerability, and efficacy profile of any programs we may develop following approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Any changes in the outcome of any of these variables
with respect to the development of programs that we may identify could mean a significant change in the costs and possible delays in timing
associated with the development of such programs. For example, if the FDA or another regulatory authority were to require us to conduct
clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a program, or
if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend
significant additional financial resources and time on the completion of clinical development. We may never obtain regulatory approval
for any of our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><i>General and Administrative</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">General and administrative expenses consist primarily
of personnel-related expenses, including salaries, bonuses, employee benefits, travel, and stock-based compensation, for our executive
and other administrative personnel. Other significant general and administrative expenses include legal services, including intellectual
property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated human resource costs, information
technology costs, and facility-related costs, including rent, utilities, maintenance, and depreciation for our leased office space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">We expect our general and administrative expenses
will increase substantially for the foreseeable future as we anticipate an increase in our personnel headcount to support the expansion
of research and development activities, as well as to support our operations generally. We also expect to continue to incur significant
expenses associated with being a public company, including costs related to accounting, audit, legal, regulatory, and tax-related&#160;services
associated with maintaining compliance with applicable Nasdaq and SEC requirements; director and officer insurance costs; and investor
and public relations costs. We also expect to incur additional intellectual property-related expenses as we file patent applications to
protect innovations arising from our research and development activities.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other Income, Net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Other income, net consists of interest earned
on our cash, cash equivalents, and marketable securities; interest expense on the convertible note from a related party (see discussion
herein); and foreign currency transactions gains and losses. Interest expense relates to a convertible note (the &#8220;Convertible Note&#8221;)
issued to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a related party, in March&#160;2024. At the effective time
of the Merger, the Convertible Note, along with the accrued interest, was automatically converted into Company Common Stock.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">No provision for income taxes was recorded for
the period from February&#160;6, 2024 (inception) through December 31, 2024. Deferred tax assets generated from our net operating losses
have been fully offset by the valuation allowance as we believe it is not more likely than not that the benefit will be realized due to
our cumulative losses generated to date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations for the Period from February 6, 2024 (inception)
to December 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The following table summarizes our results of
operations for the period presented (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from February&#160;6,<br/> 2024 (Inception) to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Research and development <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,060</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">General and administrative <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,123</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,863</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Interest expense <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,468</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,399</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(83,724</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-size: 10pt">Includes related party amount
of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: left"><span style="font-size: 10pt">Includes related party amount
of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr></table><div>
</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: left"><span style="font-size: 10pt">Includes related party amount
of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our research and
development expenses for the period presented (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February 6,<br/> 2024 (Inception) to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-size: 10pt">External research and development expenses<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,680</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other research and development expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Personnel-related (excluding stock-based compensation)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Stock-based compensation<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total research and development expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,060</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes related party amount of $32,283 for the period from February 6, 2024 (inception) to December 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes related party amount of $10,357 for the period from February 6, 2024 (inception) to December 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Research and development expenses
were $75.1&#160;million for the period from February&#160;6, 2024 (inception) to December 31, 2024 and consisted primarily of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$57.7 million of research and development expense primarily includes: $18.3 million related to Paragon services rendered under the
Option Agreements for ORKA-001, including $4.8 million for milestones achieved under the Option and License Agreements upon exercise of
the option to enter into a license agreement and achievement of development candidate for IL-23 and dosing of the first subject in a Phase
1 clinical trial; $13.3 million of research and development expense primarily related to Paragon services rendered under the Option Agreements
for ORKA-002, including $2.3 million for milestones achieved under the Option and License Agreements upon exercise of the option to enter
into a license agreement and achievement of development candidate for IL-17; $0.7 million of other research and development expense due
to Paragon; $16.5 million of research and development expense on chemistry, manufacturing, and development costs; $5.7 million in toxicology
testing with a third-party contract research organization; and $3.2 million of other external research and development costs;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$4.0 million of personnel-related costs related to salaries, benefits, and other compensation-related costs;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$12.0 million of stock-based compensation expense, including $10.4 million of stock-based compensation related to the Paruka warrant;
and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$1.4 million of other expense and allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities, and depreciation for our leased office space.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our general and administrative
expenses for the period presented (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February&#160;6,<br/> 2024 (Inception) to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-size: 10pt">Personnel-related (including stock-based compensation) <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,981</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Professional and consulting fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,606</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Other <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">476</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,063</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes related party amount of $609 for the period from February 6, 2024 (inception) to December 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes related party amount of $575 for the period from February 6, 2024 (inception) to December 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes related party amount of $180 for the period from February 6, 2024 (inception) to December 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses were $13.1 million
for the period from February&#160;6, 2024 (inception) to December 31, 2024 and consisted primarily of the following:</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$8.0 million of personnel-related costs related to salaries, benefits, other compensation-related costs, recruiting costs, including
stock-based compensation of $2.9 million, and $0.6 million of personnel-related costs are recruiting costs reimbursed to Paragon for hiring
of our executive team, legal, and finance and accounting functions;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$4.6 million of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public
company, including $0.6 million of legal fees due to Paragon associated with patent-related activities; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>$0.5 million of other business expenses and net of allocated human resource costs, information technology costs, and facility-related
costs, including rent, maintenance, utilities, and depreciation for our leased office space to research and development expenses, including
$0.2 million of other business expenses due to Paragon.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Total Other Income, Net</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Interest income from cash equivalents and marketable
securities was $5.9 million for the period from February 6, 2024 (inception) to December 31, 2024.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Interest expense was $1.5 million for the period
from February 6, 2024 (inception) to December 31, 2024 relating to the Convertible Note from Fairmount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024, we had $393.7 million of
cash, cash equivalents, and marketable securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since our inception, we have incurred significant
operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable
future as we continue the pre-clinical and clinical development of our programs and our early-stage research activities. We have not yet
commercialized any products, and we do not expect to generate revenue from sales of products for several&#160;years, if at all. Through
December 31, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock, a
convertible note, and pre-funded warrants. In March&#160;2024, we received $2.9&#160;million in net proceeds from the issuance of Pre-Merger
Oruka Series&#160;A Preferred Stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which
were related party transactions. In August 2024, we raised approximately $228.0 million in net proceeds from Pre-Closing Financing and
received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $188.7 million in
net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded warrants in connection with the PIPE
Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our primary use of cash is to fund the development
of our product candidates and advance our pipeline. This includes both the research and development costs and the general and administrative
expenses required to support those operations. Since we are a clinical stage biotechnology company, we have incurred significant operating
losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we continue to pursue clinical development
of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in
our pipeline of nonclinical candidates. We expect that our existing cash, cash equivalents, and marketable securities will be sufficient
to fund our operating plans for at least twelve months from the date of filing of this prospectus. We will need to secure additional financing
in the future to fund additional research and development, and before a commercial drug can be produced, marketed, and sold. If we are
unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect
on our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our cash flows for
the period presented (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February&#160;6,<br/> 2024 (Inception)&#160;to<br/> December 31,&#160;<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(57,837</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(330,127</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">449,539</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61,575</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Operating Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From February&#160;6, 2024 (inception) to December&#160;31,
2024, net cash used in operating activities was $57.8 million, which was primarily attributable to a net loss of $83.7 million, offset
by net non-cash charges of $14.3 million and net changes in operating activities of $11.6 million. Non-cash charges primarily consisted
of $14.9 million in stock-based compensation expense (including $10.4 million related to the Paruka warrant) and $1.5 million of non-cash
interest expense, partially offset by net accretion of premiums and discounts on marketable securities of $2.2 million. Net changes in
our operating activities primarily consisted of a $3.5 million increase in accounts payable, a $3.3 million increase in accrued expenses
and other current liabilities, a $6.0 million increase in related parties accounts payable and other current liabilities, partially offset
by a $1.1 million increase in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable,
and accrued expenses and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing
and payments. The increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses
with our contract research organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Investing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From February&#160;6, 2024 (inception) to December
31, 2024, net cash used in investing activities was $330.1 million, which was primarily attributable to purchases of marketable securities.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Financing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From February&#160;6, 2024 (inception) to December
31, 2024, net cash provided by financing activities was $449.5 million, consisting of $228.0 million of net proceeds from the Pre-Closing
Financing, $188.7 million of net proceeds from the PIPE Financing, $25.0 million of net proceeds from the issuance of notes payable to
related parties, $4.9 million of cash acquired in connection with the reverse recapitalization and $2.9 million of net proceeds from issuance
of the Pre-Merger Oruka Series A Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Contractual Obligations and Commitments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We enter into contracts in the normal course of
business with CROs, CMOs and with other vendors for preclinical research studies, clinical trials, manufacturing, and other services and
products for operating purposes. These contracts generally provide for termination on&#160;notice or may have a potential termination
fee if a purchase order is cancelled within a specified time, and therefore, are cancelable contracts. We do not expect any such contract
terminations and did not have any non-cancellable obligations under these agreements as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Paragon Therapeutics - Option Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&#160;2024, we entered into two antibody
discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon and Paruka Holding, LLC (&#8220;Paruka&#8221;). Under the
terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets
of interest to us. From time to time, we can choose to add additional targets to the collaboration upon agreement with Paragon and Paruka.
Under the Option Agreements, we have the exclusive option to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each,
an &#8220;Option&#8221;). We have initiated certain research programs with Paragon that generally focus on discovering, generating, identifying
and/or characterizing antibodies directed to a particular target (each, a &#8220;Research Program&#8221;), including for IL-23 and IL-17A/F
for ORKA-001 and ORKA-002, respectively. Our exclusive option with respect to each Research Program is exercisable at our sole discretion
at such time as specified in the Option Agreements (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option
pursuant to the Option Agreements. For each of these agreements, once we enter into the corresponding license agreements, we will be required
to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective agreement upon the achievement of certain
clinical development milestones, up to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones,
as well as a low single-digit percentage royalty for antibody products beginning on the first commercial sale in each program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may terminate any Option Agreement or any Research
Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that we must pay certain unpaid
fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with
its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon
written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities
under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each
party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other
party&#8217;s bankruptcy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, as part of the Option Agreements,
on December&#160;31, 2024 and December 31, 2025, we granted and will grant, respectively, Paruka a warrant to purchase a number of shares
equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market
value of the underlying shares on the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The warrant is liability-classified and after the
initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the consolidated statement of operations and comprehensive loss as stock-based compensation expenses under research and development
expenses. On issuance of the December 31, 2024 warrant to Paruka, the change in fair value of the warrant immediately prior to issuance
was recorded in the consolidated statement of operations and comprehensive loss and the resultant carrying value of the liability was
reclassified to equity on the consolidated balance sheet as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, we were required
to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the ORKA-001 program. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. In June
2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody
for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process.
We received the rights to at least one selected IL-23 antibody in June 2024. During the period from February 6, 2024 (inception) to December
31, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development
candidate as research and development expense in our consolidated statement of operations and comprehensive loss. In addition, during
the period from February 6, 2024 (inception) to December 31, 2024, we recorded a $2.5 million milestone payment related to the first dosing
of a human subject in a Phase 1 trial of ORKA-001 in December 2024 as research and development expense in our consolidated statement of
operations and comprehensive loss. Our share of development costs incurred for the period from February 6, 2024 (inception) to December
31, 2024 was $13.5 million, which was recorded as research and development expenses. An amount of $2.8 million related to ORKA-001 is
included in related party accounts payable and other current liabilities as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were also required to reimburse Paragon $3.3&#160;million
for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred
by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was recognized as a
research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. We are also responsible
for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection process. We recognized
an amount of $0.8&#160;million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the
ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to December
31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, we exercised our option for ORKA-002 and recorded
a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in our consolidated
statement of operations and comprehensive loss. We accounted for development costs of $7.8 million for the period from February 6, 2024
(inception) to December 31, 2024 as research and development expenses. An amount of $2.7 million related to ORKA-002 is included in related
party accounts payable and other current liabilities as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expense the service fees as the associated costs
are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying
consolidated statement of operations and comprehensive loss.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We concluded that the rights obtained under the
Option Agreements represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with
no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value
of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The
research initiation fee represents a one-time cost on a research program-by-research program basis for accessing research services or
resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research
and development costs immediately. Amounts paid as reimbursements of on-going development cost, monthly development cost fee and additional
development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements
that is associated with services being rendered under the related Research Programs are recognized as research and development expense
when incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the period from February&#160;6, 2024 (inception)
to December 31, 2024, we recognized $42.0 million of expenses in connection with services provided by Paragon and Paruka under the Option
Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Paragon Therapeutics &#8211; License Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2024, we exercised the Option to acquire
certain rights to ORKA-001, and in December 2024, we entered into the corresponding license agreement with Paragon (the &#8220;ORKA-001
License Agreement&#8221;), pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop, manufacture,
commercialize or otherwise exploit certain antibodies and products targeting IL-23 in all fields other than the field of inflammatory
bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, we exercised the Option with respect to ORKA-002 for the IL-17A/F program,
and in February 2025, we entered into the corresponding license agreement with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and
together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;), pursuant to which Paragon granted us a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-17A/F
in all fields (&#8220;ORKA-002 Field&#8221; and together with the ORKA-001 Field, the &#8220;Fields&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The License Agreements provide us with exclusive
licenses in the Fields to Paragon&#8217;s patent applications covering the related antibodies, their method of use and their method of
manufacture and Paragon has agreed not to conduct any new campaigns that generate anti-IL-23 monospecific antibodies or anti-IL-17A/F
monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively, for at least five years. Each of the ORKA-001 and
ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon, on material breach without cure, and on a party&#8217;s
insolvency or bankruptcy to the extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of each of the ORKA-001 and
ORKA-002 License Agreements, we are obligated to pay Paragon non-refundable milestone payments of up to $12.0 million under each respective
agreement upon the achievement of certain clinical development milestones and up to $10.0 million under each respective agreement upon
the achievement of certain regulatory milestones, including a $1.5 million fee for nomination of a development candidate (or initiation
of an IND-enabling toxicology study) and a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase
1 trial for each of ORKA-001 and ORKA-002. In addition, we are obligated to pay Paragon a low single-digit percentage royalty for antibody
products for each of ORKA-001 and ORKA-002. For each of the License Agreements, the royalty term ends on the later of (i) the last-to-expire
licensed patent or our patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years
from the date of first sale of a Company product. There is also a royalty step-down if there is no Paragon patent in effect during the
royalty term for each program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cell Line License Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2024, we entered into the Cell Line License
Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Biologics&#8221;). Under the
Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics&#8217; know-how,
cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell
and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License
Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain
manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In consideration for the license, we agreed to pay
WuXi Biologics a non-refundable license fee of $150,000, which was recognized as a research and development expense during the period
from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to the extent that we manufacture our commercial supplies of
bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics
at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant
to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under
the agreement to be bought out on a&#160;product-by-product&#160;basis for a&#160;lump-sum&#160;payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Cell Line License Agreement will continue indefinitely
unless terminated (i) by us upon six months&#8217; prior written notice and our payment of all undisputed amounts due to WuXi Biologics
through the effective date of termination, (ii) by WuXi Biologics for a material breach by us that remains uncured for 60 days after written
notice, (iii) by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure,
or (iv) by either party upon the other party&#8217;s bankruptcy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Note&#160;Payable with Related Party</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&#160;2024, we entered into a Series A Preferred
Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby we issued the Convertible
Note, with an initial principal amount of $25.0 million that, at the time of issuance, could be converted into Pre-Merger Oruka Series&#160;A
Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next
equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible
Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature
on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not permitted without prior written consent of Fairmount.
At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity Date. Pursuant
to the Purchase Agreement, we had the right to sell and issue additional convertible notes up to an aggregate principal amount equal to
$30.0 million, in addition to the $25.0 million initial principal amount of the Convertible Note.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Immediately prior to the completion of the Merger,
the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount of $25.0 million,
plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined based upon the Company&#8217;s fully-diluted
capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued upon the
conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock. 2,722,207
shares of Company Common Stock were issued on conversion of the Convertible Note and accrued interest. As of December 31, 2024, there
is no note payable to a related party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Lease Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our contractual obligations include minimum lease
payments under our operating lease obligation for our headquarters in Menlo Park, California. See Note 13 to the consolidated financial
statements elsewhere in this report for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our management&#8217;s discussion and analysis of
its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S.
GAAP.&#160;The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as
well as the reported revenues recognized and expenses incurred during the reporting periods. Our estimates are based on its historical
experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While our significant accounting policies are described
in more detail in Note&#160;2 to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following
accounting policies used in the preparation of our financial statements require the most significant judgments and estimates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development costs are expensed as incurred.
Research and development expenses consist of costs incurred in performing research and development activities, including salaries and
bonuses, overhead costs, contract services and other related costs. The value of goods and services received from contract research organizations
and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress
in the period in cases when we have not received an invoice from the supplier. In circumstances where amounts have been paid in excess
of costs incurred, we record a prepaid expense. When billing terms under these contracts do not coincide with the timing of when the work
is performed, we are required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates
are based on a number of factors, including our knowledge of the progress towards completion of the specific tasks to be performed, invoicing
to date under the contracts, communication from the vendors of any actual costs incurred during the period that have not yet been invoiced
and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end
of any reporting period. Actual results could differ from the estimates made by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We measure stock options granted to employees and
non-employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The
model requires management to make a number of assumptions, including common stock fair value, expected volatility, expected term, risk-free
interest rate and expected dividend yield. For restricted stock awards and restricted stock units, the estimated fair value is the fair
market value of the underlying stock on the grant date. We expense the fair value of our equity-based compensation awards on a straight-line
basis over the requisite service period, which is the period in which the related services are received. We account for award forfeitures
as they occur. The expense for stock-based awards with performance conditions is recognized when it is probable that a performance condition
is met during the vesting period.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.25in"><i>Determination of Fair Value of Common Stock&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A public trading market for Company Common Stock
has been established in connection with the completion of the Merger. As such, it is no longer necessary for our board of directors to
estimate the fair value of our stock-based awards in connection with its accounting for granted stock-based awards or other such awards
we may grant, as the fair value of Company Common Stock and share-based awards is determined based on the quoted market price of Company
Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to the merger, Pre-Merger Oruka&#8217;s common
stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock
and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which
the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if
the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the
liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;),
where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates
the fair value of common stock based upon an analysis of future values for the Company, assuming various outcomes. The common stock value
is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available
as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation
date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock.
A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The assumptions underlying these valuations represented
management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result,
if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair value of Pre-Merger Oruka&#8217;s incentive shares
and its stock-based compensation expense could have been materially different.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See Note 2 to the consolidated financial statements
included in this prospectus for more information regarding recently issued accounting pronouncements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024, we did not have any off-balance
sheet arrangements, as defined in the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><i>(a)</i></span></td>
    <td><span style="font-size: 10pt"><i>Dismissal of Independent Registered Public Accounting Firm </i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">KPMG LLP (&#8220;KPMG&#8221;) served as the independent
registered public accounting firm of ARCA prior to the consummation of the Merger. On August 30, 2024, KPMG was dismissed as the independent
registered public accounting firm of the Company. The decision to dismiss KPMG was approved by the Audit Committee (the &#8220;Audit Committee&#8221;)
of the Board of Directors of the Company (the &#8220;Board&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The reports of KPMG on the consolidated financial
statements of the Company for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or disclaimer of opinion
and were not qualified or modified as to uncertainty, audit scope or accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the Company&#8217;s two most recent fiscal
years and the subsequent period from January 1, 2024 to August 30, 2024, there were (i) no disagreements (as defined in Item 304(a)(1)(iv)
of Regulation S-K and the related instructions thereto) with KPMG on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of KPMG, would have caused it to make
reference to the subject matter of the disagreement in connection with its report and (ii) no reportable events (as described in Item
304(a)(1)(v) of Regulation S-K).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company provided KPMG with a copy of the disclosures
made in this section and requested KPMG to furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements
made by the Company and, if not, stating the respects in which it does not agree. A copy of KPMG&#8217;s letter to the SEC dated September
5, 2024 regarding these statements was filed as Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K filed on September 5, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td/>
    <td><span style="font-size: 10pt"><i>(b)</i></span></td>
    <td><span style="font-size: 10pt"><i>Appointment of New Independent Registered Public Accounting Firm</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PricewaterhouseCoopers LLP (&#8220;PwC&#8221;) served
as the independent registered public accounting firm of Oruka prior to the consummation of the Merger. On August 30, 2024, following the
consummation of the Merger, the Audit Committee engaged PwC as the independent registered public accounting firm of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During ARCA&#8217;s two most recent fiscal years
and the subsequent period from January 1, 2024 to August 30, 2024, neither ARCA nor anyone on its behalf consulted PwC regarding: (i)
the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might
be rendered on ARCA&#8217;s financial statements, and neither a written report nor oral advice was provided to the ARCA that PwC concluded
was an important factor considered by ARCA in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii)
any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto)
or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a smaller reporting company, as defined by
Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Acquisition of Pre-Merger Oruka</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 29, 2024 (the &#8220;Merger Closing&#8221;),
we completed our acquisition (the &#8220;Merger&#8221;) of Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) pursuant to an Agreement
and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following the transactions contemplated
by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc.
(&#8220;ARCA&#8221;) and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;),
with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating
Company, LLC.&#8221; Pre-Merger Oruka was a pre-clinical stage biotechnology company that was incorporated on February 6, 2024 under the
direction of Peter Harwin, a Managing Member of Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), for the purposes of holding
rights to certain intellectual property being developed by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). On August 29, 2024, we
changed our name from &#8220;ARCA biopharma, Inc.&#8221; (&#8220;ARCA&#8221;) to &#8220;Oruka Therapeutics, Inc.&#8221; and our Nasdaq
ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Company Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a clinical-stage biopharmaceutical company
focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;)
indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>, for &#8220;restoration,&#8221; and reflects
our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy
is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully
upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs
aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and
the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our lead program, ORKA-001, is designed to target
the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other
conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the
aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise
position us to set a new treatment standard in large I&amp;I markets with continued unmet need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Our Pipeline </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>ORKA-001</i>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ORKA-001 is a high affinity, extended half-life
monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in
the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory
disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared with IL-12 and a p19 subunit that is specific
to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23 signaling, while more recent IL-23 antibodies
targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, we believe that ORKA-001 could achieve
higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile
of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension technology, a specific three amino acid change in
the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH-dependent binding to the neonatal Fc receptor (&#8220;FcRn&#8221;).
As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once
or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading to
durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics of ORKA-001 increase its potential
to deliver these disease-modifying benefits.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We initiated dosing of healthy volunteers in a Phase
1 trial of ORKA-001 in the fourth quarter of 2024. We expect to share interim data from the first-in-human trial in healthy volunteers,
including initial pharmacokinetic data, in the second half of 2025 and initial efficacy on patients with PsO in the second half of 2026.
Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human to biologics license application
(&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved medicines. However,
we have no control over the length of time needed for FDA review, and this timeline could vary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>ORKA-002</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ORKA-002 is a high affinity, extended half-life
mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;). IL-17 inhibition has become central to the treatment of psoriatic diseases,
including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa (&#8220;HS&#8221;)
and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance of inhibiting the IL-17F isoform along with IL-17A has
become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients
than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab,
but incorporates half-life extension technology that could enable more convenient dosing intervals. We plan to initiate dosing of healthy
volunteers in a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We view ORKA-002 and ORKA-001 as highly complementary.
Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high
efficacy and tolerability of this mechanism. However, for patients who also have joint involvement or signs and symptoms of PsA, an IL-17
inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors are often used
in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL-23 inhibitor. Furthermore,
we have the potential opportunity to administer ORKA-002 and ORKA-001 sequentially, called ORKA-021, to combine two attractive features
of each program: the rapid response of an IL-17 inhibitor with the ideal maintenance profile of an IL-23 inhibitor. We believe that ORKA-001
and ORKA-002 provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the
opportunity to address additional I&amp;I indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Additional Pipeline Program</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a third mAb program, ORKA-003, designed
to target an undisclosed pathway. Our strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on
inflammatory dermatology conditions. Our third program provides the potential for indication expansion beyond PsO and may create combination
opportunities with our more advanced programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Team, Investors, and Paragon Collaboration&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are led by a management team with significant
experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis,
CymaBay Therapeutics and Protagonist Therapeutics. Together, our team has a proven track record of building successful biotech organizations
in high-growth environments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pre-Merger Oruka was founded in February&#160;2024
by leading healthcare investor Fairmount. Fairmount founded Paragon in 2021 to conduct biologics discovery and optimization, including
acting as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. We have entered
into license agreements with Paragon pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop,
manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 outside of the field of inflammatory bowel
disease for ORKA-001 and for ORKA-002, certain antibodies and products targeting IL-17A/F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To achieve our goal of developing leading therapeutic
antibodies for patients with inflammatory skin diseases, we are applying antibody engineering to validated modes of action. We believe
this approach will enable us to improve meaningfully upon the efficacy and convenience of standard-of-care medicines while significantly
reducing technical and biological risk. The key elements of our strategy include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:&#160;&#160;&#160;&#160;</i></b>We
and our collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with
the potential to improve upon existing therapies. These parameters include extending half-life to increase exposure and reduce dosing
frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and
enable convenient, high-dose formulations. Together, we believe these features have the potential to translate into more efficacious and
convenient medicines for patients.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Target validated mechanisms of action:&#160;&#160;&#160;&#160;</i></b>Our initial targets, IL-23p19 and IL-17A/F, have established
efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL-23 class, including
three targeting IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F.&#160;While these therapies have advanced
the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not
achieve complete skin clearance. By applying our advanced antibody engineering to these validated targets, we believe we can maximize
our chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms
may allow us to progress our programs more efficiently and rapidly.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Leverage insights from earlier entrants to optimize our approach:&#160;&#160;&#160;&#160;</i></b>We benefit from a large body
of clinical evidence generated by prior therapies targeting IL-23 and IL-17. We continue to extract and apply learnings from this precedent
to our programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations,
regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, we have designed
ORKA-001 and ORKA-002 to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab
and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure-response relationships for efficacy
and safety for other therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance of response while
maintaining safety.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Pursue opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base case&#8221; and the potential
to shift the treatment paradigm entirely as an &#8220;upside case&#8221;:&#160;&#160;&#160;&#160;</i></b>Our strategy seeks to maximize
the potential for our programs to reach a base case product profile that could meaningfully advance the standard of care&#8212;for instance,
for ORKA-001, SQ dosing one or twice a year with equal or greater efficacy compared to today&#8217;s standard of care. At the same time,
we aim to deliver an upside case that dramatically improves outcomes for patients&#8212;for instance, significantly increasing rates of
complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient-specific
dosing intervals.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Build a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I indications:&#160;&#160;&#160;&#160;</i></b>We
are assembling a team of exceptional people and helping them reach their full potential and flourish so that together we can bring forward
meaningful new medicines for patients.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that pursuing the focused strategy outlined
above will help us to succeed in our mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases
the greatest possible freedom from their condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Targeting IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our programs benefit from significant advances in
the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA-001 and ORKA-002 are designed to target two
key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator of Th17 cells, a pro-inflammatory subset
of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining Th17 cells in the tissue as well
as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved
in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA. The diagram below depicting the
immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL-23 or IL-17 can break the inflammatory
cycle that drives disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Immunopathogenesis of PsO and the role of IL-23
and IL-17</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PsO develops when environmental triggers and a genetic
predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease
manifestations. This process begins with the aberrant activation of the dendritic cells (&#8220;DCs&#8221;), specifically those producing
IL-23 and other cytokines like IL-1&#946;, IL-21, TNF-&#945;, and IL-12. These cytokines induce the differentiation of Th17 cells, as
well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that produce IFN&#947; and TNF-&#945; and T helper type
22 (&#8220;Th22&#8221;) cells that produce IL-22. IL-23 plays a key role in the differentiation and activation of Th17 cells to secrete
IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines induce keratinocyte hyperproliferation leading to plaque
formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides,
and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the
IL-23/IL-17 axis plays an important role, as supported by the success of therapies targeting this axis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While the successful treatment of PsO&#160;&#8212;&#160;for
instance, with mAbs targeting IL-23 or IL-17 &#8212;&#160;can result in lesional skin returning to an apparently normal state, disease
tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of &#8220;immunological memory&#8221;
that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this
memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue,
in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory
cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining and potentiating TRMs, as indicated by the
depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor, which may explain the longer remissions observed
with IL-23 inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL-23 blockade could modify
the disease biology of PsO, possibly leading to durable remissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The scientific discoveries that refined our understanding
of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to today&#8217;s standard of care. Before
the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments
such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use
of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells were the predominant mediators of the
disease, which led to the use of biologics targeting TNF-&#945; such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation
that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL-23 and IL-17.
This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as
cyclosporine) to more specific immunomodulators (TNF-&#945; inhibitors) to precise biologic therapies targeting the key cytokines involved
in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic class raising the bar on both safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Biologic therapies, especially mAbs, are now mainstays
in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Therapies that have improved upon efficacy and/or
reduced dosing frequency have achieved the most commercial success, even when launched many&#160;years after other biologics. Enbrel was
first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira was approved for PsO with an every-other-week
(Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3 data to Humira, but with a significantly
improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher
efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which
has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules
of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful
drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule with improvements in efficacy,
as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates (i.e., a 90% improvement in PASI score
and a 100% improvement in PASI score (complete clearance), respectively) in clinical trials. In addition, Bimzelx (bimekizumab), approved
by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although
many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have
improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Biologics have raised the bar on the standard of care in PsO, but
leave room for improvement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The biology driving PsO and PsA is well understood
today, and the standard of care has progressed dramatically. We believe that it is unlikely that a novel mechanism will emerge that is
as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation now should be focused on optimizing the
product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral
medicines have yet to match the efficacy of biologics. We believe that a better biologic with a longer dosing interval and the potential
for improved efficacy will present a more attractive product profile for most patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview of Psoriasis (PsO)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PsO is a chronic autoimmune skin disorder that affects
an estimated 125&#160;million people worldwide with steadily increasing prevalence, estimated to be around&#160;2&#160;&#8211;&#160;3%
of the population currently, according to the World Psoriasis Day consortium. It is the largest pharmaceutical market within dermatology,
with annual sales of approximately $25.0&#160;billion in 2022, which is estimated to grow to $32&#160;billion by 2028. The most common
form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated, erythematous plaques with overlying, coarse,
silvery-scaled patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees
and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur
and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients have moderate disease, defined as having
3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined as having more than 10% BSA involvement. The
chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes,
and atherosclerotic cardiovascular disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As discussed earlier, PsO is a complex immune-mediated
disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay of environmental and behavioral risk factors and
genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic component to the disease, including the observation
that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility
loci, many containing genes related to the regulation of the immune system, in genome-wide association studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Current PsO Treatments and Limitations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While patients with mild PsO typically rely on topical
corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate-to-severe
PsO.&#160;As a result, the American Academy of Dermatology-National Psoriasis Foundation recommends biologics as first-line therapy for
moderate-to-severe PsO.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Several classes of biologic therapies have been
approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured
via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha (&#8220;TNF-&#945;&#8221;) inhibitors such
as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a PASI score of PASI 90 at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50%
of patients and a PASI score of PASI 100 in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the
p40 subunit of IL-23 that is shared with IL-12, was approved next and achieved efficacy on par with Humira. IL-17 inhibitors Cosentyx
(secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients and
PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL-23p19 inhibitors
such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80%
of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally, IL-17A/F inhibitors such
as Bimzelx (bimekizumab) have recently shown even higher response rates than IL-23 inhibitors, but with slightly less tolerable profiles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Treatment expectations in PsO have evolved progressively
with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly
SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today,
Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3 clinical trials, 43% and 58% of patients
achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months. Most recently, Bimzelx (bimekizumab)
has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks in Phase&#160;3 trials. However,
the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral
candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet
need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while early signs are present, the promise
of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient dosing options has driven significant
interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety
profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic innovation in PsO, with the potential
for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview of Psoriatic Arthritis (PsA)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PsA is a chronic inflammatory condition that affects
both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third of patients with moderate-to-severe PsO also have
PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eight&#160;years between the diagnosis
of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations.
Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Enthesitis,
dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony
fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.&#160;Like
PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Current PsA Treatments and Limitations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective treatment of PsA requires a coordinated
approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis,
enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti-inflammatory
drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease manifestations. However, those with more moderate or
severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF-&#945; or IL-17, or less commonly
an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL-17
inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where
a TNF-&#945; inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF-&#945; or IL-17 inhibitors in
PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (&#8220;ACR&#8221;)
score, which measures peripheral joint disease. Approved TNF-&#945; inhibitors, including Humira (adalimumab) and Cimzia (certolizumab),
achieved a placebo-adjusted ACR50 response of around&#160;30&#160;&#8211;&#160;35% at 24&#160;weeks with Q2W dosing. Approved IL-17 inhibitors,
including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo-adjusted ACR50 response of around&#160;25&#160;&#8211;&#160;30%
at 24&#160;weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab), which was recently approved in the United&#160;States for
PsA, achieved a placebo-adjusted ACR50 response of approximately 35% at 16&#160;weeks with Q4W dosing. A significant fraction of patients
with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly
SQ dosing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview of additional opportunities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to PsO and PsA, inhibition of IL-23
or IL-17 has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including HS and axSpA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">HS is a chronic inflammatory skin disease characterized
by lesions that include deep-seated nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous
areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can
have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence
well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune
modulators, and surgery. Humira (adalimumab) was the only FDA-approved medication for the treatment of moderate-to-severe HS from its
approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023 and Bimzelx (bimekizumab) in November 2024. Now multiple
other biologics are advancing through development and have demonstrated encouraging data in Phase 2 clinical trials, though a significant
fraction of patients still do not achieve adequate responses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">axSpA is a chronic inflammatory disease that primarily
affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and
can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.&#160;Patients with axSpA may develop
further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact
on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the United&#160;States.
Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF-&#945; inhibitor
is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less
frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Solution: Half-Life Extension and Antibody Engineering Technologies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our antibody engineering campaigns are designed
to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended
serum half-life in non-human primates (&#8220;NHPs&#8221;). Half-life extension is possible by modifying the pH-dependent binding affinity
of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation
in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in
endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the
antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient enough, antibody recycling can be favored over
degradation, potentially resulting in a much longer serum half-life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Antibody engineers have discovered methods of modifying
the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past
two decades, with the so-called &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221; mutations (M428L/N434S) being the
most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical
precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification
were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in
clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively,
and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half-life
that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate
half-life in humans, with the human half-life equaling around two to four&#160;times the NHP half-life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical experience with YTE-modified mAbs predicts significant
half-life extension over wildtype mAbs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While this increasing body of clinical precedent
serves to validate half-life extension, we do not yet have clinical data showing that the introduction of these amino acid substitutions
in our programs leads to a longer serum half-life. However, we aim to establish this favorable pharmacokinetic profile early in the clinical
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-001</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Summary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ORKA-001 is a high affinity, extended half-life
mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date, we believe ORKA-001 has the potential to
become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>One to two maintenance doses per year. Standard-of-care therapies targeting IL-23 require maintenance dosing every eight to twelve
weeks. We engineered the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001 in circulation, which may
enable dosing every six to twelve months &#8212; a dosing interval made feasible by half-life extension technology. In preclinical studies,
serum levels from NHPs indicated an elimination half-life of over 30 days following SQ administration of ORKA-001. Based on published
scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, we anticipate this half-life in NHPs
to translate to a half-life in humans that could allow subcutaneous dosing every six to twelve months while maintaining high antibody
exposures.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Higher PASI 100. ORKA-001 benefits from the robust validation of IL-23 inhibition in PsO by multiple approved therapies, such as Skyrizi
(risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA-001
is designed to bind a similar epitope to the market-leading anti-IL-23 antibody, Skyrizi, with similar or greater affinity and could achieve
much higher exposures in patients due to half-life extension and higher dosing. Skyrizi and Tremfya both have a robust exposure-response
relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated
this exposure-response relationship, and ORKA-001 could lead to higher response rates, including higher rates of complete skin clearance,
or PASI 100, through increased exposure, even while having more convenient dosing with as few as one or two maintenance doses per year.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Validated IL-23p19 safety profile. Existing commercially approved antibodies targeting IL-23 provide a robust precedent for the safety
of IL-23 inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the
patient level between exposure and safety. While we are not pursuing IBD, the approved Skyrizi regimens for Crohn&#8217;s disease and
ulcerative colitis supports the safety of high peak exposures. Peak Skyrizi exposures during the IV induction phase in Crohn&#8217;s disease
and ulcerative colitis are multiple times higher than the anticipated peak ORKA-001 exposures at dose levels we currently plan to evaluate
in PsO. In addition, an exposure-response analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated
safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment, the top quartile of average exposures were
significantly higher than the highest anticipated exposures with ORKA-001 in the same periods.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Potential to offer longer term remission to some patients. Emerging evidence suggests that IL-23 blockade can modify the disease biology
of PsO, possibly leading to durable remissions and preventing the development of PsA. Dr. Andrew Blauvelt, chair of our Scientific Advisory
Board, pioneered some of this work by using two- and four-times the approved dose levels of risankizumab to achieve best-in-indication
response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23 inhibition, which could lead
to longer-lasting remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention
early in the disease course can lead to longer treatment-free remissions. In addition, retrospective claims data suggests that treatment
with an IL-23 inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial.
Given the high antibody exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable remissions for some patients,
especially those with short disease duration. We plan to pursue patient-specific dosing intervals to provide each patient the greatest
possible freedom from their disease.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that this target profile for ORKA-001
could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Preclinical Data</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We evaluated ORKA-001 in numerous preclinical studies
for several key features:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Potency that matches or exceeds Skyrizi (risankizumab) in vitro</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have tested the potency of ORKA-001 in vitro&#160;in
multiple assays, including assays evaluating the inhibition of IL-17 release from human peripheral mononuclear blood cells, in comparison
to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these experiments,
we believe ORKA-001 binds a similar epitope as risankizumab with similar potency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-001 binds to a similar epitope as risankizumab with similar
potency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Significant half-life extension in NHPs that could enable a maintenance
dosing interval of once or twice a year in humans</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We assessed ORKA-001 in NHPs in comparison to risankizumab
generated recombinantly based on amino acid sequences from patent filings. ORKA-001 had a significantly longer half-life, reaching over
30&#160;days with SQ administration. Based on clinical experience with YTE-modified mAbs and pharmacokinetic modeling, we believe that
this half-life extension could enable dosing once or twice per year, as shown in the figure below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>The incorporation of YTE mutations significantly
extends half-life in NHPs, which could enable once or twice yearly dosing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to enabling less frequent dosing, an
extended half-life would increase the exposure of ORKA-001, which has the potential to increase efficacy. Based on published literature,
Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration
correlating with higher PASI 90 and PASI 100 rates short-term (at 16&#160;weeks) and long-term (at 52&#160;weeks), as shown for PASI 100
in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four-times higher doses of Skyrizi than the approved regimen,
yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16&#160;weeks. Based on our pharmacokinetic modeling, ORKA-001
could achieve four-fold higher average exposures than the approved Skyrizi regimen over the first 16&#160;weeks and over two-fold higher
average exposures at steady-state, exceeding even the exposures in KNOCKOUT.&#160;Based on the exposure-response relationship observed
with other IL-23 inhibiting antibodies, we believe that these increased exposures could result in higher efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-001 is projected to extend the exposure-response relationship
established by studies of Skyrizi</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Safety in vitro and in vivo</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have evaluated ORKA-001 in several&#160;in vitro&#160;and&#160;in
vivo&#160;preclinical studies to assess safety. In addition, we have a nonclinical program to characterize the toxicology, toxicokinetics,
and anti-drug antibody profile of ORKA-001 in NHPs. Our nonclinical program supported the initiation of our Phase 1 clinical trial for
ORKA-001 and our continuing clinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Characteristics that support ease of manufacturing and potentially
enable high-concentration formulations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Finally, we have assessed a variety of attributes
essential for manufacturability and high-concentration formulation, including viscosity, solubility, and stability, among others. ORKA-001
shows evidence of desirable properties across these characteristics, which we believe will enhance our ability to manufacture ORKA-001
successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient, low-volume presentations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-001</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We dosed the first participants in a Phase 1 clinical
trial of ORKA-001 in healthy volunteers in the fourth quarter of 2024. This trial is a double-blind, placebo-controlled, single ascending
dose study evaluating the safety, tolerability, and pharmacokinetics of ORKA-001 in healthy volunteers. The trial is expected to enroll
approximately 24 healthy volunteers across three subcutaneous dose cohorts. We expect to share interim data from this trial in the second
half of 2025. We believe this data has the potential to provide key validation of initial safety and pharmacokinetics data, including
half-life, to support extended dosing intervals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We plan to initiate a Phase 2a proof-of-concept
study of ORKA-001 in moderate-to-severe PsO in the second half of 2025. We believe that several aspects of PsO facilitate clinical development,
including well-established, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a
rapid efficacy readout at 16 weeks, and potentially rapid enrollment due to the large patient population. Our Phase 2a clinical trial
is anticipated to evaluate the safety and efficacy of a single dose level of ORKA-001 versus placebo in approximately 80 subjects, followed
by randomization to one of two maintenance dosing arms. In one maintenance arm, subjects will receive ORKA-001 every six months. In the
other, subjects will receive only induction dosing to assess the length of time patients maintain clear skin, which could support once-yearly
dosing or even longer-term durability in some patients. The anticipated primary endpoint is PASI 100 at Week 16. After completing the
trial, subjects may have the option to roll over to an open-label extension study. We expect to share initial data from the Phase 2a trial
in the second half of 2026. We believe this data has the potential to inform efficacy at Week 16, as well as later timepoints, and provide
us information on preliminary durability, including the potential for extended dosing intervals and longer-term remissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-002</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;Summary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ORKA-002 is a high affinity, extended half-life
mAb designed to target IL-17A/F.&#160;Dual inhibition of both IL-17A and IL-17F has shown superior efficacy compared to IL-17A inhibition
alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz
(ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q4W maintenance dosing in PsO and PsA, except Bimzelx, where Q8W maintenance
dosing in PsO patients &lt;120 kg is recommended.&#160;By binding IL-17A/F at similar epitopes and affinity ranges as Bimzelx while incorporating
half-life extension technology to potentially enable dosing two to three times a year in PsO and PsA, we believe that ORKA-002 could become
the leading therapy in the IL-17 class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Preclinical Data</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preclinical program we are conducting for ORKA-002
mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these
experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab, but with a significantly longer half-life, which
we believe could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinical Development Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We plan to initiate dosing of healthy volunteers
in a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial data on ORKA-002 in healthy volunteers has
the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical
development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002 in a range of indications over time.
We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy for the approximately one-quarter
to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do
not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond PsO, including PsA with limited skin
involvement, HS, axSpA, and additional&#160;I&amp;I diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ORKA-021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The IL-17 and IL-23 classes each have distinct advantages.
IL-17 inhibitors tend to have the fastest onset and highest peak response, while IL-23 inhibitors have less frequent dosing and better
durability and safety. Combining the two mechanisms sequentially has the potential to provide two attractive features of each program:
the rapid response of an IL-17 inhibitor with the ideal maintenance profile of an IL-23 inhibitor. As a result, following ORKA-002 and
ORKA-001, we plan to explore a sequential combination regimen of ORKA-002 and ORKA-001, called &#8220;ORKA-021.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional Pipeline Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a third mAb program, ORKA-003, that targets
an undisclosed pathway. A core tenet of our strategy is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory
dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO as well as combination opportunities with
our more advanced programs. In the future, we may add additional programs to our portfolio beyond ORKA-001, ORKA-002, ORKA-021 and ORKA-003
that fit our strategic focus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We strive to protect the proprietary programs and
technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover the
composition of matter of our programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Paragon has filed, on our behalf, provisional patent
applications, and we have filed non-provisional patent applications, and may file additional patent applications directed to antibodies
that target IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies,
including ORKA-001. In addition, Paragon has filed, on our behalf, provisional patent applications, and we may file additional patent
applications directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations,
and methods of using such antibodies, including ORKA-002. We have exclusive rights to ORKA-001 and ORKA-002 and the corresponding IL-23
and IL-17 patent applications pursuant to license agreements with Paragon. If the patent applications mature into one or more issued patents
covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Commercial</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Should any of our product candidates be approved
for commercialization, we intend to develop a plan to commercialize them in the United&#160;States and other key markets, through internal
infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs. Given
our stage of development, we have not yet established a commercial organization or distribution capabilities. We have exclusive worldwide
rights to develop and commercialize ORKA-001 and ORKA-002 pursuant to license agreements with Paragon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not currently own or operate facilities for
product manufacturing, testing, storage, and distribution. We have contracted and expect to continue to contract with third parties for
the manufacture and distribution of our product candidates. Because we rely on contract manufacturers, we employ personnel with extensive
technical, manufacturing, analytical, and quality experience. Our team has deep knowledge and understanding of the regulations that govern
manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support our regulatory filings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The biotechnology and biopharmaceutical industries
are characterized by continuing technological advancement and significant competition. While we believe that our programs, technology,
development experience and scientific knowledge provide us with competitive advantages, we face competition from major pharmaceutical
and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others.
Any product candidates that we successfully develop and commercialize will compete with existing therapies and therapies that may become
available in the future. Many of the companies with which we are currently competing or will compete against in the future have significantly
greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Key competitive factors affecting the success of
all our product candidates that we develop, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level
of generic competition, and the availability of reimbursement from government and other third-party payors. Our competitors may also obtain
FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our
competitors establishing a strong market position before we are able to enter the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Specifically, there are several companies developing
or marketing treatments that may be approved for the same indications and/or diseases as our two most advanced programs, ORKA-001 and
ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of our programs and there can be no assurance
that our programs will have similar or comparable results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are several approved biologic therapies for
the treatment of moderate-to-severe PsO.&#160;These include mAbs targeting IL-23, such as Skyrizi (risankizumab) from AbbVie, Tremfya
(guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target
the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL-17, such as Bimzelx (bimekizumab)
from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL-17A,
and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL-17 receptor/A; and
biologics targeting TNF-&#945;, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from
Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including
the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib)
from Bristol-Myers Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and other&#160;I&amp;I indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we are aware of several product candidates
in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart
from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics targeting IL-17A/F.&#160;Also, there are several
oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor, DC-853 from Eli Lilly targeting IL-17A, and
TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant Agreements&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Paragon Therapeutics &#8211; Option Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&#160;2024, we entered into two antibody
discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon and Paruka Holding, LLC (&#8220;Paruka&#8221;). Paruka
is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees of Paragon.
Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic
targets of interest to us. From time to time, we can choose to add additional targets to the collaboration upon agreement with Paragon
and Paruka. Under the Option Agreements, we have the exclusive option to, on a research program-by-research program basis, be granted
an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from
the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each,
an &#8220;Option&#8221;). We have initiated certain research programs with Paragon that generally focus on discovering, generating, identifying
and/or characterizing antibodies directed to a particular target (each, a &#8220;Research Program&#8221;), including for IL-23 and IL-17A/F
for ORKA-001 and ORKA-002, respectively. Our exclusive option with respect to each Research Program is exercisable at our sole discretion
at such time as specified in the Option Agreements (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option
pursuant to the Option Agreements. For each of these agreements, once we enter into the corresponding license agreements, we will be required
to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective agreement upon the achievement of certain
clinical development milestones, up to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones,
as well as a low single-digit percentage royalty for antibody products beginning on the first commercial sale in each program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may terminate any Option Agreement or any Research
Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that we must pay certain unpaid
fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with
its activities under any terminated Research Program. Paragon may terminate any Option Agreement or a Research Program immediately upon
written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities
under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each
party has the right to terminate the Option Agreements or any Research Program upon material breach that remains uncured or the other
party&#8217;s bankruptcy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, as part of the Option Agreements,
on December&#160;31, 2024 and December 31, 2025, we granted and will grant, respectively, Paruka a warrant to purchase a number of shares
equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market
value of the underlying shares on the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Paragon Therapeutics &#8211; License Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2024, we exercised the Option to acquire
certain rights to ORKA-001, and in December 2024, we entered into the corresponding license agreement with Paragon (the &#8220;ORKA-001
License Agreement&#8221;), pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop, manufacture,
commercialize or otherwise exploit certain antibodies and products targeting IL-23 in all fields other than the field of inflammatory
bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, we exercised the Option with respect to ORKA-002 for the IL-17A/F program,
and in February 2025, we entered into the corresponding license agreement with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and
together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;), pursuant to which Paragon granted us a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-17A/F
in all fields (&#8220;ORKA-002 Field&#8221; and together with the ORKA-001 Field, the &#8220;Fields&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The License Agreements provide us with exclusive
licenses in the Fields to Paragon&#8217;s patent applications covering the related antibodies, their method of use and their method of
manufacture and Paragon has agreed not to conduct any new campaigns that generate anti-IL-23 monospecific antibodies or anti-IL-17A/F
monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively, for at least five years. Each of the ORKA-001 and
ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon, on material breach without cure, and on a party&#8217;s
insolvency or bankruptcy to the extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of each of the ORKA-001 and
ORKA-002 License Agreements, we are obligated to pay Paragon non-refundable milestone payments of up to $12.0 million under each respective
agreement upon the achievement of certain clinical development milestones and up to $10.0 million under each respective agreement upon
the achievement of certain regulatory milestones, including a $1.5 million fee for nomination of a development candidate (or initiation
of an investigational new drug (&#8220;IND&#8221;) enabling toxicology study) and a further milestone payment of $2.5 million upon the
first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, we are obligated to pay Paragon a low
single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each of the License Agreements, the royalty
term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use or sale of a licensed
antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also a royalty step-down
if there is no Paragon patent in effect during the royalty term for each program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cell Line License Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2024, we entered into the Cell Line License
Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Biologics&#8221;). Under the
Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics&#8217; know-how,
cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell
and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License
Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain
manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In consideration for the license, we agreed to pay
WuXi Biologics a non-refundable license fee of $150,000. Additionally, to the extent that we manufacture our commercial supplies of bulk
drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics
at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant
to an amendment to the Cell Line License Agreement effective in November 2024, a provision was added that permits the royalties owed under
the agreement to be bought out on a&#160;product-by-product&#160;basis for a&#160;lump-sum&#160;payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Cell Line License Agreement will continue indefinitely
unless terminated (i) by us upon six months&#8217; prior written notice and our payment of all undisputed amounts due to WuXi Biologics
through the effective date of termination, (ii) by WuXi Biologics for a material breach by us that remains uncured for 60 days after written
notice, (iii) by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure,
or (iv) by either party upon the other party&#8217;s bankruptcy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA and other regulatory authorities at federal,
state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing,
manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing.
We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements
of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product
candidates. Generally, before a new therapeutic product can be marketed, considerable data demonstrating a biological product candidate&#8217;s
quality, safety, purity and potency, or a small molecule drug candidate&#8217;s quality, safety and efficacy, must be obtained, organized
into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. For biological product
candidates, potency is similar to efficacy and is interpreted to mean the specific ability or capacity of the product, as indicated by
appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner
intended, to effect a given result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or post-marketing may subject an applicant to administrative or judicial
sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications from the sponsor,
withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total
or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and
civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our company and our products
or product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>United States Biologics Regulation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the United States, biological products are subject
to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;)
and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process
or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before
biologic product candidates may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory
Practices (&#8220;GLP&#8221;) regulation;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when
significant changes are made;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical site before the trial
is commenced;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>performance of adequate and well-controlled human clinical trials in accordance with current Good Clinical Practice (&#8220;GCP&#8221;)
requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>satisfactory completion of an FDA Advisory Committee review, if applicable;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product
is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological
product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Preclinical and Clinical Development </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to beginning any clinical trial with a product
candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an
investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol
or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology,
pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information,
and any available human data or literature to support the use of the investigational product. An IND must become effective before human
clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day
period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold
and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of
an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;In addition to the IND submission process,
supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;),
a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution.
The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may
result in some delay before initiation of a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical trials involve the administration of the
investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the
requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are
conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and
the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial
conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing
to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical
trial begins at that site, and must monitor the study until completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regulatory authorities, the IRB or the sponsor may
suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health
risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or
not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial
if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There
are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public
registries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For purposes of BLA approval, human clinical trials
are typically conducted in three sequential phases that may overlap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition.
These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product
in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate
the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple
Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an
adequate basis for product approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some cases, the FDA may require, or companies
may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called
Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal
studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for
manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity,
strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging
must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable
deterioration over its shelf life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A sponsor may choose, but is not required, to conduct
a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless
waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA
regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including
that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper
procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection
if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>BLA Submission and Review </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Assuming successful completion of all required testing
in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials
are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include
all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as
positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed
labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the
product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA
requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under the Pediatric Research Equity
Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product
candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a
sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication,
new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty days after an end-of-Phase
2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological
product for an indication for which orphan designation has been granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Within 60 days following submission of the application,
the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse
to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information.
In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal
is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six
months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended
by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product
is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the
product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application
review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Before approving a BLA, the FDA will typically inspect
the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with
GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline
the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">After the FDA evaluates a BLA and conducts inspections
of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval
letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except
that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete
Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing
the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval,
including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory
criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor
safety or efficacy of a product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If regulatory approval of a product is granted,
such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be
marketed. For example, the FDA may approve the BLA with a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to ensure the benefits
of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and
to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls
and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre-&#8201;and post-marketing requirements
is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market
studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit
further marketing of the product based on the results of these post-marketing studies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Combination Therapy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Combination therapy is a treatment modality that
involves the use of two or more drugs to be used in combination to treat a disease or condition. If those drugs are combined in one dosage
form, such as one pill, that is known as a fixed dose combination product and it is reviewed pursuant to the FDA&#8217;s Combination Rule
at 21 CFR 300.50. The rule provides that two or more drugs may be combined in a single dosage form when each component contributes to
the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective
for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug. But not all combination
therapy falls under the category of a fixed dose combination. For example, the FDA recognizes that two drugs in separate dosage forms
and in separate packaging, that otherwise might be administered as monotherapy for an indication, also may be used in combination for
the same indication. In 2013, the FDA issued guidance to assist sponsors that were developing the range of combination therapies that
fall outside the category of fixed dose combinations. That guidance provides recommendations and advice on such topics as: (1) assessment
at the outset whether two or more therapies are appropriate for use in combination; (2) guiding principles for nonclinical and clinical
development of the combination; (3) options for regulatory pathways to seek marketing approval of the combination; and (4) post-marketing
safety monitoring and reporting obligations. Given the wide range of potential combination therapy variations, the FDA indicated it intends
to assess each potential combination on a case-by case basis and encouraged sponsors to engage in early and regular consultation with
the relevant review division at the agency throughout the development process for its proposed combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Regulation of Combination Products</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain therapeutic products are comprised of multiple
components, such as drug components, biologic components, and device components, that would normally be subject to different regulatory
frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under
the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product.
The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product.
Thus, if the primary mode of action of drug/biologic-device combination product is attributable to the drug or biological product, the
FDA center responsible for premarket review of the drug or biological product would have primary jurisdiction for the combination product.
The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty
to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry.
It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of
the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination
product with a primary mode of action attributable to the drug or biologic component generally would be reviewed and approved pursuant
to the drug or biologic approval processes set forth in the FDCA. In reviewing the new drug application or BLA for such a product, however,
FDA reviewers would consult with their counterparts in the FDA&#8217;s Center for Devices and Radiological Health to ensure that the device
component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition,
under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality
System Regulation applicable to medical devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Post-Approval Requirements </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any products manufactured or distributed by us pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion
of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product
before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official
lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the
FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s
tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for
distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety,
purity, and potency or effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications
or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the
FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are
required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us
and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of
the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with
cGMPs and other aspects of regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA may withdraw approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes,
or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition
of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>fines, warning letters or holds on post-approval clinical studies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing
product approvals;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>product seizure or detention, or refusal of the FDA to permit the import or export of products;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>mandated modification of promotional materials and labeling and the issuance of corrective information;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other
safety information about the product; or</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>injunctions or the imposition of civil or criminal penalties.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA closely regulates the marketing, labeling,
advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that
are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things,
adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally
available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved
by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment
for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA
does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Biosimilars and Reference Product Exclusivity </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Patient Protection and Affordable Care Act,
as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition
and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that
are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has
issued several guidance documents outlining an approach to review and approval of biosimilars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Biosimilarity, which requires that there be no clinically
meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally
shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar
to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference
product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic
may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy
relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference
biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for
approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with
the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured,
pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. The FDA has
issued guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable
biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA.
In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference
product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference
product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from
adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain
exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221;
by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A reference biologic is granted twelve years of
exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval
pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the
abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there
is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217;
patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within
the 42-month period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A biological product can also obtain pediatric market
exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms.
This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary
completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. The BPCIA is complex
and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development
and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics
and biosimilars. On December 20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar
review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference
product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference
product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the
subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As discussed below, the Inflation Reduction Act
of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Patent Term Extension</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the United States, after a BLA is approved, owners
of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the
patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between,
the latter of the effective date of an IND and issue date of the patent for which extension is sought, and the submission date of a BLA,
plus the time between BLA submission date and the BLA approval date up to a maximum of five years. The time can be shortened if the FDA
determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14
years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only
those claims covering the product, a method for using it, or a method for manufacturing it may be extended and the application for the
extension must be submitted prior to the expiration of the patent in question. However, we may not be granted an extension because of,
for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable
deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but
not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less
stringent and comprehensive than those of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Healthcare Laws and Compliance Requirements </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pharmaceutical companies are subject to additional
healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they
conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False
Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign,
federal and state fraud, abuse and transparency laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The AKS prohibits, among other things, persons and
entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the
referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare
program. The term remuneration has been interpreted broadly to include anything of value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The AKS has been interpreted to apply to arrangements
between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position
that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes
for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS
prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to
be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe
harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.
Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct
per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative
review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent
to violate it in order to have committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Civil and criminal false claims laws, including
the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other
things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds,
including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted
under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal
healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim
for purposes of the FCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">HIPAA created additional federal criminal statutes
that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors,
and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare
fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDCA addresses, among other things, the design,
production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction
into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce
of unlicensed or mislabeled biological products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The U.S. federal Physician Payments Sunshine Act
requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid &amp; Medicare
Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including
physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives,
and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning
on January 1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments
database established under the federal Physician Payments Sunshine Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also subject to federal price reporting laws
and federal consumer protection and unfair competition laws. Federal price reporting laws require manufacturers to calculate and report
complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/ or discounts
on approved products. Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that
potentially harm consumers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also subject to additional similar U.S. state
and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may
not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or
any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative
penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in
other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement,
individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Data Privacy and Security </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Numerous state, federal, and foreign laws govern
the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information.
In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information
privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of
health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as
amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing
regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health
care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain
services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health
information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered
entities and business associates include entering into agreements that require business associates protect PHI provided by the covered
entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure
of a patient&#8217;s past, present, or future physical or mental health or condition or information about a patient&#8217;s receipt of
health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity,
and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably
anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to
individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative
fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective
action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non-compliance. A
covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any
of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH
also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs
associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that
do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, state health information privacy laws,
such as California&#8217;s Confidentiality of Medical Information Act and Washington&#8217;s My Health My Data Act, govern the privacy
and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even when HIPAA and state health information privacy
laws do not apply, according to the FTC and state Attorneys General, violating consumers&#8217; privacy rights or failing to take appropriate
steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation
of Section 5(a) of the Federal Trade Commission Act and state consumer protection laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">In addition, certain state laws, such as the California Consumer Privacy
Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CCPA&#8221;), govern the privacy and security of personal
information, including health-related information in certain circumstances, some of which are more stringent than HIPAA in various ways.
Numerous other states have passed similar laws, but many differ from each other in significant ways and may not have the same effect,
thus complicating compliance efforts. The CCPA applies to personal data of consumers, business representatives, and employees, and imposes
obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords
rights to California residents in relation to their personal information. Health information falls under the CCPA&#8217;s definition of
personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably
be linked, directly or indirectly, with a particular consumer or household - unless it is subject to HIPAA - and is included under a new
category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. The numerous other
comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels, also
exempt some data processed in the context of clinical trials; but others exempt covered entities and business associates subject to HIPAA
altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for us and the third parties upon
whom we rely. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding
the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Failure to comply with these laws, where applicable,
can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations,
and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations,
proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Coverage and Reimbursement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the United States and markets in other countries,
patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage
and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product
acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate
reimbursement for these products and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow it to
establish or maintain pricing sufficient to realize a sufficient return on its investment. Government authorities and third-party payors,
such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement
levels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Significant uncertainty exists as to the coverage
and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if
approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign
government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for
such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage
and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement
exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely
upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval
process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process
that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider
in determining reimbursement are based on whether the product is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.25in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>a covered benefit under its health plan;</td>
  </tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  </tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
  <td>&#9679;</td>
  <td>safe, effective and medically necessary;</td>
  </tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.25in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>cost-effective; and</td>
  </tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  </tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
  <td>&#9679;</td>
  <td>neither experimental nor investigational.</td>
  </tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Third-party payors are increasingly challenging
the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical
or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further
limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party
not to cover a product could reduce physician usage and patient demand for the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For products administered under the supervision
of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated
with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used
may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement
separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to
obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the U.S. government, state legislatures
and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and
reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to
curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices
and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered
under Medicare Part B and Part D that do not have generic or biosimilar competition. On August 29, 2023, HHS announced the list of the
first ten drugs subject to price negotiations. These price negotiations occurred in 2024. In January 2025, CMS announced a list of 15
additional Medicare Part D drugs that will be subject to price negotiations. The IRA also provides a new &#8220;inflation rebate&#8221;
covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation
rebate provision requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare
Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying
biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar
exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price
negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition
remains largely uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, net prices for drugs may be reduced
by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that
presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party
payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged
for medical products. We cannot be sure that reimbursement will be available for any product candidate that we may commercialize and,
if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain
price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics
are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Finally, in some foreign countries, the proposed
pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country
to country. For example, the European Union (&#8220;EU&#8221;) provides options for its member states to restrict the range of medicinal
products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human
use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the
cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for
the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched
in the EU do not follow price structures of the United States and generally prices tend to be significantly lower.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Healthcare Reform</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The United States and some foreign jurisdictions
are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United
States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state
legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical
products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The ACA, which was enacted in March 2010, substantially
changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the
pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries,
including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers
under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual
fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial
and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA
in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage
in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other legislative changes have been proposed and
adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal
year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013
and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the Bipartisan Budget Act of 2018,
among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree
to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible
beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare
Part D.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Moreover, there has recently been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries
and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more
transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the
option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five
of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases
and lower cost therapeutic alternatives, which went into effect on January 1, 2021. In response to the Biden administration&#8217;s October
2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center
which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear
whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration
announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December
8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering
the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding
to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the
new framework.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Notwithstanding the IRA, continued legislative and
enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators
to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship
between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Individual states in the United States have also
become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure
and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls
on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and
prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine
what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could
reduce the ultimate demand for its drugs or put pressure on its drug pricing, which could negatively affect our business, financial condition,
results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Government Regulation Outside of the United States </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to regulations in the United States,
we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials,
testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export
and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as
well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination
risks, their use may be restricted in some countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Whether or not we obtain FDA approval for a product,
we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or
marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission
of a clinical trial application much like the IND prior to the commencement of human clinical trials. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The requirements and process governing the conduct
of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization
requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country
to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the
regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval
varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review
period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may
not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Regulation in the European Union </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>European Data Laws </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The collection and use of personal health data and
other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;),
which came into force in May 2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict
obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals,
in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to
the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to
the individuals prior to processing their personal data, the personal data breaches which may have to be notified to the national data
protection authorities and data subjects, the measures to be taken when engaging processors, and the security and confidentiality of the
personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their
national legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the GDPR imposes specific restrictions
on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the
European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable
such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;).
When relying on SCCs, data exporters are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices
of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and
adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential
equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. With regard
to the transfer of data from the EEA to the United States, on July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy
Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework.
With regard to the transfer of data from the EU to the United Kingdom (&#8220;UK&#8221;), personal data may freely flow from the EEA to
the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8216;sunset clause&#8217;
which entails that the decisions will automatically expire four years after their entry into force, unless renewed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Failure to comply with the requirements of the GDPR
and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up
to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties
and a number of criminal offenses for organizations and, in certain cases, their directors and officers, as well as civil liability claims
from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement
certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and
guidelines, which adds to the complexity of processing personal data in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, there are specific requirements relating
to processing health data from clinical trials, including public disclosure obligations provided in the EU Clinical Trials Regulation
No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry.
Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our
reputation, and adversely impact our business and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, following the UK&#8217;s withdrawal
from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined in
section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018 (the &#8220;DPA 2018&#8221;)), the DPA 2018, and related
data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to
the greater of &#163;17.5 million or 4% of global turnover. Companies are subject to specific transfer rules under the UK regime, which
broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer
agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international
data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022
and replaced the old SCCs for the purposes of the UK regime. Regarding transfers from the UK to the EEA, personal data may flow freely
since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. With regard to the transfer of personal
data from the UK to the United States, the UK government has adopted an adequacy decision for the United States, the UK-US Data Bridge,
which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection
where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Drug and Biologic Development Process </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regardless of where they are conducted, all
clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been
carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical
trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those
set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical
trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive
2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials
for medicinal products in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the former regime, which will expire
after a transition period of three years as outlined below in more detail, before a clinical trial can be initiated it must be approved
in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate
entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. The NCA of the EU Member States in which
the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive
opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial
changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by
the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated
drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A more unified procedure will apply under the new
CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal
(the Clinical Trials Information System or &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed
by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned
EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval
is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited
circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such member state.
The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as
mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period. EU
Member States will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission of initial clinical trial
applications via CTIS is mandatory and CTIS serves as the single entry point for submission of clinical trial-related information and
data. By January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and
have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning the steps to be taken in this transition. This
guidance provides, among other things, that (i) documentation which was previously assessed will not be reassessed, (ii) templates that
were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)
there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under both the former regime and the new CTR, national
laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International
Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical
principles that have their origin in the Declaration of Helsinki.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the development of a medicinal product, the
EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level,
this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;)
on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly
reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality
(chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management
programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product
concerned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Drug Marketing Authorization </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EEA, after completion of all required clinical
testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain a MA of a drug under EU regulatory systems,
an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To be used or sold in the UK, a drug must have an
effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human
Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency
(&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210 days, excluding time
taken to provide any additional information or data required by the MHRA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 30, 2023, the MHRA published detailed
guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January 1,
2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada,
Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to
undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Applicants can submit initial MAAs to the IRP but
the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations
and renewals. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Centralized Authorization Procedure </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The centralized procedure provides for the grant
of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member
States as well as in the three additional EEA Member States (Norway, Iceland and Liechtenstein). The centralized procedure is compulsory
for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated
as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) (gene therapy, somatic cell therapy or tissue engineered
medicines) and medicinal products with a new active substance indicated for the treatment of certain diseases (HIV/AIDS, cancer, neurodegenerative
disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the
EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic,
scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public
health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the centralized procedure, the CHMP established
at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization
and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure,
the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this
timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions
asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment.
Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public
health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150
days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding
the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which
has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Decentralized Authorization Procedure </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Medicines that fall outside the mandatory scope
of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern
a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)
they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member
state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized
in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual
recognition procedure).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The decentralized procedure permits companies to
file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such
medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products
not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference
member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member
States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The
only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk
to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision
is binding for all EU Member States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risk Management Plan </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All new MAAs must include a Risk Management Plan
(&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize
the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information
becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national competent authority, or (ii) whenever the
risk-management system is modified, especially as the result of new information being received that may lead to a significant change to
the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory
authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products
are published by the EMA, subject only to limited redactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>MA Validity Period </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">MAs have an initial duration of five years. After
these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed,
the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance,
to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the
five-year period expires.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any authorization which is not followed by the actual
placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three
years after authorization ceases to be valid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the UK, the period of three years during which
the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Conversion refers
to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern
Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great
Britain only.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On the other hand, for the EU, in the case the drug
has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January 31,
2020 and ending on December 31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the
Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three-year period will start
running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Advanced Therapy Medicinal Products </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, medicinal products, including ATMPs are
subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene
therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone
substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair
or replace a human tissue. Pursuant to the Regulation (EC) No 1394/2007, the Committee for Advanced Therapies (&#8220;CAT&#8221;) is responsible
in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These
guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs
and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding,
compliance with them is often necessary to gain and maintain approval for product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the mandatory RMP, the holder of
a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including
all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging,
storage, transport and delivery to the relevant healthcare institution where the product is used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exceptional Circumstances/Conditional Approval</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Similar to accelerated approval regulations in the
United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products
where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number
of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it is likely that the applicant will be in a
position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled by the grant of the MA and (iv) the benefit
to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact
that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfil specific obligations within
defined timelines. A conditional MA is valid for one year and must be renewed annually, but it can be converted into a standard MA once
the MA holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its
risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Data and Market Exclusivity </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As in the United States, it may be possible to obtain
a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s
generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant
from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting
an application, obtaining MA or placing the product on the market. Innovative medicinal products, referred to as New Chemical Entities
(&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An additional non-cumulative one-year period of
marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period),
the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit
compared to existing therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The data exclusivity period begins on the date of
the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely
on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first
MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product)
if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally,
another non-cumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is
made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out
in relation to the new indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Another year of data exclusivity may be added to
the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial
tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the
same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was
authorized).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Products may not be granted data exclusivity since
there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE. Even if a compound
is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless
could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of
pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 26, 2023, the EC submitted a proposal for
the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity,
however, there is currently neither a final version of this draft nor a date for its entry into force. While the European Parliament adopted
its approving position on the reform on April 10, 2024, no further required legislative steps have been taken since.&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Pediatric Development </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, companies developing a new medicinal
product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the
EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric
clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness
and safety in adults is available) or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by
the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information
collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials
may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in
accordance with the approved PIP are eligible for a six-month extension of the protection under a supplementary protection certificate
(if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two-year extension of the orphan market
exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the
approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form
or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the UK, the MHRA has published guidance on the
procedures for UK Paediatric Investigation Plans (&#8220;PIPs&#8221;) which, where possible, mirror the submission format and requirements
of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted
as UK PIPs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Post-Approval Regulation </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Similar to the United States, both MA holders and
manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory
authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes
control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements
governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Failure by us or by any of our third-party partners,
including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States
governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before
and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result
in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials
or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension
of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and
criminal penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The holder of an MA for a medicinal product must
also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting
pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These pharmacovigilance rules can impose on holders
of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products
and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies
or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management
measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance
system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations
include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;)
in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized
procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing
MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization
Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to
fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">More generally, non-compliance with pharmacovigilance
obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other
enforcement measures.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The manufacturing process for pharmaceutical products
in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.
Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements
set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC (repealed by Directive
2017/1572 on January 31, 2022), Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;).
These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients,
including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical
ingredients into the EU. Amendments or replacements of at least Directive 2001/83/EC and Regulation (EC) No 726/2004 are part of the reform
proposal for European pharmaceutical legislation. Similarly, the distribution of pharmaceutical products into and within the EU is subject
to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for
distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who
is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for
commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the
competent authorities for compliance with GMP.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Sales and Marketing Regulations </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The advertising and promotion of our products is
also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising
and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and
promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising
in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is
the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic
and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is
considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved
SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited
in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures,
fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and
may also impose limitations on its promotional activities with healthcare professionals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">EU regulation with regards to dispensing, sale and
purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However,
organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common
logo no longer apply to UK-based online sellers, except for those established in Northern Ireland.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Anti-Corruption Legislation </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, interactions between pharmaceutical companies
and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of
professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to
induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited
in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States.
Violation of these laws could result in substantial fines and imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Payments made to physicians in certain EU Member
States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval
by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU
Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the
individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative
penalties, fines or imprisonment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the UK, the pharmaceutical sector is recognized
as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery
Act 2010&#8217;s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its
scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried
out there and the person has a close connection with the UK, an offense will still have been committed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Bribery Act 2010 is comprised of four offenses
that cover (i) individuals, companies and partnerships that give, promise or offer bribes, (ii) individuals, companies and partnerships
that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships that bribe foreign public officials, and
(iv) companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the
Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a
maximum term of ten years and in some cases both.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Regulations in the UK and Other Markets </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The UK formally left the EU on January 31, 2020
and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as
amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and
the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life sciences sector (including
on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections
of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition
of UK and EU pharmaceutical regulations and product standards.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The UK government has adopted the Medicines and
Medical Devices Act 2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s
departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials
of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and
medical devices in the UK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For other countries outside of the EU, such as countries
in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we fail to comply with applicable foreign regulatory
requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were formed as a Delaware corporation in 1992
under the name &#8220;Nuvelo, Inc.&#8221; and subsequently, in 2009, we completed a business combination with ARCA biopharma, Inc. On
August 29, 2024, we completed the Merger with Pre-Merger Oruka and changed our name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka
Therapeutics, Inc.&#8221; Our corporate headquarters are located at 855 Oak Grove Avenue, Suite 100, Menlo Park, California 94025. The
telephone number at our corporate headquarters is (650) 606-7910. Our corporate website address is <i>www.orukatx.com</i>. We do not incorporate
information contained on, or accessible through, our website into this prospectus, and you should not consider it part of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees and Human Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and as of February 28, 2025,
we had 28 full-time employees and 36 full-time employees, respectively. We also engage temporary employees and consultants to augment
our existing workforce. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We
consider our relationship with our employees to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recognize that attracting, motivating, and retaining
talent at all levels is vital to continuing our success. We invest in our employees through high-quality benefits, professional development
opportunities, and various health and wellness initiatives and offer competitive compensation packages (base salary and incentive plans),
ensuring fairness in internal compensation practices. The principal purposes of our incentive plans (bonus and equity) are to align with
the long-term interests of our stakeholders and stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Executive Officers and Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the names, ages as
of March 6, 2025, and positions of the individuals who currently serve as executive officers and directors of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; width: 35%; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding: 0.75pt 0.75pt 1.5pt 6.85pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 6%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 57%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt"><i>Executive Officers and Employee Director</i></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Lawrence Klein, Ph.D.</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">42</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">President, Chief Executive Officer and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Arjun Agarwal</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">49</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Senior Vice President, Finance and Treasurer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Joana Goncalves, MBChB</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">51</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Chief Medical Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Paul Quinlan</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">62</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">General Counsel and Corporate Secretary</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt"><i>Non-Employee Directors</i></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Samarth Kulkarni, Ph.D.<sup>(2)(3)</sup></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">46</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Chair and Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Kristine Ball<sup>(1)(3)</sup></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">53</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Carl Dambkowski, M.D.<sup>(1)</sup></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">40</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Peter Harwin<sup>(2)(3)</sup></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">39</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Cameron Turtle, D.Phil.<sup>(1)(2)</sup></span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-size: 10pt">35</span></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt">&#160;</td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Member of the Audit Committee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Member of the Compensation Committee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Member of the Nominating and Governance Committee (the &#8220;Governance Committee&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business affairs are managed under the direction
of our Board, which currently consists of six members. Our Board is divided into three classes, with members of each class holding office
for staggered three-year terms. There are currently two Class I directors, who are up for election at the 2025 Annual Meeting of Stockholders
for a term expiring at the 2028 Annual Meeting of Stockholders; two Class II directors, whose terms expire at the 2026 Annual Meeting
of Stockholders; and two Class III directors, whose terms expire at the 2027 Annual Meeting of Stockholders. Each executive officer serves
at the discretion of the of the Board and holds office until their successor is duly appointed and qualified or until their earlier resignation
or removal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Biographical and other information regarding our
executive officers and directors is set forth below. There are no family relationships among any of our executive officers or directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Executive Officers and Employee Director</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Lawrence Klein, Ph.D.</i></b> Dr.&#160;Klein
has served as Chief Executive Officer and as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger
Oruka from February 2024 through the Merger Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Klein was a Partner at Versant Venture
Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested
in and helped to grow early-stage&#160;biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR
Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022,
Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017
to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute
on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led
several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp;
Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board
of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq:
JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of
Wisconsin-Madison&#160;and his Ph.D. in biophysics from Stanford University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Dr. Klein is qualified to serve as a
member of the Board because of his business development, operational and senior management experience in the biotechnology industry and
his academic expertise and accomplishments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Joana Goncalves, MBChB.</i></b> Dr.&#160;Goncalves
has served as the Chief Medical Officer of the Company since the Merger Closing and of Pre-Merger Oruka from April&#160;2024 through the
Merger Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq:
CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics
in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional
terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions
at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol-Myers&#160;Squibb Company, from April&#160;2014
to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental
in planning and executing medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene,
Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO
Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She
began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001
to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Paul Quinlan.</i></b> Mr.&#160;Quinlan has
served as General Counsel and Corporate Secretary of the Company since the Merger Closing and of Pre-Merger Oruka since April&#160;2024
through the Merger Closing. Prior to joining Pre-Merger Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and
Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was
responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020, he served
as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s legal
affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer
from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision
of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical
company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical
company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan
received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Arjun Agarwal.</i></b>&#160;Mr.&#160;Agarwal
has served as the Senior Vice President of Finance of the Company since the Merger Closing and of Pre-Merger Oruka from March&#160;2024
through the Merger Closing, where he is responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining
Pre-Merger Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from
June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition to become a publicly
traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc.
(Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s
finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility
at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal
worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce
and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute
of Chartered Accountants of India.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Non-Employee Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Samarth Kulkarni, Ph.D.</i></b> Dr.&#160;Kulkarni
has served as Chair and a member of the board of directors of the Company since the Merger Closing and as a member of the board of directors
of Pre-Merger Oruka from February&#160;2024 through the Merger Closing. Dr.&#160;Kulkarni has served as the Chief Executive Officer of
CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and
chair of the board of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s
President and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior
to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with
various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served
as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), Repare Therapeutics Inc. (Nasdaq: RPTX), and
Centessa Pharmaceuticals plc (Nasdaq: CNTA). Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University
of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading
scientific and business journals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that Dr. Kulkarni is qualified to serve
as a member of the Board because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic
expertise and accomplishments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Kristine Ball.</i></b> Ms. Ball has served
as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger Oruka since May&#160;2024 through the
Merger Closing. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical
company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private
biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President,
Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listed&#160;biopharmaceutical company, which later
became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non-R&amp;D
functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology.
Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq-listed&#160;pharmaceutical
company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various
other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial
Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology
company. Prior to that, Ms. Ball served as a senior manager in the life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball
has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria
from 2020 to 2022 and Forty Seven, Inc. (Nasdaq: FTSV), a Nasdaq-listed&#160;biotechnology company, which was acquired by Gilead Sciences,
Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Ms. Ball is qualified to serve as a member
of the Board because of her experience as an executive officer and director of life sciences companies and her background in finance,
corporate development and strategic planning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Carl Dambkowski, M.D.</i></b> Dr.&#160;Dambkowski
has served as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger Oruka from February&#160;2024
through the Merger Closing. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a
biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader
for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021
to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018
to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022,
where he served as the clinical lead starting prior to IND for BBP-398&#160;through the out licensing of the compound to Bristol-Myers&#160;Squibb
based on initial clinical data and for low-dose&#160;infigratinib in achondroplasia through initial proof-of-concept&#160;data. He was
part of the core team that brought TRUSELTIQ&#174;&#160;(infigratinib) and NULIBRY&#174;&#160;(fosdenopterin) through regulatory review
and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski
was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and pharmaceutical companies
across the world on a range of research and development activities. Dr.&#160;Dambkowski co-founded&#160;Novonate, Inc., a private medical
device company focused on building life-saving&#160;devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski has coauthored numerous
peer-reviewed&#160;publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.&#160;Dambkowski
was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received
a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Dr. Dambkowski is qualified to serve
as a member of the Board because of his significant experience and innovations in the biotechnology industry and his academic expertise
and accomplishments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Peter Harwin.</i></b> Mr.&#160;Harwin has
served as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger Oruka from February&#160;2024 through
the Merger Closing. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co-founded&#160;in
April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment
fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent
Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics,
Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A.
from Emory University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Mr. Harwin is qualified to serve as a
member of the Board because of his experience serving as a director of biotechnology companies and as a manager of funds specializing
in the area of life sciences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Cameron Turtle, D.Phil.</i></b> Dr.&#160;Turtle
has served as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger Oruka from February&#160;2024
through the Merger Closing. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics,
Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief
Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics,
Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs,
a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology
company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical
company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational
functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was
a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device
companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received
his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University
of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes
30 Under&#160;30, San Francisco Business Times 40 Under&#160;40, and the Biocom Life Sciences Catalyst Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe Dr. Turtle is qualified to serve as a
member of the Board because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical
development to late-stage clinical trials and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have adopted a Code of Business Conduct and Ethics
that establishes the standards of ethical conduct applicable to all our directors, officers and employees, including our principal executive
officer, principal financial officer and principal accounting officer, or persons performing similar functions. It addresses, among other
matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications,
confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. A copy of the code is available
on our website located at&#160;https://ir.oruka.com/corporate-governance&#160;under &#8220;Governance Documents.&#8221; We intend to disclose
any amendments to the code, or any waivers of its requirements, on our website to the extent required by applicable rules. The Audit Committee
is responsible for applying and interpreting the code in situations where questions are presented to it. Information contained on, or
that can be accessed through, the Company&#8217;s website is not incorporated by reference into this report, and you should not consider
information on the Company&#8217;s website to be part of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Insider Trading Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have adopted insider trading policies and procedures
governing the purchase, sale and other transactions in Company securities by our directors, officers and employees, and other covered
persons, as well as the Company itself, that we believe are reasonably designed to promote compliance with insider trading laws, rules
and regulations, and Nasdaq Stock Market (&#8220;Nasdaq&#8221;) listing rules, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As part of these policies and procedures, we prohibit
any employee, director or other covered person from engaging in short sales, transactions involving publicly traded options or other derivative
securities based on the Company&#8217;s securities, hedging transactions, margin accounts, pledges, or other inherently speculative transactions
with respect to the Company&#8217;s securities at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Audit Committee and Audit Committee Financial
Expert</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a separately designated standing Audit Committee.
The members of our Audit Committee are Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an &#8220;independent&#8221;
director for audit committee purposes as defined under Nasdaq listing rules and the rules and regulations established by the SEC. Ms.
Ball chairs the Audit Committee and qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined under the rules
and regulations established by the SEC, and all members of the Audit Committee are financially literate under Nasdaq listing rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Delinquent Section 16(a) Reports</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section 16(a) of the Exchange Act requires our directors,
officers and persons who beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial reports
of ownership and reports of changes in ownership of our common stock and other equity securities. To our knowledge, based solely on our
review of Forms 3, 4 and 5 filed with the SEC or written representations that no Form 5 was required, during the year ended December 31,
2024, we believe that all of our directors, officers and persons who beneficially own more than 10% of a registered class of our equity
securities timely filed all reports required under Section 16(a) of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Stockholder Proposals and Director Nominations
for 2025 Annual Meeting of Stockholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will hold our 2025 Annual Meeting of Stockholders
(the &#8220;Annual Meeting&#8221;) on Monday, June 2, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Rule&#160;14a-8&#160;of the Exchange
Act, stockholders who wish to submit proposals for inclusion in the proxy statement for the Annual Meeting must send such proposals to
our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025. Such proposals must be received by us a
reasonable time before we begin to print and mail our proxy materials and must comply with Rule 14a-8 of the Exchange Act. The submission
of a stockholder proposal does not guarantee that it will be included in the proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 29, 2024, in connection with the Merger
Closing, the Board adopted an amendment and restatement of our Bylaws, effective as of such date, as described in our Current Report on
Form 8-K filed on September 5, 2024. As set forth in our Bylaws, if a stockholder intends to make a nomination for director election or
present a proposal for other business (other than pursuant to Rule&#160;14a-8&#160;of the Exchange Act) at the Annual Meeting, the stockholder&#8217;s
notice must be received by our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025 no earlier than
the 120th&#160;day and no later than the close of business on the 90th day before the anniversary of the last annual meeting; provided,
however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, the stockholder&#8217;s
notice must be delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close
of business on the later of the 90th day prior to such annual meeting or the 10th day following the date on which the first public announcement
of the date of such annual meeting is made by the Company. Therefore, notice of proposed nominations or proposals (other than pursuant
to Rule&#160;14a-8&#160;of the Exchange Act) must be received by our Corporate Secretary no later than the close of business on March
16, 2025. Any such director nomination or stockholder proposal must be a proper matter for stockholder action and must comply with the
terms and conditions set forth in our Bylaws (which includes the timing and information required under Rule&#160;14a-19 of the Exchange
Act). If a stockholder fails to meet these deadlines or fails to satisfy the requirements of Rule 14a-4 of the Exchange Act, we may exercise
discretionary voting authority under proxies we solicit to vote on any such proposal as we determine appropriate. We reserve the right
to reject, rule out of order or take other appropriate action with respect to any nomination or proposal that does not comply with these
and other applicable requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">This section provides information
regarding the compensation of our principal executive officer (Dr.&#160;Klein), and our two other highest paid executive officers who
were serving as executive officers on December&#160;31, 2024 (Dr. Goncalves and Mr. Quinlan). This section also includes compensation
information for certain former executives of the Company (then known as ARCA). The individuals listed below are collectively referred
to herein as the &#8220;NEOs&#8221; or &#8220;Named Executive Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 28%; font-weight: bold">Name</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 71%; font-weight: bold">Title</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lawrence Klein, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Executive Officer<sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Joana Goncalves, MBChB</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Chief Medical Officer<sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paul Quinlan</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">General Counsel and Corporate Secretary<sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Michael Bristow, M.D.</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Former President and Chief Executive Officer<sup>(2)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas A. Keuer</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Former President and Chief Operating Officer<sup>(3)</sup></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">C. Jeffrey Dekker</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Former Chief Financial Officer<sup>(3)</sup></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Drs. Klein and Goncalves and Mr. Quinlan were appointed to these positions in connection with the consummation of the Merger. Prior to the Merger, they each served in these positions at Pre-Merger Oruka.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Dr. Bristow&#8217;s employment with the Company terminated on April 3, 2024. Following his termination, Dr. Bristow provided transition services as a consultant.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Mr. Keuer&#8217;s and Mr. Dekker&#8217;s employment with the Company terminated in connection with the Merger. Following the Merger, Mr. Dekker provided transition services as a consultant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>A Year of Transition </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">2024 was a year of transition
for the Company as we completed the Merger, shifted our drug candidate pipeline to focus on novel biologics designed to set a new standard
for the treatment of chronic skin diseases and transformed our management team. Our mission is to offer patients suffering from chronic
skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance
with dosing as infrequently as once or twice per year. The compensation described below reflects both compensatory decisions necessary
to engage a new leadership team that is critical to lead the advancement of the Company&#8217;s pipeline of novel biologics and improve
the standard of care for the treatment of chronic skin diseases and compensatory decisions made by ARCA prior to the consummation of the
Merger with respect to the former executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>2024 Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The following table shows information
regarding the compensation earned by the NEOs during the fiscal years ending December&#160;31, 2024 and 2023, by our named executive officers.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Name and Principal Position<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Salary<br/> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Bonus<br/> ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Option Awards</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)<sup>(4)</sup></b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Non-Equity<br/> Incentive Plan<br/> Compensation<br/> ($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Lawrence Klein, Ph.D.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 7%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">203,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">317,623</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">520,911</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Joana Goncalves, MBChB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,986</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paul Quinlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">General Counsel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Michael Bristow, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,875</td><td style="padding-bottom: 6pt; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">510,416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former President and Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas A. Keuer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235,385</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,651</td><td style="padding-bottom: 6pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853,520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Former President and Chief Operating Officer</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: center">2023</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">340,000</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">&#8212;</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">&#8212;</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">&#8212;</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">60,802</td><td style="vertical-align: top; text-align: right">&#160;</td><td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td><td style="vertical-align: top; text-align: right">400,802</td><td style="vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">C. Jeffrey Dekker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,734</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">756,604</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Former Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,072</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The amounts reflected herein for Drs. Klein and Goncalves and Mr. Quinlan do not include any compensation they received from Pre-Merger Oruka prior to the Merger.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes $157,595 of consulting fees for Dr. Bristow and $20,000 of consulting fees for Mr. Keuer, in each case, pursuant to their respective consulting agreements as described in more detail under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Amounts reported in this column represent retention bonuses, as described in more detail under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Amounts reported in this column represent the incremental fair value under Accounting Standards Codification Topic 718 (&#8220;ASC 718&#8221;) resulting from the acceleration of the Named Executive Officer&#8217;s stock options in the Merger, as described in more detail under &#8220;Narrative to Summary Compensation Table&#8212;ARCA Arrangements&#8221; below.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Amounts reported in this column represent the annual bonuses earned under the 2024 annual bonus program, as described in more detail under &#8220;<i>Narrative to Summary Compensation Table&#8212;Elements of Compensation&#8212;Annual Bonus Program</i>&#8221; below.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes $3,875 of Company contributions under the ARCA 401(k) plan and $370,000 of severance payments and benefits, as described in more detail under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes $16,800 of Company contributions under the ARCA 401(k) plan, $340,000 of severance payments and $69,715 in COBRA continuation premiums, as described in more detail under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below, and $4,136 for group term life insurance premiums.</span></td></tr>
  </table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes $14,687 of Company contributions under the ARCA 401(k) plan, $270,000 of severance payments and $69,715 in COBRA continuation premiums, as described in more detail under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below, $2,692 for group term life insurance premiums and $2,640 for healthcare reimbursements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Narrative Disclosure to Summary Compensation
Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In December 2024, our Compensation
Committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under this philosophy, compensation
positioning is used to attract and retain key employees for the Company&#8217;s continued success and growth. While market data is helpful
to the Compensation Committee in setting compensation framework and guiding decisions, other factors such as Company strategy, stockholder
feedback, tenure, performance and criticality are also considered. The compensation philosophy serves as the foundation to reinforce the
Company&#8217;s business strategy and desired culture, while balancing internal and external alignment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Peer Group</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In July 2024, Pre-Merger Oruka,
in consultation with Alpine, the Compensation Committee&#8217;s independent compensation consultant, established a peer group that focuses
on U.S.-based, pre-clinical or early clinical biopharma companies (with priority placed on companies with a similar therapeutic focus)
with a market capitalization ranging from $250 million to $2 billion and less than 100 employees. The peer group, which was used in making
compensation decisions in connection with establishing post-Merger executive compensation for 2024, includes the following companies (the
&#8220;Peer Group&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="width: 33%; text-align: left">Apogee Therapeutics</td><td style="width: 1%">&#160;</td>
    <td style="width: 33%; text-align: left">Astria Therapeutics</td><td style="width: 1%">&#160;</td>
    <td style="width: 32%; text-align: left">Cabaletta Bio</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CARGO Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Celldex Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Contineum Therapeutics</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Entrada Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Janux Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Kymera Therapeutics</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Kyverna Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Lexeo Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Longboard Pharmaceuticals</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lyell Immunopharma</td><td>&#160;</td>
    <td style="text-align: left">Pliant Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Prime Medicine</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Spyre Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Structure Therapeutics</td><td>&#160;</td>
    <td style="text-align: left">Third Harmonic Bio</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Elements of Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Base Salaries</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our Compensation Committee
recognizes the importance of base salary as an element of compensation to provide our executive officers with steady cash flow during
the year that is not contingent on short-term variations in our corporate performance. The setting of base salaries also includes an evaluation
of each individual&#8217;s job duties, responsibilities, performance and experience, as well as internal pay equity among the executive
officer team. The Compensation Committee reviews base salaries at least annually and may recommend adjustment from time to time based
on the results of that review. The Compensation Committee determines salary increases using a combination of relevant competitive market
data, scope of responsibilities and assessment of individual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">For 2024, the annual base salaries
of Drs. Klein and Goncalves and Mr. Quinlan were established in connection with the consummation of their employment with Pre-Merger Oruka
as a result of negotiations in the context of a competitive recruitment process. The annual base salaries as of December 31, 2024 for
each of our continuing NEOs were as follows: $600,000 for Dr. Klein and $460,000 for each of Dr. Goncalves and Mr. Quinlan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Annual Bonus Program</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">We have an annual cash incentive
plan under which cash incentives may be paid to each of our employees, including our executive officers, after the end of each calendar
year. The Compensation Committee generally determines target bonuses based on Peer Group practices and each individual&#8217;s job duties.
For 2024, the target bonuses for each NEO (excluding the former ARCA executive officers), which were established by Pre-Merger Oruka in
connection with the consummation of their employment with Pre-Merger Oruka, were as follows: 50% of base salary for Dr. Klein and 40%
of base salary for each of Dr. Goncalves and Mr. Quinlan, in each case, pro-rated based on their respective start dates with Pre-Merger
Oruka.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Pre-Merger Oruka established
the corporate goals and targets for the 2024 bonus program, which were heavily weighted towards the preclinical development of ORKA-001
and ORKA-002, progress towards the commencement of their respective Phase 1 clinical studies and regulatory progress. In addition, the
corporate goals included measures designed to ensure adequate funding for the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The Board, upon the recommendation
of the Compensation Committee, reviewed our achievement against our 2024 corporate goals and determined the achievement to have been 125%
of target, based on the achievement of substantially all the goals, with overperformance on several of the goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Based on our corporate performance,
the 2024 annual bonuses awarded to our continuing NEOs were as follows: $317,623 for Dr. Klein, $162,132 for Dr. Goncalves and $154,591
for Mr. Quinlan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Long-Term Incentives</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">We intend our equity incentive
program to reward longer-term performance and to align the interests of our executive officers with those of our stockholders. We also
believe that our equity incentive program, which currently consists predominantly of time-based stock options (or, for certain grants
by Pre-Merger Oruka, time-based compensatory warrants), is an important retention tool for our employees, including our NEOs. The Compensation
Committee believes that stock options, which require increased stock price performance for value realization, create a key connection
between the interests of the NEOs and stockholders. Each of the grants described below are presented after giving effect to the share
conversion completed in the Merger and the subsequent 1-for-12 reverse stock split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection with his appointment
as Chief Executive Officer of Pre-Merger Oruka, Dr. Klein purchased 852,338 shares of restricted stock at fair market value, which vests
as to 25% on February 26, 2025 and in equal monthly installments thereafter through February 26, 2028. In accordance with the anti-dilution
provisions of his offer letter, as described in more detail below, on July 15, 2024, Dr. Klein received a compensatory warrant to purchase
1,628,513 shares of our common stock, which vests as to 25% on April 3, 2025 and in equal monthly installments thereafter through April
3, 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection with her appointment
as Chief Medical Officer of Pre-Merger Oruka, Dr. Goncalves was granted stock options to purchase 228,563 shares of our common stock,
which vests as to 25% on April 18, 2025 and in equal monthly installments thereafter through April 18, 2028. On July 15, 2024, Dr. Goncalves
was granted a compensatory warrant to purchase 199,992 shares of our common stock, which vests on the same schedule as her initial stock
option grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection with his appointment
as General Counsel of Pre-Merger Oruka, Mr. Quinlan was granted stock options to purchase 228,563 shares of our common stock, which vests
as to 25% on April 30, 2025 and in equal monthly installments thereafter through April 30, 2028. On July 15, 2024, Mr. Quinlan was granted
a compensatory warrant to purchase 99,996 shares of our common stock, which vests on the same schedule as his initial stock option grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">None of the former ARCA executive
officers received grants of equity incentive awards during 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Offer Letters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection with their appointments,
we entered into offer letters with each of Dr. Klein, Dr. Goncalves and Mr. Quinlan, each of which was amended and restated as of October
3, 2024 (for Dr. Klein) or October 1, 2024 (for Dr. Goncalves and Mr. Quinlan) following the Merger (collectively, the &#8220;Offer Letters&#8221;).
The Offer Letters provided for each NEO&#8217;s initial base salary, target annual bonus and initial equity incentive award. The Offer
Letter with Dr. Klein also provided for periodic grants of stock options sufficient to maintain Dr.&#160;Klein&#8217;s ownership at approximately
5% on a fully-diluted&#160;basis until Oruka raised an aggregate of $200 million in financing, which obligations were fully satisfied
prior to the consummation of the Merger through the warrant issued on July 15, 2024. The Offer Letter with Dr. Goncalves also provided
for a sign-on bonus of $100,000, which is subject to repayment in the event of a termination for cause or resignation without good reason
prior to April 18, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Under the Offer Letters, the
NEOs are eligible for certain payments or benefits upon certain terminations of employment, as described under &#8220;Additional Narrative
Disclosure&#8212;Potential Payments Upon Termination or Change in Control&#8221; below. Each of Dr. Klein, Dr. Goncalves and Mr. Quinlan
is also party to our standard employee invention assignment, confidentiality and non-competition agreement, which, among other things,
provides standard protections regarding our ownership of intellectual property, the confidentiality of our proprietary information, non-competition
and non-solicitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>ARCA Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><i>Michael Bristow, M.D.</i>
Dr.&#160;Bristow served as the Company&#8217;s President and Chief Executive Officer through April 3, 2024. In connection with his separation,
the Company (then known as ARCA) and Dr.&#160;Bristow entered into a separation agreement pursuant to which Dr. Bristow provided a release
of claims in favor of the Company and the Company paid Dr.&#160;Bristow a lump sum severance payment of $370,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The Company and Dr.&#160;Bristow
also entered into a consulting agreement, effective April&#160;3, 2024, pursuant to which Dr.&#160;Bristow provided certain consulting
services to the Company through the Merger. Under the consulting agreement, Dr.&#160;Bristow continued to vest in his outstanding equity
awards during the consulting term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><i>Thomas A.&#160;Keuer and
C. Jeffrey Dekker.</i> Mr.&#160;Keuer served as the Company&#8217;s President and Chief Operating Officer and Mr. Dekker served as the
Company&#8217;s Chief Financial Officer, in each case, through the consummation of the Merger. Pursuant to retention bonus letters approved
by the ARCA Compensation Committee prior to the Merger, each of Messrs. Keuer and Dekker were paid a retention bonus upon consummation
of the Merger of $165,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As a result of the Merger and
the accompanying termination of their employment, the Company and each of Mr. Keuer and Mr. Dekker entered into a separation agreement,
pursuant to which Mr. Keuer and Mr. Dekker each provided a release of claims in favor of the Company and the Company provided the following
severance payments and benefits, in accordance with the terms of their employment agreement: (i) a lump sum cash severance payment equal
to 12 months of their respective annual base salary ($340,000 and $270,000, respectively) and (ii) a lump sum cash payment of $69,715
in lieu of 12 months of group health plan continuation premiums.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><i>Treatment of ARCA Equity
Awards.</i> In connection with the Merger, all outstanding ARCA stock options held by the NEOs were accelerated and cashed out for an
amount equal to the difference between $3.9489 and the applicable per share exercise price; however, any ARCA stock options having an
exercise price in excess of $3.9489 were cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Outstanding Equity Awards at Fiscal Year
End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The following table presents
information regarding outstanding stock options, compensatory warrants and restricted stock held by each NEO as of December&#160;31, 2024.
The equity awards reflected below give effect to the share conversion completed in the Merger and the subsequent 1-for-12 reverse stock
split. None of the former ARCA executive officers held any outstanding equity awards as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Option Awards</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Stock Awards</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Exercisable</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Unexercisable</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Option<br/> Exercise Price<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Option Expiration<br/> Date</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number of<br/> Shares or<br/> Units of Stock <br/> That Have Not<br/> Vested <br/> (#)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Market Value<br/> of Shares or<br/> Units of Stock<br/> That Have Not<br/> Vested<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Lawrence Klein, Ph.D.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,628,513</td><td style="padding-bottom: 6pt; width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7/14/2034</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">852,338</td><td style="padding-bottom: 6pt; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,526,834</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Joana Goncalves, MBChB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,563</td><td style="padding-bottom: 6pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10/30/2034</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,992</td><td style="padding-bottom: 6pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">7/14/2034</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paul Quinlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,563</td><td style="padding-bottom: 6pt; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10/30/2034</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,996</td><td style="padding-bottom: 6pt; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">7/14/2034</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Michael Bristow, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas A. Keuer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">C. Jeffrey Dekker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The market value was determined by multiplying the numbers of shares by $19.39, the closing price of our common stock on December 31, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">These compensatory warrants vest as to 25% on April 3, 2025 and in equal monthly installments thereafter through April 3, 2028, subject to Dr. Klein&#8217;s continued services to us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">These restricted shares vest as to 25% on February 26, 2025 and in equal monthly installments thereafter through February 26, 2028, subject to Dr. Klein&#8217;s continued services to us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">These stock options and compensatory warrants vest as to 25% on April 18, 2025 and in equal monthly installments thereafter through April 18, 2028, subject to Dr. Goncalves&#8217; continued services to us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">These stock options and compensatory warrants vest as to 25% on April 30, 2025 and in equal monthly installments thereafter through April 30, 2028, subject to Mr. Quinlan&#8217;s continued services to us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Additional Narrative Disclosures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Employee Benefits and Perquisites</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our NEOs are eligible to participate
in our employee benefit plans, including our health and welfare plans, term life insurance, disability insurance and a 401(k) plan, in
each case on the same basis as all our other employees. During 2024, following the Merger, we did not provide any Company contributions
under the 401(k) plan; however, in 2025, the Company will make matching contributions of 100% of the first 3% of eligible compensation
deferred by participants, subject to legal maximum contributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Following the Merger, we generally
do not provide perquisites or personal benefits to our NEOs, except in limited circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Potential Payments Upon Termination
or Change in Control</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Pursuant to the terms of the
Offer Letters, in the event each NEO that is a current executive officer is terminated by the Company without &#8220;cause&#8221; or as
a result of a resignation for &#8220;good reason&#8221; (collectively, an &#8220;Involuntary Termination&#8221;), such NEO will, subject
to the execution of a release in favor of the Company, receive: (i) severance payments equal to 12 months of base salary; (ii) Company-paid
continuation coverage under the Company&#8217;s group health plans for up to 12 months; and (iii) in the case of Dr. Klein, accelerated
vesting of 30% of any outstanding time-based equity. However, if the Involuntary Termination is within three months before or 12 months
after a change in control of the Company, the NEO will instead receive: (A) severance payments equal to 1.0 times (or, for Dr. Klein,
1.5x times) the sum of the NEO&#8217;s base salary and target bonus; (B) Company-paid continuation coverage under the Company&#8217;s
group health plans for up to 12 months (or, for Dr. Klein, up to 18 months); and (C) full acceleration of all equity awards. In addition,
upon severance due to the death or disability of the named executive officer, the officer&#8217;s equity awards shall accelerate in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As used in the Offer Letters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#8220;Cause&#8221; generally
means the NEO&#8217;s (i) dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or
prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably
anticipated to result in material harm to the Company; (ii) conviction or plea of no contest to a felony or misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; (iii) failure to perform his or her duties or responsibilities, subject to a 30-day cure period;
(iv) gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v)
violation of any material provision of any agreement with the Company or any written Company policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#8220;Good reason&#8221; generally
means (i) a material diminution in the named executive officer&#8217;s base salary or target bonus (excluding across-the-board reductions
of less than 10%); (ii) a material geographic relocation or requirement to change the named executive officer&#8217;s remote work location;
(iii) a material reduction in the named executive officer&#8217;s duties, authority or responsibilities; (iv) the failure of the Company
to obtain the assumption of the Offer Letter by a successor; or (v) the material breach of any agreement between the NEO and the Company,
in each case, subject to standard notice and cure periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Clawback Policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">We maintain a Compensation
Recoupment (Clawback) Policy, which is intended to comply with the requirements of Nasdaq Listing Standard 5608 implementing Rule 10D-1
under the Exchange Act. In the event the Company is required to prepare an accounting restatement of the Company&#8217;s financial statements
due to material non-compliance with any financial reporting requirement under the federal securities laws, the Company will recover, on
a reasonably prompt basis, the excess incentive-based compensation received by any covered executive, including the NEOs, during the prior
three fiscal years that exceeds the amount that the executive otherwise would have received had the incentive-based compensation been
determined based on the restated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Equity Grant Practices</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Following the Merger, we generally
grant annual equity awards, including stock options, in January of each year. We also grant stock options as new hire awards as of their
date of employment commencement. Employees, including the NEOs, may enroll to purchase shares under the terms of our 2024 Employee Stock
Purchase Plan, as amended (the &#8220;ESPP&#8221;), with purchase dates generally occurring during open trading windows in June and December
of each year using payroll deductions accumulated during the prior six-month period. During 2024, the Compensation Committee did not take
material nonpublic information into account when determining the timing and terms of stock options, and the Company did not time the disclosure
of material nonpublic information for the purpose of affecting the value of executive compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Director Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The following table provides
information for the year ended December 31, 2024 regarding all compensation awarded to, earned by or paid to each person who served as
a non-employee director for some portion of 2024. Employees who served on our Board during 2024 did not receive additional compensation
for such service:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Name<sup>(1)(2)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees<br/> Earned or<br/> Paid in<br/> Cash<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Option Awards<br/> ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Kristine Ball</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,548</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,548</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Carl Dambkowski, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,267</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Harwin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Samarth Kulkarni, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,740</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Cameron Turtle, D.Phil.<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,377</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dan Mitchell</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,810</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Raymond Woosley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Robert Conway</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,916</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,655</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">James Flynn</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,662</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Linda Grais</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,863</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Anders Hove</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,322</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jacob Ma-Weaver</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,382</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The amounts reflected herein for directors who served on the Pre-Merger Oruka board of directors do not include any compensation they received from Pre-Merger Oruka prior to the Merger.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Messrs. Woosley and Mitchell resigned from our Board effective as of February 2, 2024. In connection with the Merger on August 29, 2024, Drs. Hove and Grais as well as Messrs. Conway, Ma-Weaver and Flynn resigned from our Board and Drs. Turtle, Dambkowski and Kulkarni as well as Ms. Ball and Mr. Harwin were appointed to our Board.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">In connection with the Merger, all outstanding ARCA stock options held by Drs. Hove and Grais and Messrs. Conway, Ma-Weaver and Flynn were accelerated and cashed out for an amount equal to the difference between $3.9489 and the applicable per share exercise price; however, any ARCA stock options having an exercise price in excess of $3.9489 were cancelled for no consideration. Amounts reported in this column represent the incremental fair value under ASC Topic 718 resulting from the acceleration of the stock options in the Merger. As of December 31, 2024, each of Drs. Turtle and Dambkowski and Ms. Ball held outstanding options or compensatory warrants to purchase 94,282 shares of our common stock (which were assumed by the Company in connection with the Merger), Dr. Kulkarni held outstanding options or compensatory warrants to purchase 199,992 shares of our common stock (which were assumed by the Company in connection with the Merger), and no other non-employee directors held any outstanding options or compensatory warrants.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Prior to the Merger, Dr. Turtle purchased 85,233 shares (after giving effect to the share conversion completed in the Merger and the subsequent 1-for-12 reverse stock split) of restricted common stock that vest as to 25% on March 1, 2025 and in and in equal monthly installments thereafter through March 1, 2028. All of such restricted shares were outstanding as of December 31, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Non-Employee Director Compensation Program</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Non-employee members of the
Board are eligible to receive cash and equity compensation in accordance with our non-employee director compensation program. This program
provides for the following annual cash retainers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pre-Merger</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Post-Merger</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Annual Cash Retainer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Annual Board Chair Retainer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Audit Committee Retainers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Non-Chair Member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation Committee Retainers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Non-Chair Member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nominating and Corporate Governance Committee Retainers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Non-Chair Member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection with the Company&#8217;s
annual meeting of stockholders, each member of the Board will receive an annual grant of stock options to purchase 17,500 shares of common
stock, which will vest in equal monthly installments over 12 months so long as such director joined the Board prior to January 1 of the
year in which such annual meeting occurs. Prior to the Merger, the annual grant of stock options was for 6,000 shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In addition, in connection
with a non-employee director&#8217;s initial appointment to the Board, they will receive an initial grant of stock options to purchase
35,000 shares of common stock, which will vest in equal monthly installments over 36 months. Prior to the Merger, the initial grant of
stock options was for 12,000 shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">All members of the Board are
also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection with attending meetings
and activities of the Board and its committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND<br/>
RELATED STOCKHOLDER MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;The following table sets forth information,
to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our Common Stock as of February
15, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>each person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5% of Common Stock;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>each of our directors;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>each of our named executive officers; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>all of our current directors and executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The column entitled &#8220;Percentage of Shares
Outstanding Beneficially Owned&#8221; is based on a total of 37,440,510 shares of our Common Stock outstanding as of February 15, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Beneficial ownership is determined in accordance
with the rules and regulations of the SEC and includes voting or investment power with respect to the Common Stock. Shares of Common Stock
subject to options that are currently exercisable or exercisable within 60 days of the date of this table are considered outstanding and
beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for
the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table
have sole voting and investing power with respect to all the shares of Common Stock beneficially owned by them, subject to community property
laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics,
Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares<br/> Beneficially<br/> Owned</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> of Shares<br/> Outstanding<br/> Beneficially<br/> Owned</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">5% Stockholders:</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Entities affiliated with Fairmount Funds Management LLC<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,511,824</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">FMR LLC<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,561,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.86</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Entities affiliated with Venrock Healthcare Capital Partners<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,148,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Entities affiliated with RTW Investments, LP<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,058,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Named Executive Officers and Directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Lawrence Klein<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522,440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.02</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Arjun Agarwal<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Joana Goncalves<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Paul Quinlan<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Michael R. Bristow<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Thomas A. Keuer<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">C. Jeffrey Dekker<sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cameron Turtle<sup>(12)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Samarth Kulkarni<sup>(13)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Peter Harwin<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,511,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Carl Dambkowski<sup>(14)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kristine Ball</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">All current executive officers and directors as a group (9&#160;persons)<sup>(15)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,287,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.69</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Consists of (i) (A) 798,614 shares of common stock, (B) 409,326 shares of common stock issuable upon the exercise of pre-funded warrants and (C) 4,730,576 shares of common stock issuable upon conversion of 56,767 shares of Series B Preferred Stock held by Fairmount Healthcare Fund II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i) 4,888,338 shares of common stock issuable upon the exercise of the pre-funded warrants and (ii) 6,697,573 shares of common stock issuable upon the conversion of 80,371 shares of Series B Preferred Stock. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99% and the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of 19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or conversion, a number of shares of common stock in excess of the applicable ownership limitation. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of common stock, the beneficial ownership limitation applicable to the shares of Series B Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 days&#8217; notice, Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities they hold. As managers of Fairmount, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">All of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Consists of (i) 3,205,865 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;), (ii) 856,747 shares of common stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;), and (iii) 85,816 shares of common stock held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;). Excludes 405,980, 107,788 and 10,775 shares of common stock issuable upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Consists of 2,058,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;RTW Master Fund&#8221;), RTW Innovation Master Fund, Ltd. (&#8220;RTW Innovation Master Fund&#8221;), and RTW Biotech Opportunities Operating Ltd. (&#8220;RTW Biotech&#8221; and together with RTW Master Fund and RTW Innovation Fund, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes (i) 852,338 shares of common stock, (ii) 421,503 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table and (iii) 248,599 shares of common stock issuable upon the vesting of restricted stock awards that will vest within 60 days of the date of this table. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes 61,068 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes (i) 191 shares of common stock and (ii) 10,156 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes 10,156 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for Michael Bristow&#8217;s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(10)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Mr. Keuer resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(11)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Mr. Dekker resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(12)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes (i) 85,233 shares of common stock held by the Turtle Family Trust, for which Mr. Turtle serves as Trustee, (ii) 2,262 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table and (iii) 23,084 shares of common stock issuable upon the vesting of restricted stock awards that will vest within 60 days of the date of this table.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(13)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes 35,713 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(14)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes 25,058 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(15)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">See notes (1), (5), (6), (7), (8), (12), (13) and (14) above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;Other than the compensation agreements and
other arrangements disclosed above under &#8220;Executive Compensation,&#8221; below we describe the transactions to which we or Pre-Merger
Oruka were or are a party since January 1, 2023, in which the amount involved exceeds the lesser of $120,000 or one percent of the average
of our or Pre-Merger Oruka&#8217;s total assets at year-end for the last two completed fiscal years and in which our or Pre-Merger Oruka
directors, executive officers, holders of more than 5% of our common stock, or members of their immediate family had a direct or indirect
material interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>ARCA Transactions </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Transactions With ARCA&#8217;s Former
President and Chief Executive Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ARCA previously entered into unrestricted research
grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding
of any unrestricted research grants was contingent upon ARCA&#8217;s financial condition, and could be deferred or terminated at ARCA&#8217;s
discretion. There was no expense under these arrangements for the year ended December&#160;31, 2024. Total expense under these arrangements
for the&#160;year ended December&#160;31, 2023 was $(91,000). In December&#160;2023, ARCA made a payment of $125,000 for the grant period
July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Pre-Merger Oruka Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Private Placements of Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Pre-Merger Oruka Series&#160;A Preferred
Stock and Convertible Note&#160;Financing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March&#160;6, 2024, Oruka entered into a Convertible
Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount Fund II&#8221;), whereby Oruka issued and sold to Fairmount
Fund II (i)&#160;an aggregate of 20,000,000 shares of Pre-Merger Oruka Series A Preferred Stock at a purchase price of $0.15 per share
and (ii)&#160;a convertible note (the &#8220;Convertible Note&#8221;) with an initial principal amount of $25.0 million at an interest
rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund II contributed the aggregate principal amount
of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $1.5 million divided by the conversion
price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre-Merger Oruka Common Stock and Pre-Merger
Oruka pre-funded warrants in connection with the Pre-Merger Closing Financing (as defined below), immediately prior to the completion
of the Merger. Fairmount Funds Management (&#8220;Fairmount&#8221;) is the investment manager of Fairmount Fund II. Peter Harwin, one
of our directors, is a managing member of Fairmount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Pre-Merger Oruka Pre-Merger Closing Financing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April&#160;3, 2024, in connection with the execution
of the Merger Agreement, Pre-Merger Oruka entered into the Subscription Agreement to consummate the Pre-Merger Closing Financing. Pursuant
to the Subscription Agreement, the Financing Investors purchased 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger
Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes $25.0 million of proceeds previously received
from the issuance of the Convertible Note and accrued interest on such note, which converted to 4,764,032 shares of Pre-Merger Oruka common
stock), immediately prior to the Merger Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates
were beneficial holders of more than 5% of Pre-Merger Oruka&#8217;s capital stock, and the table below sets forth the number of shares
of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants purchased by such holders at the closing of the Pre-Merger Closing
Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Participant</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of<br/> Pre-Merger<br/> Oruka<br/> Common<br/> Stock</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pre-funded<br/> Warrants of<br/> Pre-Merger<br/> Oruka</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> Purchase<br/> Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Entities affiliated with Fairmount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,139,797</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,271,241</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">79,907,282</td><td style="padding-bottom: 6pt; width: 1%; text-align: left"><sup>(1)</sup></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Entities affiliated with Venrock Healthcare Capital Partners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,011,172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392,967</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,996,067</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Entities affiliated with FMR LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,503,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,999,974</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Includes $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price paid in cash.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Company Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>September 2024 Private Placement </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 11, 2024, the Company entered into
a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain selling stockholders to consummate a private placement (the &#8220;Private
Placement&#8221;). Pursuant to the SPA, the selling stockholders purchased (i) an aggregate of 5,600,000 shares of Common Stock, at a
price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock, at a price per share of $23,000.00, and (iii)
pre-funded warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per pre-funded warrant,
which represents the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each
pre-funded warrant, for an aggregate purchase price of approximately $200.5 million. Three of the selling stockholders or their affiliates
were beneficial holders of more than 5% of the Company&#8217;s capital stock, and the table below sets forth the number of shares of Common
Stock, Series A Preferred Stock and pre-funded warrants purchased by such holders at the closing of the Private Placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Participant</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of<br/> Common<br/> Stock</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A<br/> Preferred<br/> Stock</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pre-Funded<br/> Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> Purchase<br/> Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Entities affiliated with FMR LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,105,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">830</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">67,505,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Entities affiliated with Venrock Healthcare Capital Partners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,949,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Entities affiliated with Fairmount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,005,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Our Relationship with Paragon and Paruka</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are party to a number of agreements with Paragon
and Paruka. Paragon and Paruka do not beneficially own more than 5% of our capital stock through their joint holdings of our Common Stock.
Fairmount beneficially owns more than 5% of our capital, one of Fairmount&#8217;s employees serves on our Board, and Fairmount beneficially
owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s securities. Paruka is an entity formed by Paragon
as a vehicle to hold equity in our Company in order to share profits with certain employees of Paragon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&#160;2024, Pre-Merger Oruka entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23
(ORKA-001) and IL-17A/F (ORKA-002). Under each of the Option Agreements, we have the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and potential products
directed to the selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing ORKA-001 for the treatment of inflammatory
bowel disease. In September 2024, we exercised our Option to acquire the rights to ORKA-001 and executed the corresponding license agreement
(the &#8220;IL-23 License Agreement&#8221;) on December 17, 2024. In December 2024 we exercised our Option to acquire the rights to ORKA-002
and executed the corresponding license agreement (the IL-17A/F License Agreement) on February 4, 2025. Under each license agreement we
are required to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective agreement upon the achievement
of certain clinical development milestones, up to $10.0 million under each respective agreement upon the achievement of certain regulatory
milestones, as well as a low single-digit percentage royalty for antibody products beginning on the first commercial sale in each program.
From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon. During 2024, we accrued
two $1.5 million milestone payments related to the achievement of development candidates as research and development expense in our consolidated
statements of operations and comprehensive loss for the year ended December 31, 2024. As of December 31, 2024, this amount is included
under related party accounts payable and other current liabilities on the consolidated balance sheet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the Option Agreements,
the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing
antibodies directed to the respective target. For each Research Program, the parties established a Research Plan (each, a &#8220;Research
Plan&#8221;) that sets forth the activities that will be conducted, and the associated research budget. We and Paragon agreed on initial
Research Plans that outlined the services that were performed commencing at inception of the arrangement related to IL-17 and IL-23. Our
exclusive option with respect to each Research Program was exercisable at our sole discretion at any time during the period beginning
on the initiation of activities under the associated Research Program and ending a specified number of days following the delivery of
the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option
pursuant to the Option Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the Research Plan for each respective research program, the Company was
required to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February 6 (inception) to December 31, 2024. In June 2024,
pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL-23 antibodies
for the ORKA-001 program. The Company was responsible for 50% of the development costs incurred through the completion of the IL-23 selection
process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During 2024, the Company exercised its
option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and
development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss. In addition, during the period
from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $2.5 million milestone payment related to the first dosing
of a human subject in a Phase 1 trial of ORKA-001 in December 2024 as research and development expense in its consolidated statement of
operations and comprehensive loss. The Company&#8217;s share of development costs incurred during the period from February 6, 2024 (inception)
to December 31, 2024 was $13.5 million, which was recorded as research and development expenses. An amount of $2.8 million related to
ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is also required to reimburse Paragon
$3.3 million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs
incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a
research and development expense during the period from February 6 (inception) to December 31, 2024. The Company is also responsible for
development costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. The Company recognized
an amount of $0.8 million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002
research plan. This was recognized as research and development expenses in the period from February 6 (inception) to December 31, 2024.
During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a
$1.5 million milestone payment related to the achievement of development candidate as research and development expense in its consolidated
statement of operations and comprehensive loss. The Company accounted for development costs of $7.8 million during the period from February
6, 2024 (inception) to December 31, 2024 as research and development expenses. An amount of $2.7 million related to ORKA-002 is included
in related party accounts payable and other current liabilities as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, the Option Agreements provide for an
annual equity grant of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of our stock, on a fully
diluted basis, on each of December 31, 2024 and December 31, 2025, during the term of the Option Agreements, at the fair market value
determined by our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Indemnification Agreements and Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into an indemnification agreement
with each of our directors and senior officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification
agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Review, Approval or Ratification of Transactions
with Related Parties </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to the Merger Closing, Pre-Merger Oruka did
not have a formal policy regarding approval of transactions with related parties. All disclosable transactions with related parties that
occurred prior to the Merger Closing were approved by the directors not interested in such transactions, pursuant to Section 144(a)(1)
of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board has adopted a written related person transactions
policy. Under this policy, our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of
our Common Stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted
to enter into a material related person transaction with us without the review and approval of our Audit Committee, or a committee composed
solely of independent directors in the event it is inappropriate for our Audit Committee to review such transaction due to a conflict
of interest. The policy provides that, subject to limited exceptions, any transaction, arrangement or relationship or series of similar
transactions, arrangements or relationships in which (1) the aggregate amount involved since the beginning of the Company&#8217;s last
completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any of our subsidiaries is a participant, and (3)
any related person has or will have a direct or indirect interest, will be presented to our Audit Committee for review, consideration
and approval. In approving or rejecting any such proposal, our Audit Committee will consider the material facts and other factors it deems
appropriate, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an
unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board has reviewed the independence of all directors
in light of each director&#8217;s (or any family member&#8217;s, if applicable) affiliations with the Company and members of management,
as well as significant holdings of our securities and all other facts and circumstances that the Board has deemed relevant in determining
the independence of each director. The Board has determined that each of the directors other than Lawrence Klein, our current President
and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, qualify as &#8220;independent
directors&#8221; as defined by the Nasdaq listing rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Nasdaq listing rules have objective tests and a
subjective test for determining who is an &#8220;independent director.&#8221; The subjective test states that an independent director
must be a person who lacks a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. The Board has not established categorical standards or guidelines to make these subjective
determinations but considers all relevant facts and circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, ARCA&#8217;s board of directors determined
that former directors Drs. Linda Grais, Anders Hove and Raymond Woosley, and Messrs. Robert Conway, Daniel Mitchell and James Flynn were
independent during the period each served on the Board in 2024. ARCA&#8217;s board of directors determined Dr. Michael R. Bristow, ARCA&#8217;s
former President and Chief Executive Officer, was not an independent director in 2024 by virtue of his employment relationship with ARCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SELLING STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus covers the resale or other disposition
from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 8,719,000 shares of our Common Stock.
The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus
and any accompanying prospectus supplement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 11, 2024, we entered into the SPA,
pursuant to which we sold an aggregate of (i) 5,600,000 shares of our Common Stock, (ii) 2,439 shares of our Series A Preferred Stock,
which automatically converted into 2,439,000 shares of Common Stock, following stockholder approval, and (iii) Pre-Funded Warrants to
purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per
share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for
an aggregate purchase price of approximately $200.5 million. This prospectus covers the resale or other disposition by the Selling Stockholders
or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus of
up to the total number of shares of Common Stock, shares of Common Stock issued upon the conversion of the Series A Preferred Stock, and
shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants sold to the Selling Stockholders pursuant to the SPA. This
prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number of Private
Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants issued to the Selling Stockholders upon conversion
of the Private Placement Preferred Shares and exercise of the Pre-Funded Warrants issued pursuant to the SPA. Throughout this prospectus,
when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the SPA listed in the table below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are registering the Resale Shares to permit the
Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive their shares after the date
of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of Distribution&#8221; herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise disclosed herein, the Selling
Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the names of the Selling Stockholders,
the number of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered
under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders
assuming all of the shares registered for resale hereby are sold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholders may sell some, all or none
of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently
have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the
Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information set forth below is based upon information
obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Private Placement Common Shares,
Private Placement Preferred Shares and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants in connection with
the September 2024 PIPE. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 37,440,510
shares of Common Stock outstanding as of February 15, 2025, and, for each Selling Stockholder, assumes exercise of only the Pre-Funded
Warrants owned by such Selling Stockholder but not the Pre-Funded Warrants owned by any other Selling Stockholder. The numbers of shares
of Common Stock beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership
Limitations with respect to the Pre-Funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"/>
    <td><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Common<br/>
Stock<br/>
Beneficially<br/>
Owned </b></span></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Common<br/>
    Stock that<br/>
    May<br/>
    Be Offered<br/></b></span></td>
    <td><b>&#160;</b></td>
    <td colspan="7" style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Common Stock<br/>
    Beneficially<br/>
    Owned After the<br/>
    Offering <sup>(2)</sup></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 54%"><span style="font-size: 10pt"><b>Name of Selling Stockholders<sup>(1)</sup></b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><b>Before the<br/>
    Offering&#160;<sup>(2)</sup></b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><b>Pursuant&#160;to<br/>
    Prospectus</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-size: 10pt"><b>Percentage<br/>
    (%)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Securities Fund: Fidelity Small Cap Growth
    Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">555,043</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">179,838</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">375,205</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.00</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Securities Fund: Fidelity Small Cap Growth
    K6 Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">228,121</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">86,378</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">141,743</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology
    Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">655,962</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">197,572</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">458,390</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.12</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Select Portfolios: Biotechnology Portfolio<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">704,983</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">704,883</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Advisor Series VII: Fidelity Advisor Health
    Care Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">629,689</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">67,978</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">561,711</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.50</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Select Portfolios: Health Care Portfolio<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">999,710</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">110,356</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">889,354</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2.38</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Variable Insurance Products Fund IV: VIP Health
    Care Portfolio<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">159,859</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25,109</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">134,750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Mt. Vernon Street Trust: Fidelity Series
    Growth Company Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">78,239</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">78,239</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Mt. Vernon Street Trust: Fidelity Growth
Company Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">297,445</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">297,445</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Growth Company Commingled Pool (3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">401,039</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">401,039</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Mt. Vernon Street Trust: Fidelity Growth
    Company K6 Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">91,935</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">91,935</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Capital Trust: Fidelity Stock Selector
    Small Cap Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">283,456</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">283,456</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Fidelity Securities Fund: Fidelity Series Small
    Cap Opportunities Fund<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">410,772</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">410,772</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Braidwell Partners Master Fund LP<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,952,426</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,630,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">322,426</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities Associated with Venrock Healthcare Capital
    Partners<sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,148,428</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">650,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,022,971</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.67</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left-width: 0cm; border-left-color: Black">Entities associated
    with Fairmount Funds Management LLC<sup>(6)</sup></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8,511,824</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">435,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8,511,824</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">19.99</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">AI Biotechnology LLC<sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,791,052</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,441,052</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.85</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities associated with Blackstone Alternative
    Asset Management Associates LLC<sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">783,653</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">433,653</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.16</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Point72 Associates, LLC<sup>(9)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">330,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">340,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities Associated with Frazier Life Sciences    <sup>(10)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">583,327</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">326,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">257,327</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities Associated with Paradigm BioCapital Advisors
    LP<sup>(11)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">819,660</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">305,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">514,660</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.38</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities associated with RTW Investments, LP<sup>(12)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,058,147</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">285,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,773,147</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4.74</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities advised or subadvised by T. Rowe Price
    Associates, Inc.<sup>(13)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">431,140</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">215,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">216,140</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">SR One Capital Opportunities Fund I, LP<sup>(14)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">430,330</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">173,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">257,330</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Entities associated with Janus Henderson Investors
    US LLC<sup>(15)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Commodore Capital Master LP<sup>(16)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,419,714</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,269,714</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.39</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Kalehua Capital Partners LP<sup>(17)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">150,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Avidity Private Master Fund I LP<sup>(18)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">352,124</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">110,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">242,124</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Adage Capital Partners LP<sup>(19)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">69,200 </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Affinity Healthcare Fund, LP<sup>(20)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">520,362</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">45,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">475,362</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1.27</span></td>
    <td><span style="font-size: 10pt">%&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="font-size: 10pt">Allostery Master Fund, LP<sup>(21)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(1)</span></td>
    <td><span style="font-size: 10pt">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(4)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 1,572,426 shares of Common Stock held by Braidwell Partners Master Fund LP (&#8220;Braidwell Partners&#8221;) and (ii) 380,000 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants held by Braidwell Partners. Braidwell LP (the &#8220;Braidwell Investment Manager&#8221;) is the investment manager of Braidwell Partners. Braidwell GP LLC (the &#8220;Braidwell GP&#8221;) is the general partner of Braidwell Partners. Braidwell Management LLC (the &#8220;Braidwell IM GP&#8221;) is the general partner of the Braidwell Investment Manager and the managing member of the Braidwell GP. Messrs. Alexander T. Karnal and Brian J. Kreiter (together with Braidwell Partners, the Braidwell Investment Manager, the Braidwell GP and the Braidwell IM GP, the &#8220;Braidwell Parties&#8221;) together own, directly or indirectly, the Braidwell Investment Manager, the Braidwell GP and the Braidwell IM GP. The address of Braidwell Partners is c/o Maples Corporate Services Limited, P.O Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. The principal address of the Braidwell Investment Manager, the Braidwell GP and the Co-Founders is One Harbor Point, 2200 Atlantic Street, 4th Floor, Stamford, Connecticut 06902. The Braidwell Parties may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held by Braidwell Partners. Each of the Braidwell Parties disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(5)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of (i) 3,205,865 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;), (ii) 856,747 shares of common stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;), and (iii) 85,816 shares of common stock held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;). Excludes 405,980, 107,788 and 10,775 shares of common stock issuable upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(6)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of (i) (A) 798,614 shares of common stock, (B) 409,326 shares of common stock issuable upon the exercise of pre-funded warrants and (C) 4,730,576 shares of common stock issuable upon conversion of 56,767 shares of Series B Preferred Stock held by Fairmount Healthcare Fund II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i) 4,888,338 shares of common stock issuable upon the exercise of the pre-funded warrants and (ii) 6,697,573 shares of common stock issuable upon the conversion of 80,371 shares of Series B Preferred Stock. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99% and the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of 19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or conversion, a number of shares of common stock in excess of the applicable ownership limitation. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of common stock, the beneficial ownership limitation applicable to the shares of Series B Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 days&#8217; notice, Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities they hold. As managers of Fairmount, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(7)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 1,441,052 shares of Common Stock purchased pursuant to a Subscription Agreement, dated August 3, 2024, among the Company and the purchasers thereto (including AI Biotechnology LLC) (ii) 125,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by AI Biotechnology LLC and (ii) 225,000 shares of Common Stock held by AI Biotechnology LLC. Access Industries Holdings LLC, or AIH, directly controls all of the outstanding voting interest in AI Biotechnology LLC. Access Industries Management, LLC, or AIM, controls AIH. Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. Each of Len Blavatnik, AIM and AIH may be deemed to have voting and investment power over the shares held by AI Biotechnology LLC and disclaims beneficial ownership of such shares. The address of each of AI Biotechnology LLC, AIM, AIH and Len Blavatnik is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(8)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 72,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Spruce Street Aggregator L.P. (&#8220;Spruce Street Fund&#8221;), (ii) 304,421 shares of Common Stock held by Spruce Street Fund, (iii) 53,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Blackstone Annex Master Fund L.P. (&#8220;Annex Fund&#8221;), and (iv) 354,232 shares of Common Stock held by Annex Fund. Blackstone Alternative Asset Management Associates LLC is the general partner of Annex Fund and Spruce Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C. Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by the Annex Fund and the Aggregator Fund directly or indirectly controlled by it or him, but each (other than each of the Annex Fund and the Aggregator Fund to the extent of their respective direct holdings) disclaims beneficial ownership of such securities. The address of each of the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(9)</span></td>
    <td><span style="font-size: 10pt">Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the securities directly held by Point72 Associates, LLC reflected herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any such securities. The address for Point72 Associates, LLC is c/o Point72 Asset Management, L.P., 72 Cummings Point Road, Stamford, CT 06902.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(10)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 1,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Frazier Life Sciences X, L.P. (&#8220;FLS X&#8221;), (ii) 23,785 shares of Common Stock held by FLS X, (iii) 1,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Frazier Life Sciences XI, L.P. (&#8220;FLS XI&#8221;), (iv) 40,967 shares of Common Stock held by FLS XI, (v) 81,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held Frazier Life Sciences Public Fund, L.P. (&#8220;FLS Public Fund&#8221;), (vi) 297,560 shares of Common Stock held by FLS Public Fund, (vii) 23,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Frazier Life Sciences Public Overage Fund, L.P. (&#8220;FLS Overage Fund&#8221;) and (viii) 115,015 shares of Common Stock held by FLS Overage Fund. FHMLSP, L.P. is the general partner of FLS Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N. Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by FLS Public Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any. FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Overage Fund except to the extent of their pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper, Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except to the extent of their pecuniary interests in such shares, if any. The principal business address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(11)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 86,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Paradigm BioCapital International Fund Ltd. (&#8220;Paradigm Fund&#8221;), (ii) 617,323 shares of Common Stock held by Paradigm Fund, (iii) 14,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Paradigm BioCapital Advisors LP (&#8220;Paradigm Advisor&#8221;), as discretionary investment manager on behalf of a separate account client solely with respect to the assets for which Paradigm Advisor acts as its investment manager (the &#8220;Separate Account&#8221;), and (iv) 102,337 shares of Common Stock held by Paradigm Advisor, as discretionary investment manager on behalf of the Separate Account. The shares of Common Stock may be deemed to be indirectly beneficially owned by each of Paradigm Advisor, Paradigm BioCapital Advisors GP LLC (&#8220;Paradigm Advisor GP&#8221;), and Senai Asefaw, M.D. Paradigm Advisor GP is the general partner of Paradigm Advisor, and Senai Asefaw, M.D. is the managing member of Paradigm Advisor GP. Paradigm Advisor is the investment manager of Paradigm Fund. Paradigm Advisor, Paradigm Advisor GP, and Senai Asefaw, M.D. may be deemed to have full investment and voting discretion over the shares of Common Stock held by Paradigm Fund and the Separate Account. The business address for each person and entity named in this footnote is 767 Third Avenue, 17th Floor, New York, NY 10017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(12)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 95,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock and (ii) 1,963,147 shares of Common Stock, in each case of (i) and (ii) as held in the aggregate by RTW Master Fund, Ltd. RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd, (collectively, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(13)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 404,144 shares of Common Stock held by T. Rowe Price Health Sciences Fund, Inc. and (ii) 26,996 shares of Common Stock held by T. Rowe Price Health Sciences Portfolio. T. Rowe Price Associates, Inc. (&#8220;TRPA&#8221;), as investment adviser, has dispositive and voting power with respect to the shares held by these funds and accounts. For purposes of the Securities Exchange Act of 1934, TRPA may be deemed to be the beneficial owner of these aforementioned shares; however, TRPA expressly disclaims that it is, in fact, the beneficial owner of such securities. TRPA is a wholly owned subsidiary of T. Rowe Price Group, Inc., which is a publicly traded financial services holding company. The principal business address of TRPA is 100 East Pratt Street, Baltimore, MD 21202.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(14)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 55,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by SR One Capital Opportunities Fund I, LP (&#8220;Opportunities Fund&#8221;) and (ii) 375,330 shares of Common Stock held by Opportunities Fund. SR One Capital Opportunities Partners I, LP (&#8220;SR One Partners&#8221;) is the general partner of Opportunities Fund. SR One Capital Management, LLC (&#8220;SR One Management&#8221;) is the general partner of SR One Partners. Simeon George, M.D. is the manager of SR One Management. SR One Partners, SR One Management, and Simeon George share voting and investment power with respect to the shares directly held by Opportunities Fund. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. The address of these persons and funds is 985 Old Eagle School Road, Suite 511, Wayne, Pennsylvania 19087.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(15)</span></td>
    <td><span style="font-size: 10pt">Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment adviser registered under the Investment Advisers Act of 1940, acts as investment adviser for Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation Master Fund II Limited (the &#8220;Janus Funds&#8221;) and has the ability to make decisions with respect to the voting and deposition of the shares subject to the oversight of the board of directors of the Janus Funds. Under the terms of its management contract with the Janus Funds, Janus has overall responsibility for directing the investments of the Janus Funds in accordance with the Janus Funds&#8217; investment objective, policies and limitations. The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure of Janus who make decisions with respect to the disposition of the shares of common stock offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206. The portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(16)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 50,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Commodore Capital Master LP and (ii) 1,369,714 shares of Common Stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(17)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 50,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Kalehua Capital Partners LP and (ii) 100,000 shares of Common Stock held by Kalehua Capital Partners LP. Kalehua Capital Partners LP is a buyout fund managed by Kalehua Capital Management LLC. Tai-Li Chang is the sole member of Kalehua Capital Management LLC. The address of these persons and funds is 3819 Maple Avenue, Dallas, Texas 75219.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(18)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of 352,124 shares of Common Stock held by Avidity Private Master Fund I LP, which is a Cayman exempted limited partnership. The general partner of Avidity Private Master Fund I LP is Avidity Capital Partners Fund (GP) LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP) LLC, a Delaware limited liability company. Avidity Partners Management LP is the investment manager of Avidity Private Master Fund I LP. Avidity Partners Management (GP) LLC is the general partner of Avidity Partners Management LP. Michael Gregory is the managing member of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP) LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially own the shares held by the Avidity entities. Certain affiliates of the Avidity entities, which are not selling stockholders, may also own shares. The address of Avidity Private Master Fund I LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(19)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of 69,200 shares of Common Stock held by Adage Capital Partners LP (&#8220;Adage&#8221;). Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by Adage Capital Partners, LP and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The address of these funds and persons is 200 Clarendon St., 52<sup>nd</sup> Floor, Boston, MA 02116.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-size: 10pt">(20)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of 520,362 shares of Common Stock held by Affinity Healthcare Fund, LP (the &#8220;Fund&#8221;). Affinity Asset Advisors, LLC (the &#8220;Advisor&#8221;) is the investment manager of the Fund and exercises investment discretion with regard to the shares of Common Stock owned by the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of such shares of Common Stock of the Issuer owned by the Fund. The Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The principal business address of each of the Fund and the Advisor is 450 Park Avenue, Suite 1403, New York, NY 10022.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(21)</span></td>
    <td><span style="font-size: 10pt">Shares listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of (i) 8,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Allostery Master Fund, LP (&#8220;Allostry Master Fund&#8221;) and (ii) 12,000 shares of Common Stock held by Allostry Master Fund. Allostery Funds GP LLC (&#8220;Allostery Funds GP&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master Fund because it is the general partner of Allostery Master Fund. Allostery Investments LP (&#8220;Allostery Investments&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master Fund because it is the investment manager of Allostery Master Fund. Allostery Investments GP LLC (the &#8220;Investments GP&#8221;) may be deemed the beneficial owner of the shares beneficially held by Allostery Investments because it is the general partner of Allostery Investments. Christopher Staral and David Modest may be deemed the beneficial owners of the shares beneficially held by each of Investments GP and Allostery Funds GP by virtue of their positions as managing members of Investments GP and Allostery Funds GP. The address of Allostery Master Fund is c/o Maples Corporate Services Limited, Ugland House, South Church Street, Grand Cayman KY1-1104, Cayman Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Relationship with the Selling Stockholders </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the SPA, in connection with the Private
Placement, we entered into the RRA (as defined below) on September 13, 2024 with the Selling Stockholders. Certain of the September 2024
investors were, immediately prior to the closing of the September 2024 PIPE, or became holders of more than 5% of our Common Stock and
were parties to the Pre-Closing Financing. See &#8220;<i>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Registration Rights Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 13, 2024, we entered into a registration
rights agreement (the &#8220;RRA&#8221;) with the Private Placement investors. Pursuant to the RRA, we agreed to file a resale registration
statement to register the Registrable Securities (as defined in the RRA) (the &#8220;Registration Statement&#8221;). This registration
statement is being filed to satisfy our obligations under the RRA. We have agreed to use our commercially reasonable efforts to cause
this Registration Statement to be declared effective by the SEC as soon as practicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have also agreed, among other things, to indemnify
the Selling Stockholders and each of their respective officers, directors, members, employees, partners, managers, stockholders, affiliates,
investment advisors and agents, each person who controls any such Selling Stockholder and the officers, directors, members, employees,
partners, managers, stockholders, affiliates, investment advisors and agents of each such controlling person from certain liabilities
and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions)
incident to our obligations under the RRA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are registering the Resale Shares issued to the
Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling Stockholders or their donees, pledgees,
transferees or other successors-in-interest from time to time after the date of this prospectus. We will not receive any of the proceeds
from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to, bear all fees and expenses incident to our
obligation to register the Resale Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholders may sell all or a portion
of the Resale Shares beneficially owned by them and offered hereby from time to time, directly or through one or more underwriters, broker-dealers
or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting
discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation
in this offering) or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation
service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise
than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market
prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected
in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods
when selling Resale Shares:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                  </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block
as principal to facilitate the transaction;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                                          </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>an exchange distribution in accordance with the rules of the applicable exchange;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                   </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>privately negotiated transactions;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                                                   </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                                                   </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange
or otherwise;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                       </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>a combination of any such methods of sale; and</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any other method permitted pursuant to applicable law.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholders also may resell all or
a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted by that rule, or Section 4(a)(1) under
the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements
of those provisions. The Selling Stockholders also may dispose of the Resales Shares through distributions to members, partners, stockholders
or other equityholders of the Selling Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Broker-dealers engaged by the Selling Stockholders
may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Resale Shares
to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form
of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they
may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth
in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in
compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2121.01.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with sales of the Resale Shares or
otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may
in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume. The Selling Stockholders may also
sell Resale Shares short and if such short sale takes place after the date that this registration statement is declared effective by the
SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions and to return borrowed
Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares to broker-dealers that
in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other
transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or
other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding
the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has been registered
on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this
prospectus forms a part, has been declared effective by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholders may, from time to time,
pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their
secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time to time pursuant to this prospectus
or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary,
the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this
prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in which case the transferees,
donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholders and any broker-dealer or
agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section
2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed
to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221; within the meaning of Section 2(11) of
the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder
and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and
Rule 10b-5 under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each Selling Stockholder has informed us that it
is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person
to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that any material arrangement has been entered
into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution
or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities
Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares
involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to
such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set
out in this prospectus, and (vi) other facts material to the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the securities laws of some U.S. states, the
Resale Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the
Resale Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration
or qualification is available and is complied with.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There can be no assurance that any Selling Stockholder
will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus forms a part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each Selling Stockholder and any other person participating
in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including,
without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any
of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict
the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale
Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making
activities with respect to the Resale Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will pay all expenses of the registration of
the Resale Shares pursuant to the September 2024 RRA, including, without limitation, SEC filing fees and expenses of compliance with state
securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will pay all underwriting discounts and selling
commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholders against certain liabilities,
including some liabilities under the Securities Act, in accordance with the September 2024 RRA, or the Selling Stockholders will be entitled
to contribution. We may be indemnified by the Selling Stockholders against certain civil liabilities set forth in the September 2024 RRA,
including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders
specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF CAPITAL STOCK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following description summarizes the material
terms of our capital stock, as well as other material terms of our amended and restated certificate of incorporation (&#8220;Certificate
of Incorporation&#8221;) and amended and restated bylaws (&#8220;Bylaws&#8221;) and certain provisions of Delaware law. This summary does
not purport to be complete and is qualified in its entirety by the provisions of our Certificate of Incorporation and Bylaws, copies of
which are filed as exhibits to our Current Report on Form 8-K filed on September 5, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our authorized capital stock consists of 545,000,000
shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share (&#8220;Preferred
Stock&#8221;), of which 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share (the &#8220;Series
B Preferred Stock&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024, there were 37,440,510 shares
of our Common Stock and 137,138 shares of Series B Preferred Stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Certificate of Incorporation authorizes the
issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividend rights </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to preferences that may apply to any shares of Preferred Stock
outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our Board,
in its discretion, determines to issue dividends and then only at the times and in the amounts that our Board may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Voting rights </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to our Bylaws, holders of our Common Stock
are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting
for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders
of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a
classified Board, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual
meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>No preemptive or similar rights </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Common Stock is not entitled to preemptive rights,
and is not subject to conversion, redemption or sinking fund provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Right to receive liquidation distributions </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Upon our liquidation, dissolution or winding-up,
the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock
and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities
and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Preferred Stock </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of our Certificate of Incorporation,
our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of Preferred Stock in one
or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers,
preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without
further vote or action by our stockholders. Subject to any certificates of designation, the Board can also increase or decrease the number
of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote
or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of our Common Stock. The issuance of Preferred Stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring
or preventing a change in control of our company and might adversely affect the market price of our Common Stock and the voting and other
rights of the holders of our Common Stock. We issued shares of our Series B Preferred Stock in connection with the Merger and have no
current plan to issue any additional shares of Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series B Preferred Stock </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain holders of our Series B Preferred Stock
are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock basis, and in
the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate of Designation
or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B
Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares
of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock,
(ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, our Certificate
of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock, or file any articles
of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action
would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series
B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation
or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series B Preferred
Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of
authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued Series B Preferred Stock remains
issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or
(y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which
the stockholders of the Company immediately before such transaction do not hold at least a majority of our capital stock immediately after
such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank on parity
with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up of the Company. Each share of
Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration
by the holder. As of December 31, 2024, each outstanding share of Series B Preferred Stock was convertible into common stock at a ratio
of approximately 83.3332:1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The provisions of Delaware law, our Certificate
of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of
our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed,
in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe that the benefits of increased
protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging
a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Delaware law </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to the provisions of Section 203
of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging in a
business combination with an interested stockholder for a period of three years following the date on which the person became an interested
stockholder unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                               </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of
determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by
persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the
right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                      </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation
and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3%
of the outstanding voting stock which is not owned by the interested stockholder.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Section 203 defines a &#8220;business combination&#8221; to include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any merger or consolidation involving the corporation and the interested stockholder;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                        </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                                                                        </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                        </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series
of the corporation beneficially owned by the interested stockholder; and</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                  </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In general, Section 203 defines an &#8220;interested
stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of
the corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certificate of Incorporation and Bylaw Provisions </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Certificate of Incorporation and our Bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Board of Directors vacancies</i></b>. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders,
fill any directorships that become vacant or are created by an increase in the authorized number of directors by the affirmative vote
of a majority of the remaining directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors
constituting our Board is permitted to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent
a stockholder from increasing the size of our Board and then gaining control of the Board by filling the resulting vacancies with its
own nominees. This makes it more difficult to change the composition of the Board but promotes continuity of management.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Classified board</i></b>. Our Certificate of Incorporation provides that our Board is classified into three classes of directors,
each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control
of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Stockholder action; special meetings of stockholders</i></b>. Our Certificate of Incorporation and Bylaws provide that our stockholders
may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder
controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our
stockholders called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only
by the Board, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders
to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the
removal of directors.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Advance notice requirements for stockholder proposals and director nominations</i></b>. Our Bylaws provide advance notice procedures
for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors
at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s
notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making
nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions
might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate
of directors or otherwise attempting to obtain control of our company.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>No cumulative voting</i></b>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election
of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws
do not provide for cumulative voting.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                               </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Directors removed only for cause</i></b>. Our Bylaws provide that stockholders may remove directors only for cause, and only
by the affirmative vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally
in the election of directors.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                       </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Amendment of charter provisions</i></b>. Any amendment of the above provisions in our Certificate of Incorporation requires
approval by holders of at least two-thirds of our outstanding Common Stock.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Issuance of Preferred Stock</i></b>. Our Board has the authority, without further action by the stockholders, to issue up to
5,000,000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The
existence of authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt
to obtain control of us by merger, tender offer, proxy contest or other means.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                        </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><b><i>Choice of forum</i></b>. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware
is the sole and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the
federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the
Exchange Act.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer Agent and Registrar </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The transfer agent and registrar for our Common
Stock and Series B Preferred Stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall Street, Suite
101, Canton, MA 02021, and its telephone number is (800) 344-5128.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange Listing </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Common Stock is listed on The Nasdaq Global
Market under the symbol &#8220;ORKA.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain legal matters, including the legality of
the securities offered, has been passed upon for us by Gibson, Dunn &amp; Crutcher LLP, San Francisco, California. Additional legal matters
may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements as of December 31, 2024
and February 6, 2024 and for the period from February 6, 2024 (inception) to December 31, 2024 included in this Prospectus have been so
included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to the informational requirements
of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC.
The SEC maintains an Internet website (http://www.sec.gov) that contains reports, proxy and information statements, and various other
information about us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Information about us is also available at our website
at http://www.orukatx.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. However, the information on our website is not a part of this prospectus and is not incorporated
by reference into this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed a registration statement on Form S-1
with the SEC relating to the securities covered by this prospectus. This prospectus is a part of the registration statement and does not
contain all of the information in the registration statement. Whenever a reference is made in this prospectus to a contract or other document
of ours, please be aware that the reference is only a summary and that you should refer to the exhibits that are part of the registration
statement for a copy of the contract or other document. You may review a copy of the registration statement through the SEC&#8217;s website
or our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited
    Financial Statements:</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%; text-align: left"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm (PCAOB ID 238)</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Operations and Comprehensive Loss</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Convertible Preferred Stock and Stockholders&#8217; Equity</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Cash Flows</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span></a></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Financial Statements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2024 and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible
preferred stock and stockholders&#8217; equity and of cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024,
including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2024
and February 6, 2024, and the results of its operations and its cash flows for the period from February&#160;6,&#160;2024 (inception)
to December&#160;31,&#160;2024 in conformity with accounting principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require
that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial
reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial
reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matters</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that
was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material
to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication
of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>External
Research and Development Costs</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 2 to the consolidated financial statements, research and development costs are expensed as incurred. Research and development
costs include salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged
to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility-related
costs, including rent, maintenance, utilities, and depreciation. As disclosed by management, the Company&#8217;s research and development
expense for the period from February 6, 2024 (inception) to December 31, 2024 was $75.1 million, $57.7 million of which relates to external
research and development costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal consideration for our determination that performing procedures relating to external research and development costs is a critical
audit matter is a high degree of auditor effort in performing procedures related to the Company&#8217;s external research and development
costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included, among others, testing external research and development costs, on a sample basis, by
obtaining and agreeing the contractual terms of the agreement, amounts incurred to date, and estimates of work performed to date to the
(i) underlying agreements with vendors engaged to conduct research and development; (ii) purchase orders; (iii) invoices received; (iv)
underlying payments made for expenses incurred on the contracts; and (v) external confirmations or communications obtained by management
from vendors.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
PricewaterhouseCoopers LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
Massachusetts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
6, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 6,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18672">61,575</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18673">314,073</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-18674">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-18675">1,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-18676">376,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-18677">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18678">18,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-18679">162</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18680">876</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-18681">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-18682">396,019</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-18683">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-18684">3,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-18685">3,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liability, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-18686">213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Related party accounts payable and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-18687">6,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-18688">13,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liability, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-18689">755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-18690">13,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Commitments and contingencies (Note 13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Series A convertible preferred stock, $<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18691"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18692">0.0001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-24">no</span> shares and <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-18693">20,000,000</ix:nonFraction> shares authorized as of December 31, 2024 and February 6, 2024, respectively; <span style="-sec-ix-hidden: hidden-fact-20"><span style="-sec-ix-hidden: hidden-fact-21"><span style="-sec-ix-hidden: hidden-fact-22"><span style="-sec-ix-hidden: hidden-fact-23">none</span></span></span></span> issued and outstanding as of December 31, 2024 and February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Series A non-voting convertible preferred stock, $<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18694"><ix:nonFraction contextRef="c8" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18695">0.001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-27"><span style="-sec-ix-hidden: hidden-fact-29"><span style="-sec-ix-hidden: hidden-fact-31">none</span></span></span> authorized as of December 31, 2024 and February 6, 2024; <span style="-sec-ix-hidden: hidden-fact-28"><span style="-sec-ix-hidden: hidden-fact-30"><span style="-sec-ix-hidden: hidden-fact-32">none</span></span></span> issued and outstanding as of December 31, 2024 and February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Series B non-voting convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18696"><ix:nonFraction contextRef="c10" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18697">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18698">251,504</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-35"><span style="-sec-ix-hidden: hidden-fact-36">no</span></span> shares authorized as of December 31, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-18699"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18700">137,138</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-34">no</span> shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-18701">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18702">0.001</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18703">0.001</ix:nonFraction> par value as of December 31, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18704">545,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18705">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-18706"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18707">37,440,510</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-18708"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18709">3,197,975</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-18710">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-18711">463,018</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-18712">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-18713">41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-18714">83,724</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18715">382,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18716">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total liabilities, convertible preferred stock and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-18717">396,019</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-18718">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Operating expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">75,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">13,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-18721">88,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18722">88,123</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-18723">5,863</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">1,468</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-18725">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-18726">4,399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18727">83,724</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized loss on marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-18728">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-18729">83,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18730"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18731">3.87</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18732"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18733">3,873.25</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18734"><ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18735">322.81</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18736"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18737">16,789,362</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18738"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18739">495</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18740"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18741">51,946</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: left"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-18742">42,640</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-18743">1,364</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: left"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-18744">1,468</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A<br/> Convertible<br/> Preferred Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A<br/> Non-Voting<br/> Convertible<br/> Preferred Stock</span></td><td style="border-right: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    B<br/> Non-Voting<br/> Convertible<br/> Preferred Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional<br/>
    Paid-In</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    Other<br/> Comprehensive</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    Stockholders&#8217;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="border-right: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Gain
    (Loss)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balances as of
    February 6, 2024 (inception)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-18745">3,197,975</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18746">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18747">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18748">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-18749">2,207,553</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-18750">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd" id="ixv-18751">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series A convertible preferred stock, net of issuance costs of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-18752">69</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-18753">20,000,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-18754">2,931</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exchange of Series A convertible
    preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares" id="ixv-18755">20,000,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" sign="-" unitRef="usd" id="ixv-18756">2,931</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-18757">137,138</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-18758">2,931</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-18759">2,931</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion of convertible notes
    (including accrued interest) into common stock upon the closing of the reverse recapitalization</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-18760">2,722,207</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-18761">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-18762">26,445</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-18763">26,448</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock and
    pre-funded warrants in the Pre-Closing Financing</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" scale="0" unitRef="shares" id="ixv-18764">20,061,932</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-18765">20</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-18766">248,437</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-18767">248,457</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance costs of Pre-Closing
    Financing and reverse recapitalization</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" unitRef="usd" id="ixv-18768">20,504</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" unitRef="usd" id="ixv-18769">20,504</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock to
    former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" scale="0" unitRef="shares" id="ixv-18770">1,208,883</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-18771">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-18772">4,999</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-18773">5,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock, Series
    A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-18774">2,439</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-18775">56,097</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-18776">5,600,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-18777">6</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-18778">144,433</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-18779">144,439</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance costs of PIPE Financing</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-18780">3,263</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-18781">8,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-18782">8,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion of Series A non-voting
    convertible preferred stock to common stock</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" scale="0" sign="-" unitRef="shares" id="ixv-18783">2,439</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" sign="-" unitRef="usd" id="ixv-18784">52,834</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" scale="0" unitRef="shares" id="ixv-18785">2,439,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-18786">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-18787">52,832</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-18788">52,834</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock under
    employee stock purchase plan</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares" id="ixv-18789">2,960</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-18790">53</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-18791">53</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reclassification of the Paruka
    warrant from liability to equity</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-18792">10,357</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-18793">10,357</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based compensation expense</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-18794">4,562</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-18795">4,562</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unrealized loss on marketable
    securities</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-18796">41</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-18797">41</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-149; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-150; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-152; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18798">83,724</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18799">83,724</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balances
    as of December 31, 2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="border-right: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-18800">137,138</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18801">2,931</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-18802">37,440,510</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18803">37</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18804">463,018</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18805">41</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18806">83,724</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18807">382,221</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 88%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18808">83,724</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18809">14,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net accretion of premiums and discounts on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd" id="ixv-18810">2,245</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-18811">1,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-18812">127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-18813">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-18814">1,128</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Other non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-18815">43</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-18816">3,462</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-18817">3,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-18818">14</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Related party accounts payable and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" unitRef="usd" id="ixv-18819">6,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.625in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18820">57,837</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18821">189</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchases of marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" unitRef="usd" id="ixv-18822">329,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.625in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18823">330,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" unitRef="usd" id="ixv-18824">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of notes payable to related party, net of issuance costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-18825">24,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from the Pre-Closing Financing, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" unitRef="usd" id="ixv-18826">227,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from the PIPE Financing, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-18827">188,681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Cash acquired in connection with the reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CashAcquiredInConnectionWithTheReverseRecapitalization" scale="3" unitRef="usd" id="ixv-18828">4,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-18829">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.625in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-18830">449,539</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-18831">61,575</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18832">61,575</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental disclosures of non-cash operating and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liability arising from obtaining operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-18833">982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Assets acquired in connection with the reverse capitalization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" scale="3" unitRef="usd" id="ixv-18834">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other liabilities assumed in connection with the reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="3" unitRef="usd" id="ixv-18835">54</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash accrued interest on convertible note converted to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" scale="3" unitRef="usd" id="ixv-18836">1,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" scale="3" unitRef="usd" id="ixv-18837">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Conversion of Series A non-voting convertible preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" unitRef="usd" id="ixv-18838">52,834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Reclassification of the Paruka warrant from liability to equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity" scale="3" unitRef="usd" id="ixv-18839">10,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-13839"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), the Company completed the acquisition (the &#8220;Merger&#8221;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company,
LLC.&#8221; On August 29, 2024, the Company changed its name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221;
and its Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
consummation of the Merger, the Company effected a <ix:nonNumeric contextRef="c38" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-18840">1-for-12</ix:nonNumeric> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the common
stock, par value $<ix:nonFraction contextRef="c39" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18841">0.001</ix:nonFraction> per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $<ix:nonFraction contextRef="c40" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-18842">275.0</ix:nonFraction>
million (which includes $<ix:nonFraction contextRef="c40" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" unitRef="usd" id="ixv-18843">25.0</ix:nonFraction> million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $<ix:nonFraction contextRef="c41" decimals="-5" format="ixt:num-dot-decimal" name="orka:AdditionalPaidInCapitalTransacationCost" scale="6" unitRef="usd" id="ixv-18844">20.5</ix:nonFraction> million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First
Effective Time&#8221;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of <ix:nonFraction contextRef="c42" decimals="4" format="ixt:num-dot-decimal" name="orka:ExchangeRatio" scale="0" unitRef="pure" id="ixv-18845">6.8569</ix:nonFraction> shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $<ix:nonFraction contextRef="c43" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18846">0.0001</ix:nonFraction> (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $<ix:nonFraction contextRef="c44" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18847">0.001</ix:nonFraction> per share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately <ix:nonNumeric contextRef="c45" name="orka:CommonStocksConversionRatio" id="ixv-18848">83:3332:1</ix:nonNumeric> (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="orka:InvestorsClosingShares" scale="0" unitRef="shares" id="ixv-18849">22,784,139</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18850">39,873,706</ix:nonFraction> shares of Pre-Merger Oruka Common Stock (which includes the issuance of <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-18851">2,722,207</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18852">4,764,032</ix:nonFraction> shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:PreFundedWarrantsOfCommonStockShares" scale="0" unitRef="shares" id="ixv-18853">5,522,207</ix:nonFraction> Company pre-funded warrants in exchange for <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-18854">9,664,208</ix:nonFraction> Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberOfSharesPurchased" scale="0" unitRef="shares" id="ixv-18855">5,600,000</ix:nonFraction> shares of Company Common Stock at a purchase
price of $<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18856">23.00</ix:nonFraction> per share, an aggregate of <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberofAggregateShares" scale="0" unitRef="shares" id="ixv-18857">2,439</ix:nonFraction> shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value
$<ix:nonFraction contextRef="c50" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-18858">0.001</ix:nonFraction> per share (&#8220;Company Series A Preferred Stock&#8221;), at a purchase price of $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18859">23,000.00</ix:nonFraction> per share (each Company Series A
Preferred Stock is convertible into <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-18860">1,000</ix:nonFraction> shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="orka:PrefundedWarrantstoPurchaseAnAggregateShares" scale="0" unitRef="shares" id="ixv-18861">680,000</ix:nonFraction>
shares of Company Common Stock at a purchase price of $<ix:nonFraction contextRef="c52" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18862">22.999</ix:nonFraction> per pre-funded warrant, for aggregate net proceeds of approximately $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-18863">188.7</ix:nonFraction>
million (net of issuance costs of $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-18864">11.9</ix:nonFraction> million).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-18865">83.7</ix:nonFraction> million and used net cash of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd" id="ixv-18866">57.8</ix:nonFraction> million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsAndCash" scale="6" unitRef="usd" id="ixv-18867">393.7</ix:nonFraction> million. The Company&#8217;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#8217;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#8217;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#8217;s business opportunities, as desired, which could materially harm the Company&#8217;s business, financial
condition and results of operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-13967"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-13975"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b>&#160;</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-13987"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" scale="0" unitRef="usd" id="ixv-18868">250,000</ix:nonFraction> per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-14020"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_MarketableSecuritiesPolicy-c0_cont_1" escape="true" name="us-gaap:MarketableSecuritiesPolicy" id="ixv-14032"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable
Securities</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_2" id="_MarketableSecuritiesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_3" id="_MarketableSecuritiesPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_4" id="_MarketableSecuritiesPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_MarketableSecuritiesPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-14059"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debt
Issuance Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-14071"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Receivable&#160;</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-14099"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements&#160;</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;Quoted
    prices in active markets that are identical assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices
    in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
    by observable market data.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
    including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-14149"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-14156"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18869">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c55" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18870">5</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18871">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18872">5</ix:nonNumeric> years</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1" escape="true" name="orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock" id="ixv-14181"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1" escape="true" name="orka:NotePayableToRelatedPartyPolicyTextBlock" id="ixv-14219"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note&#160;Payable
to Related Party</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1" escape="true" name="orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" id="ixv-14231"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-14248"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-14286"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Reporting</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#8220;CODM&#8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-14298"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-14315"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-14327"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commitments
and Contingencies</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-14339"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="orka:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-14392"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Loss</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-14404"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_OtherIncomeExpenseNetPolicyTextBlock-c0_cont_1" escape="true" name="orka:OtherIncomeExpenseNetPolicyTextBlock" id="ixv-14431"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income, net</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_OtherIncomeExpenseNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-14459"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-14476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-14488"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-14522"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Reverse Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-14532"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">August 29,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" unitRef="usd" id="ixv-18873">4,940</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" unitRef="usd" id="ixv-18874">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" unitRef="usd" id="ixv-18875">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" unitRef="usd" id="ixv-18876">5,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-14573"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="ixv-14579"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18877">6,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18878">6,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18879">19,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18880">19,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18881">3,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18882">3,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18883">22,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18884">22,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18885">6,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18886">45,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18887">52,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18888">190,792</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18889">190,792</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18890">12,966</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18891">12,966</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18892">34,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18893">34,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18894">75,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18895">75,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18896">314,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18897">314,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18898">13,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18899">13,607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18900">4,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18901">4,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18902">18,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18903">18,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-18904">6,350</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-18905">377,967</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-18906">384,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers in or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CashCashEquivalentsAndMarketableSecuritiesTextBlock-c0_cont_1" escape="true" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="ixv-14970"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
Cash equivalents and marketable Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MarketableSecuritiesTextBlock" id="ixv-14976"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18907">6,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18908">6,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18909">19,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18910">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18911">19,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18912">3,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18913">3,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18914">22,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18915">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18916">22,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18917">52,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18918">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18919">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18920">52,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18921">190,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18922">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18923">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18924">190,792</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18925">12,967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18926">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18927">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18928">12,966</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18929">34,808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18930">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18931">34,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18932">75,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18933">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18934">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18935">75,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18936">314,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18937">66</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18938">53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18939">314,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18940">13,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18941">32</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18942">13,607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18943">4,485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18944">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18945">4,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18946">18,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18947">55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18948">18,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-18949">384,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-18950">70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-18951">111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-18952">384,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="ixv-15333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 months or longer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 28%; text-align: left">Commercial papers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18953">18,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18954">3</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18955">18,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18956">3</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18957">49,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18958">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18959">49,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18960">11</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18961">4,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18962">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18963">4,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18964">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Corporate debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18965">39,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18966">40</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18967">39,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18968">40</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18969">13,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18970">32</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18971">13,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18972">32</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18973">4,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18974">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18975">4,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18976">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-18977">130,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18978">111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-18979">130,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-18980">111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="ixv-15696"><ix:continuation id="_CashCashEquivalentsAndMarketableSecuritiesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Due in one year or less</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-18981">314,073</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in 1-2 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-18982">18,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd" id="ixv-18983">332,142</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-15732"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
Accrued Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-15738"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued employee compensation and benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd" id="ixv-18984">2,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional and consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-18985">221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:AccruedResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-18986">1,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-18987">3,346</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-15779"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby Pre-Merger Oruka issued a convertible
note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c100" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-18988">25.0</ix:nonFraction> million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" unitRef="usd" id="ixv-18989">25.0</ix:nonFraction>&#160;million. The Convertible Note accrued interest at a rate of <ix:nonFraction contextRef="c102" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-18990">12.0</ix:nonFraction>% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on <ix:nonNumeric contextRef="c102" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-18991">December&#160;31, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company paid debt issuance costs of less than $<ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" unitRef="usd" id="ixv-18992">0.1</ix:nonFraction>&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $<ix:nonFraction contextRef="c104" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-18993">1.5</ix:nonFraction> million, which includes non-cash interest
expense related to the amortization of debt issuance.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $<ix:nonFraction contextRef="c105" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-18994">25.0</ix:nonFraction> million, plus unpaid accrued interest of $<ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" unitRef="usd" id="ixv-18995">1.5</ix:nonFraction> million divided by the conversion price which
was determined based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into <ix:nonFraction contextRef="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-18996">2,722,207</ix:nonFraction> shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-15818"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for <ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18997">5,522,207</ix:nonFraction> shares of Company Common Stock at
a purchase price of approximately $<ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18998">9.70</ix:nonFraction> per warrant. After the Merger, there are <ix:nonFraction contextRef="c108" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-18999">5,522,207</ix:nonFraction> pre-funded warrants outstanding and are exercisable
for <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantsExercisable" scale="0" unitRef="shares" id="ixv-19000">5,522,207</ix:nonFraction> shares of the Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19001">0.01</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, in connection with the PIPE Financing, the Company issued and sold <ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19002">680,000</ix:nonFraction> pre-funded warrants, at a purchase price of
$<ix:nonFraction contextRef="c112" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-19003">22.999</ix:nonFraction> per warrant, exercisable for <ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantsExercisable" scale="0" unitRef="shares" id="ixv-19004">680,000</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c114" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19005">0.001</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-203">no</span> expiration
date. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-204">none</span> of the pre-funded warrants have been exercised and <ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-19006">6,202,207</ix:nonFraction> pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19007">3,054,358</ix:nonFraction> employee warrants were issued at an exercise price of $<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19008">7.80</ix:nonFraction> per warrant. These warrants
vest over a period of <ix:nonNumeric contextRef="c118" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19009">four years</ix:nonNumeric>. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-205">none</span> of the warrants have been exercised and <ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-19010">3,054,358</ix:nonFraction> warrants
remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of <ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19011">20,000,000</ix:nonFraction> shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-19012">0.15</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-19013">3.0</ix:nonFraction>&#160;million.
Pre-Merger Oruka incurred less than $<ix:nonFraction contextRef="c122" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-19014">0.1</ix:nonFraction>&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to <ix:nonFraction contextRef="c123" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-19015">137,138</ix:nonFraction> shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of <ix:nonFraction contextRef="c124" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19016">2,439</ix:nonFraction> shares of the Company Series
A Preferred Stock at a purchase price of $<ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-19017">23,000.00</ix:nonFraction> per share.&#160;In November 2024, the <ix:nonFraction contextRef="c126" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-19018">2,439</ix:nonFraction> shares of the Company Series A Preferred
Stock were converted to <ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-19019">2,439,000</ix:nonFraction> shares of Company Common Stock. As of December 31, 2024, there are <span style="-sec-ix-hidden: hidden-fact-206">no</span> outstanding shares of Company
Series A Preferred Stock.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="orka:ScheduleOfConvertiblePreferredStockTableTextBlock" id="ixv-15892"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock <br/>
Issued&#160;and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock<br/> Issuable<br/> Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series B convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-19020">251,504</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-19021"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-19022">137,138</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-19023">2,931</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19024">11,428,149</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#8220;Series A Certificate of Designation&#8221;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#8217;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#8220;Stockholder Approval&#8221;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into <ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-19025">1,000</ix:nonFraction> shares of Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately <ix:nonNumeric contextRef="c45" name="orka:CommonStockConversionRatio" id="ixv-19026">83.3332:1</ix:nonNumeric>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paruka
Warrant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase <ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="orka:WarrantsToPurchaseCommonStock" scale="0" unitRef="shares" id="ixv-19027">596,930</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19028">19.39</ix:nonFraction> per share. The warrant has a term of <ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19029">10</ix:nonNumeric> years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Certificate of Incorporation provides for <ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-19030">545,000,000</ix:nonFraction> authorized shares of Company Common Stock. As of December
31, 2024, <ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-19031"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-19032">37,440,510</ix:nonFraction></ix:nonFraction> shares of Company Common Stock were issued and outstanding, including <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-19033"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-19034">2,207,553</ix:nonFraction></ix:nonFraction> shares of RSAs issued and outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="ixv-15989"><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Shares issuable on conversion of Company Series B Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19035">11,428,149</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Shares issuable upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19036">6,202,207</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issuable upon exercise of warrant under the Paruka Warrant Obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19037">596,930</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding and issued stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19038">1,567,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19039">3,054,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shares available for grant under 2024 Stock Incentive Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19040">4,246,324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2024 Employee Stock Purchase Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19041">460,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total shares of common stock reserved</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19042">27,556,257</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-16055"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although two non-employee
stock options were granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common stock
available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is <ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-19043">4,634,891</ix:nonFraction> shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19044">388,567</ix:nonFraction> shares were subject to outstanding
stock options, and as of December 31, 2024, there were <ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-19045">4,246,324</ix:nonFraction> shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to <ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" scale="-2" unitRef="pure" id="ixv-19046">5</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective on August 29, 2024, at which time <ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19047">463,489</ix:nonFraction> shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-19048">85</ix:nonFraction>% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;<ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" unitRef="pure" id="ixv-19049">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP" scale="0" unitRef="usd" id="ixv-19050">25,000</ix:nonFraction>&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" scale="-2" unitRef="pure" id="ixv-19051">1</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-19052">2,960</ix:nonFraction> shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were <ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-19053">460,529</ix:nonFraction> shares of Company Common Stock available in the pool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $<ix:nonFraction contextRef="c143" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-19054">0.1</ix:nonFraction>
million.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-16123"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c144" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19055">6.1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19056">100.21</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19057">4.26</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-16174"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19058">1,567,760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19059">11.39</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-19060">1,567,760</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19061">11.39</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-19062">9.4</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-19063">15,470</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-19064">1,567,760</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19065">11.39</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19066">9.4</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-19067">15,470</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19068">9.12</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024 and March&#160;2024, the Company issued <ix:nonFraction contextRef="c145" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-19069">2,207,553</ix:nonFraction> shares of RSAs to certain employees, directors, and consultants at a
price of $<ix:nonFraction contextRef="c131" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-19070">0.0001</ix:nonFraction> per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $<ix:nonFraction contextRef="c145" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-19071">0.1</ix:nonFraction> million.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-16379"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> RSAs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested balance as of February 6, 2024 (inception)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c145" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19072">2,207,553</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Unvested balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-19073">2,207,553</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Agreements and the Paruka Warrant Obligation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to <ix:nonFraction contextRef="c146" decimals="4" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" scale="-2" unitRef="pure" id="ixv-19074">1.00</ix:nonFraction>% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#8220;Paruka Warrant Obligation&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="orka:EstimatedFairValueOfWarrantsToBeGranted" scale="6" unitRef="usd" id="ixv-19075">10.4</ix:nonFraction> million. For the period from February 6, 2024 (inception)
to December 31, 2024, $<ix:nonFraction contextRef="c146" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-19076">10.4</ix:nonFraction> million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued
to certain Pre-Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during
the period from February 6, 2024 (inception) to December 31, 2024, the Company issued <ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRight" scale="0" unitRef="shares" id="ixv-19077">3,054,358</ix:nonFraction> warrants at an exercise price of $<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19078">7.80</ix:nonFraction>
per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance
and service based vesting requirements and upon completion of the Merger the performance-based requirements had been achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" id="ixv-16459"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Employee<br/> Warrants<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19079">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c150" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19080">7.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-19081">3,054,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19082">7.80</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-19083">9.5</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-19084">35,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-19085">3,054,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19086">7.80</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" id="ixv-19087">9.5</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" scale="3" unitRef="usd" id="ixv-19088">35,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#8212;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $<ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19089">6.27</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c118" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19090">6.1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19091">99.02</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19092">4.15</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-16703"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19093">11,992</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19094">2,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19095">14,919</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-19096">12.7</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c144" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-19097">3.2</ix:nonNumeric> years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $<ix:nonFraction contextRef="c131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-19098">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c145" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-19099">3.1</ix:nonNumeric>
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $<ix:nonFraction contextRef="c117" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-19100">16.3</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of <ix:nonNumeric contextRef="c118" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-19101">3.3</ix:nonNumeric> years.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-16743"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paruka Warrant Obligation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19102">10,357</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19103">2,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19104">1,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Employee stock purchase plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19105">37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19106">14,919</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-16808"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
Segment disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business activities on a consolidated basis and operates in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-19107"><ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-19108">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#8220;CODM&#8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#8217;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="ixv-16826"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development personnel-related (excluding stock-based compensation)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19109">3,959</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative personnel-related (excluding stock-based compensation)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19110">5,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19111">11,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19112">2,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">External research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19113">57,680</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19114">1,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative, excluding personnel-related and stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19115">5,082</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-19116">88,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19117">88,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-16899"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-239">No</span>
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-16910"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd" id="ixv-19118">83,724</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Loss before income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-19119">83,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period from February 6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from
income taxes. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-19120">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory
federal income tax rate to income before income taxes is as follows:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-19121">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-19122">0.18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure" id="ixv-19123">3.41</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-19124">0.87</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-19125">25.46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-19126">0.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-17017"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-19127">2,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-19128">3,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-19129">3,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" unitRef="usd" id="ixv-19130">424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-19131">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-19132">1,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-19133">10,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-19134">21,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-19135">184</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-19136">184</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19137">21,317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<ix:nonNumeric contextRef="c0" continuedAt="_SummaryOfValuationAllowanceTextBlock-c0_cont_1" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-19138">he
Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding
the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by
$<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd" id="ixv-19139">21.3</ix:nonFraction>&#160;million primarily due to continuing loss from operations.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_SummaryOfValuationAllowanceTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19140">21,317</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19141">21,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" unitRef="usd" id="ixv-19142">10.8</ix:nonFraction>&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" scale="-2" unitRef="pure" id="ixv-19143">80</ix:nonFraction>% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$<ix:nonFraction contextRef="c162" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" unitRef="usd" id="ixv-19144">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c163" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" unitRef="usd" id="ixv-19145">0.4</ix:nonFraction>&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="ixv-17156"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Changes related to tax positions taken in the current year</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" unitRef="usd" id="ixv-19146">1,047</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" unitRef="usd" id="ixv-19147">1,047</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="orka_OptionAgreementsAndLicenseAgreementsTextBlock-c0_cont_1" escape="true" name="orka:OptionAgreementsAndLicenseAgreementsTextBlock" id="ixv-17219"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Option Agreements and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#8220;Option&#8221;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#8220;Research
Program&#8221;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#8217;s sole discretion at such time as specified in the Option Agreements (the &#8220;Option
Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $<ix:nonFraction contextRef="c164" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19148">12.0</ix:nonFraction> million under each respective agreement upon the achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c165" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19149">10.0</ix:nonFraction> million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with
the ORKA-001 Field, the &#8220;Fields&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon,
on material breach without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="orka_OptionAgreementsAndLicenseAgreementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $<ix:nonFraction contextRef="c166" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19150"><ix:nonFraction contextRef="c167" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19151">12.0</ix:nonFraction></ix:nonFraction> million under each respective agreement upon the achievement of certain clinical development milestones and up
to $<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19152">10.0</ix:nonFraction> million under each respective agreement upon the achievement of certain regulatory milestones, including a $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19153">1.5</ix:nonFraction> million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $<ix:nonFraction contextRef="c170" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19154"><ix:nonFraction contextRef="c171" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-19155">2.5</ix:nonFraction></ix:nonFraction>
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a <ix:nonNumeric contextRef="c172" name="orka:RoyaltyPayableOnProductSales" id="ixv-19156">low single-digit percentage royalty for antibody products</ix:nonNumeric> for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to <ix:nonFraction contextRef="c173" decimals="4" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" scale="-2" unitRef="pure" id="ixv-19157">1.00</ix:nonFraction>% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-19158">0.8</ix:nonFraction>&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for <ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-19159">50</ix:nonFraction>% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $<ix:nonFraction contextRef="c176" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-19160">1.5</ix:nonFraction> million milestone payment related to the achievement of development candidate as research and development expense in the Company&#8217;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $<ix:nonFraction contextRef="c177" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-19161">2.5</ix:nonFraction> million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#8217;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-19162">13.5</ix:nonFraction> million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $<ix:nonFraction contextRef="c178" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="6" unitRef="usd" id="ixv-19163">2.8</ix:nonFraction> million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was also required to reimburse Paragon $<ix:nonFraction contextRef="c179" decimals="-5" format="ixt:num-dot-decimal" name="orka:OtherDevelopmentCost" scale="6" unitRef="usd" id="ixv-19164">3.3</ix:nonFraction>&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $<ix:nonFraction contextRef="c180" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitialFee" scale="6" unitRef="usd" id="ixv-19165">0.8</ix:nonFraction>&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $<ix:nonFraction contextRef="c181" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-19166">1.5</ix:nonFraction> million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $<ix:nonFraction contextRef="c180" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-19167">7.8</ix:nonFraction> million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $<ix:nonFraction contextRef="c182" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="6" unitRef="usd" id="ixv-19168">2.7</ix:nonFraction> million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-19169">42.0</ix:nonFraction> million of expenses in connection
with services provided by Paragon and Paruka under the Option Agreements.&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-17305"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c183" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-19170">39.5</ix:nonNumeric> months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" unitRef="usd" id="ixv-19171">0.9</ix:nonFraction> million of operating lease right-of-use assets, operating lease liability, current of $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" unitRef="usd" id="ixv-19172">0.2</ix:nonFraction>
million, and operating lease liability, noncurrent of $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-19173">0.8</ix:nonFraction> million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of <ix:nonNumeric contextRef="c184" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-19174">33</ix:nonNumeric> months and a discount rate of <ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-19175">17.95</ix:nonFraction>%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-19176">0.3</ix:nonFraction> million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="ixv-17326"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-19177">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-17350"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-19178">369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-19179">494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-19180">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-19181">1,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-19182">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total discounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19183">968</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: current portion of lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-19184">213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Non-current portion of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-19185">755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell
Line License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company entered into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics
Ireland Limited (&#8220;WuXi Biologics&#8221;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide,
sublicensable license to certain of WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed
Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use
of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;).
Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002
programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:NonRefundableLicenseFee" scale="0" unitRef="usd" id="ixv-19186">150,000</ix:nonFraction>, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon six months&#8217; prior written notice
and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for
a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails
to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other
party&#8217;s bankruptcy.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-17445"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-17451"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February 6, 2024<br/> (Inception) to <br/> December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss<br/> Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Shares<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss Per<br/> Share,<br/> Basic and<br/> Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19187">65,037</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-19188"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-19189">16,789,362</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-19190"><ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-19191">3.87</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series A Preferred Stock <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c185" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">1,918</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares"><ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">495</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-19195"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-19196">3,873.25</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series B Preferred Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">16,769</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">51,946</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-19200"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-19201">322.81</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19202">83,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: left"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-19203">495,191</ix:nonFraction> for the period
from February 6, 2024 (inception) to December 31, 2024.</span></ix:footnote></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: left"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-19204">4,328,844</ix:nonFraction> for the
period from February 6, 2024 (inception) to December 31, 2024.</span></ix:footnote></td>
</tr></table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-17567"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c186" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-19205">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-19206">2,207,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c188" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-19207">1,567,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued warrant to Paruka</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c189" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-19208">596,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-19209">7,426,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-17614"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paragon
and Paruka each <ix:nonNumeric contextRef="c191" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-19210"><ix:nonNumeric contextRef="c190" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-19211">beneficially own less than 5%</ix:nonNumeric></ix:nonNumeric> of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fairmount
beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Board, and <ix:nonNumeric contextRef="c193" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-19212"><ix:nonNumeric contextRef="c192" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-19213">beneficially
owns more than 5%</ix:nonNumeric></ix:nonNumeric> of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="ixv-17628"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paragon reimbursable Option Agreements&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19214">1,482</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Paragon milestone payments for Option Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19215">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paragon reimbursable other research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19216">515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Paragon reimbursable patent expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19217">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19218">6,022</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-17675"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of <ix:nonNumeric contextRef="c198" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-19219">54</ix:nonNumeric> months. The Company expects to pay approximately $<ix:nonFraction contextRef="c198" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" unitRef="usd" id="ixv-19220">1.6</ix:nonFraction> million over the lease term.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;13. Other Expenses of Issuance and Distribution </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The expenses payable by us in connection with the issuance and distribution
of the securities being registered hereunder on Form S-1 (other than underwriting discounts and commissions, if any) are set forth below.
The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC registration fee:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,913</td><td style="width: 1%; text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Printing and engraving</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,087</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">170,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: left">Previously paid.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;14. Indemnification of Officers and Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 145 of the DGCL authorizes a court to award, or a corporation&#8217;s
board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms
of Section 145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement
of expenses incurred, arising under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by the DGCL, the Registrant&#8217;s Certificate of Incorporation
contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as
a director, except liability for the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any breach of the director&#8217;s duty of loyalty to the Registrant or its stockholders;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>under Section 174 of the DGCL (regarding unlawful dividends and stock purchases); or</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>any transaction from which the director derived an improper personal benefit.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by the DGCL, the Registrant&#8217;s Bylaws provide that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the DGCL, subject
to very limited exceptions;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the Registrant may indemnify its other employees and agents as set forth in the DGCL;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding
to the fullest extent permitted by the DGCL, subject to very limited exceptions; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>the rights conferred in the Bylaws are not exclusive.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant has entered, and intends to continue to enter, into
separate indemnification agreements with its directors and executive officers to provide these directors and executive officers additional
contractual assurances regarding the scope of the indemnification set forth in the Registrant&#8217;s Certificate of Incorporation and
Bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director
or executive officer of the Registrant regarding which indemnification is sought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indemnification provisions in the Registrant&#8217;s Certificate
of Incorporation, Bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its
directors and executive officers may be sufficiently broad to permit indemnification of the Registrant&#8217;s directors and executive
officers for liabilities arising under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 163; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant currently carries liability insurance for its directors
and officers. One of the Registrant&#8217;s directors, Peter Harwin, is also indemnified by his employer with regard to their service
on the Registrant&#8217;s board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;15. Recent Sales of Unregistered Securities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 13, 2024, we completed the Private Placement of Private
Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants pursuant to the SPA with the Selling Stockholders
in the September 2024 PIPE. We sold an aggregate of 5,600,000 shares of Common Stock, 2,439 shares of our Series A Preferred Stock and
pre-funded warrants to purchase 680,000 shares of Common Stock in the September 2024 PIPE for an aggregate purchase price of approximately
$200.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2024, following stockholder approval, each share of Series
A Preferred Stock converted into 1,000 shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares issued pursuant to the September 2024 PIPE were offered
and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation
D thereunder. Each of the investors represented that it was an &#8220;accredited investor,&#8221; as defined in Regulation D, and acquired
the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof.
The shares of Series A Preferred Stock issued pursuant to the September 2024 PIPE have not been registered under the Securities Act and
such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities
Act and any applicable state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;16. Exhibits and Financial Statement Schedules</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>(a)</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Exhibits</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 9%"><span style="font-size: 10pt"><b>EXHIBIT<br/>
NUMBER</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-size: 10pt"><b>DESCRIPTION OF EXHIBIT</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">2.1*&#8224;</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm"><span style="font-size: 10pt">Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.&#8217;s Form 8-K filed with the SEC on April 3, 2024).</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">3.1*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-5_oruka.htm"><span style="font-size: 10pt">Amended and Restated Certificate of Incorporation of the Company, filed September 3, 2024 (incorporated by reference to Exhibit 3.5 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">3.2*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-6_oruka.htm"><span style="font-size: 10pt">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.6 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">3.3*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex3-1_oruka.htm"><span style="font-size: 10pt">Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">3.4*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-9_oruka.htm"><span style="font-size: 10pt">Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.9 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.1*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-2_oruka.htm"><span style="font-size: 10pt">Form of Registration Rights Agreement, dated as of September 13, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.2*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-1_oruka.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto (incorporated by reference to Exhibit 10.1 the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.3*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex4-3_orukathe.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.4*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex4-1_oruka.htm"><span style="font-size: 10pt">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="ea023317001ex5-1_oruka.htm">Opinion of Gibson, Dunn &amp; Crutcher LLP.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1*&#8224; </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm"><span style="font-size: 10pt">Form of Amendment to Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on July 9, 2024).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.2*&#8224; </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm"><span style="font-size: 10pt">Form of Amended &amp; Restated Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on July 9, 2024).</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.3*</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024097443/ea021692901ex10-4_oruka.htm"><span style="font-size: 10pt">Form of Registration Rights Agreement, dated as of August 29, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.4* </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm"><span style="font-size: 10pt">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on April 3, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.5*&#8224;&#8224;#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm"><span style="font-size: 10pt">Separation Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on April 4, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.6*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and Thomas A. Keuer, dated April 22, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on April 23, 2024)</a>.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.7*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and C. Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on April 23, 2024).</a></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.8*&#8224;#</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-25_oruka.htm"><span style="font-size: 10pt">Consulting Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (incorporated by reference to Exhibit 10.25 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.9*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-19_orukathe.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.10*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-10_oruka.htm"><span style="font-size: 10pt">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.11*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-11_oruka.htm"><span style="font-size: 10pt">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.12*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm"><span style="font-size: 10pt">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated by reference to Exhibit 10.40 to ARCA biopharma, Inc.&#8217;s Registration Statement on Form S-4 filed with the SEC on May 14, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.13*# </span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-13_oruka.htm"><span style="font-size: 10pt">Second Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan, effective as of May 7, 2024 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.14*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-20_orukathe.htm">Non-Employee Directors Compensation Program (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.15*# </span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm"><span style="font-size: 10pt">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma, Inc.&#8217;s Registration Statement on Form S-4 filed with the SEC on May 14, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm"><span style="font-size: 10pt">Form of Stock Option Agreement under the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to ARCA biopharma, Inc.&#8217;s Registration Statement on Form S-4 filed with the SEC on May 14, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.17*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-16_oruka.htm"><span style="font-size: 10pt">Form of Employee Warrant Agreement (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.18*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024098574/ea022059801ex99-2_oruka.htm">Form of Grant Notice for Nonqualified Stock Option and Standard Terms and Conditions for Stock Options (Directors) (incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Registration Statement on Form S-8 filed with the SEC on November 14, 2024).</a> </td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.19*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024098574/ea022059801ex99-3_oruka.htm"><span style="font-size: 10pt">Form of Grant Notice for Stock Option and Standard Terms and Conditions for Stock Options (Employees) (incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form S-8 filed with the SEC on November 14, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.20*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm"><span style="font-size: 10pt">Amended and Restated Director Offer Letter, dated March 22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated by reference to Exhibit 10.43 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.21*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm"><span style="font-size: 10pt">Director Offer Letter, dated April 24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit 10.44 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.22*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-1_oruka.htm"><span style="font-size: 10pt">Amended and Restated Employment Offer Letter by and between Oruka Therapeutics, Inc. and Lawrence Klein, dated as of October 3, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No. 241354944).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.23*#</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-2_oruka.htm"><span style="font-size: 10pt">Amended and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No. 241354944).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.24*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-18_orukathe.htm">Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Joana Goncalves, dated October 1, 2024 (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.25*#</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-17_orukathe.htm">Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Paul Quinlan, dated October 1, 2024 (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024069662/ea021147201ex10-1_arcabio.htm"><span style="font-size: 10pt">Asset Purchase Agreement, dated August 14, 2024, by and between ARCA biopharma, Inc. and Genvara Biopharma, Inc. (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on August 15, 2024).</span></a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.27*&#8224;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm"><span style="font-size: 10pt">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March 28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.&#8217;s Registration Statement on Form S-4/A filed with the SEC on June 18, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.28*&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-29_orukathe.htm">IL-17 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated February 4, 2025 (incorporated by reference to Exhibit 10.29 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">10.29*&#8224;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm"><span style="font-size: 10pt">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March 28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.&#8217;s Registration Statement on Form S-4/A filed with the SEC on June 18, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="font-size: 10pt">10.30*&#8224;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-31_orukathe.htm">IL-23 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated December 17, 2024 (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">10.31*&#8224;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-32_orukathe.htm">Cell Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated March 4, 2024 (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="font-size: 10pt">10.32*&#8224;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex10-33_orukathe.htm">Amendment No. 1 to the Cell Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated November 20, 2024 (incorporated by reference to Exhibit 10.33 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap"><span style="font-size: 10pt">16.1*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex16-1_oruka.htm"><span style="font-size: 10pt">Letter from KPMG LLP, dated September 5, 2024 (incorporated by reference to Exhibit 16.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; white-space: nowrap"><span style="font-size: 10pt">21.1*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea023044501ex21-1_orukathe.htm">List of Subsidiaries of Oruka Therapeutics, Inc (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap"><span style="font-size: 10pt">23.1</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="ea023317001ex23-1_oruka.htm">Consent of PricewaterhouseCoopers LLP</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap"><span style="font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ea023317001ex5-1_oruka.htm">Consent of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit 5.1)</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">24.1</span></td>
    <td>&#160;</td>
    <td><a href="#p_001"><span style="font-size: 10pt">Power of Attorney (included on the signature page to the registration statement)</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">107*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024097737/ea022056701ex-fee_oruka.htm">Filing Fee Table (incorporated by reference to Exhibit 107 to the Registrant&#8217;s Registration Statement on Form S-1 filed with the SEC on November 14, 2024).</a></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Previously filed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">#</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">&#8224;</span></td>
    <td><span style="font-size: 10pt">Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i) not material and (ii) is the type of information that the registrant both customarily and actually treats as private and confidential.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>(b)</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Financial statements schedules</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;17. Undertakings </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The undersigned Registrant hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) to include any prospectus required by Section 10(a)(3) of the Securities
Act;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii) to reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase
or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the
maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; in the effective registration statement; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) to include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) That, for the purpose of determining any liability under the Securities
Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) That, for the purpose of determining liability under the Securities
Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other
than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. <i>Provided, however</i>, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise,
the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense
of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="p_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, the Registrant
has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo
Park, California, on March 6, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%"><span style="font-size: 10pt"><b>ORUKA THERAPEUTICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Lawrence Klein</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Lawrence Klein</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, this registration
statement has been signed by the following persons in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 33%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 50%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Lawrence Klein</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chief Executive Officer &amp; Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Lawrence Klein</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Arjun Agarwal</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Senior Vice President, Finance and Treasurer </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Arjun Agarwal</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Samarth Kulkarni</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chairman of the Board</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Samarth Kulkarni</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Kristine Ball</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Kristine Ball</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Carl Dambkowski</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Carl Dambkowski</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Peter Harwin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Peter Harwin</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Cameron Turtle</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Cameron Turtle</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">II-6</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">POS AM</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="orka:SubscriptionReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-8" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:AccountsPayableTradeCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="us-gaap:AccountsPayableOtherCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-13" name="us-gaap:LiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-14" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-15" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-16" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-17" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-18" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-19" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-20" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-21" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-22" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-23" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-24" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-25" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-26" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-27" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-28" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-29" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-30" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-31" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-32" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-33" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-34" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-35" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-36" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-37" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-38" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-39" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-40" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-41" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-42" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-43" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-44" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-45" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-46" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-47" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-53" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-54" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-55" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-57" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-58" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-59" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-60" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-61" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-62" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-63" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-64" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-65" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-67" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-68" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-69" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-70" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-71" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-72" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-73" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-77" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-78" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-82" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-83" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-84" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-85" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-86" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-87" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-88" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-89" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-90" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-92" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-93" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-94" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-95" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-96" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-97" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-98" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-99" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-100" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-101" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-102" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-103" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-104" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-105" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-106" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-107" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-108" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-109" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-110" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-111" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-112" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-113" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-114" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-115" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-116" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-117" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-118" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-119" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-120" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-121" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-122" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-123" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-124" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-125" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-126" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-127" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-128" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-129" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-130" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-131" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-132" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-133" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-134" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-135" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-136" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-137" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-138" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-139" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-141" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-142" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-143" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-144" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-145" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-146" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-147" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-148" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-149" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-150" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-151" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-152" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-153" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-154" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-155" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-156" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-157" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-158" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-159" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-160" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-161" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-162" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-163" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-164" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-165" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-166" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-167" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-168" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-169" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-170" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-171" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-172" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-173" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-174" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-175" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-176" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-177" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-178" name="orka:FairValueCashEquivalentsAndMarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-179" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-180" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-181" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-182" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-183" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-184" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-185" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-186" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-187" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-188" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-189" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-190" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-191" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-192" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-193" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-194" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-195" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-196" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-197" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-198" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-199" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-200" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-201" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-202" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c115" id="hidden-fact-203" name="orka:ClassOfWarrantOrRightExpirationDate" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c115" id="hidden-fact-204" name="orka:ClassOfWarrantOrRightWarrantsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-205" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c128" id="hidden-fact-206" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-209" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-210" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c147" id="hidden-fact-211" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-213" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-214" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-215" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-216" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-218" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-220" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-222" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-224" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-226" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-228" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-229" name="orka:WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-231" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-232" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-233" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-234" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-235" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-236" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-237" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-238" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-239" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-19463">0000907654</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-19464">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="orka-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact ix_4_fact ix_5_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact ix_8_fact" toRefs="ix_4_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-03</xbrli:startDate>
    <xbrli:endDate>2024-09-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmL2iE4T0ATe8B6c9E/C4wQk=] CSR-->
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-29</xbrli:startDate>
    <xbrli:endDate>2024-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-07</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingStockBasedCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ExternalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:NominationOfADevelopmentCandidateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AntibodyProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:RestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountsOwnershipInterestInParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMilestonePaymentsForOptionAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea023317001ex5-1_oruka.htm
<DESCRIPTION>OPINION OF GIBSON, DUNN & CRUTCHER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 70%; vertical-align: middle">&nbsp;<IMG SRC="ex5-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gibson, Dunn &amp; Crutcher LLP</P>
                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Embarcadero Center, Suite 2600<BR>
San Francisco, CA 94111-3715</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel 415.393.8200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">gibsondunn.com</P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">March 6, 2025</P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 70%">&nbsp;</TD>
  <TD STYLE="width: 30%">Client: 68823-00001</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">855 Oak Grove Avenue</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 100</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Menlo Park, CA 94025</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Oruka Therapeutics, Inc.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Registration Statement on Form S-1&nbsp;</TD></TR>
     </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to Oruka Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
of a Registration Statement on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;) pursuant to the Securities Act of 1933, as amended
(the &ldquo;<U>Securities Act</U>&rdquo;), relating to the resale from time to time by the selling stockholders named therein of (i) up
to 5,600,000 shares (the &ldquo;<U>Common Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<U>Common
Stock</U>&rdquo;), (ii) 2,439,000 shares (the &ldquo;<U>Conversion Shares</U>&rdquo;) of Common Stock issued upon the conversion of 2,439
shares of the Company&rsquo;s Series A preferred stock, par value $0.001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;) in November
2024 and (iii) 680,000 shares of Common Stock (the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;) issuable upon the exercise of pre-funded
warrants (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In arriving at the opinion expressed below, we have examined originals,
or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common
stock certificates, form of Pre-Funded Warrant and such other documents, corporate records, certificates of officers of the Company and
of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination,
we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents
submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the foregoing, and subject to the assumptions, exceptions,
qualifications and limitations set forth herein, we are of the opinion that (i) the Common Shares are validly issued, fully paid and non-assessable
and the Conversion Shares, issued upon the conversion of the Preferred Stock in November 2024, are validly issued, fully paid and non-assessable,
(ii) provided that the Pre-Funded Warrants have been duly executed and delivered by the Company and duly delivered to the purchaser thereof
against payment therefor, then the Pre-Funded Warrants, when issued and sold as described in the Registration Statement, assuming a sufficient
number of Pre-Funded Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles
(regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and
fair dealing and (iii) the Pre-Funded Warrant Shares, when issued upon a valid exercise of the Pre-Funded Warrants in accordance with
their terms, will have been duly authorized and validly issued and will be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the filing of this opinion as an exhibit to the Registration
Statement, and we further consent to the use of our name under the caption &ldquo;Legal Matters&rdquo; in the Registration Statement and
the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Gibson, Dunn &amp; Crutcher LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Gibson, Dunn &amp; Crutcher LLP</B>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">One Embarcadero Center Suite 2600 | San Francisco,
CA 94111-3715 | T: 415.393.8200 | F: 415.393.8306 | gibsondunn.com</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea023317001ex23-1_oruka.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use in this Registration Statement on
Form<B>&nbsp;</B>S-1 of Oruka Therapeutics, Inc. of our report dated March 6, 2025 relating to the financial statements of Oruka Therapeutics, Inc., which
appears in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts<BR>
March 6, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 .X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZBBJFH:A
M;Z;9RW5S*$B0<G^@]Z$KB;45=EAY%C&6X &23T%<SJGCK2K)FBA+W<J]HONY
M_P!X\?EFN(U_Q1>ZY(4W-#: _+"#R?=O4^W2L/G&.WI7;3PW61X6(S1WY:7W
MG83_ !$OG<_9[&WB7MO)8_IBHE^(6K!LM!:,/3:P_K7)XHKH5&'8\YXVNW?F
M._L?B-$6 OK%HQ_>A;</R.*Z_3M:L-5B,EG<+* ,E1PP^H/(KQ&I;>YGM)TG
MMY7BE0Y5T.#64\-%_"=5',ZD7:>J/>**Y;PGXI&LH;:[*I>QKD@# D'J/ZBN
MI!!Z5PRBXNS/H*56-6/-$****DU"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** $9MHS7DGB[7SK&I-$C_Z';L50#HS="Q_D/_KUWWB_4CIO
MARXD1MLLG[I#Z%N/Y9KEM T&UTVWM]4U=,RS.J6MN1DY/3([G^0KIHVBN=GE
M8USJR5&.BZF3I/A#4=303OMM;8\^9*.2/4+_ (UU>F^!]$:,.TTMX,D%M^U2
M1Z;:K>,]0D:]2R1V6-(]SJ.A)]?PKJM$MQ;:-9QC&!$"?J>3_.G4J3:O<G#X
M6BI.-KVZE,>#M! Q_9\?_?3?XU1N_ &CS@F 36S=BCY _ YKJZ*P522ZG?+"
MT9*SBCR?5_!.HZ:KRP8NX%Y)C&' ]U_PKFJ]\89!KC/%GA)+U'O;"-4NP,O&
MHXE'_P 5_.NJEB-;2/)Q66I+FI?<>?6-Y+I]]#=P'$D+!A[^H_$<5[?:3I<V
MD4\9RDBAU/L>:\(P?0]<<BO7?#5PT?AS2!)UD0)^AQ_(4\5%63%E4VI2@SH*
M**Y?QMXMB\(Z*UV566ZE;R[:(G 9O4^PZG\/6N**<G9'NRDHJ[.E>18QER%7
MN2<"F1W<,Q(BECD(_NN#_*O!-+\.^+?B5(VI7VHM'9%L++,3L)!Y$<8XP/6M
M"_\ @UK>EQ?:]'U=)YXQD(H,+D_[+ GFM_916CEJ<WMIO51T/<1R*8\@0C..
M?4XKR;X<_$*^N=47P]XA=FN<E()Y!M?>.L;^_!P?;%)\<V(M]"PQ'[V;H<=E
MJ51?/R,MUU[-S1ZUYJ_WE_.E#9KPG1?A'>ZUHEEJ2:VD2W4*RB,Q,=N1G&=U
M5=7T3Q=\,Y8+VWU5I+1W"AXG8Q[O[KHW'..M5[&+=E+4CV\DN:4=#Z =M@&:
M19 S8!!^AKB+C7T\2_";4-51?+:6QE$D8.=C@$,!^(X^M<W\"R3#KF23\\/4
M^SU'LWRN3Z&GMESJ*ZGKU1><IXRN?3-2UX%8,W_"^G&YL?VE+QGC[C4H0Y[^
M0ZE3DMYGO)E SG QZFG*V[I7DGQT)%EHV"1^\EZ'V%=UX.GCM_ FD2S.$C2R
M1G=C@ !>230Z=H*7<%5O-Q['1,P523C'O31("3@@X]#7B'B;Q+J?Q'U]/#WA
MW<-.#9:0Y D /,C^B#L.Y_"O5?"WABR\+:0EC9@N3\TT[_>E?U/]!VHE3Y5K
MN$*G/)I;&[3=XW8R,_6J6LZE!H^DW.I7+8AMHVD;GK@<#\3Q^-?,KW&M33OX
MNW./]/\ ]=G@3??"_3''Z55*ESW=R:M94VD?5/>BLSP_JT.NZ'::I ?DN8P^
M/[I[K^!R/PK3K)JSL;IW5T8&M:<-3U'38YL&U@9[B4'H2  H_,D_A7)VNIMK
M_CZU?)^S0NWDKVPH//U)Y_*NV\2221>'-0DAX<0-@^G'->9^$)5A\5V1/"L6
M4?BIQ7325X-GD8R7+6C'N]2_K\K3:Y>L3G$A4?AQ7HNDRB72K-U.085_E7G6
MNQF+7+Q6&"92WY\UU7@S4%FL#9.W[R DJ/5#_P#7I5%>"9IAIVK23ZG44445
MS'J!2,H;KFEHH \Q\6^'Y%\0P&TC^74&V@#^&3^(_3'/YUU%ZZ6;6-G"?EM5
M7], ?H*UK^ZAM(UED57E&?+7'.?:N9W23W(9SN=W&3Z\UT<SDE?H><J,:4Y.
M/4[45X7\;IG?Q+IUNQ(B2T+#V+.03^@KW05YE\7O"T^K:7#J]G$99[$,)449
M+1'DD?[IY^A-30:4U<Z<1%RIZ'H&DV5O8Z19VENH$,,*H@'3  JXRA@ 21SG
M@UY5X"^*6G?V3;Z9KUQ]GN($")<L/DE4<#)'1L>O%=/K'Q*\*Z;:&0:E%>2@
M92&U.]F/U' _$TI4Y\UK#C5ARWN>7?$J-=+^*45U9@+*WD7!V<?/NQGZG:*Z
M+XY?\>N@_P#76;^2USGABQO_ (B?$-M9NXRMI%,LTQ'W5"_<B![G@?J:Z/XY
MC%MH6?\ GK-_):ZEI4A'JCC:O3G+HSI/!_BO0;/P?HUO<ZUI\,L=I&CQO<*&
M4@<@C/!KEOBIXVT?5-$&D:;=QW<CRK)))$<HBKSUZ$DXZ=JD\.?"70]7\.:;
MJ-Q=7PFNK=)7".H4$C)QQ7)R:9!\/_B'#%K-FE[IJMOC>5<YC)X<#H64]1_B
M*F,:?.VGJBI2J<B36C.YT#3)]+^!^H)<QM')/:W%QL88*A@<?H ?QJG\"O\
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M5)4XV04R:))X9(945XY%*LK#((/!!I]%9FI%;V\=K;QV\,:QQ1J$1$& J@<
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ G # 2(  A$! Q$!_\0
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M7HE1MIVVQ(/T/>O./&&+R61;%]]Y$P,R*?F"X[]\#^M<P^J:GJ$"6]W$+J*
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M>WF>I)\:/"#RK'YE\I8X^:U(Q]:Z"+QMH\J!D-Q@_P#3(U\]2Z-J<BEK[;-
M#N"J_P"\4^@..:[G0HY7T6!X]RQ[0,2')X]?4TG2B5"O-NS/5H_$VFS(75Y-
MH&22F*QH?B9X;GO)[5)KCS83AP8L?E7*7%W::9IA:1E!QR"W0_C7EVIZGI4>
MLK<:?;2AR3YOHV>H%)4DQSKN*/>I?B?X<A9P[7GRKDD6YP?I51OC!X56S6[8
MWXB9MH)M3UKQ":_<3C]SOMC\R2#G!'4$>WM3=5UJ::WBM_(MV$D>00A.1]"/
MUJO8Q,_K,CWD?%7PT;!+U6O6@;N+8G'UJ#_A;WA8QI(IOW#D@!+4D@^XKP+1
MKS48%8VBO-"G,D)Y&/IUKH[C0K6YMQ=V>Z*7[QC#=^X]C1[&(OK,^ECUJ;XO
M^%8!'YC7RLXR%-L<@9[CM1)\7O"\4:R.-0",<*WV1L'Z5XS;17%]:S"2$/N
M59'.XY7L,U3U6+;IT2LC0NC95 #@C'?WI^PB)XJ>Y[@GQC\)N&(>]!7L;8Y/
MTH7XQ>%6&5:_8>UJ3FOGE K%8_M/DC&69LE>_H,^E6)+MY9E=9]F ,D>HXXQ
MSSUH]C$2Q4[=#Z+C^)WA^3;@7P++NPUL01]1VJ ?%?PV;K[.5U!&SC>]J57/
MU-?/<.H16GVB1;B1KETV@[2<_B3QWK)N;RYN !+/)(%Z;F)Q2]E$T6)DSZ@F
M^)_AR".*1I+IED9@"D!.,=2<=!58?%[PJ>DMW_X#FOG!+J[CA6V>5UC.#Y6>
M/;(_&MO1M,6\67-P1-$>80N<^G/2A48F<\546R1]%6GCS1;RR^UQ-<>5NVY,
M1!S]*T8?$-A, 5,HR,C*8KS30K&2/11;-$HX#8S@Y_K6G;W4A=0[ %1C;C&#
M4.FNAO&M+E3D=Z-;LR< R?\ ?%3#4;<C(W8_W:Y"";<P)!![^];ML%D4?3I6
M;BD;1J-FD=2MQ_>_[YIAU6V_Z:?]\U7>!< XQ5.X*(N2#^%"BBG)HOOKEDG4
MR?\ ?%-.OV0_YZ_]^ZYR20B;< "F.F.:<,.!A,_6K]FC%U9&\?$5AG'[[_OV
M:1O$NGKU\[_OW6%(ZJ"2,_054F=67)_*CD0.JSJ4\2Z<_(:3_OBDF\3:="/F
M:4_[L9->>G4EBNFAD@9%W[=Q/'UJ2:XBN+8M'-\AXRO'-5[)$+$G>IXHTUQE
M3-C_ *YU877;)P2#)Q_L5Y/82?9+L1%I2&/S"5\]/2NNM6)MMZ\GI0Z214*[
MEN=)/XGTRW?;)(X/^[2'Q/IH&=TF.OW*\PU-7EN68GD= #7/7]SJ-NX)E<HP
M^4C&!5*@F93Q4H]#W$>)M-89WOC_ '*FT_7++5)Y8;5G9X@"V5P.:^?DU74&
MD"+.1N.!G %>A?"JXEDOM2CD8-MC0Y#9R=QI5**C&X4<9[2:C8H?'=V6ST)5
M .Z:7@]_E6O$O)EEF"!06)^ZI%>T_'PXL="]Y9O_ $%:\5B0R/A!EL=/6KI?
M"8XG^(S>\)^"M4\8WTD.G[8K:(CSKF3.Q,]O4GVKUNQ^!6@PP 76HW\\IZNI
M5!^ P?YUVG@K1+?0/"6GV,"@?NEDD8?Q.PRQ_7]*Z&L)5&WH=M.A%1U5SS/_
M (4=X8YQ=:F,^DR__$TJ?!'PTC _:]3//(,JX/\ X[7I=%3SR[E^PI]CSO\
MX4SX;!.)[\+G(7S5PO/0?+6P/A]I/V8V[37;QGL\@;'Z5UE%'/+N4J4%LCB9
MOA?HLNE'3EN;^&WW;@(90I!^N.?QK+/P3\.OGS+[57!QNS.O(';[M>E44N>7
M</90['$_\*L\.K9M:PI-#$QRWEL 6]B<<UF_\*5\-HX>"YU&!AT\J91C_P =
MKTBBCGEW#V4.QPNG_"W2],#BVU/4QO)+;I$;)/\ P&M0^"[0,A2_O8U1=H5'
M4#\?EKIJ*.9CY(]CB]2^&FEZJFRXO]0V=U5U&[Z_+R/:HM&^%FD:%<--9W^I
MY8Y96F4J?J-M=S11S2[A[.-[V,J/1%B/RWEQ@]5)4@_I7+ZW\(?#6M7DER/M
M-B\O,HLG6,2'N2,&N]HI78W%,\K'P"\*#_E[U4_69/\ XFE'P$\+#_E\U7_O
M\G_Q->IT4^9B]G'L>;+\$_#2Z>UE]JU$Q,=V3*N0?;Y:KCX#^%QTO-4_[_+_
M /$UZC11SR[B]E#L>91? [PW#(LD=]JJNO((G4$?^.U=N?A%H=T8B][J(,2D
M+M=!UZG[O6O0**?/+N+V,.QYW'\&O#B(4>>^E7J!)(IV_3Y>*N:/\+M&T2Z:
MXM;S4&=NHDE4CZ_=ZUW%%+GEW&J4%K8XZ/X;:/%J[ZF)[PW+C!)=<?RK0B\%
MZ1!!+!%&R1RG<ZC')]>E=#11SR[C4(KH<3>?"WP_>3&;==0R$Y+0R!<GUZ5M
MZ'X9M]!MY((;N[GB<YVSN&VGVP!6W10YR>C8E3@G=(P9O".F7%TUQ()2S'+
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M5D+I+:[C:TE8@9ED3:,J6!+!B.0IXZTZ#Q387$E@L:RL+UG5' !5-K%06.>
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M,=<=Q5=/#"1VWV>.^NECDB6&<97,J $ $XX(4[<CD@#O6M]@@_O3_P#?]_\
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MM]@_Z>[K_OY_]:C[!_T]W7_?S_ZU%WV"WF6<^]5[ZU2_T^YLY&94GC:-BO4
MC!Q2QV?ER!OM-P^/X6?(/Z5++$)4*[W0G^)#@BGJ%C/&BV*/:-%!'$MLS.J1
MHJJQ*[<D8]#6;_PAFF['W-,TN08I2P#0X<N-F./O$GFMK[!_T]W7_?8_PI?L
M!_Y^[K_OY_\ 6I7?8=O,QY/"L,TC2R7L[3<!)61"R@.K#=\OS\J/O9JW<:3/
M<Z6UBVIS)N;+2Q1HI*_W< 8P>_>KOV#_ *>[K_OY_P#6H^P?]/=U_P!_/_K4
M7?85O,=:PFVMHX3)OV*%W;0O3V' _"I\^]5OL'_3W=?]_/\ ZU'V#_I[NO\
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M_P#?H_XT?5J@?VE0\_N/7-PHS7D7_"R]=_NV?_?H_P"-)_PLS7?[MG_WZ/\
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M0UH5%.ZL?5T;;HU;&,C-<V=-OYKD)*Y%L]Q-\H7!4," V<\CVQ72(I6-5/4
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M5#E' 93Z@USB^#(%B*_;')((PT*&-02I^5,87[HZ8Y)-;]C:BQLH;42R2B)
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M#_H'P_\ @0G^-)_PJWQA_P! ^'_P(3_&OH?%&*/K=0?U"EYGSO\ \*L\8?\
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M52?H,TU_,4X9'! S@J0<57U:'<R_M+$>7W'KO_"R-!_Z>_\ OS_]>D_X63H
M_P"?O_OS_P#7KR("5QE(I&'JJDU$7YI_58!_:5?R^X]A_P"%E:!_T]_]^?\
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MW@VJ1(9/,9A)$5EQMRHYS'[CWK>T?6)=4EE_<(D"$H',OSLZXW?)C@<\'/\
M.@#8I#2TAZB@#SV2<L\H)YW'!/;FMCPE=B:ZNXL-E$4DGH>37(3S,MU*021O
M/\ZZ?P6&^UWC$]8UXQTY-=,U:)Y]*5ZAS7QLR;;1 .IEE_DM<_)J<=OH]E%]
MEDP\2@%C@Y[8KJOB^4\G1UD0,/,E//;A>]<Q86D$CB:0^=$J[I& .(\#Y0/?
M^E53^ SJI^VE;R/;[48M8L]=B]?I6=XHM[RZ\,ZA!8;OM+Q$(%;:6]0#V)&1
M^-:5L0;:(@D@HO7Z5+7+>SN>G:ZL>6ZGIJ7FGZI_86AW-E9/8K#)"]HT8EF\
MU2/W?\150V6[YZFF-H&IV\LMG;PI:WG]IVSK/9V6VU6(*X$JH. PR0V3U [5
MZK15^T9E[)'E\VFW]YH%IX;31M\B74AU!IF:..XV=)/,P<ERRMWY!':K\[>(
M+_P4EG<:9GR8DCNB)#YLACD <*FWYE9%)SGG/2O0:*3G?H-4[.]SR:[TF]>T
MAV:7<F&47(TR/R3FT=IU:,D?\L_D!Y.,#CVK=T.&!_B!>3Q:==VGE"5/->WD
M_P!+9B"SM(1C:,81<^IXKO**;J:6!4[/<****S-3QOXE/CQ:P_Z=X_ZU3US4
M['4HH3'<_P"JDD9D*LK,"%Q@X(S\IZU+\3I OC-QG_EWC_K7&&8>M>K2BG"+
M/F:\G&K-);LWH]1A_LB6R\YXE-U'(G&65<-N)( R1D5IQ>)+".\NI9?-DCN)
M!;!!_!:@8[@YSD' YXKC#,/44PRCU%6X19C&K..W]?U<ZN]UNTCTMK&TD,HB
MF18BV],H(R"_!')8G@US9E]ZK&4>M-,P]151BH[$SDY[HLF2F&2JYE'J*891
M_>%7H3REDR>],,E5S*/44PRC^\*-!\K+/F4TR>]5C*/[PIAF'J*97*RR9*:9
M*K&4>M-,J_WA0'*RP9/>O3?@NV=6U?\ ZX1_^A&O+K:&XOKA;>T@DN)F.%CB
M4L3^5?0'PW\)3>&=%D:]P+^[8/,H.?+ ^ZN?S)^M<N)FE3:[G?@J4G54NB.V
MHHHKRSW@HHHH **** "BBB@ HHHH *SKZ]6"6&"6U>2&8[&?C:,\8(/6M&J%
MUI4%Y<1S2F0,F/E5R%;!R,COSS43O;0<;7U*!U.WG5#)ILC1.K?9CM5O, Z@
M#J.G>D37H%N+=!:%);IB'RRC!!V\G^+VJ4^'+7S2ZS7*_*R*HEX0'KM]*E70
MX ( 9KATAQA7DX;!R 1WP:QM5N:MT[:&K12"EKI,0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH CE("'<,KCGZ5S%[K^@M9O9RV,E
MP8 =MF;0D@*FX8!' QWKIYHQ-$T;9VL"IP<'!K M/!NG6DK2*]P[-$8CO<?=
M*;.P'\/>@"C!X@\/RF:>?36@F+!#NM,M(5*8 P.2"R<=N/2B76M ^W2M=:4B
M>2<M<2VXP#F0GMG<"C'ZFM)?".GB.!6>Y?R9#*K-(,EB5//'^POZT]_"UD]R
M9Q+<(Y9G.V08W$N<]/\ IHU #K:ST2ZTP2+IT"6H!)66W";0#D\$>V<^U8&K
M:SH(TQX/L5U+;S,+B2-(BO" ,AP1]U@@ ]>:Z.PT*+3X7MXY7>UD5M\3@89F
M)+-P!CCC  %4Y/!VGR0B-YKIL*$#F4;@@4J$Z= "??WH KMJWA>.:$20P12I
MF(![<*T(SMPP(X&3C\:DTW4/#]W)!:65EM\Z/<J_9"H$;'()XX!*Y_#Z5:/A
M>Q&H27J-*DTKEY"K#Y\D''(X&1VP>33HO#5G'+I[!YBM@JK"I88&T$ DXSWY
MP0#W% %H:'I0##^SK7YSEOW*\GGKQ[G\S4\5A:07+W$5M$DSJ%:14 8@= 35
MFB@ I#2TAH \<,ZBXG!R")&_G74> W=]2OVW$QF),?F:Y&90U[/P!MD.>>O-
M=CX#4"[O2!C]VG?/<UUU/@/,I?Q44?BU&LVFZ?&=Q=I'V*O5C@<9]/6N-MA$
MNC0VM[<#]XI*NIXY]_0# KT_QD]C!:P7-W&KR1"0Q;QE5X&6(]A7E&JVMA/H
MR3Z7?;O(("(.2^6ZL.M*F[QL575IMH][M!BUA Z"-<?E4U0VF1:0@\GRUS^5
M35RGH+8****!A1110 4444 %%%% $,EI;2OODMXG;U9 33?[/LO^?2W_ ._8
M_P *D,JJV"5'U-'G)_?7_OJGJ3[I'_9]E_SZ0?\ ?L?X4G]GV7_/G;_]^E_P
MJ;S4_OK_ -]4>;'_ 'T_[ZHU#W2'^S[+_GTM_P#OTO\ A1_9]E_SYV__ 'Z'
M^%3>;'_?7\Z/-3^^OYT:A[I#_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z7_"I?
M.3^^GYTOG1_WU_.C4/=(?[/LO^?.W_[]+_A1_9UC_P ^=O\ ]^E_PJ82*QP&
M4_0T[-%V%D5_[.L?^?.W_P"_2_X4?V;8_P#/E;_]^E_PJS11=CLBK_9MC_SY
M6_\ WZ7_  H_LVQ_Y\K;_OTO^%6J*+L+(BBM;>#/DP11YZ[$ S^52!0*6BD,
M**** "BBB@ HHHH **** "BBB@ HHHH ,4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@ Q1110
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M6KAB>((O_0FK*\5:&;]C<6DBK-&S#YV"AESTS6[\'M/GL]1U5YS&&:*-3&K
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M: : %HI"VT$FFB0%<]J 'T4F<T$X% "T4SS!S[4H8-TH =13#( X4]3[T^@
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M6W%M&T=MLC6/>K,2NXY9MH!Y ]JC;P):*6M8F@726OHKT6;09"E0=R9[J>"
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M HHHH **** /,O&_@W6M=\2/>V,<#0&%$!>4*<C.>/QKFS\,_$Y_Y8VO_?\
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MW4<ENKWN61>9,KA<_4TNK^(K>Q>-GEW*_*+'R<#^5#BNP*36K9U7]LN 2;7
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M[2H2XBM FZ(1$J[ [>.,YX^ZOY47'8Y];[P]<?;G?3H(4AB1EDG51YVY2<
MY)&.@ZT0R>%9+>9X].MHF2,O&)XA&)<%A\N>OS*1ZUT$6@Z9;1/##:*L<Z".
M5=Q.\<]<GK\QYZ\TZ+2+"!62.V55*>21DGY"22/S8_G3NR>5=C!M]2T"ZT_;
M<:?Y16 2RP/!]T';^?WUJ**7PK=,F-&.2,IOM,9^4LN.>X!(^G:M^;PWI$Y#
M268)&%X=AD   '!Y'RKP?04/X=TF:(PR62-'A1C<W\*E1W[ D478<J[&3'J7
MA[5I8[=K)I-SB,F2#Y4<E@%)SC)*,.,U#!J.B6.KF"TTG:'C;8\,'S3,K$$*
M.X&&.>.E;MKH&EVCCR+4+F02D[F)+C)!Y/JS?G3'\-Z3)<2S-:GS&.0RRN"N
M<D[<'Y<DG.,9R?6B['9=C*;Q'H#AY(TW(I!=S ?F&TMP.O0=Q2IJF@+-M6PE
M$JNJ2*+;F+<0%W<\ DC%:C>&=&:7)L5/R[ "[85<8PHS@#'I6#XCL;:'4%DB
MBV.9+=V*DC<3,!SZ\*.#P*+@S2U/4X--NXH6L78/:2W'RQ,[*4*_*0H.!\W6
MH=-OTU"6T1M-@2\?<9P#D1QA0P8'J=VY<?4^E:UG9P7-E9W$Z&28V@B+LQ)*
MN 6!Y[X%17]E;V>EWEQ;1"&<6XB\Q"0VQ,[1GVR:28[%2\UVQTS49[6]B,5M
M"B-YX3<N6#'!]/N'%9U]J7AJ[LUGFT])PS-&OF0@A9.RDY[G'3/6NGN='T^]
M>1KFU24R%2^[/.T$#\@S?G5-_"VC2R)YEF7*C +2N2<'(R<\X/K0F)I,Y"RE
M\,7$@^T>%(8H@F2ZP!\-OV]NQ.,5NG3_  I-9[SI=H;42*A=H1L#%00<^F"!
MGUXK8@T'3(78QVBC<5)^9NH(8=_[P!JOI&FV4_AI;*6W1K:9I#)&1PV7)/ZT
M^9BY8]C$N=4\.):1>7IBM Y$8$D!56C!VOM]=O3%6/M?AG3IGMX=-V-&%+>5
M;?*H.W;D^^Y1^-;,GA[29)9'>S1BS;B"Q(!)R<#.!D\G'7O21>'=*@5@EI_K
M=N\M(S%L8(R2<]57\J+L+(P[?Q5X=-M&\\7V>1HED:)E!*L0&"=>N"/;GK5_
M3[_2-5N'6SLWD8 >;)Y(VJ3G@G/7@],U<'AO2$^1;,!"@0KYC8P. <9Z@ 8/
M48'-))8V^G-9FU5HS-<(LA$C$N K8R2>:+CL<Y>:[#9S7S'3;.2*WE>*38K[
MD52!O;C&#Z#G)%;EB++4-&:[ELK=;)PS(GWB8Q_>'9NN1VZ=:U'TZT>WDMVA
M!BF<RNN3RV=V?S -9-W#'9WM\MN#&DUE+.Z G:9">6QTS2N[!9'/)_PB'VJ-
M$\.1+!-;EY6:TPR*2FTLO]TAO_K5:>X\(VIG3^Q<2(<21I:Y;:JEMW7H%4^_
MM6QI&@:6=%LRUJ&,UJBR,SL2P*J<$DYQE5^F*LQ>&-&@+^79*-ZE&^=C\I!4
MCD\#!(JFWL+ECV,2-_#!)"Z(5>(,0C6H!X(# 9..-PSSCFH[=_"+M]KM=&5S
M(R@2QVF?,D8 [ ?[V"/\:Z&;P_I=SEI;0%@QD!#L"&)!)!!_V13$\,:.D>Q+
M/8J@!0LKC:5Z$8/## ^;KQUI*3'RQ[')6DG@VYO[R2/1;(2VLL8\P6Y+!6"@
M$^AR6&/]FK<MSX)E:(7.E0B4X8)+; ,JD*0V">AW+TY]JZ/_ (1G1D9=EA&O
MS?PDC/ Z\\_='Y5+_P (_I;2I+]E D7: RNP.%  !P>1A1P>.*+ON+E78Y+3
MAX3U".)SX;C6>0[O)2UWN@P"6;'4?,.1ZULZ5IGAK6(/M5KI%OM5BF9(0#6@
MGAK2(P EIMP=_P LC@\]1G/3@<=.!Q5O3M.M-/$JVT13S'W.2Q8L<8Y))/0
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FX:T2--J:7:JN<X$8ZU;M=-LK$LUI:Q0E_O%%QFK=%%V-)+8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '6 G # 2(  A$! Q$!_\0
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MEE673K9Q+.+F0-&#NE'1S_M5(ND6"71N5LXEG,IF,@7YO,*[2V?7''TK1HH
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M==(M!!.P:1!&,,1R#^!Z8I9?">@S101/I%FR6_$0,0PHSG\>>>:VZ* &J,
M# %.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,4HU(R=D-P:W+ CD#9-P,'HN<TOE(>"ZG\!437L.T^6NYAVVXJG)=N., >@
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MS743)9+-"KW@@7,2M&['H,<NH&2.,UTYLY+J)XGC,D4BE&!^7*GM55]'M50
MP2!@^_S/-<R;MNW[^<]..OK7HQK1:O*)R.E*_NLPX]6U2>P@DCN(5D>$,CR
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MS'JX+EE2G'J=IJFE1Z?:R7_VAV$$?S!\#Y?P YKE;+4=0.JVTL=Q)#Y\Z)'
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MJ2E&33.EM.*-Q^94_&H[#_C]OO\ ?7_T$422,K(Y1@H//K26#*;R^(/\:_\
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MCS$#8SG&:LX%<K6H[F1I^D26>HSWLU]+<R3*$_>1J"H'8$#IWQ[U-K)QI_\
MVVB_]&+6@>E9^M?\@[_MM%_Z,6ABN3OT?\:QM$XO-2XS^\3^1K:DZ-^-8VB2
M)'>:D7=5RZ8R<9X-<AV(VHA@$D8R>E*O#M3?M$'_ #VC_P"^A3#<PAN)8_\
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M(N588].<CZ5=C^)BM92WTFAW$=M+;/<V+><I^THC!#Q_ ?F!Y[4.XKG>XHK
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MHS5.O4[E$5M EM;QP1KM1!M4>@J:DHS6 "UG:Q_R#_\ MM%_Z,6M#-4-8/\
MH _Z[1?^C%H LLN2:RY]"MKB0NZY)K5/4_6BN1[G:C%_X1NS_N4?\(U9_P!P
M5M44 8O_  C5G_<%'_"-6?\ <K:HH Q?^$:L_P"Y1_PC5G_<K:HH Q'T"U@C
M:1%PP!P12CP]:2@.ZY8@$FM6Y_X])?I3X_\ 5)_NBF!C_P#"-V8Z)1_PC=G_
M '*VJ* ,7_A&[/\ N4?\(U9_W*VJ*-0,7_A&[/\ N"@>&K+(^0=:VJ!U'UH
MHKX<LE8,$&:U8HQ$@0=!4E%;(S$-5C]XU9-5C]XU$RD%%%%04%%%% !1110
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MHS^M%9%W"CO10.M"![%L4M(*6MT9B&JQ^\:LFJQ/S&HF4@HHS1FH*"BC-&:
M"BC-&: "BC-&: "BC-&: "BC-% "4444 %%%9&HZR(9&M+",75[T95^[%[L?
MZ4TKB;L2ZAK-O83);A7GN7&5AB&6QZG/0>]9UQ+K%^3&6CL;<_>$;;Y3_P "
MZ#\*=961M]\T[B6[F.9I<?>/;'L.F*N5LH(AR*MMIUK:(%BA3W9AN)^I-6!'
M&.D:#Z*!3J*T($(##!&1Z$9%49]&T^<[FME5_P"]&=A_2K]%&@&;#<3Z X\Z
M66XTP\?-\\D!^O=?Y5T<,T4\*S0R+)&XRKJ>"*S2 PP>AZ@\UF2QMHKB]LF,
M=LKYNK?.4*GJP'8CVK*4.Q:D=312(P=59&W(PRI'0BEK$T"BBB@ HHHH ***
M* &ON\MMA <CY=W3/O7/0^&YK81R0WC23,H\\S$D.P;>#@=!G/X&NCQ1BFI-
M$M)G,'P]>M);.]S$!&Y=U0,HSN)P!W'/>G3>&I9(Y09X\LN!N!./N_X?K72U
MD>*9)(?"^H2Q.T;K&"&4X(^8=ZM3D]!.*2*SZ%<K>R303QK'+\LBLIX'F;QM
MP>O)%/AT%HH8T#IO0H=P7^ZY;^M;47^ICSU*@Y_"GT.;6@**.8@\.W\!D?[1
M;RR,W20,RXVE?7CKG KH;. VMG#;ERYC0*6/>IJ*ER;W*2L%%%%2,**** "B
MBB@ HHHH **;)(D4;22.J(HR68X %<[=>(KB\D\G0[83H>#>2';"A]N['Z52
MBV]#.511W-75#B.U/_3RG\ZJ^)V2?1YX8I8FE4JVQG +!2">M94ND7UQY4MY
MJ,EW,D@<HW[N+'IM7^N:T$B=!A;"QQ[LQ_\ 9:V5/2S,88AQGS6.2TN!HM4T
MAG:,1R,LN\R+\H4LQ!YZX8=*[S5)XI;*,QRJ_P"_C^Z?]H51*RD(/L%CB,83
M)/R\8_NU4O--:]B$9M[> EU8O#(P88/;@4HTK&N)QDJS3L=/WI:Y8C6],;S+
M.Y-_;][:Y.'Q_LO_ (UKZ9K=IJF8T+172#]Y;2C#Q_AZ>XXJ)4VM285E)V>A
MI4445F;A1110 4444 %5[ZY6SLY;A@"$&<9QWQU[=:L5#=6R7EL]O)N"..2I
MP1@YX]^*%;J)F5'K]E/YQN$C"P'YF7]XN<*<K@<_> IW_"1:4V[+.."Q5[=@
M6P=I !')!(&.HJ7^PK4W#W$CS232$%G9@"<8QT '\(IMWX?L;L@RJ[;=Y )!
M&6<.3@C'4"M>:!G:0D6M:=,VQ"IX#H-O.2#GC&5Q@Y)I\>N6$MSY&Z590%Y>
M%U!!Z88CGGTJJ^AZ7I5M)=I&Z"&,DL@4-LYR.!WR:FAT6VDA:19[G%P$?+%2
M5Q@KCCM3]VU[AK<=/K>FP2-&P8LV=P2!G&<]\#U!I)=;TP%" 6D,?FQMY)Y&
M,XR1@' Z5/%I%O#T:1F^4DLW.02?3W-5CX9L#,DN9=Z#:#D<#&.N,].W2E>.
MPVI%VPU&#4$9X"X92 Z21E&4D9&0?6KF!56SL([)I61Y'>7&YY,$D 8 XXQB
MK59.U]"U?J&!2@<_C24HZ_C0,LTM Z45NC,0]*JG[QJT>E53]XUG,N(4445
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MM?:,'EOQ-;]<TW=FT5H%,,,3'+1(6[DJ.:?14%D?D0_\\8_^^108(<?ZJ/\
M[Y%250U>ZFL]/\V XD\Z),XSPS@']#0(M^1",_NH_P#OD4ODQ#_EDG_?(K)T
M[6E;25NKJ0O(9I(R(HV<\.RC*J"<8%8PU/59)KS[/JL<UM&H E6.,.T^X_NX
MMV 1@8RV>13L(ZXI"HR4CQU^Z*SWU2RW8C@,@!QN6,8/TK*AU274/"-A>7#
MR3IF8QC )&<@#\*HRZI'%",(8Y,A0DG'& ?RP:\C&8R=*7+ ZZ-!37,SJ[:[
MM+O<(T0,O560 BK6R/\ N+GTVBN(:_N$N%EB,:DDK"RC)&.H/M70^3K(7/VV
M#'_7*M,/C74BW):H52ARO1FG*8(HF=P@51DG:.*R1J_[_P S[*OV;UQ\X]\5
MDW&HW#1Q&[9IP[[8HXUQD@$Y//M3'OW">9%%NC,!E7U)R.,?C7'7S"3DO9]#
M6&&5O>.PC,4B!D"E6&0=O6G[4QPB_E7)Z/JDD&\/M,*2;75 < G'(S]>E=8#
MD9SFO4P^(5>-SFJ4N1AM7^ZOY4;5_NK^5+1749V$VK_=7\J,#T'Y4M% 6&/$
MDJ[74%3R13E4*NT  >@%+10%CG?% Q=Z))_"MY@_BI%:%5?%5OYFC"XR0UI,
MEP,>QY_0FK(8.-PZ$9KJI_"CSZFE1B]*X_Q!JTT]T]C;R>7!&=LC(<%CW&?2
MNND;9$[C^%2?R%>:Q\IDDDL2Q)ZG/-;P5V<&+J.*Y4*%51A0!]*7/?G/UHHK
M;0\NXA QZ8Y!7@@^WI77>'-5:[B^QW+[KF%<AO[Z^OU'>N2Z59TR:2VU:TDB
M.W$@1_\ :4\8_/!J91NC>A4<9'H-%!&"1Z<45SGM!67=?-XFT(#J&F;\-HK4
M/2J%J5N/%O'S?9+3+?[+.?\ !:F6P)7:1T#*KKAE##N#47V6#_GDOY5-17(>
MC8B%K /^62_E44-A!#,TRJ"Y/&>U6J*!V(IE9H_E )!!QZXK-?3W-X+F*2>.
M3<S']V&!R!D<_2M>BKC/E,ITE/4SFLX_)$:Q3(/,61L=R#GN>^*C?3XW$X>.
M9O.G6=\J#DJ1@?3BM6BJ]JR'03*T49$B;(O*C3)QM Y/L*IZCIHO906WX5@X
MV 'G:5[^QK5H_6CVCO<ITERV,VTLS!'$LGG3M" L3% N!^!YI@T]"J*\<S*+
M@W!!4<GJ!UZ?X5;OK!-0B$3S3P@-NS!(8R?8D5SWAK3VN%FNIK^_D>WO9416
MN&*E5; !'>M%.ZN8^RUL:/\ 9"BX6Z03?:A,9C*1C?D8VGGICBM>)2D2J3R!
MS3@.*6L92YC>%-1#-+GFDH[U!H]BX.E+2#I2UNC(0U4)Y/UJV:J'J?K43+B&
M:,TE%9E"YHS244#L+FC-)10 N:,TE% 6%S1FDHH 7-&:2B@04444!<9)&DT;
M1R*K(XPP(R"*YRP#V%_/I$KLRQKYL#G^*+/3ZKTKIJH:GID>HQI^\:&:-MT<
MR?>0_P!1[5<969+5R(@."&4$,,$'GBL6X\/H7+6DOE _\LF&5_#N*LBYNM.F
M2WU15_>-MCND^XY[!O0UI5T)IF1S/]AZ@&QB CUWG_"IXO#[LZ_:9_E!^98Q
M][VW'M^%;_ HIV$1PPQP1K%&H5%X %2449__ %46 .U9NI76\_V;:DO>7 V@
M+SY2GJS>E27U\T3+;6H\V^EXC0<[?]H^PK2TK3$TVU"D^9<.,S3'[SMU//I[
M5G.:2*2+%G:I964-LA^2% @/3.*GH_#%%<][FNP4444#N%,EACGCV2HKID'#
M#(R.0?P.#3Z*+B*-IHVFV%S-<6=A:V\\_P#K9(H@K/DY.2.O//-5D\+:!$DZ
M)HM@JW Q,HMUQ)SGYN.>>:UZ*+@9^I:>+K33;0;8BJXC & .,8QZ8KGS%!;J
MT$Z&-C]Y7YS]#WZ5V'XUD:GK+Z:9#)I5S+#'@>:A7:<^@ZUPXC K$2NF;TZ[
MI&9!I)O9&DA!A4\F0CK] :TSI>H'_F+/]/*%6[&[ENP_G6,UJ5( \T@[OIBK
ME72P4*2Y0E7E/4Y2_P!"EBBCDEG::*.7S& 4 C@CM]:##!Y0^4>6(]HQT"_Y
M%=/,Q2"1UB:4A20B]6]JY=;A?[1\L:%?F7;YOD;EQ@\9ZUQU<L<Y7INRZFL<
M796D7=)TI3MF,86$'<D?4L?[Q-;PZ4V-BT2,5*$J"5/\/M3^U=]"A&C'E1SS
MFYN["BBBN@SN%%%% [A1110*Y%<VZW5K-!)RDL;1M]",5SF@SR"T?3YVS=6#
M>1)[@=#^(Q74&N>UZUGL[N/6+./?L7;=PJ/FDC'\0]2M;4GT9S5X;21>9=\;
M+V8$?G7FH1XRT<B[7C9D(/;!Q_*O1K6XBN[:.>!P\;KN5AZ5RWB739(+QK^-
M"T$H EVC[K#O^-=4'9V/+Q4.9)HPZ*0,",CD>HI>U;GEA4^GQM/JMG&%)+2@
MM[ <D_Y]:KE@@))X!Q75>&M*>V5KVX0K-*NU%;JJ>_H34R=D=%"FYRN=#WHH
MHSCD"N<]B]B.>9+:WDGD.$C4NQ^G-5_#%I(MG-J-PA2XU!_.9#_ O\(_*J3Q
MMXAU(6D1_P")9:R W4BGB5QR(QZC/6NJ Q651VT-:,7)\S%HHHKG.VX4444!
M<**** N%%%)G_(H"XM%)N&,TI.*!7#I6%X4_X\;[_K_G_P#0JW??M56QL(-.
MAECMPVV25ICN/=CDU47[K0NI:HHZ#FBI*"@=1]:*!U'UHZB+G:EI.U+6Z,Q#
M5,_>/UJX:J'J3[U$RXB4445F,**** N%%%% 7"BBB@+A1110 4444@"BBDS0
M.PM%&:* (;FUAO+9[>XC#Q2##*>]93:#/#%Y=EJDT:KPB3() !^/-;?XT4^9
MH5CFGGU73SB^L_M,?::S&?S4]*3^UY7/[K2=0<>IBV_S-=-WSWHW9J_:LGD.
M8_M>7.TZ1J._T\KK^.:L0:;J6H;GOYS9P,/EMX#\X'^T_P#A6_N/K29P0*'4
M;'R(IV&D66F _98 K-]YV.YC[$FKO^111695@HHH/% K!129I1R: "BJZWMN
M\<#J_P LV0AQU(Z_RI1>0&4QB5"P3S#@Y&W.,YI\K%=$DDJ0QM)(0J("S,>@
M ZFL.WU76[^(7-EI5NML_,37$^UG7LV . :T-16._L;VP64+(\.TG&<!@<'C
MKT-362+;V5O;[PQBA1..,X&,X[=*T6BV$V9WVGQ+_P! W3O_  */^%02VFN:
MK-##?BSMK!'5Y4@<N\N#D+D]!G%;YDC7[S*#Z$XIDMU%%&7>10H4MD'/'K0I
M-[(7*NY+W]SS14<,T=Q$LD3JZ,,A@<U)63O?4T0<UCZI8Z@;R&_TJ2 3HACD
MAG!V2H3G&1T(/>MC-(2!DG&!USVJHMK84DF8OVGQ+_T#=._\"F_PH^T^)<9.
MF:>?;[4<_P JNKK.ER6\ERNHVI@B.V23S1A3Z'GK4L=_93I&\5U#(LF=A5P=
MV.N/7%:)M[HBR[E;2=7&IK.DD#VUU;.(YX7.2I/((/<$=ZTJQ;$6L.L75^M_
M;R+J6P0*K#YBBD$#UK5FN(;8)Y\L<6]@BEVVACZ"IFM=!I]R6BH$O+:266-)
MXV>'_6*&&4^H[5)%-%/"LL,BR1N,JRG((]JAIHI:CZ*,T9I!8*/7\Z,T9H#E
MZ,YR\T>YTN1[S1AYB.V^:Q)PK'NR'^$^W0T6>JV>H(8B3'*1A[:==KK]5/;W
MKHZH:EHUAJRK]KMU=U^[(IVNOT8<UO"K;1G+.AK>)S=UX4M9.;29[=NNT_.@
M/MGD"J2^$;TMAK^WV^JQ-G]36\FBZM9G_1=6^TQ]H[V/+#_@2X/\Z9-+K]L%
MSI$5UZF"Y Q^# 5T*HNYQ2PRO=H98^'K*QE68[YY5^ZTO('T7I6MVK'_ +0U
MT\)X;FS[W*#%61;Z_<+PME: CJ6,K+_(5+DGNS2$.7X46Y[B&VC,D\J1(.=T
MC "LI'O?$$ABM5EM=-SB2Z8;7F]D'I[U=M?"]NLRW&I3RZC.IRIFQL0_[*C@
M5O<#@=*RE4ML;PHMN\BO965OI]G':VL2Q01C"H.W^)JQ1FBN=MMZG8HV5D%%
M&:,T#L%%&:,T!8**,T9H"P55U%2VG7 42EC&0!%]_P##WJUFC- FCCH#>Z=9
MR)81DQF1<RI$X."#_"V><@9(]:NQZAJ:EFG\X2@*?*2 %2G&3GUQGCK6I=:K
M#9W_ -FFRD?V<SM)V4;@O/'3GK44VOV,,4A60LRIN"[6&3M+*,D<$@<5O=]C
M-KS*,=U?RZHMPL3BU;*,S(00F]@N!^(SWQ1%-JR6RNI8!1L$0BX $0;/KG=D
M5?AURVFC@?<2)(FD&U2QPN <8'(YZU)'K%BT*SB9@C8"ED(Z\CC&:+OL%EW,
MZ2\U*Z:9[9Y8XE9C'F#EAE0.OU-,GO=3@N(H5\V3%QL9O*&UT\S&3@=<<]JT
MH];L9W*K+)D#.#$PZ#/IZ'--_MZT65LM((]I+N4;Y3G!R,<4TWV"WF0^'FN/
M)\J9I61(D \V/;M;G(SWZ"MH<D?@:!@@'KQP:4=163=V6E9%OM2TE+6J($-4
MR>3]:N&J9ZGZU$RX!FC-)161=A<T9I** L+FC-)10%A<T9I** L+FC-)10%@
MS2YI/PHH **** ,3Q/K,VB65I-!$DIGO(K<ANP<G/X\4FG>([9_"^F:QJDT5
MI]MC3&XD*78<**T=0TVTU2&.*\A$J1RK,@)Z.N<']:Q;71/#_A5V:"-X4=#D
M23LZ(@Y) 8D*,D=!W%4K"9E_\)/XF>'6_+TVQ>2Q*F)XW9T)Y+1\#YW"@'CN
M:U(_%\(TO0+B6VDEN=93]S#;$,-X3<PR>,=:SHO#/@J#3C&D;-:W[ @^?(=Q
M#<L#GY3GJ>.M6O$7A;2KN'0H)+>18+&X,=M;6[E%;<A7!;JHP*=D2*/'VF2
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M$#U*@UB6'A3PZUDHMK K#YC,%:5CL."A R>!@D8]ZZ&&)+>".")=L<:A$7T
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M1;1]^?,&_P"]AO\ 9V_R%01>&K*)-BO/L8_O%WX$@SG! %;-%'.PY4(!@8'
M]!2CJ/K10.H^M)#>Q='2EI!TI:W1D(:IMU/UJZ:I-U/UJ)EP$HHHK(L****
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MW!W_ *41>"8P@,TD,LNX?,T>=J^64VCVY!Q[4!=G0ZAJUMIT2//(P5^A5"V
M.K''0#UJ ^(]/#3*)&9HAG"H29.<?)_>Y(%0ZAI5W=65I:QW$0BB&+A'5OWP
M QMR"#CU]:IR>'[]5(MKZ"%E600/L;*^8^YCU[<@8H"[-&+Q#8S36\4<K$S\
M*2AP#SA6/9N#Q[4MUX@LK.^2RFDD$QV[BL994W'"[B.F3TJG;Z'=17=J[26W
MV2W4%(%5\*^3E^O+<\$^II-5T"YOM3-W#<00$JB^;L(EC"G) (."#Z$=Z!79
MM->VZ!B]S"H1MK9D P?0^E.6ZB:8PB:+S0,E XW?EUKDE\%-YT+7$]O*D22+
MDQ'=,65@'DYP6&[-5])\.7]CK^EDQAX;%9!+=LF&ES"J+SDDC()]J!W9UTNJ
M6T%RMN\H$A8+ST!(+8)^@)J1=0M6)VW<#8&>)5Z9Q_.L*_T":_N+Q#-Y<<DO
MFH[#.<Q%"/P)S52Y\#Q3*T<,D$0:=92%BQE1L)7Z'9^M 7.JCO;>8_NKF%QQ
M]R0'KT_.G"YA\P1>='YA!(7>,D>N*YG_ (11H)HI;*6VADCD9\>40KGSA(,X
M/0#BE_X1(&V8/<(+EE5?M"(0R\," ?0[OTH"[.B>]@CM)+OSE:"-"[.AW#"\
MGI56UURQNXX9(KE#'+!]H5S\H\O.,DGISVJC8Z!+:Z'>6!ECW7*.NY =JY7;
MGGGWJA-X.E:XE:*]5+9DC"VY3 #!PS<C^%L=/4F@+LZ2/4;2:::&.[A>2 *9
M55P2H/(SZ9%2?;;<R>7]HAWX)V[QG Z\>W>N/?P'YC B[CC5\+,L:$>:F&RC
M'/(R5(_W:D'@F4P&+[7"S.@$LYB/F,VQE)!SP&SD_2@5V=(-7LF2X=;A66W(
M$C+@C[H;CUX(J34-1@TRQ>]N9"(4P3L&XG/I7//X9:REN[JS*MYD)C6W"_*,
MQJO Z Y7.?0FK6J>'7OO#=GI/VKB!8T;S<D3;5Q\V.??ZB@+LTY-7M4TV+4!
M*SV\RJT9C4L7#<K@>XJ&+Q#837"0I<9,B!U.TA1D9 )]< G'M5./2=7B\,P:
M:FJJ;V+"F\9.67/./1L<9[4EOX=DAO(6+P"V61)FB5#]Y8RF!D_=P<\\T#NR
M^NOZ:]E%>+=H;>6?[/&^?OON*X'X@_@*34]>M=)GCAN//+R(SCRHBX51U9L=
M ,UF77A(74<6+V6*2"X>:/RQ\@#2;^GKCC-3ZWH4NJ7*2I);X^SO;D3!C]X@
MY&TCTH%=FNNH6I _TJ')02<N =IZ'![57AUW3I[F6"*\B=HD+NP8;0 Q4\].
MH(KEKKP)<74@$U_#+'YBGYHCN:,;/D.#C^']:FNO!#374DT%U%#%YA=84C*J
MXWLVU\=1\W;N!0%V=(NN:<]_]A2_MVN?,\OR@XW;MN['_?/-,U'7M/TJ94O+
MGRPVW)(X7<<+D]LFL'2O!CZ9JEO=BXMW,4QF8&([N8O+(SGU (S[U?O=)>\U
MF7S8PUG*892S#*G9N4H1[ALYH'=FLNI6S,Z?:(U9)/+.\A<MUP,]?PI]OJ%I
M=VXN+>ZADB)QO5QC.<?S!KD)O!5T\#PC4P\/F,\?G(2R#(*C<#R0%QF@^";I
M;2YM(KRV2"<Q[L1,"NQR1C!QR#S0%V=DEY!(559XBS E0K@Y X)'K6;?>);'
M3[TVUQYX*!6DD6(LD8;IN8<"L^V\)K::E:SPO&L5ND:A,-E2@.=O. &SS4NJ
M^&1J=Q=W'VCRY91%Y1P2%*<X89PP/<4!<W!=P,YC\^,R9 VAQNYY''TS4<.I
M6T[,J3IQ(8QE@-S#D@>M<Y)X1D>>XF^UH)79WBF"G>CE@1WZ#D#V)J!/ HAE
M*Q72?9S)E4(.8U^7A3GJ=IR: NSL&NHHX_,>:-4 R2S@#'UJ*[U&WL["2^D<
MM B[BT8W9'MCK7)+X&G!GWZBMQ',S.8Y4. V<(!@\*J# 'KS6S%HDT?ADZ2+
MA&D'W9"IVK\P8#'6@+ENRU^POXGD2;R2F R7"^4RYZ9#>M76NH8TW23QHO'+
M, .>G7UKG+GPO/J.LP:EJ,]O,T6!Y21G;@*X7J>3N<GGTJC?^';Y+4!A%?-Y
M*VZQ+$2N%C90S9(YRV<T"NSI=3UNUTDP"X\YS.3L$$1<G R3QVJ2VU>RNXA+
M#<Q-$Q4(Y; <L,@#/4U0;3K_ &:3);3P)<6<!1Q,I8$E%4XP>Q%9,'@A[6QC
MMHKQ6\MPX=U.X':H)'..JY'UH'<ZPWMLOF[[B$>5CS,N!L]-WI^-*;N 1F0S
MQ",=6WC'YUS<GA:9B-LMHP6=IAOA)\_))Q*<_,!GCZ"JA\#R!AY=^OD)ME$&
MP[3-GYV//0K@8]A18+LZX7ELTBH+F$NXRJAQDCM@=Z;:W\%W).D,RNT+!' .
M<$C/\C7)R>$S9Z;=^2JO?S21F":%.;<J,9!8YVCG\":V]'TTV%[<;(%@MTBB
MMX5!SN"@DM^;$?A0!N44M%(8E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 G # 2(  A$! Q$!_\0
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M'_"\=2_Z(/\ 'K_PF/"?_P W->]44 >"_P#"\=2_Z(/\>O\ PF/"?_S<T?\
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M'_"\=2_Z(/\ 'K_PE_"?_P W->]44 >"_P#"\=2_Z(/\>O\ PE_"?_S<T?\
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M!_CT?IX8\)__ #<U[U10!X-_PO'4O^B#_'GM_P RQX3[_P#<\_G0?CCJ0/\
MR0?X]'Z>&/"?_P W->\T4 >"_P#"\=2_Z(/\>O\ PE_"?_S<TO\ PO'4L9_X
M4/\ 'GZ?\(QX3S_ZG->\T4 >#?\ "\-2_P"B#_'G_P )CPG[?]3S[_H?2C_A
M>&I<_P#%A_CSQG_F6/"?./3_ (KG\J]YHH \&_X7AJ7_ $0?X\_^$QX3]O\
MJ>??]#2?\+QU+_H@_P >O_"7\)__ #<U[U10!X-_PO'4O^B#_'GO_P RQX3[
M?]SSW[4G_"\=2_Z(/\>O_"7\)_\ S<U[U10!X+_PO'4O^B#_ !Z_\)?PG_\
M-S1_PO'4O^B#_'K_ ,)CPG_\W->]44 >"_\ "\=2_P"B#_'K_P )CPG[?]3S
M_G!H_P"%XZE_T0?X]?\ A,>$_P#YN:]ZHH \&_X7CJ7'_%A_CSS_ -2QX3X^
MO_%<TG_"\=2_Z(/\>O\ PF/"?_S<U[U10!X+_P +QU+_ *(/\>O_  E_"?\
M\W/?_P#7BE_X7CJ7/_%A_CUQ_P!2QX3Y^G_%<U[S10!\YZU^T1_PCVCZMK^M
M?!+X[:?HVAZ;?ZQJU_+X6\+O%8Z9I=K+>W]Y(D/C:69X[:T@EF988I)76,K%
M&[E5/T%8W<6H65I?VY8P7MM!=P%E*L8;F)9HBRGE6,;J64\J25/(KS/X\<?
M[XS'_JE/Q$_]1#6*[KPQ_P BUX>_[ >D_P#I!;T ;E%%% !1110 5\P?M)?\
MAS]E[_LY_P (_P#JO/BC7T_7S!^TE_R'/V7O^SG_  C_ .J\^*- 'T_1110
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M]9]?85Z%X8_Y%KP]_P!@/2?_ $@MZ\G^.=SGX(_&8%AS\)_B1P""23X-UGC
M'X^U>K^%SGPUX=_[ 6D''_</MZPJ4W3:T=FNM]^NZ3_0ZL-B88A2<6GRM)VU
MWV_4W:***S.H***@FN;>V\K[1/#!YT@AA\Z6.+S9F!*Q1^8R^9(P5BL:;F(4
MD# - $]?,'[27_(<_9>_[.?\(_\ JO/BC7TS%<03-(L,L<K0R-#,(Y$D,,J@
M,T4H1B8Y &!,;[7 ()4"OF;]I+_D.?LO?]G/^$?_ %7GQ1H ^GZ*** "BBB@
M HHHH **** "D)QCW('YG^E+37Z?0YZXQ[_T_&D]GZ -\P=#@-Z'()/<#CT!
M_P#U<TX-V/!XX^O3'//^>E?E7^V=\+/VQO&7QO\ A)K?P7\2R1>"M/U.T_L@
MZ7<G3+;P-KZ*3JNN>-H3*1KFEW=F)$MV\N9!"9-+^R++.)V^H_VE/''BCPA\
M)K?PQI/@_P 5?%;XN>*]*;3_  ]HGP[AETBZ;7-/LHI-1\5RWYO((?#FB:;<
M.+D/<WFZX:2'38%GDE8+\SDW$&*S3.>(<JK9#FV64<CQ.&P^'S/&TZ4<#G,:
M^'59ULOG"<I3A2>C4E)V:<Y4ZBG0C[V:9+A\NRO(<QI9WE>95<YPV(Q&(R[!
M5*LL9D\J&(E1C0S",Z<(1J58I3CRNR=XQ52GR5Y_54=[:2W%S:Q7,,ES9F$7
M<$<BO+;&X0RP"=%):(S1@R1AP"Z?,N1S5FORBU'4?CIX!\0^&-/^%VB_$RXL
MH_!&A>(O'MA=:#=WVI^+/&&KZ%X@O=;GU76-3T6^@$FDW=KHOAX6,&MV][8[
MX;C2[34D\^0^EVWQN_:ET%(9=7^&MSJ>AZ?;O;7$=GX.\2:EXMG2TT[Q9;Q7
MSB&2&VOKR[N?#NE:G+Y5I!'.WB.UM(XX=RO7TYX)^B)(')..U+7YOW7Q@_:O
MUE[+2]1\&Q>&K&)/ NH:GXE\->%O%<]_<6NH36.LZ]-I>FZKIVW[)96J:AX<
MU73;R6#5C<QI-;V]LMU%,OU?\"_%/Q5\:^$;3Q-\4- TWP?JUZ^HP7'A""QU
M&VO]$N;'49+2$3W=]-)'?PWEG"E^)[9/(WW8CMIIX(A*X![C1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7&^)[H0-9DL5+^9@J0#D <<@
M\C)QQT'6NRKQ_P"*&H#3Y-&''[P7/./[H7GL?4DYSZ\"O1RFB\1F&&HI-N;F
MDDKMVIR;_!'R_&681RKAS,<?*2@J$:#<G>RY\31@KVULW*WS'_VD/^>LN?\
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MZ#VY.#WXP.<']?<T?\) /[O\_KZ?Y/6C^PZG_/N?_@,?\@_XB%1_Z"*/W/\
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M_P"$@7^[GGKSU/<<?K_]:C^PZG_/N?\ X#'_ "#_ (B'0?\ S$4?Q_1'J_\
M:0_YZR?]\K_A2_VG_P!-I/\ OD<_I]/R%>3CQ"O91Z=3Z].G7/./QH'B =E_
M4CZCIQR.??\ "C^PZG_/N?\ X#'_ "#_ (B%1_Z"*/XK\T>K_P!I#_GK)SS]
MU?\ "E&I_P#3:3_OD#/UX^OYFO)_^$A7/(&?J<^PX!_#_P"N*/\ A(5.< 'U
MP3W^H'X_KWH_L.I_S[G_ . Q'_Q$*C_T$4?N?^1;^-VI*?@M\8E,C9;X4?$<
M9.-O_(FZSUQ^ YXYXKZ+\*_\BSX>_P"P%HXXXX_LZW(X[=37P_\ &G7E?X-?
M%U#@%_A;\0UQD\Y\(:P.N#CKC)'%?;WA,Y\,>',XS_8&C9QW)TVV/_UQ[&OE
M^(<%+!SPJ<7'VD:FZ2ORR2TMZGZGX;\04\^I9K*$XR^K5,(GRNZ3J0K.U_/E
M['%?&3Q+\1_"_@R>[^$WA+PQXT\?7U_8:1H&C^,_&2^!O"\=SJ4K0C4M8UI-
M-U>_FMM/P)3I&D:=<ZMJSE+.R\EW:XA^ ?@)^UK^TOXQ_:$UKX*^+G_9A^)W
M_"+:G>Z?X\C^$4/QI^'>M>"X])U6VT+Q3J7AS4?BGI>J>#/C+9>!=<O+/1O&
M=GX2US2=4T6^O(4FB-RT5E)[K_P4/US5-!_9>\63:&GP^?6M1U_P7HNG-\1I
M/"L>GV_]J^)].MM2O?##>.=9\->#O^%@V.C-J5WX''B/Q1X:TQM?AM1)K5E)
MY;-\_?L;^ _A_P#L^:CX4\9?$CXD_!>T^-G[0.@Z#HGBSP_-KOAKQ-\2;_XD
MW4L,D6B>$O&.B^(KYM<T/4 DEUKFE6]EK5O%J\5M-;^*=0T^RBNKCYT_3C]8
M <@'U&?\YQ7Y$_ME^#?VB[K]K;X5>//A[X(F^)/AO1? G@[2_AUX7UKX?6'C
M?X<6GQ$N/B[#<?$[5O%OB"\U:S/PAU6T^&_]C:QX;^(5OI]QJ,A\/ZEX?TR]
M634;G2M5_74<C_/^?\]3UI: /R#_ .">OPJ^*/@KXE76L^(?A_\ $7X?6UG\
M -"\$_'G4?'KW$2_%[]IVT^(^OZOJ'Q$TF2:_OH_&4L7A>XOQJ/Q#M!%9:Q9
M^(M#TFWGN1I#6NE_6W[2$?C3_A9/[,$AN?"Y\"']HKPB!:_8M6_X2T:T/A[\
M5/WBW_V\Z-_9F/*/DG3A=#;+^_)==OV-7S!^TE_R'/V7O^SG_"/_ *KSXHT
M?3PZ#Z#KU_&EHHH **** "BBB@ HHHH *, ]1FBB@!-J_P!T<]>!S3#%&9!-
MY:"81F(2[!Y@B+!S&'^\$+*&*@@;@#C(!J2BBRWMK_P_^;^]@>:Z]\-K77]:
MN]9EU_Q!I[7=E;V3V^DZA-IZ!;>X2=9/-MI$E9R4,:ECNBCDF2-E65U.2OPA
MABFO;B+QGXR\Z_EB>5YM8N96B2W)-NENPDC>-H6\L!]["2.&.*9)$#!O8**
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MDM6U</N"BOE*Y_;>_9?L_BZ_P.N/B=$GQ BUQO"<D:^'/$\GA5?&L>E-K;^
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MK:;<Q7FGZGIFH6\=U8W]C=0LT-Q:W5O+'-!-&S))&ZL#SQHU(!1110 4444
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MKWXH#)]LD#/3)QUH ^GJ\=^/?BCQ3X,^$_C#Q/X+?3X?$6D65I<6,^J+(]E
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M+X0\"^ _ \%Y:^!/"?ACPK:ZC=-=ZA!X8T?3-(M[V^ *F>\738(4EN$#$;I
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M]/\ &C^R#[=_3\._>G_;LO\ GY^0O^(=X7_H'C]S/)QX?/9?_'0/?T_R:/[
M/IWQT_\ K=/?I7K T@]PH_(_UH_L@_[/Z>OUZXY].V:/[=E_/^0?\0[PO_0/
M'[F>3_V ?[O_ ([]?;]/\:/[ /\ =_\ '?P]*]8_L@^WZ?X_Y]*/[(/M^G^/
M]*/[=E_S\_%!_P 0[PO_ $#Q^Y_Y'DXT ]A^F/7V^OY^])_8'^S[?=]<^W^?
MQKUG^R#[?I_B.E)_9!]%_,?XT?V[+^?\4'_$.\+_ - \?N?^1Y1_8!X^7Z?+
M_P#6XH_L ^G_ ([[?3T_+I7J_P#9#>B_F*7^R#Z#]/\ &C^W9?\ /S\4'_$.
M\)_T#Q^Y_P"1Y.- /4#VZ8/\NGZ4#P^><#] /Z<UZQ_9!]%_,>WO]?R]^#^R
M#Z#VZ?X_XT?V[+_GY^*#_B'>%_Z!X_<>3_V >?E^OR^_TYY_QI/[ _V?_'?_
M *U>L_V0?1?S'^-']D'T7\Q[?_7_ "]Z/[=E_P _/Q0_^(=X3_H'C]S_ ,CR
M?^P#Z>_0?X>_\_>D_L#_ &?_ !W_ .M7K/\ 9!]!^G^-)_9#>B_F*/[=E_S\
M_%"_XAWA?^@>/W/_ "/*/[ /]W_QWU'T].OY&C^P#_=]?X?S[=_UKU?^R#Z+
M^8_Q]?\ 'VI?[(/HO?T_#OWH_MV7_/S\4'_$.\+_ - \?N?^1Y/_ & ?3]/P
M';_(YZ4'0#W'?^[GG\OUKUC^R#[?I_C1_9!]%_,?XT?V[+_GY^*#_B'>$_Z!
MX_<SR?\ L _W?I\OO]./\GI1_8!X^7Z?+CU]N/\ /K7J_P#9#>B_F*7^R#Z#
M'X?RS_6C^W9?\_/Q0_\ B'>%_P"@>/W/_(\G_L \_+]?E_#TYZ_SH_L ^G?T
M]\^GKSFO6/[(/MV]/Q[]J/[(/H/T_P :/[=E_/\ D+_B'>%_Z!X_<SY<^-.@
ME?@W\77QRGPM^(9Z#MX0U@^G.3Q[=0:^X/"G_(L^&QUQH&C]_P#J'6OX]OUS
MZU\Y_&[2=OP5^,3$#CX4?$;!XSQX-UHCOZ_7UZ\CZ.\*\>&_#HXP=!T<CGGC
M3[89^G/X_P _E>(L;+&3PK;O[-5%_P"!.#_]M_(_5O#;A^GD-+-84Z:IK$U,
M+)I*R;IPJI=.TG==.YXE^U=X]NOA]\#?&^H67AKXT>([G7]+O/!L,WP"\#W'
MQ$^(_A*7Q5I]]I4/CO3_  K9WEG?WMCX2GFBU6_EL&GO+9(4D@M9F^[^*_\
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M7]*N$N2<9)VL_P!&C&O25:G*F]I6O\I)_H<Y_9_^P/S[X]_7IGIZ4O\ 9_\
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MZ^G^'^>]&Q?3_.<_Y_QYH^LONO\ P%A_9E#_ )]1^]_YF'_9_P#L#_OH4O\
M9_\ LC\Q[^W^<_6MORU_3'^>/_K?C1Y:^G;';TQZ?_6_"CZR^Z^YA_9E#_GU
M'[W_ )F)_9_^R/S'I_CQ^M)_9_\ LC_OH<?I_+-;FQ?\_P"?QH\M3^OIW_"C
MZR^Z^YA_9E#_ )]1^]_YF'_9_P#L#_OH4?V?_LC_ +Z'^'^<?2MORD]/Y?X4
MNQ>F/\BCZR^Z^YB_LRA_SZC][_S,3^S_ /9';N/Q_*C^S^ORCVY'/^%;?EKZ
M?R]O;V_SQ2[%]*/K+[K_ ,!8_P"S*'_/J/WO_,P_[/Z_*/;D<_X4?V?_ +([
M]Q_GGFMLQJ?\_P"(H\M?3U]._'I_GOFCZR^Z_P# 6']F4/\ GU'[W_F8AT__
M &0>?4=/7_ZU)_9_^P/^^A6YY:^GK^N?\:/+7T]?U_S_ (YH^LONO_ 6+^S*
M'_/J/WO_ #,/^S_]@?\ ?0].G]*4Z?Z*#^(__7^GYUM^6O/'48_S_G'M1Y:\
M<=,_K_GM1]9?=?\ @+#^S*'_ #ZC][_S,3^S^/NC/ID>W?VY_*C^S_\ 9'YB
MMORU]/3]/_U?Y%'EKZ=R?S_S]?6CZR^Z_P# 6']F4/\ GU'[W_F8?]GG^X/^
M^A2_V?SRJ_7(_P /\_EG;\M?3_.<_P"?\>:!&HQQTS^OT_I1]9?=?^ L/[,H
M?\^H_>_\S$_L_K\HZ\<CD<\_Y]:/[._V1^8_P_S[5M^6OI_G)/\ 7_)S1Y:X
M(QU_S]/SH^LONO\ P%A_9E#_ )]Q^]_YGB7QRL0OP2^,A*#_ ))/\1^X./\
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M7T;:VT5G;06L"A(;>*.&)%5$58XD"*%2-511A1PJ@#L!TJ>B@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"'Z?\ ^=/1_P )O^TA_P!$!\"_^'Z?_P"=/0!]"45\]_\ ";_M(?\ 1 ?
MO_A^G_\ G3T?\)O^TA_T0'P+_P"'Z?\ ^=/0!]"45\I>#?C'^T+XTT-==LOV
M=?"5A VIZYI?V;4/CL([H2Z%K-]HL\Q2/X52*(;BXL)9[5BVZ2UDAE*KO KJ
M?^$W_:0_Z(#X%_\ #]/_ /.GH ^A**^>_P#A-_VD/^B ^!?_  _3_P#SIZ/^
M$W_:0_Z(#X%_\/T__P Z>@#Z$HKY[_X3?]I#_H@/@7_P_3__ #IZY'7?C/\
MM":!XC\#^&[C]G3PI<7/CK4]9TNQNK;XZ[[/3Y=%\-ZIXEFFU*1OA4K0P7%O
MI<MI;NB.6O)H(V"J^X 'UE17SW_PF_[2'_1 ? O_ (?I_P#YT]'_  F_[2'_
M $0'P+_X?I__ )T] 'T)17SW_P )O^TA_P!$!\"_^'Z?_P"=/1_PF_[2'_1
M? O_ (?I_P#YT] 'T)17SW_PF_[2'?X ^!1_W7I__G3UR/@/XT?M!^/_  CH
MGC#3OV=?"NGV6N6\UQ!9:K\=/L^H6ZPW=Q9LES#'\*Y41V>V9U D;]VR$X)(
M !]945\]_P#";_M(?]$!\"_^'Z?_ .=/1_PF_P"TA_T0'P+_ .'Z?_YT] 'T
M)17SW_PF_P"TA_T0'P+_ .'Z?_YT]'_";_M(?]$!\"_^'Z?_ .=/0!]"45\M
MWGQ9_:(LO$FA^&7_ &>/!SW.NZ?KFHP74?QX!M+>+0GTI+B*Y8_"H2+-<'5H
M3;*L;"00W!+#RS70?\)O^TA_T0'P+_X?I_\ YT] 'T)17SW_ ,)O^TA_T0'P
M+_X?I_\ YT]'_";_ +2'_1 ? O\ X?I__G3T ?0E%?/?_";_ +2'_1 ? O\
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M#, "0#ZGHKY[_P"$W_:0_P"B ^!?_#]/_P#.GH_X3?\ :0_Z(#X%_P##]/\
M_.GH ^A**^>_^$W_ &D/^B ^!?\ P_3_ /SIZ/\ A-_VD/\ H@/@7_P_3_\
MSIZ /H2BOE!_C)^T(GC>W\"G]G;PD;^X\+W'BI;_ /X7L!IJVEMJD.E-9F4_
M"L2&^::=)EB6,K]G#R%AL(KJ_P#A-_VD/^B ^!?_  _3_P#SIZ /H2BOGO\
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M]I#_ *(#X%_\/T__ ,Z>C_A-_P!I#_H@/@7_ ,/T_P#\Z>@#Z$HKY[_X3?\
M:0_Z(#X%_P##]/\ _.GH_P"$W_:0_P"B ^!?_#]/_P#.GH Z[X[_ /)#_C+_
M -DI^(G_ *B&L5W7AC_D6O#W_8#TG_T@MZ^2OC5XQ_:,NO@W\6K6;X">#(HK
MCX9>/()9;;XXR7MQ''+X5U6-W@LU^%<+W<R*Q:*V66(SN%B$B%MP^M/"V?\
MA&?#H8$,-"T@,#U##3[?(/ Y!X/ YH W:*** "BBB@ KYV^-O[4/P:_9]O\
M0M/^)NOZMIUUKMCJ.N&+0O"7BGQA_P (]X1T:XL;77?'OC4^%=(U9?!?P_T.
M[U*PM]8\;>)SIOAS3YKB-+F_C8,%^B:_/?\ :W_8O\3_ +0GC+5/%7@WX@:!
MX-'Q$_9R^(G[)7Q8MO$GAW5/$+3_  <^)NO:/KNNZKX%.F:]HD6D^/[)M/O;
M+3;S64U31S'J*7$]F7L4CN1J_P#7]=P/T"B,<L4<L4@DCE1)4D1@R.C@,CHP
M)!5E(*D$@@@C@U-56QM(]/L;.PA+&&RM;>TB+D%S';0I"A<@ %BJ L0 "<X
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MN^#/$]C%,,K;ZWX5\36.F:_H5^G_ "VT_5K"TO(<KYD*[AGI:\&_9F^$&L?
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W G # 2(  A$! Q$!_\0
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M:Z$S3- ;7[.WG*ZC<P*=1@$'\:KR_#^&[2XEOM7OKN^D2-(KN0(&@"-O7:H
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M=R*D7Q18;TA?S!<.H*Q!22Q..!Z]:Z3QC:HK(M_$-K=17[1!C)9JS21D$$
MD9]"<=*9%XGL)-BL)TD(4NC1'*!B I/L20!0!M45EMXATU--;4&G(M5<H9"A
MP&&<C]"/KQ40\4:6?+(F;;(#M;8<' SC]* -FBL1O%&G@9_>KW/F1E>."?Q
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MU'/7@5JT5L>>48M'L(0XCMD7?&8VQGYE/4'UJ%/#FE(5(M1E<<EV.<8(!YY
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M&G+X=TM%PML<DY+>8Q8\8ZYSTHHH EAT:SMX6AB1UA:,QM'YC$$$Y)ZYS[U
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D <0# 2(  A$! Q$!_\0
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MVB+:'V$[QC=Z?7VJ.+4[">X-O#>V\DXSF-9 6'X4 6Z*3>I8J&&X#)&>:6@
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M-H[F_P B3=;V_(*J?G;G@@CH/:KL4,<*;8T5%SD@#&3ZT^BJ$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!^,-2U*]\36WAG3[
MZRTY&M3>375U&LF</M554\9SSFN\KAO''A676+ZWOX= TK6#''Y;0W;M'(!G
M/RN.,>QH C\!/)9Z[KFCW)TZYN8A%<-?V42Q^>'S]\#^($&NRO\ 4[+2X5EO
MKF.!&<(I=L;F)P /4YKB/"&A:QI>H%K;PQI/A^TD(^TF.<S2S = ,<#K6WXW
MTI-0T59$L_M%U%-$8L+DI^\4DC\!0!IW?B/2+#4HM.N;Z..ZDQM0]L],GH,]
MLT1>(](FU=M*COHVO5)!C'J.2,],CTKCM:M;Q-0U_3QIUS<2ZM) UK.D>Y%
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MJ:R=#L9+5)))EVNQP![5K54W=B@K(****@L*E086HU&6J:FB6%%%%4(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\7:+X/GB&
MK>*K6S:.!?+$]R2 H)Z?G745QOQ,2V/A02W-_%8^3<QRQS26_G_.#P G\1-
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M*#10 48S14JKCGO0)L51M&*6BBK)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y/XA26</A^"2ZLKF[=;N+[/%;,%8RY^7
MD\ >N:ZRN.^)E@^H^$_)40N!<Q.\4]QY"2*#DJ7[9H S_AUI-U9:AJ=S=Z;J
M-F75$A6[N4E58\D[%V]@3WKT&N ^&]I:VLFH&WTFSL-P3)MM1^U;^O7^[7?T
M 5)M+L+B]CO)K."2YC^Y*R LOT-*NFV*7[7RVD*W;#:TP0;R/K5JB@#SSXI?
M\?'@_P#[#L/\FKM]3TVWU:R:TN@3$Q!.#@\5Q/Q2_P"/CP?_ -AV'^35Z%0!
M0ATBTM]3>_C0B=XEB)SQM%2V5C#8VQ@AW;"S-R<G).34DMPJ<+RU56FD?JWX
M"@"N?#]@(?*+/M\EH?O?PDY/ZTG_  C6F/!*C1[WD;<92<N#QC![=*FH!(.0
M2* (H_#=E'<>;OF;YF<(S\!FX+?6I]-T:VTR262$NTDN S.<\#I4D=RRG#_,
M*N*P900<@T +114<]Q%;1^9,X1<@9/J>E $E4Y;X>;Y-NGG3#!*@X !.,YZ?
MA48%U?X)WVL'!QTD)!Z'M@BKD,$5O$(X4"(.@% %:&QRXFNW$\P '3Y!@\$+
MZ^]6'7!S4M%)H""BGLG<4RI*3"HKB86\#RD$A1G J6@@$8(R*&,S[S5(;>RE
MF*2L%0G 0U!I&K0W6EP2".51MQ@H>U:<X8P.%7>2,!?6H[%'BLXXWC$;*N"H
MK*TN;<N\>78=;7"W,9D52!N(Y]JFI  .@Q2UHB HHHI@% !/ IX0GKQ3P !@
M4[";$50OUIU%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<7\0M9TNUTT:=<SZ(UY*5D2VU9R(V4'D\5VE<'\1
MK/5M4L)]-TWPQ!J)N;8I]LDE13"2>@R,^] &=\+H;=M5U>]MY] 42I$K6NC%
MF52,_,Q/<_TKTVN4\%_VBEO)#?\ AF#1S%&BJ\4B-YV!@YVC^?K75T %%<+X
MCBNF\0I'8:K>R:K(\;6]K"^(K:('YVD'0@C/7D]JJ6L^H67BA=0U+?-:W>H/
M;V[P7Y94XPH,8XQP<]Q0 [XI?\?'@_\ [#L/\FKN[B;;\B]3U]J\@\;>*;K6
M-;\,V<_A[4M/2'6XV%Q<J DF,C QZ]:]5<Y=B?6@!**** "BF2RK#&9'.%'4
MTD,R7$8DC.5/>@!7FBB($DB(3T#,!FK-M)M<+V;I7*>*M(2]\B]:X9#;?\LU
M7)<9'05J6_FZE#&Y9H;8CA%;#G!X.1T'M0!KRWY>3RK.,3R=2V?D S@_-Z^U
M.@L0DGG3R&>?&-[# QG(&.E6(HHX4"QHJ+UPHQ3Z "BBB@ HHHH *:5!ZBG4
M4 1F,]C3=I':IJ*5AW(**GHHL%R'!]*78Q[5+118+D8C]33PH'04M%%A!111
M3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH PKCP?HUSJLNIO;R"[E*F21)67=MZ9P:FA\+Z-!
MJYU2.QC6[)+;^<!CU8#H"?6M>B@#SKXK??\ "7_8<A_DU=-=6<LUZLJR[54C
M*^M<S\5O]9X1_P"PY#_)J[-OO'ZT 1RRK#$TC_=49-49;V:>W62R0D[L,"*M
M7L9FM)(U&6(X%5+5QIUEMN 1)DD1H,LP]AWH O>6)[<)*,[E^852$^(V@TQ%
M?;G]XW^K4@\@]\U5FDN+R^^RS82(MS&K]5Z\FMI55!M50!Z 4 9NEQRO(\UR
MC-.,A9''."<X'M4C#^S[KS1Q:RM^\'_/-O[WT/>GS_;/MB>5_J.-U:,$*R[M
MZ@H1@@]Z +HQ@8.12UD7&H?V=.+*&.+;'#O!EEV\9Q@>O2GQ:Y;M$LDN8]RJ
M0F"6R>V/PH U**I-JMFLJ1F0Y;&#M..1GK4+:Y:,F^)]PW*#D;< G[W/:@#3
MHK/.KVZEF))C"AMP4DXYYQZ<5)'J=I+%YJ2_+\O)!'WNE %RBLW^W=/W;?./
MUV'&,XS]*+C6[6%)MK%GB0MMP0&QUP>] &E15>TO8;V,M"Q.WA@1@C\*L4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117!66M:P]U9ZM+?!K2
M[U)[+[#L&U$!8!@>N[*Y/UH A^*7_'QX0_[#D/\ )J[2=/*<D\*><UY%\1/B
M!HVH7OA^.&'45-CK"2R[[-U!50P.W/WC["NFNOBAX7O"%FM]::+!#1?V?)M?
MZ\4 =,UU)<,T5FO3*F=A\J,.V.]306D<#%\L\I).]SDC/4#T'M7(GXI>&E&$
MM]9 ' ']FR?X4G_"U/#O_/MK/_@NDH [#[+#]H\_;^\]:FKB?^%J>'?^??6?
M_!=)3U^*?AK/S0:R?;^SI/\ "@#MHXFE; Z=S5Y5"*%'05P:_%SPTHP+76 /
M^P=)_A2_\+>\-_\ /MK/_@ND_P * .NN=)@O+J26=0ZO%Y6TCIR3D53?07DC
M(>Y#OA1ETZX! _'FN9'QD\+&<P"/53,!N,?V!]P'KCKBI/\ A;WAO_GVUG_P
M72?X4 = WAUF="UVS!"I!9<G@8Q]*FFT&*XCCBE?=&L:1E<?>"G-<S_PM[PW
M_P ^VL_^"Z3_  H_X6]X;_Y]M9_\%TG^% '1R:',R;%O2!M5#E<[E4G /YT]
M]'FDEW&Z4*Q1I%5,9*],>@KF?^%O>&_^?;6?_!=)_A1_PM[PW_S[:S_X+I/\
M* .H.BJ8?+\W_EB8<X]3G-57\-EW9FNCDJZ@[>?F]?I6#_PM[PW_ ,^VL_\
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M  H [VBN"_X6]X;_ .?;6?\ P72?X4?\+>\-_P#/MK/_ (+I/\* .]HK@O\
MA;WAO_GVUG_P72?X4?\ "WO#?_/MK/\ X+I/\* .]HK@O^%O>&_^?;6?_!=)
M_A5C3OBEX=U/5[33(EU"*YNWV0B>T>,,<9ZF@#M:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P8/".FV^L?VBAGR)
M6F2W,A,22-P7"]B:WJ* .:\6>&/^$BET9A=);_V??I=D%<^9M!&W]:Z3:O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M322+-IDCR0A3P2PP<UAZA\.--OIKFX6\NH;B:_&H"1"#LD"[> 1@C'K79T4
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M6SMAC7"Y]R<FNCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; G # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)Q0
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M\.?\];G_ +\-2?\ "S/#?_/:X_\  =J/9S[!]8I?S(["BN._X6;X;_Y[7/\
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MH\,R01SM&PAE+"-R.&QUQ]*@+#UKIM>UO3+Z2Q^R0N8(+J69XV0*"KLK8 _
MUJ2^(-*O+V[N()!;!+5PDQMAO4F52H"D_,5&>F.*/:22V!48-OWCB?LUP81.
M(G,1!.\#(P.I_457+#U%=P/%6F);WD, EM_M"3J&2$'[[*5R/<!OIFI8O$&D
M7>I*5;8BK-)$TD"J+6/RB!$HZ.=W//I[TO:S6\2_8P>TC@21GK04<0F4JWEA
MMI?' /IGUKN'\5:*8)E-N9)GC19I7M\?:R(RI) /R_-@_K69X>\066G:0MC?
MK)(J7@GV"(,"-A7//<-AL'KBJ]I)J]B?90O;F.5)'KQ2O%(D4<KH5CESL8]&
MQUQ72RZWI[>*M+U!P]Q#;*BW4SP!6N&&<L4Z="!^%7M/\6V2):M>E_M*I,LT
MWD GYI 1M(Z?*,=/:FYR6MA1IP;=Y'#D\TZ.&6:.62*-G2%-\C*.$7. 3[9-
M=I!XCT&"SCMQ]I=%N4F$<L"G;B;<>F!RO^'2I+?QKIJ*\MW:FYE:.2,J8@JE
M?/#H#CKM4<9[\4O:S_E-%2AUDCA)8WBCCDD4JDH+1L>C '&1^-1$CU%>@:=X
MITBT$>^_NUDBMY8]XLU<2.TCL'=2><!AQQS]*BLO$^@P30W$PFD<+:1R)]F'
M(A8EFSGG<#T_"CVL_P"4/90_F."W#UIZ032P33QQLT4(4RN!P@)P,_4UU\_B
MJQO+.&"[$A#0QB8QVZ!C(LV[<..?W> .W:M/_A--&6>5XKBYBDDACC:X%H&)
MV3%^5)P<J<4.I/\ E&J4/YCS<],]J[KX7>*;C1O$MOILLKM87S"(QEN(W/W6
M [<\&N.U*>"YU*ZN+:'R8)9G>./^ZI.0*TO!UG+?^,](A@4LPN4D; Z*IW$_
MD*JI:5-W"BW&HDCZF%+2 8I:\8^B1QGCW6Y;"UCL;:0I+<9+,IP50?XUYGCZ
MY]37;?$>V<:E:7>#Y;1&/..A!S_6N*->EATN2Z/E<QG)UW%[#34L=E>2VS7$
M=M*\0S\X4XXZU":W+'5+& V-Q*]PMQ9Q-&(%3*/G.#G/'7FM9MK8Y:48M^\[
M&1)I][';B=[640D!@^WC!Z'Z5$]K<I'([P.JQOL<D8VMZ?6MV?7K:6S:W6/R
M7^R11^<D?S,5^\A_V3ZBEO-<T_4KF)[J-HH[6X,D2Q1\2(>3NYX;('/O4*<^
MQU.E2Z2.=N()[67RKB%XGP&VN,'!IYTZ]WQ)]DFW3#,8*'YAZBM+5-8M-3$-
MQ-;2/<*'0JTG!!.5;(]"2,5?N]?T^Y0Q[IU6?S&E?R^8BR*H &>1\OZTW.=M
MA1I4[OWCF'MIT$Q:&11"=LA*D;#TP?2H/O$*.6)P /6MS4-;%VVKJK2B&ZD5
MX4/3((R3[D"G6NK647A[[#-O$ROO'EQCD[@>3Z8!]#5<\DKV)]G!RLF8$L;P
MR/'(I1T.UE/4'TJ,L/6NMN/$=E=77GN7CGW7 2<0 F)6(*''? W?G1'XCTDF
MXBN+1FCDE*[Q& ?+8#>V.S%ER/K2]I+L/V-.^DCD,CUI"<'DUTM[KME?:!+;
M,KI<-(74)& ,[\C)^GT-16FL6$&G6D$WF%8F!FMA K+*=^=V\\CCC'M3YY6V
M#V4+VYD<X6''-,+#'6NMF\16:3>;"SR7'E,OV@P*I.9 P&/901FK4.OZ?>->
MR>8+:2..X,,A@7*(S(8PH[D<G%3[678T5"#=N9'$%AQS3"P_O#\Z[3_A(=$Q
M?8BF"W ?,1A&UFVJ _'0D@DYZ9XIL?B?37O-1EN3*8IF=(81 NWRRA"_B&.:
M/:2["]A#^9')"TNFN5ME@D,[@%8\?,01D$#Z<U7SS79Q>*-.1K)I&FD\CR0$
M\D Q%(RKD'/.XD?E67KVLV&H:/!;6L&UTV8!CP8\+A@&S@@GGI352?5#=&"6
MDCG2PS]X4NQVC>158HF [ <+GIFNZNM>TBU:SBF_TM52V<(D*D0$)\S!OXB2
M1\I]*J?\)/IP@GMY3-<B0VS2R& +]J,;DN&&>,J0/PH]K+I$?LH+>2.++#^\
M/SII8>M=E?\ BJR-R\]D")OW0$IMP&*B0L0<Y_A.*CF\06+6<<.G;H9%N"ZV
MQ@39*WF[@Q<]/EP,4>TEV'[*'21R*JTCA(P7=C@*O))]*:X*N58893@@]0:Z
MS4M3T_3/&5@VG#_0-.D!+1@,6+,6?'KC.!]*=J'B/2KC2;NW3S'>6-U$;6Z@
M/*9-PG+]0=O&*KVDM- ]E'7WCD(XY)Y"D2EV +$#T R341/?-=58^([:UTS3
MK-P_E16]TMPHB!WR/N\LYZG /X5<N/$NC37.GSJ\\3V\;*/*@"HGR  8Y/4'
M.#],4>TDG\(XTH-?$<,S =Q4S6ER)Y(3"XEC3S'0CE5QG/Y5VMSXLTAII4A@
M*VT[W)E7[,N6#QJ%'KPP)-0W'BK2;B+ BDA(MI82!$&$CM&JB4]]P((QTQBD
MZD_Y1^QI_P QPV\'N*0L/45WFI>)-%NW6'[7=/;BQ:W$DEFHD63<K;FP?FSM
MQVQ45WXRLUGNS8*T<<HN&4-;K]YMOEGVQ@_2CVLOY1^QA_,CAL@L #R>![T^
MXAFM;B2WN(VBFC;:\;C!4^A%=K'XET+R]5$BW!%X\C>48%VY*KL;CH<@YST[
M=ZH^,?$5CKKL]L\LSM=/,C2PB,PQE0/+&/O<Y.::J2<K-!*E!1NI')&GV]Q/
M:7,=Q;3/#/&=R2(V"#3#3:V:3W,4[;'T[X&\0MXG\+6VH2#$XS%./5UZGZ'K
M^-=,*\]^#MC-:>"?-E5E^U7#S(&_N\ $>QQ7H5>)424W8^DHMN";"D/-+2&H
M-3C?$G@Q=3F>\L76.Z;EU?[K_P"!KDF\$Z^&Q]B4^XE6O7L'-+BMHUYQ5C@J
MX"C4ES-6/'O^$)\0?\^0_P"_J_XTA\$>(3_RXC_OZO\ C7L6*,5?UJ9E_9='
MS/&_^$'\0_\ /B/^_J_XTA\#>(O^? ?]_4_QKV7%&*/K,P_LRCYGC'_""^(_
M^? ?]_E_QI/^$$\1?\^"_P#?Y?\ &O:,44?69C_LRCYGBI\!^(_^@>/^_J?X
MTG_"!>)!_P P\?\ ?Y/\:]JP:4<4_K4Q?V91\SQ+_A O$G_0/'_?Y/\ &F_\
M(#XE_P"@>/\ O\G^->X44?6IC_LVCYGAW_" >)?^@>O_ '^3_&D/P^\3?] Y
M?^_R?XU[E11]:F/^S:7F>%GX>^)C_P P]?\ O\G^-)_PKSQ/T&G+C_KNG^->
MZT4?6IA_9U+S/"3\//%'_0/7_O\ I_C3?^%=^*/^@<O_ '_3_&O>**/K4P_L
MZEYG@Q^'?BC_ *!R_P#?]/\ &FGX=>*?^@:O_?\ 3_&O>Z*/K4P_LVEYG@?_
M  KGQ3_T#E_[_I_C33\-_%/_ $#5_P"_Z?XU[[1BCZU,?]G4O,\!/PW\5]M-
M7_O^G^--/PU\5G_F&+_W_3_&OH&BCZW4#^SJ7F?/I^&OBS_H&+_W_3_&D/PU
M\6?] M?_  (3_&OH.BCZW4#^SZ7F?/7_  K3Q;G_ )!B_P#?]/\ &D/PR\6'
M_F%K_P"!"?XU]#44_K=0?]GTO,^=S\,?%Q'_ "#%_P# A/\ &D/PP\7'_F%K
M_P"!"?XU]$T4?6Z@?4*7F?.A^%_B_P#Z!B_^!"?XTW_A5WC#_H%I_P"!$?\
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M444 %%%% !1110 4444 %%&<5S_B?Q-:>'+-I)"9;N1&-O;(,M(P'IZ9QDT
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M38XUBC6-%"HHPJ@8 'H*=0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %17,PM[=YF1G"#=M09)QZ5+5743$--N?/F2&'RV\R60
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M.0.8F Y&>N/3]>.M"7B.JL%E&X*0#$P/S=.H_/T[T 6:*J-J$0C+[)]H&?\
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M))(]C"S27*W;DKUF"[0_UQQ6)J'A_P %@)87UC8KLA9UB<?<C1=I;V 7C)H
MZ73KZWU/3[>^M'\RVN(Q)$^,;E/(.*M5S^B7>EZ5HNFZ=:332P1[;2)W0@[@
MN0&X&"1^==!0 4444 %%%% !1110 4444 %,E)6)F4$D#( [^U/J*YGBMK:2
M>>18XHU+,[G 4#N30!XNOQ2\0-)+.\EI'#N^2$P<YS@IG.?:L36K^XUG4]4U
M9I+B$S',4;XRJ!<!3],52\R75[B^DF5+<S3-<IY:XVY8G@>E9YU26UOXK746
M0V[9VS+P"?0T :#+#$(+JXF,D8 9$P,AB/UZ]ZCN;JVO+:6.YG$8Q_J^OTQC
MK3&TJV6"1HG))8%%,F5QUX%63"7F1K=8XYE3:V1E3_\ 7H KZ="?[+2UO%'
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MVS=@DJ0Q]<%1Q6W10!@:3IEO=:4R7KQ7LLLADF<1E!NR&P!G( VKW[5OT44
M)@4C(K*5900>H(IU<MXMU%].O=)E5IF57FD,$+$-.5A9E3 ^]D@<4 .NO##3
M^2BW:K"#BX0QY,B"7S5"G/RD'COQ6Y8Z?:Z>DBVL0C$CF1N226/N?; QV  %
M>4QZAXSTU;2WODU19!=)=R3^5]I'ER1-NC(3JJR#@=<$>E;UGJVI_P!G>*YI
M972ZBBMW,0;=]F=X%:0+Z8))QVQ0!Z'1FO,]9O?%E_;7]E:^;;1/,\%M-;PL
M)45)(@LF_)SN5G/3^&J_AO4O$TVOM<:FM]#'=7L"Q6TZ_*(_+D$@ ^JAOQ%
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MLVFH75LNEV++#,\8)=\D*Q']*TA3E4=HF52K&FKR/;LTM>$_\+RUK_H$Z?\
M]]O1_P +RUK_ *!-A_WV]:?5JG8Q^N4NY[M29KPK_A>6M_\ 0)L/^^WH_P"%
MY:W_ - FP_[[>CZM4[!]<I=SW7-&:\*_X7EK7_0)L/\ OMZ/^%XZU_T";#_O
MMZ/JU3L'UREW/=<T5XO<?&/5X=&L+Y=+LB]S)*K*7? V$ 8_.J7_  O'6_\
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M$!G#/A2>F33^K5.P?6Z7<]S'%+7A;_&_7(G*2:/8(PZJS."/PIO_  O+6O\
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M[%36NWSQ\D8XZA #0Z_NN*6XXX9\ZDWMY%\4M(*6N8[0HHHH **** "BBB@
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MH]]:FUE2Y$+3RSNJ7#+O,GWPV#RI]#72T4 1PQ+#&L:*%15"JHZ #H!4E%%
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M-2U#-XZ(*,444AB8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M"8HQ2T4 )BC%+10 F*,4M% !BC%%% !BDQ2T4 )BC%+10 8HQ110 F*,4M%
M"8HQ2T4 )BC%+10 F*,4M% !28I:* "BBB@ Q1BBB@ Q28I:* $Q1BEHH 3%
M&*6B@ Q28I:* #%)BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@ Q1BBB@ Q
M28I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q2T44 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $4 G # 2(  A$! Q$!_\0
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MZ\]*UI4W4E8PKUE2C<[+5OC=;173QZ3I37,8.!-.^P-]% S^=9__  O'4O\
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M!#:_NHI98MIFG.=L>.V2#^52H4"O:8I=3J?^%R7_ /T!K;_O^W^%+_PN._\
M^@/;?]_V_P *XK2=#>],TUYY]K9PQ-(\HA))P0,+G )R:T9_![VMK<E[K-W&
MLTL<6SY7BC(#,6SP><@4W"@B56Q+5[G2_P#"XK__ * ]M_W_ &_PI1\8;\_\
MP>V_[_-_A7&:EHL>GW6F0I>+<+>1(YEC'R@LVWY?4"IK_P ,WEIJ;VL)CEC,
MTD,4ID4;BAP0>>&Y''O1[.B2Z^)UU.O_ .%OWW_0(M_^_P W^% ^+]]_T![?
M_O\ '_"N*N/#VJ6=K-<W%N(XH9#&Y+C[PQD>_6H[?2KR[L)KV"-7AA!,F'&Y
M0.IQU[U7LJ)+Q&)3M<[P?%Z_Q_R![?\ [_-_A2_\+=OS_P PBV_[_-_A7#0:
M3<76GO>6S13)$"9T1OGA4?Q,/3Z5H3^'&DDLQI,S7PNHFD0%0C-M."0">1WQ
MUQ2=.@@6(Q3U3.I'Q;ON^DV__?X_X4O_  MF^_Z!-O\ ]_C_ (5Q=GI+7$FH
MQ.^);.(OMC(<,P8+MS]34O\ PCNI^8$\J(G#EB)E*IL&6#'/! [4>RHH7UC%
M/9G8?\+9O3_S";?_ +_-_A2CXKWO_0*M_P#OZ?\ "N0_X1W4Q*T;11JZML >
M91O.W=\O//!!X]:='X<U67R"EKGSL;07 (R"1N],@&CV5$/K&*[LZ\?%:^_Z
M!5O_ -_6_P *4?%:^_Z!-O\ ]_F_PKC;+2FO&O4$T2R6T88?O%V,2P7&[..]
M2QZ#?L\JM&%$$FR?Y@6C^8*3CTR:3IT4"Q&+>J9UW_"U+W_H%6__ '^;_"E_
MX6G>_P#0+M_^_I_PKF-2T+[!%^ZDDN)S/)&L:*"=B'!8@<_TJZOA9?MR0M<N
ML7):5@HX$8<@<]><<\4N2AN/VV,O:YMCXHWI_P"87;_]_3_A1_PM"\_Z!<'_
M ']/^%<?=:5=VD'VB2/$#, IW D9&5R!TR.:J#I5JC2>J1C+&8F+M)G>_P#"
MT+S'_(+@_P"_I_PIP^)UX?\ F&0?]_6_PK@AT-.'2CV%/L1]>K_S'>#XFWG_
M $#8/^_I_P *5?B9>'_F&0?]_3_A7"#J*>*/84^POK^(_F_([G_A9=W_ - V
M#_OX?\*7_A9-V0?^)=!_W\/^%<-WIX[T>PI]@^OXC^;\CUIO$$LGA-=9M+>.
M63:&DB+'Y><-S[5S@^)%WC_D'0?]_#_A3/ %^/M%SI,^##.I=5/KT(_$5S&K
M6#Z9JMS9NI C<[,]U['\JQA2BIN,D=M;%U?91J0?D_4ZG_A95W_T#8/^_A_P
MI/\ A9=W_P! R#_OZ?\ "N)--/>MO84^QQ?7\1_-^1VY^)EWVTV#_OZ?\*0_
M$V\_Z!D'_?T_X5RECISZA!>M&3YEO$)%48^?D#&3TJ6]T*YM[KR8@9!F)220
M#O==P7^?-0Z=).S-EB<6X\R>ATO_  LZ\_Z!=O\ ]_C_ (4T_$^]'_,+M_\
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M;$GB34I;>2)I$W2P1P22JF'=4;<N3W(P!FK;>*]>S)<0S?9R\RSS2PQ[?,?
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MQB/^84O_ ($1_P"-?1QHI_6JA/U&EYGSD/A;XP_Z!2_^!$?^-+_PJ_QA_P!
MI?\ P(C_ ,:^C,48H^M5!?4*7F?.O_"K_%__ $"U_P# B/\ QI1\,/%__0+7
M_P "(_\ &OHG%&*/K50/J%+S/GC_ (5CXN_Z!:_^!$?^-+_PK+Q=_P! M?\
MO_'_ (U]#8HQ1]:J!_9]+S/GO_A6?BW_ *!:_P#?]/\ &G#X:>+?^@6/_ A/
M\:^@L44?6J@?V?2\SY^_X5KXL'_,,'_?]/\ &G#X;>*_^@8/^_Z?XU[_ $4?
M6J@?V?2\SP'_ (5OXJ_Z!@_[_I_C2_\ "N/%?_0,'_?]/\:]]HQ1]:J"_LZE
MYG@@^'/BKK_9H_[_ *?XTH^'/BG_ *!H_P"_Z?XU[U11]:J!_9U'S/!Q\._%
M(Y_LU?\ O^G^-*/AWXHS_P @Y?\ O\G^->[T4?6IA_9U+S/"O^%>>*/^@>/^
M_P"G^-+_ ,*\\3_] Y?^_P G^->Z44?6IA_9U+S/#?\ A7OB?_H'C_O^G^-+
M_P *^\38_P"0</\ O\G^->XXHQ1]:F+^SJ/F>'CX?^)O^@>/^_R?XTX> /$O
M_0/'_?Y/\:]NQ1CZ4?6IB_LVCYGB7_"!>)?^@>/^_P G^-.'@/Q)_P! \?\
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M/^$'\0_] \?]_4_QKV/CI2YI_6IA_9E'S/&CX&\1'_EP'_?Y/\::? OB(]+
M?]_D_P :]GZT4OK4P_LRCYGB_P#P@OB49Q8XSUQ,HS^M-_X0/Q)G_D'C_O\
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MKG@#7K74]+%C'I[:=/9Q+NMA (H]K%@&102 ,JPQG@@T =C1110!4U'<=/N
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M?)/&:;K'AG2?$$EM)J=A%<FW?=&7'Z'U'MTXJ.3PO:A +*XO-/*]/LLY"_\
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MWL4I*USH:*C2:-XU=&#*PR&7D$>M.#J:18ZBDSFES0 4444 %%&:* "BBB@
MHHHH #29I&[?6O-5/BRTN8+DI/+!'-?%(U1B^#GR]^3AAW44TKDRERGI>:,]
M\UYS-_PDNI11,_VN)S)$DGEH4W(+@Y..,93!/M5O4#XC;6Y'6"6&-TB4>4YD
M1/\ 6Y8=.?NYX]*KE(]IUL=WFC(]:X7P[-XBMM2L].O(Y6L5@0O+)$223'N8
ML_\ >#G&*K7EYKK*\-E]I82SS>8T46\B19@ A;/R*$&:7+J/VFE['H@HK"\*
MSSSV%YYKM)''>S) [<EHPW'/?'(_"MVIV+3NKA1110,**** .=\90R7&B>6B
MW6SSXVD:V@$SJH;).P_>'0$8/TKDX;;5)18K>Z5<B_<6_P!BDA@V+"J3,7+X
MXC)3:2O?.*].HH \R\0+K9\>>$QJJZ=<0&XNQ#':I(K']R?O;B0<#TKT"^D6
M&-)WF,:1N&8@9!!XP?SKD_&94>-O!&]V0?:KD;EZ_P"I-=I-&)8V1@K CHPR
M/QJ&,)9DAA>61U2- 69B<  =33HW$D8=6#*PRK#H1ZUBWB1W<6F6VH*S2-."
M5A/R%E5CAO\ 9]OI5S2&D6S\B2S^RB!VAC0'(**<*P]B,5:V);U-&BBB@857
MF^TY3R#&!GYMX/3VQ5BDS2: J)]OW+N-OMS\V%;I[>]9'B\W"Z;;E?M8L_M*
M?;39[O-\K!^[MYQNVYQSC-='5/4-5L-*MOM-_=1VT.X)YDC8&3T%"5@/+]0@
M\13VZR69U8P0VL\D!::5)0GG (Q'\<@7)"MU J]8WNMV6IRZCJ(U"YTQ+BY-
MK&D<F\N%!4NHZH1N"CH":]"M-2L;]5:TNHYU9!(IC;<"I) /Y@C\*M9'^U^5
M,#SWP[<^,+'3[VQNM,FGNF(GBDN+D':KJ<@-@@[7'"]<$5@12^)/[/MOL[ZZ
M83)\AF#^:;K9'D-W\O=YG7Y?TKUR2[MH98HI)D227/EH6Y? R<#O@513Q'HL
ML4<J:E;M'))Y*,).&?T'K0!DZ6-3M+CQ2T\MQ<%)]]H91A<>2"%0=-H;C\*R
M/L-S.OVRWO\ 55*:.'9DDD=))9%P"$!P2H4GCG)%=_D'H#Q4<:QP1A$38B#
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M<"NY2-OER<^IVD$CU[T2>$]1D65(M4^RI/YA>*+<P1CGR]A." I8YZ9P*[3
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MXL6[_O)'9%7CJ67D#W'-<I\(?^2>VQ$BR W-P0ZL6#?O6Y!/)!]3S78ZIO\
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M,/NLC8QGZ,/RITY8_$&Q4D;5TV8@=\^8E.\5-]BM(-84D'3Y1*^,\QM\KY_
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MR =,^ASCZ&IV8=+FIFBJ=C=/<V<,LD+PR.H+1.>4/<?A5RG8H**** "BBB@
MI#2TUB>PH R;6*VDUK5)$BD\XB**5G^ZP"D@+[?,<U+I<DZA[6[DMC/$Y^2
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M@#-DAN=+C926^S[_ ##<0(-V>XD3'/U'UQ7/>%?$-V^K7S7\ZFV!W,RJ.&)
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MU()' /3I3Z$O<[X4M)2TB@HHHH **** "BBB@ HHHH **** "BBB@ HQ110
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M)/MMVRC"3)ST'.0<^_- &3]N^(W_ $ O#W_@QE_^-T?;OB-_T O#W_@QE_\
MC==I10!Q?V[XC?\ 0"\/?^#&7_XW1]N^(O\ T O#W_@QE_\ C==I69K%Y=V5
MLLEI!#(2QWR3R^7'"H!)9CR<<8X'>@#C='\4>/-;AN9;30=""VUU+:/OOY!\
M\;;6QA.F:T?MWQ&_Z 7A[_P8R_\ QNDLO%2QR1^3I*P6CSV\=P5;:PFN &!"
M@<CYER3@\^U=H.@SUH XS[=\1O\ H!>'O_!C+_\ &Z/MWQ&_Z 7A[_P8R_\
MQNNTHH XO[=\1O\ H!>'O_!C+_\ &ZI6/B+Q[J,]]#!H6@[K*?[/+NU"0?-M
M5N/DZ885UVM:M%H^F2W<HWL 1%$" 97P<*,]^/PZUAV7B*1Q'<0:= EM-]F>
MZD$F'\R<+C  ^;&5R21[=* (OMWQ&_Z 7A[_ ,&,O_QNC[=\1O\ H!>'O_!C
M+_\ &Z[)>5&>M.H XO[=\1O^@%X>_P#!C+_\;H^W?$;_ * 7A[_P8R__ !NN
MTK'\0ZT-$L8Y_+$CS3I;QJQ(&]C@9P"?R!)Z4 <GIWB?QYJ=UJ-O;Z%H6^PN
M/L\VZ_D +[0W'R=,,*T/MWQ&_P"@%X>_\&,O_P ;I;;Q/B622#3;<1A8IKZ6
M-]IW2.8Q@;06(VY.[! XZUV*YV\]: .-^W?$;_H!>'O_  8R_P#QNC[=\1O^
M@%X>_P#!C+_\;KM** .+^W?$;_H!>'O_  8R_P#QNL^P\4>.]1U/4]/@T'0O
M.TV5(I]U_( 2R!QM^3GAA^-==XAU?^PM&N-0,8D$6T!2<#E@N?4@9S@ GTKG
M;/Q:LI-Q9Z9#N:+[3>RJQ4LHD,0(RH).$)PP& ,=: )/MWQ&_P"@%X>_\&,O
M_P ;I/MOQ&_Z 7A[_P &,O\ \;KLTY'?\:=0!Q?V[XC?] +P]_X,9?\ XW1]
MN^(W_0"\/?\ @QE_^-UVE8?B37)M"@M98K%[E9KF*!V#A5B#NJ;CW/WN /TH
M I^&]=UJ]UK4=*URPLK6XM(H9E-I.TJLKEAR2HP?D-=17&S^*#:7LD_]F1E9
MVE@@F5\/(T3A 'XX4EB1UP :W]'U"XODN4NX%AN+:<P2JC[E) # J>#@A@>:
M -.BBB@ HHHH **** "BBB@ KA]?:=?$05&OA<EK;[ ("^S'F-YV['RXQC.[
MMC%=Q2;1Z4 >?ZC8>/+W6K*_6ST ?V?)*UL/M$OSAU*_-\O''IWJWY_Q([:;
MX9_\"9O_ (FNUP*",*<4 ><6OB7Q[>^(-2T6+3/#PN-/2)Y6:XEVD2 E<<>W
M-:?G_$C_ *!WAG_P)F_^)K0T_7+2Y\97.FV]E&#]F\R2]& 9F1@I3U(7/4^X
M%=+0!Q7VCXD8_P"0=X9_\"9O_B:/M'Q(_P"@=X9_\"9O_B:[6B@#BOM'Q(_Z
M!WAG_P "9O\ XFLO7O$OCWP[IJW]WI?AUXC-'!B.XESN=@HZCIDBO2:Y?5]:
MCAO+NSO],WVEM:->B67:RRE&7A5YQ@L.3WH I?:/B1_T#O#/_@3-_P#$T?:/
MB1_T#O#/_@3-_P#$UM^'M8EU:&X,\<<<T,@1D3>,94,,AU4C@^G/45M4 <3Y
M_P 2.VG>&1_V\S?_ !-'VCXD?] [PS_X$S?_ !-=M10!Q/VCXD$\Z;X9_P#
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M  K0HHH *3< <4M>?^./$&NZ-K=II^F21!]5A\FP#0AO+N0XW,WJOED\>HH
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M@0(TVU@P#$#)&0,CO6U2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4$]E:W,\$\]M%++;L6A=T!:,D8)
M4]CCCBIZ* ,J;PWHEQ:I:RZ39/;I(9%B,"[58]2!CJ>_K3G\/:-+=37,FE63
M3SQF*61H%)=",%3QR" !^%:=% &5<>&M#N?]?I%E)\_F?- O+8 ST] !^ K4
M    & .U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ G # 2(  A$! Q$!_\0
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M7RX\DDLKR2NSR.Q9W8Y+$]2:ZL/0535['#BL2Z5E'<]?_P"%Y<\: <>]S_\
M8T?\+Q_Z@'_DS_\ 8UY .M+7;]6I]CSOKE7N>O\ _"\/^H!_Y,__ &-*/C?G
M_F _^3/_ -C7D-.7K1]6I]A?7*W?\CUW_A=O_4!/_@3_ /8TO_"[/^H#_P"3
M/_V->1BG"CZM3[!]<K=_R/6Q\:\_\P'_ ,F?_L:7_A=7_4"_\F/_ +&O)5ZT
MX4?5J?87URMW_(]9_P"%T_\ 4"_\F/\ [&E'QH_Z@9_\"/\ [&O)Q6Q:^'-0
MO;"UN[*(W)N&E411CYE$>W+'/&/F%0Z%*.K0XXK$2TB_R/01\9_^H'_Y,?\
MV-+_ ,+FS_S _P#R8_\ L:X;3?!^LZA?/:FSDM_*<I-+*ORQ-MW8./;TSUJD
M-&U(YQ8S'"QMPN?E<X0_\"/2CV-"]A_6<3:_Z'H__"Y3_P! 3_R8_P#L:7_A
M<G_4$_\ )C_[&N(B\'ZTT5T\UHT'V<(663J0S8R,=<<Y_P :KW'A[4[=+J86
M<TEM;2-').$(4%3@G!YQ_*E[&CL#Q&*M?]#T ?&+/_,$_P#)C_ZU+_PN$_\
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M^1ZY_P +M_Z@)_\  G_[&E_X79_U ?\ R9_^QKR0=:6CZM3[!]<K=_R/7/\
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M_P#6I1\7#_T!O_(__P!:O/+O2[_3XHI;NTEACE&49Q][C/YX[5?A\.7<US/
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MG*!&2'R.A R?K@'/%6+G0-0MKN2 0F4(2/,7A6Q@$\]LD#ZTO941?6\5O?\
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M_=-_[[?_ .)H]O3[B^JUOY3SL4X5Z)_PICQ#_P _NF_]]O\ _$TO_"F?$/\
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M[?\ ^)H;H=Q*&*5]#-TOQE_9WV8G34E>""*%7,N#\C$YZ'@[NGMUJ5?'#QI
M(]/4RPS+*KRRE\ ,3A>,C(..N/0"KW_"I==_Y^]/_P"^W_\ B:7_ (5-KO\
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M-'MZ?</JM;^4\['6EKT0?!GQ#G_C]TW_ +[?_P")I?\ A3/B'_G]TW_OM_\
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M^4%*'>!C(Z\&M:LL_P#(U)_UY-_Z&*U* "BBB@ HHHH **** "BBB@ HHHH
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MMKUU!#H-\)IHXRUM*%WL!N.T\#/4T :-O_Q[1?[@_E4E16Q_T:+_ '!_*I:
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M05$X65S:A7<II%^BBBL#T@HHHH *1@2.*6B@#E;SP<E[-=>9=,(9GED^6/\
M>!I%VD%L\J.H7'8>E:^EZ;+92W=Q<W GN;J17D=8]BC:H4 #)[#UZFM.BA 8
MD-G;6OBPM;V\4326;,Y1 -Q\P<G'7J:VZRS_ ,C4G_7DW_H8K4H **** "BB
MB@ HHHH **** "BBB@ HHHH ***0]* %R/6DR/6L_6)Y[;3WEM_]:&4*/7+
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MU10!6^PQG[\D[_65OZ4#3[0=8$;_ 'OF_G5FB@");>%/NQ1CZ*!4@&!@4M%
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M!P ,"G5D=""BBB@ I&Z4M(>AH XS6_%EUIFJ2V\1TUH4D"'>)RZ_(&8MM0@
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MHHH **** "BBB@ HHHH ****  UEWF@:=>I<+/;EA<2++(PD96WJ %((.5(
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M&))3O8>GH/P&* ,R[UN>UUZ'3UM=\;[<OSDY[CV%;@.:3:,YP,^M+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &4W_(TI_P!>3?\ HP5:L_WC27)_Y:M\O^X.
M!_4_C6=?,RZ_A#AWLBB_4R**VHT6.-44851@?2@!U%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %4-;_P"0#J/_ %ZR_P#H)J_5#6_^0#J/_7K+_P"@F@ ?
M][#:6_42 ,W^Z "?UP/QJ_5&P'F,TW4!5B3Z <_J?TJ]0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM@R%&:)/W9"%E&656Z$@?U]* )O[;C_Y\-1_\!'H_MN/_GPU'_P$>M$<T[%
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MNFCNUBC"VZJ&D)4-L/\ > 8'/&?7B@!/#_B/[4L%I+916[O;FXS%)E78C<X
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MF X'S#/!Z=ZK2>.H8S%NLV_>(2%\T;E< '##& .1SG..<4VY\662/<1I9K+
M(R98FBPQ<;1L(S@]2,]!CO3H/$VA$Q":S5+ATP46W4L@.0%..3G!'RY'TI@6
M]-U^YNM7>UN+>,1O-Y<3Q3!PK"(.1P.1UY_#%+IFL/,L5Q?:G:JMPKEK5@%,
M)5L8W9[=#GOTQ4D.M:8NFVUY!:.L4LQBC2.)=R$*22<'  53SGV]JY_5-?TO
M58U@M;+?!=L#=S<1L5W(!\RG)R'SSGI@@4 =K;R6$ BM+:6!<+^[B1QG'J!W
MKE'\</'>G-FTD4D2R0QQON8#YR2Q .TX484_G46FW6A'5[:ZTL7DC*'*VT:;
MRX;GS"2W"@-@#J,]*T1K6F?V-9ZA=:8(DOMLC*8D;:Q( +>IR1TR>: *U[XQ
MD$"36\/E!Y2J[G5G*JV&W)U4\''/<5,?%%Q?>'+Z^LK4V\\?E^7YQ)7#D8/(
MZ@'ICKW-.L-;MI]-?4+G3(Q*]S'$$MX@[.[(A!YQW;&<]!23^)])M8%CMM/>
M3[00RQK&B"0EE#9&>HW#.1VZT /LO%C7>H6=C%9%I+GYE<S#A!NR6 '#?*?E
M]^O7&?J_BC4-+DNI/,66-92D,<*+)O"NH*C!W!\$@AAC/0U<M_%NB"0B.$FX
M9OF\F  M(<#'7.?F')X]Z2/Q1I;WT[2:9*F7CB\\PIEF.3ACGC:5QUY(XS3
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MD=.>:**70"*71M-N+2*VFLXI(80?+1AD+N!4_F&.?K4;Z#I?S?Z&@#*%(#,
M,8P0 >#P.1SQUHHH8"?\(_I63_H:AL??5F#=A]X'/\*_E26.EVUO=/-"'CV,
M(U16PH15"A<=P,D\]SFBBF \Z%I30^4UC$8\*-I!(X# ?D&;\ZC'AW2&VDV$
M9*$D9).XY/+9/S'D\G/6BB@">WTNQLC^XMU4LA1BQ+$J><$DGBH6T#2O)$1L
ME:-&W!&=B#TX()Y' X/'%%%# =!HFF08,5E&I&TYR3]T@KW[$#\JC7PQHFXN
M-.B!QV+#'3D<\'@<^PHHH )/#VDR1/"]DAC9B2NYN_! YX!R>!Q[4QM$T^XU
M6[GN+<2L\<:;7)V@ ,.!ZX[]:**%N#V)9]"TNXF>66R1I)'WLVY@0W7(P?E.
M0,D8SCFF/X7T1CN.G1 C&-I9<$8Y&#P?E'/L***0F2IX>T@?\N$.< 9YYZ=?
M7H*$\/Z5&BA+-5"9 PS<CGKSS^/3M113&2P:380Q+%';*$20RKDECO(P6))R
M3@D<U##H>EJ@ LDPN2H8LV.0<#)Z?*O'3BBB@.@HT#2P% LUPK[U^9N#Z#GI
M_L]/:DE\/Z3/!#')8QLD *1KEL*N0<=>F0#CVHHI/8""[T2P>QBM$@\J W,<
MI6)BN2N,<]>P''I4@\-:-YA8:?$&Z<$C' YX/!^4<]>***$!)'H.EQL&2S1<
M;< %L9!!!QG&>!SUXI'\/:2Y;=9(=[98;F ;D]1GGJ>M%%#V$+<:)I]W!%!>
M0?:5BW;#*Y)PV<C.>1[>PI)?#VDS0B*2QC**NP $C"\G&0<X^9OSHHIC'W.B
M:9=O$\]G'(8E"H#G  Z CH<9.,YZT^#2;"" 0QVRB-)!, 22=XZ,23DD8'Y4
M44F(@;P[I 5L6$6"N, G Z<CG@\#D<\5+/I&GW$TL\UJKR. 'R3A^G49P>@'
MTXHHIC(U\/Z27!^P1<  #G'!R.,XX_EQTJ,>&=%&%_L^/&0Q^9N<8QGGD#:O
M!XX%%% $Z:78PVDL:6R^6[!V0DD$KRO!/ ! X'%-GT33+N=YKBS1W<AGR3AC
M@#)&<'H/RHHI -MO#NCV]RLT5A&DBYVD$\?09XJ>32+!EM@;9<6RA8L$C:HQ
MA>#R.!P<CBBB@"*+0=*C1(TLHPL<GF(,GY6P.>OL/RH?0=*+$?8H_O[\@D$D
M]>A[^G2BBA 5H]'L(-;M?)MDC$*/,@7H'*JF>?\ 9XKH***8!1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 +@# 2(  A$! Q$!_\0
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4T445%?$5*D8<[O96'"G&+=D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>orka-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.orukatx.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:orka="http://www.orukatx.com/20241231" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet" id="orka_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" id="orka_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" id="orka_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Consolidated Statement of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" id="orka_r_ConsolidatedComprehensiveIncome_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3" id="orka_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" id="orka_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>006 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow" id="orka_r_ConsolidatedCashFlow">
        <link:definition>007 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" id="orka_r_NatureoftheBusinessandBasisofPresentation">
        <link:definition>008 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" id="orka_r_SummaryofSignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" id="orka_r_ReverseRecapitalizationandPreClosingFinancing">
        <link:definition>010 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurements" id="orka_r_FairValueMeasurements">
        <link:definition>011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" id="orka_r_CashequivalentsandMarketableSecurities">
        <link:definition>012 - Disclosure - Cash equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" id="orka_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>013 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty" id="orka_r_NotePayablewithRelatedParty">
        <link:definition>014 - Disclosure - Note Payable with Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" id="orka_r_ConvertiblePreferredStockandStockholdersEquity">
        <link:definition>015 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensation" id="orka_r_StockBasedCompensation">
        <link:definition>016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosures" id="orka_r_SegmentDisclosures">
        <link:definition>017 - Disclosure - Segment Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxes" id="orka_r_IncomeTaxes">
        <link:definition>018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" id="orka_r_OptionAgreementsandLicenseAgreements">
        <link:definition>019 - Disclosure - Option Agreements and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingencies" id="orka_r_CommitmentandContingencies">
        <link:definition>020 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShare" id="orka_r_NetLossPerShare">
        <link:definition>021 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactions" id="orka_r_RelatedPartyTransactions">
        <link:definition>022 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEvents" id="orka_r_SubsequentEvents">
        <link:definition>023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy" id="orka_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" id="orka_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" id="orka_r_ReverseRecapitalizationandPreClosingFinancingTables">
        <link:definition>996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables" id="orka_r_FairValueMeasurementsTables">
        <link:definition>996003 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" id="orka_r_CashequivalentsandMarketableSecuritiesTables">
        <link:definition>996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" id="orka_r_ConvertiblePreferredStockandStockholdersEquityTables">
        <link:definition>996006 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationTables" id="orka_r_StockBasedCompensationTables">
        <link:definition>996007 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables" id="orka_r_SegmentDisclosuresTables">
        <link:definition>996008 - Disclosure - Segment Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxesTables" id="orka_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables" id="orka_r_CommitmentandContingenciesTables">
        <link:definition>996010 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareTables" id="orka_r_NetLossPerShareTables">
        <link:definition>996011 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables" id="orka_r_RelatedPartyTransactionsTables">
        <link:definition>996012 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" id="orka_r_NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" id="orka_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" id="orka_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" id="orka_r_ScheduleoftheAssetsandLiabilitiesTable">
        <link:definition>996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" id="orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable">
        <link:definition>996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" id="orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable">
        <link:definition>996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" id="orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable">
        <link:definition>996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" id="orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable">
        <link:definition>996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" id="orka_r_NotePayablewithRelatedPartyDetails">
        <link:definition>996022 - Disclosure - Note Payable with Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" id="orka_r_ConvertiblePreferredStockandStockholdersEquityDetails">
        <link:definition>996023 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" id="orka_r_ScheduleofConvertiblePreferredStockTable">
        <link:definition>996024 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" id="orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable">
        <link:definition>996025 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails" id="orka_r_StockBasedCompensationDetails">
        <link:definition>996026 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" id="orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable">
        <link:definition>996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmG2VNT1WAmGBEAH/9UJyoAQ=] CSR-->
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" id="orka_r_ScheduleofStockOptionActivityTable">
        <link:definition>996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable" id="orka_r_ScheduleofRSAActivityTable">
        <link:definition>996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" id="orka_r_ScheduleofEmployeeWarrantActivityTable">
        <link:definition>996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996031 - Disclosure - Stock-Based Compensation - Schedule of Company&#8217;s Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails" id="orka_r_SegmentDisclosuresDetails">
        <link:definition>996033 - Disclosure - Segment Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" id="orka_r_ScheduleofSegmentLossfromOperationsTable">
        <link:definition>996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxesDetails" id="orka_r_IncomeTaxesDetails">
        <link:definition>996035 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" id="orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable">
        <link:definition>996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" id="orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable">
        <link:definition>996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" id="orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" id="orka_r_ScheduleofNetDeferredTaxAssetsTable">
        <link:definition>996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" id="orka_r_ScheduleofUnrecognizedTaxBenefitsTable">
        <link:definition>996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" id="orka_r_OptionAgreementsandLicenseAgreementsDetails">
        <link:definition>996041 - Disclosure - Option Agreements and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails" id="orka_r_CommitmentandContingenciesDetails">
        <link:definition>996042 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" id="orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable">
        <link:definition>996043 - Disclosure - Commitment and Contingencies - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" id="orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable">
        <link:definition>996044 - Disclosure - Commitment and Contingencies - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareDetails" id="orka_r_NetLossPerShareDetails">
        <link:definition>996045 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" id="orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable">
        <link:definition>996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" id="orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable">
        <link:definition>996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" id="orka_r_RelatedPartyTransactionsDetails">
        <link:definition>996048 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable">
        <link:definition>996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEventsDetails" id="orka_r_SubsequentEventsDetails">
        <link:definition>996050 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
  <xs:element name="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
  <xs:element name="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
  <xs:element name="ScheduleOfConvertiblePreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfConvertiblePreferredStockAbstract"/>
  <xs:element name="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRsaActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRsaActivityAbstract"/>
  <xs:element name="ScheduleOfEmployeeWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfSegmentLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
  <xs:element name="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="SubscriptionReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivables"/>
  <xs:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
  <xs:element name="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
  <xs:element name="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
  <xs:element name="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
  <xs:element name="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
  <xs:element name="IssuanceCostOfPIPEFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceCostOfPIPEFinancing"/>
  <xs:element name="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
  <xs:element name="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
  <xs:element name="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
  <xs:element name="CashAcquiredInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
  <xs:element name="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
  <xs:element name="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
  <xs:element name="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
  <xs:element name="OptionAgreementsAndLicenseAgreementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
  <xs:element name="SubscriptionReceivablePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivablePolicyTextBlock"/>
  <xs:element name="ClassificationOfConvertiblePreferredStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
  <xs:element name="NotePayableToRelatedPartyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NotePayableToRelatedPartyPolicyTextBlock"/>
  <xs:element name="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="OtherIncomeExpenseNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherIncomeExpenseNetPolicyTextBlock"/>
  <xs:element name="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfConvertiblePreferredStockTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
  <xs:element name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
  <xs:element name="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
  <xs:element name="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
  <xs:element name="FairValueCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_FairValueCashEquivalentsAndMarketableSecurities"/>
  <xs:element name="MarketableSecuritiesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesDomainDomain"/>
  <xs:element name="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
  <xs:element name="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
  <xs:element name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_AccruedResearchAndDevelopment"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofRSAActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
  <xs:element name="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
  <xs:element name="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
  <xs:element name="NatureoftheBusinessandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
  <xs:element name="AdditionalPaidInCapitalTransacationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_AdditionalPaidInCapitalTransacationCost"/>
  <xs:element name="ExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExchangeRatio"/>
  <xs:element name="CommonStocksConversionRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStocksConversionRatio"/>
  <xs:element name="InvestorsClosingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_InvestorsClosingShares"/>
  <xs:element name="PreFundedWarrantsOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsOfCommonStockShares"/>
  <xs:element name="NumberOfSharesPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_NumberOfSharesPurchased"/>
  <xs:element name="NumberofAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NumberofAggregateShares"/>
  <xs:element name="PrefundedWarrantstoPurchaseAnAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="NotePayablewithRelatedPartyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NotePayablewithRelatedPartyDetailsTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
  <xs:element name="ClassOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantsExercisable"/>
  <xs:element name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightExpirationDate"/>
  <xs:element name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightWarrantsExercised"/>
  <xs:element name="CommonStockConversionRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockConversionRatio"/>
  <xs:element name="WarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_WarrantsToPurchaseCommonStock"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
  <xs:element name="EmployeeStockPurchasePlanESPPCashContributionsToESPP" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
  <xs:element name="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
  <xs:element name="EstimatedFairValueOfWarrantsToBeGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_EstimatedFairValueOfWarrantsToBeGranted"/>
  <xs:element name="ClassOfWarrantOrRight" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRight"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
  <xs:element name="OptionAgreementsandLicenseAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
  <xs:element name="NonRefundableMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NonRefundableMilestonePayments"/>
  <xs:element name="RoyaltyPayableOnProductSales" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_RoyaltyPayableOnProductSales"/>
  <xs:element name="DevelopmentCostsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DevelopmentCostsPercentage"/>
  <xs:element name="MilestoneConsiderationPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_MilestoneConsiderationPaid"/>
  <xs:element name="OtherDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherDevelopmentCost"/>
  <xs:element name="ResearchInitialFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchInitialFee"/>
  <xs:element name="CommitmentandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CommitmentandContingenciesDetailsTable"/>
  <xs:element name="NonRefundableLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_NonRefundableLicenseFee"/>
  <xs:element name="NetLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_SubsequentEventsDetailsTable"/>
  <xs:element name="MarketableSecuritiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="orka_MarketableSecuritiesAxis"/>
  <xs:element name="ARCACommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ARCACommonStockMember"/>
  <xs:element name="AchievementOfDevelopmentCandidateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_AchievementOfDevelopmentCandidateMember"/>
  <xs:element name="AntibodyProductsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_AntibodyProductsMember"/>
  <xs:element name="ClinicalDevelopmentMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClinicalDevelopmentMilestonesMember"/>
  <xs:element name="ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertibleNoteMember"/>
  <xs:element name="EmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeStockPurchasePlanMember"/>
  <xs:element name="EmployeeWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeWarrantsMember"/>
  <xs:element name="ExternalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExternalMember"/>
  <xs:element name="FairmountHealthcareFundIILPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountHealthcareFundIILPMember"/>
  <xs:element name="FairmountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountMember"/>
  <xs:element name="FairmountsOwnershipInterestInParagonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountsOwnershipInterestInParagonMember"/>
  <xs:element name="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
  <xs:element name="MarketableSecuritiesCurrentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesCurrentMember"/>
  <xs:element name="MarketableSecuritiesLongTermMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesLongTermMember"/>
  <xs:element name="MarketableSecuritiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesMember"/>
  <xs:element name="MarketableSecuritiesNoncurrentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesNoncurrentMember"/>
  <xs:element name="NominationOfADevelopmentCandidateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NominationOfADevelopmentCandidateMember"/>
  <xs:element name="ORKAZeroZeroOneLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroOneLicenseAgreementMember"/>
  <xs:element name="ORKAZeroZeroOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroOneMember"/>
  <xs:element name="ORKAZeroZeroTwoLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
  <xs:element name="ORKAZeroZeroTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroTwoMember"/>
  <xs:element name="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
  <xs:element name="OperatingExpenseExcludingStockBasedCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
  <xs:element name="OrukaCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaCommonStockMember"/>
  <xs:element name="OrukaSeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaSeriesAConvertiblePreferredStockMember"/>
  <xs:element name="OtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherMember"/>
  <xs:element name="PIPEFinancingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PIPEFinancingMember"/>
  <xs:element name="ParagonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonMember"/>
  <xs:element name="ParagonMilestonePaymentsForOptionAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
  <xs:element name="ParagonReimbursableOptionAgreementsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOptionAgreementsFeesMember"/>
  <xs:element name="ParagonReimbursableOtherResearchExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOtherResearchExpensesMember"/>
  <xs:element name="ParagonReimbursablePatentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursablePatentExpensesMember"/>
  <xs:element name="ParukaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaMember"/>
  <xs:element name="ParukaWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantMember"/>
  <xs:element name="ParukaWarrantObligationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantObligationMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsMember"/>
  <xs:element name="PreMergerOrukaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreMergerOrukaMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PrefundedWarrantsMember"/>
  <xs:element name="RegulatoryMilestonesMemberMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RegulatoryMilestonesMemberMember"/>
  <xs:element name="RestrictedStockAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RestrictedStockAwardsMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="SeriesBConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockAmountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockOptionsMember"/>
  <xs:element name="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
  <xs:element name="TwoThousandTwentyFourStockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
  <xs:element name="USGovernmentAgencySecuritiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_USGovernmentAgencySecuritiesMember"/>
  <xs:element name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
  <xs:element name="OptionAgreementsAndLicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>orka-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="orka_SubscriptionReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmOpFXkp/ECjD0IBewLPhuZU=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="orka_AccruedResearchAndDevelopment" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>orka-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecurities" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosures" roleURI="http://www.orukatx.com/role/SegmentDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreements" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingencies" roleURI="http://www.orukatx.com/role/CommitmentandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecuritiesTables" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresTables" roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesTables" roleURI="http://www.orukatx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable" roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRSAActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofSegmentLossfromOperationsTable" roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresDetails" roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_SubscriptionReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceCostOfPIPEFinancing" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" order="31" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_SubscriptionReceivablePolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_MarketableSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_MarketableSecuritiesLongTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="orka_MarketableSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain_0" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesCurrentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesNoncurrentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_USGovernmentAgencySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecurities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="orka_AccruedResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmH+otLjd4TYrAA70kHc/v08=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_StockOptionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_EmployeeStockPurchasePlanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_ExternalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OtherMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_RestrictedStockAwardsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_StockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_ParukaWarrantMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursablePatentExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PreMergerOrukaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_ARCACommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PIPEFinancingMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_AdditionalPaidInCapitalTransacationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ExchangeRatio" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_CommonStocksConversionRatio" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_InvestorsClosingShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_PreFundedWarrantsOfCommonStockShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NumberOfSharesPurchased" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NumberofAggregateShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="orka_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="orka_ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_PreMergerOrukaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="orka_FairmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PreMergerOrukaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PIPEFinancingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantOrRightExpirationDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_CommonStockConversionRatio" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_WarrantsToPurchaseCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ClassOfWarrantOrRight" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OptionAgreementsandLicenseAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroTwoMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_NominationOfADevelopmentCandidateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_ClinicalDevelopmentMilestonesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_RegulatoryMilestonesMemberMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_AntibodyProductsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_AchievementOfDevelopmentCandidateMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_NonRefundableMilestonePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_RoyaltyPayableOnProductSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_DevelopmentCostsPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_MilestoneConsiderationPaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OtherDevelopmentCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_ResearchInitialFee" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="orka_CommitmentandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CommitmentandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="orka_NonRefundableLicenseFee" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="orka_NetLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_ParukaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_FairmountsOwnershipInterestInParagonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="orka_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>orka-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash operating activities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="orka_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesAxis_lbl" xml:lang="en-US">Marketable Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US">Schedule of Marketable Securities at Estimated Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Note Payable with Related Party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested balance, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested balance, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Option Agreements and License Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="orka_OptionAgreementsAndLicenseAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitment and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental disclosures of non-cash operating and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Future lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total discounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerUnitAbstract_lbl" xml:lang="en-US">Net Loss per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerUnitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Due in one year or less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivables_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable securities, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl0" xml:lang="en-US">Due in 1-2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Carrying Value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Non-voting convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development personnel-related expense (excluding stock-based compensation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Related party amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative personnel-related expense (excluding stock-based compensation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to stockholders, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Loss per share &#8211; Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to stockholders, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Loss per share &#8211; Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average shares outstanding &#8211; Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average shares outstanding &#8211; Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl" xml:lang="en-US">Issuance costs of PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of the Paruka warrant from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of notes payable to related party, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from the Pre-Closing Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from the PIPE Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability arising from obtaining operating right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl" xml:lang="en-US">Assets acquired in connection with the reverse capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl" xml:lang="en-US">Non-cash accrued interest on convertible note converted to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl" xml:lang="en-US">Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of the Paruka warrant from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs of Pre-Closing Financing and reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Net accretion of premiums and discounts on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xml:lang="en-US">Other liabilities assumed in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0" xml:lang="en-US">Series B Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and development stock-based compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl2" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and administrative stock-based compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract_lbl" xml:lang="en-US">Marketable securities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl" xml:lang="en-US">Marketable securities, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl" xml:lang="en-US">Cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash Equivalents and marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Fair Value, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US">Less than 12 months, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US">12 months or longer, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US">12 months or longer, Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Securities at Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional and consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Note Payable with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock Issuable Upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Total shares of common stock reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Shares reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Stock Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercisable,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSA Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Unvested balance, Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average,Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Accruals and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized R&amp;D expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Changes related to tax positions taken in the current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl" xml:lang="en-US">Option Agreements and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitment and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US">Less than 12 months, Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit derived by applying the federal statutory rate to income before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in the valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right- of- use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl0" xml:lang="en-US">Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl1" xml:lang="en-US">U.S. treasury securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US">US Government Agency Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0" xml:lang="en-US">U.S. government agency securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Papers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl0" xml:lang="en-US">Commercial papers	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommercialPaperMember_lbl1" xml:lang="en-US">Commercial papers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl0" xml:lang="en-US">Corporate debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US">Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesMember_lbl" xml:lang="en-US">Marketable Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesMember" xlink:to="orka_MarketableSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesLongTermMember_lbl" xml:lang="en-US">Marketable Securities,Long-Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesLongTermMember" xlink:to="orka_MarketableSecuritiesLongTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesCurrentMember_lbl" xml:lang="en-US">Marketable securities, current [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesCurrentMember" xlink:to="orka_MarketableSecuritiesCurrentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_USGovernmentAgencySecuritiesMember_lbl" xml:lang="en-US">U.S. government agency securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_USGovernmentAgencySecuritiesMember" xlink:to="orka_USGovernmentAgencySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesNoncurrentMember_lbl" xml:lang="en-US">Marketable securities, long-term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesNoncurrentMember" xlink:to="orka_MarketableSecuritiesNoncurrentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Shares issuable on conversion of Company Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantObligationMember_lbl" xml:lang="en-US">Paruka Warrant Obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_ParukaWarrantObligationMember_lbl0" xml:lang="en-US">Paruka warrant obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding and Issued Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl2" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeWarrantsMember_lbl" xml:lang="en-US">Employee Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_EmployeeWarrantsMember_lbl0" xml:lang="en-US">Employee warrants	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl" xml:lang="en-US">2024 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Award [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockMember_lbl1" xml:lang="en-US">RSA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee stock purchase plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanMember" xlink:to="orka_EmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl" xml:lang="en-US">Operating Expense Excluding StockBased Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl0" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExternalMember_lbl" xml:lang="en-US">External [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExternalMember" xlink:to="orka_ExternalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherMember" xlink:to="orka_OtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockAwardsMember" xlink:to="orka_RestrictedStockAwardsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockOptionsMember" xlink:to="orka_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantMember_lbl" xml:lang="en-US">Paruka Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantMember" xlink:to="orka_ParukaWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl" xml:lang="en-US">Paragon reimbursable Option Agreements&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl" xml:lang="en-US">Paragon milestone payments for Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable other research expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable patent expenses	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of convertible note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl" xml:lang="en-US">Additional paid-in capital transaction costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExchangeRatio_lbl" xml:lang="en-US">Exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStocksConversionRatio_lbl" xml:lang="en-US">Conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_InvestorsClosingShares_lbl" xml:lang="en-US">Investors shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Exchange shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl" xml:lang="en-US">Pre-funded warrants of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Warrants exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NumberOfSharesPurchased_lbl" xml:lang="en-US">Aggregate of purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NumberofAggregateShares_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Convertible shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl" xml:lang="en-US">Prefunded warrants to purchase an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Cash, cash equivalents, and marketable securities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xml:lang="en-US">Federal Deposit Insurance Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Initial principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Aggregate proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Unpaid accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">RSAs price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantsExercisable_lbl" xml:lang="en-US">Warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price per warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Employee warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Converted shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStockConversionRatio_lbl" xml:lang="en-US">Conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Warrant purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl" xml:lang="en-US">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase price of common stock expressed as a percentage of its fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Maximum contribution of employee&apos;s eligible compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl" xml:lang="en-US">Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">RSAs issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl" xml:lang="en-US">Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl0" xml:lang="en-US">Warrant purchase percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl" xml:lang="en-US">Estimated fair value of warrants to be granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRight_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reporting segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance due to continuing loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl" xml:lang="en-US">Operating loss carryforwards as a percentage of taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-refundable milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RoyaltyPayableOnProductSales_lbl" xml:lang="en-US">Royalty payable on product sales, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Initiation fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DevelopmentCostsPercentage_lbl" xml:lang="en-US">Development costs, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MilestoneConsiderationPaid_lbl" xml:lang="en-US">Milestone consideration paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherDevelopmentCost_lbl" xml:lang="en-US">Development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchInitialFee_lbl" xml:lang="en-US">Research initial fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lease initial period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lease discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmCduJJcghm0QVvu/4WmrLZ4=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl" xml:lang="en-US">Variable lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NonRefundableLicenseFee_lbl" xml:lang="en-US">Non-refundable license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" xml:lang="en-US">Weighted-average number of shares of as-converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl" xml:lang="en-US">Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Classification of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl" xml:lang="en-US">Note Payable to Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl" xml:lang="en-US">Research and Development Contract Costs Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share Attributable to Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaCommonStockMember_lbl" xml:lang="en-US">Oruka Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreMergerOrukaMember_lbl" xml:lang="en-US">Pre-Merger Oruka [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreMergerOrukaMember" xlink:to="orka_PreMergerOrukaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ARCACommonStockMember_lbl" xml:lang="en-US">ARCA common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Oruka Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PIPEFinancingMember_lbl" xml:lang="en-US">PIPE Financing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PIPEFinancingMember" xlink:to="orka_PIPEFinancingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl" xml:lang="en-US">Fairmount Healthcare Fund II, L.P. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl0" xml:lang="en-US">Fairmount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountMember_lbl" xml:lang="en-US">Fairmount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountMember" xlink:to="orka_FairmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonMember_lbl" xml:lang="en-US">Paragon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US">Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RegulatoryMilestonesMemberMember_lbl" xml:lang="en-US">Regulatory Milestones Member [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RegulatoryMilestonesMemberMember" xlink:to="orka_RegulatoryMilestonesMemberMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl" xml:lang="en-US">ORKA-001 License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl" xml:lang="en-US">ORKA-002 License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NominationOfADevelopmentCandidateMember_lbl" xml:lang="en-US">Nomination Of A Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NominationOfADevelopmentCandidateMember" xlink:to="orka_NominationOfADevelopmentCandidateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl" xml:lang="en-US">First Dosing of Human Patient in Phase1Trial Milestone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroOneMember_lbl" xml:lang="en-US">ORKA-001 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroTwoMember_lbl" xml:lang="en-US">ORKA-002 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AntibodyProductsMember_lbl" xml:lang="en-US">Antibody Products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AntibodyProductsMember" xlink:to="orka_AntibodyProductsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl" xml:lang="en-US">Achievement of Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl0" xml:lang="en-US">Achievement Of Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US">California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaMember_lbl" xml:lang="en-US">Paruka [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaMember" xlink:to="orka_ParukaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountsOwnershipInterestInParagonMember_lbl" xml:lang="en-US">Fairmount&apos;s Ownership Interest in Paragon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountsOwnershipInterestInParagonMember" xlink:to="orka_FairmountsOwnershipInterestInParagonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesDomainDomain_lbl" xml:lang="en-US">MarketableSecuritiesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl" xml:lang="en-US">Schedule of Convertible Preferred Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of RSA Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Schedule of RSA Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US">Schedule of Employee Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US">Schedule of Segment Loss from Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable_lbl" xml:lang="en-US">Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="orka_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable_lbl" xml:lang="en-US">Note Payable with Related Party (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Note Payable with Related Party [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl0" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="orka_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IncomeTaxesDetailsTable" xlink:to="orka_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable_lbl" xml:lang="en-US">Option Agreements and License Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="orka_OptionAgreementsandLicenseAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Option Agreements and License Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommitmentandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitment and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommitmentandContingenciesDetailsTable" xlink:to="orka_CommitmentandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitment and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="orka_NetLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Net Loss per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="orka_RelatedPartyTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="orka_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AccruedResearchAndDevelopment_lbl0" xml:lang="en-US">Accrued research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl0" xml:lang="en-US">The amount of additional paid-in capital transacation cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Represent the amount of cash acquired in connection with the reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRight_lbl0" xml:lang="en-US">Number of warrants or rights issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl0" xml:lang="en-US">The class of warrant or right expiration date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl1" xml:lang="en-US">class of warrant or right to purchase percentage of outstanding diluted stock maximum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl0" xml:lang="en-US">The class of Warrant or Right warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantsExercisable_lbl0" xml:lang="en-US">Represent the number of warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0" xml:lang="en-US">Classification of Convertible Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommonStockConversionRatio_lbl0" xml:lang="en-US">Percentage of common stock conversion ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommonStocksConversionRatio_lbl0" xml:lang="en-US">Percentage of common stock conversion ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Description of minority interest ownership percentage by noncontrolling owners.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DevelopmentCostsPercentage_lbl0" xml:lang="en-US">Percentage of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl0" xml:lang="en-US">This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0" xml:lang="en-US">Estimated fair value of warrants to be granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ExchangeRatio_lbl0" xml:lang="en-US">Exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl0" xml:lang="en-US">Amount of cash equivalents and marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_InvestorsClosingShares_lbl0" xml:lang="en-US">Number of investors closing shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl0" xml:lang="en-US">Issuance cost of PIPE financing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl0" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_MilestoneConsiderationPaid_lbl0" xml:lang="en-US">The milestone consideration paid amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NonRefundableLicenseFee_lbl0" xml:lang="en-US">Amount of non refundable license fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NonRefundableMilestonePayments_lbl0" xml:lang="en-US">Non-refundable milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0" xml:lang="en-US">Represent the amount of non-cash accrued interest on convertible note converted to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl0" xml:lang="en-US">Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0" xml:lang="en-US">Note Payable to Related Party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NumberOfSharesPurchased_lbl0" xml:lang="en-US">Number of shares purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NumberofAggregateShares_lbl0" xml:lang="en-US">Number of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl0" xml:lang="en-US">Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl0" xml:lang="en-US">The entire disclosure of option agreements and license agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OtherDevelopmentCost_lbl0" xml:lang="en-US">Represent the amount of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl0" xml:lang="en-US">Represents of other income (expense), net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl0" xml:lang="en-US">Pre-funded warrants of common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl0" xml:lang="en-US">Number of prefunded warrants to purchase an aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Represents of recently adopted accounting pronouncements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl0" xml:lang="en-US">Represent the amount of reclassification of the paruka warrant from liability to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0" xml:lang="en-US">Research and development contract costs accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchInitialFee_lbl0" xml:lang="en-US">The amount of research initial fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_RoyaltyPayableOnProductSales_lbl0" xml:lang="en-US">Royalty payable on product sales, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of common stock reserved for future issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0" xml:lang="en-US">Number of Warrants, Exercised (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Vested and expected to vest, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl0" xml:lang="en-US">Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Vested and expected to vest, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl0" xml:lang="en-US">Number of employee warrants outstanding, vested and exercisable shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Vested and Exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl0" xml:lang="en-US">Share based compensation arrangement diluted stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl0" xml:lang="en-US">Represent the amount of conversion of non-voting convertible preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl0" xml:lang="en-US">Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl0" xml:lang="en-US">Number of shares conversion of non-voting convertible preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl0" xml:lang="en-US">Subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivables_lbl0" xml:lang="en-US">Amount of subscription receivable from investors who have been allocated common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Number of shares classified as temporary equity issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Number of shares classified as temporary equity issued conversion of convertible securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Value of stock classified as temporary equity conversion of convertible securities during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl0" xml:lang="en-US">The shares issued of warrants to purchase common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl0" xml:lang="en-US">Weighted average exercise price per share exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl1" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AntibodyProductsMember_lbl0" xml:lang="en-US">Antibody Products Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AntibodyProductsMember" xlink:to="orka_AntibodyProductsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRight_lbl1" xml:lang="en-US">Class Of Warrant Or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl1" xml:lang="en-US">Noncash Exchange Of Pre Merger Oruka Series APreferred Stock For Series BConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1" xml:lang="en-US">Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRsaActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRsaActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRsaActivityAbstract_lbl" xml:lang="en-US">Schedule Of Rsa Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRsaActivityAbstract" xlink:to="orka_ScheduleOfRsaActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl1" xml:lang="en-US">Shock Issued During Period Shares Conversion Of Nonvoting Convertible Preferred Stock To Common Stockin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1" xml:lang="en-US">Note Payable To Related Party Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl1" xml:lang="en-US">Warrants To Purchase Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Option Agreements Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PIPEFinancingMember_lbl0" xml:lang="en-US">PIPEFinancing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PIPEFinancingMember" xlink:to="orka_PIPEFinancingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract_lbl" xml:lang="en-US">Schedule Of Available For Sale Securities In An Unrealized Loss Position Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:to="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2" xml:lang="en-US">Series ANon Voting Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1" xml:lang="en-US">Research And Development Contract Costs Accruals Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Temporory Equity Issued During Period Shares Conversion Of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanMember" xlink:to="orka_EmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreMergerOrukaMember_lbl0" xml:lang="en-US">Pre Merger Oruka Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreMergerOrukaMember" xlink:to="orka_PreMergerOrukaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Company SStock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl0" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RoyaltyPayableOnProductSales_lbl1" xml:lang="en-US">Royalty Payable On Product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl2" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1" xml:lang="en-US">Series BNon Voting Convertible Preferred Stock Amount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series BConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Temporory Equity Issued During Period Value Conversion Of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RegulatoryMilestonesMemberMember_lbl0" xml:lang="en-US">Regulatory Milestones Member Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RegulatoryMilestonesMemberMember" xlink:to="orka_RegulatoryMilestonesMemberMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Oruka Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0" xml:lang="en-US">Operating Lease, Variable Lease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NonRefundableLicenseFee_lbl1" xml:lang="en-US">Non Refundable License Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RestrictedStockAwardsMember_lbl0" xml:lang="en-US">Restricted Stock Awards Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockAwardsMember" xlink:to="orka_RestrictedStockAwardsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Schedule Of Convertible Preferred Stock Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl2" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherDevelopmentCost_lbl1" xml:lang="en-US">Other Development Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl0" xml:lang="en-US">ORKAZero Zero One License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xml:lang="en-US">Description Of Minority Interest Ownership Percentage By Noncontrolling Owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantMember_lbl0" xml:lang="en-US">Paruka Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantMember" xlink:to="orka_ParukaWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NumberofAggregateShares_lbl1" xml:lang="en-US">Numberof Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroTwoMember_lbl0" xml:lang="en-US">ORKAZero Zero Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series ANon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl1" xml:lang="en-US">Share Issued During Period Value Conversion Of Nonvoting Convertible Preferred Stock To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Employee Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesMember_lbl0" xml:lang="en-US">Marketable Securities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesMember" xlink:to="orka_MarketableSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AccruedResearchAndDevelopment_lbl1" xml:lang="en-US">Accrued Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl1" xml:lang="en-US">Additional Paid In Capital Transacation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series BNon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DevelopmentCostsPercentage_lbl1" xml:lang="en-US">Development Costs Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Convertible Preferred Stock Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl1" xml:lang="en-US">Class Of Warrant Or Right Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeWarrantsMember_lbl1" xml:lang="en-US">Employee Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Twenty Four Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl0" xml:lang="en-US">First Dosing Of Human Patient In Phase One Trial Milestone Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl0" xml:lang="en-US">Debt Securities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Other Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl1" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl1" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl0" xml:lang="en-US">Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStocksConversionRatio_lbl1" xml:lang="en-US">Common Stocks Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaCommonStockMember_lbl0" xml:lang="en-US">Oruka Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl0" xml:lang="en-US">CALIFORNIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountsOwnershipInterestInParagonMember_lbl0" xml:lang="en-US">Fairmounts Ownership Interest In Paragon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountsOwnershipInterestInParagonMember" xlink:to="orka_FairmountsOwnershipInterestInParagonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl2" xml:lang="en-US">Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Expected To Vest Outstanding Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonMember_lbl0" xml:lang="en-US">Paragon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1" xml:lang="en-US">Noncash Accrued Interest On Convertible Note Converted To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl1" xml:lang="en-US">Subscription Receivable Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl0" xml:lang="en-US">Other Nonoperating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl1" xml:lang="en-US">Other Income Expense Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl0" xml:lang="en-US">Clinical Development Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl0" xml:lang="en-US">Costs and Expenses, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1" xml:lang="en-US">Classification Of Convertible Preferred Stock Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MilestoneConsiderationPaid_lbl1" xml:lang="en-US">Milestone Consideration Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl1" xml:lang="en-US">Option Agreements And License Agreements Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl1" xml:lang="en-US">Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl0" xml:lang="en-US">Interest Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl1" xml:lang="en-US">Share Based Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Diluted Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl1" xml:lang="en-US">Prefunded Warrantsto Purchase An Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountMember_lbl0" xml:lang="en-US">Fairmount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountMember" xlink:to="orka_FairmountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Assumptions Used In Calculating The Fair Value Of The Awards Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:to="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl1" xml:lang="en-US">Fair Value Cash Equivalents And Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl2" xml:lang="en-US">US Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl1" xml:lang="en-US">Fairmount Healthcare Fund IILPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl1" xml:lang="en-US">Reclassification Of The Paruka Warrant From Liability To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesLongTermMember_lbl0" xml:lang="en-US">Marketable Securities Long Term Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesLongTermMember" xlink:to="orka_MarketableSecuritiesLongTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="orka_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl1" xml:lang="en-US">Weighted Aver Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Per Share Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl1" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaMember_lbl0" xml:lang="en-US">Paruka Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaMember" xlink:to="orka_ParukaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Patent Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">Cash Acquired In Connection With The Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl1" xml:lang="en-US">Operating Loss Carryforwards As APercentage Of Taxable Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl0" xml:lang="en-US">ORKAZero Zero Two License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_USGovernmentAgencySecuritiesMember_lbl0" xml:lang="en-US">USGovernment Agency Securities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_USGovernmentAgencySecuritiesMember" xlink:to="orka_USGovernmentAgencySecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesNoncurrentMember_lbl0" xml:lang="en-US">Marketable Securities Noncurrent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesNoncurrentMember" xlink:to="orka_MarketableSecuritiesNoncurrentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl1" xml:lang="en-US">Employee Stock Purchase Plan ESPPCash Contributions To ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract_lbl" xml:lang="en-US">Schedule Of Basic And Diluted Net Loss Per Share Attributable To Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:to="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl0" xml:lang="en-US">Paragon Milestone Payments For Option Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NonRefundableMilestonePayments_lbl1" xml:lang="en-US">Non Refundable Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherMember_lbl0" xml:lang="en-US">Other Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherMember" xlink:to="orka_OtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl2" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl2" xml:lang="en-US">Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_InvestorsClosingShares_lbl1" xml:lang="en-US">Investors Closing Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Other Research Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExchangeRatio_lbl1" xml:lang="en-US">Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExternalMember_lbl0" xml:lang="en-US">External Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExternalMember" xlink:to="orka_ExternalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroOneMember_lbl0" xml:lang="en-US">ORKAZero Zero One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesAxis_lbl0" xml:lang="en-US">Marketable Securities Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1" xml:lang="en-US">Estimated Fair Value Of Warrants To Be Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockOptionsMember" xlink:to="orka_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NominationOfADevelopmentCandidateMember_lbl0" xml:lang="en-US">Nomination Of ADevelopment Candidate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NominationOfADevelopmentCandidateMember" xlink:to="orka_NominationOfADevelopmentCandidateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Expected To Vest Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl0" xml:lang="en-US">Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0" xml:lang="en-US">Weighted Average Number of Shares, Contingently Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl1" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockConversionRatio_lbl1" xml:lang="en-US">Common Stock Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchInitialFee_lbl1" xml:lang="en-US">Research Initial Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl0" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl0" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1" xml:lang="en-US">Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl0" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl1" xml:lang="en-US">Operating Expense Excluding Stock Based Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NumberOfSharesPurchased_lbl1" xml:lang="en-US">Number Of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ARCACommonStockMember_lbl0" xml:lang="en-US">ARCACommon Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl1" xml:lang="en-US">Issuance Cost Of PIPEFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl1" xml:lang="en-US">Share Based Payment Arrangement Warrant Activitiy Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Award Types Of Company SStock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantObligationMember_lbl1" xml:lang="en-US">Paruka Warrant Obligation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivables_lbl1" xml:lang="en-US">Subscription Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl1" xml:lang="en-US">Pre Funded Warrants Of Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertibleNoteMember_lbl0" xml:lang="en-US">Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesCurrentMember_lbl0" xml:lang="en-US">Marketable Securities Current Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesCurrentMember" xlink:to="orka_MarketableSecuritiesCurrentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl1" xml:lang="en-US">Class Of Warrant Or Right Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfSegmentLossFromOperationsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfSegmentLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Segment Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfSegmentLossFromOperationsAbstract" xlink:to="orka_ScheduleOfSegmentLossFromOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl0" xml:lang="en-US">Investments and Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl1" xml:lang="en-US">Achievement Of Development Candidate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Cash Equivalents And Marketable Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract_lbl0" xml:lang="en-US">Debt Securities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantsExercisable_lbl1" xml:lang="en-US">Class Of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>orka-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 21:45:39 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecurities" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosures" roleURI="http://www.orukatx.com/role/SegmentDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreements" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingencies" roleURI="http://www.orukatx.com/role/CommitmentandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecuritiesTables" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresTables" roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesTables" roleURI="http://www.orukatx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable" roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRSAActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofSegmentLossfromOperationsTable" roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresDetails" roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.orukatx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="SubscriptionReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockholdersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockholdersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_InterestExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostOfPIPEFinancing" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashAcquiredInConnectionWithTheReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="OptionAgreementsAndLicenseAgreementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SubscriptionReceivablePolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NotePayableToRelatedPartyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OtherIncomeExpenseNetPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ScheduleOfConvertiblePreferredStockTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueCashEquivalentsAndMarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="MarketableSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="MarketableSecuritiesLongTermMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:to="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="MarketableSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesCurrentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesNoncurrentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="USGovernmentAgencySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ConversionOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:to="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9QkTkphW4jRnhy1/e+x62BCJI/TNc+ooItJoHc4DLXQcRbdr+EO+SC+Dwld6MgwRSfopc3n1L8fOpmbwAvdblG7fCvb4m+7qZSifNrqyumM53VcQgZO8i3Jv8+IlCwW81khQXLWDghuLpTqvvfCydmAUZJmfvJUQqkR9i/BhKB1k=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsaActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRsaActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsaActivityAbstract" xlink:to="StockBasedCompensationScheduleofRSAActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_StockOptionMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="EmployeeStockPurchasePlanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentLossFromOperationsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentLossFromOperationsAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OperatingExpenseExcludingStockBasedCompensationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ExternalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OtherMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:to="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="RestrictedStockAwardsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="ParukaWarrantMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursableOptionAgreementsFeesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonMilestonePaymentsForOptionAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursableOtherResearchExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursablePatentExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureoftheBusinessandBasisofPresentationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreMergerOrukaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ARCACommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaSeriesAConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PIPEFinancingMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember_0" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AdditionalPaidInCapitalTransacationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ExchangeRatio" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStocksConversionRatio" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="InvestorsClosingShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PreFundedWarrantsOfCommonStockShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NumberOfSharesPurchased" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NumberofAggregateShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PrefundedWarrantstoPurchaseAnAggregateShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="NotePayablewithRelatedPartyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PreMergerOrukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FairmountHealthcareFundIILPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreMergerOrukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PIPEFinancingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="FairmountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantsExercisable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExpirationDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightWarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockConversionRatio" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantsToPurchaseCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember_0" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="EmployeeStockPurchasePlanESPPCashContributionsToESPP" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="EstimatedFairValueOfWarrantsToBeGranted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ClassOfWarrantOrRight" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="OptionAgreementsandLicenseAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroOneLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroTwoLicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroTwoMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NominationOfADevelopmentCandidateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="ParagonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="ClinicalDevelopmentMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="RegulatoryMilestonesMemberMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="AntibodyProductsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="AchievementOfDevelopmentCandidateMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPayableOnProductSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="DevelopmentCostsPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestoneConsiderationPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="OtherDevelopmentCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ResearchInitialFee" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_CA" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="NonRefundableLicenseFee" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="NetLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ParagonMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ParukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FairmountHealthcareFundIILPMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FairmountsOwnershipInterestInParagonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="orka-20241231.xsd#orka_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079536720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oruka Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Oruka Therapeutics, Inc., a Delaware corporation, filed a Registration
Statement on Form S-1 on November 14,2024, which was declared effective on November 26, 2024 (the &#8220;registration statement&#8221;).
This Post-Effective Amendment No. 1 to Form S-1 (the &#8220;Post-Effective Amendment&#8221;) is being provided to include the fiscal year
ended December 31, 2024 financial statements, contained in the Form 10-K for the year-ended December 31, 2024 filed on March 6, 2025,
as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K and updated selling stockholder
information.The information included in this filing amends the registration statement
and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective
Amendment. All applicable registration fees were paid at the time of the original filing of the registration statement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079289952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,575<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivables', window );">Subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">376,869<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">162<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">396,019<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">213<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,043<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">755<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,798<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</a></td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">463,018<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(83,724)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">382,221<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">396,019<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673074246720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">545,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">37,440,510<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">37,440,510<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-voting convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-voting convertible preferred stock, shares authorized</a></td>
<td class="nump">251,504<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-voting convertible preferred stock, shares issued</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-voting convertible preferred stock, shares outstanding</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080198560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations and Comprehensive Loss<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">11 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 75,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(88,123)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,468)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">4,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,724)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (83,765)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember', window );">Series A Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember', window );">Series B Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080223920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">$ 42,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">$ 1,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673074138560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity - 11 months ended Dec. 31, 2024 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Non-Voting</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series B Non-Voting</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</a></td>
<td class="num">$ (2,931)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)</a></td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">26,445<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">26,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">248,437<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">248,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,061,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of Pre-Closing Financing and reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,208,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">144,433<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">144,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceCostOfPIPEFinancing', window );">Issuance costs of PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,263)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(8,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock', window );">Conversion of Series A non-voting convertible preferred stock to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (52,834)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">52,832<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">52,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares', window );">Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,439)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of the Paruka warrant from liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,357<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,562<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(65,037)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(83,724)<span></span>
</td>
<td colspan="2" class="num">$ (1,918)<span></span>
</td>
<td class="num">(83,724)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 463,018<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (83,724)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceCostOfPIPEFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of PIPE financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceCostOfPIPEFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of conversion of non-voting convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares conversion of non-voting convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares classified as temporary equity issued conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock classified as temporary equity conversion of convertible securities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079406240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts', window );">Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080258464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of premiums and discounts on marketable securities</a></td>
<td class="num">(2,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(329,938)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(330,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</a></td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable to related party, net of issuance costs paid</a></td>
<td class="nump">24,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Proceeds from the Pre-Closing Financing, net</a></td>
<td class="nump">227,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the PIPE Financing, net</a></td>
<td class="nump">188,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">449,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">61,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">61,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining operating right-of-use asset</a></td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1', window );">Assets acquired in connection with the reverse capitalization</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Other liabilities assumed in connection with the reverse recapitalization</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock', window );">Non-cash accrued interest on convertible note converted to common stock</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock', window );">Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</a></td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series A non-voting convertible preferred stock to common stock</a></td>
<td class="nump">52,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity', window );">Reclassification of the Paruka warrant from liability to equity</a></td>
<td class="nump">$ 10,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cash acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashAcquiredInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of non-cash accrued interest on convertible note converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of reclassification of the paruka warrant from liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, classified as other, acquired in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084684288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), the Company completed the acquisition (the &#8220;Merger&#8221;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company,
LLC.&#8221; On August 29, 2024, the Company changed its name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221;
and its Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the common
stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First
Effective Time&#8221;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $0.001 per share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company
Common Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase
price of $23.00 per share, an aggregate of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value
$0.001 per share (&#8220;Company Series A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A
Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000
shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7
million (net of issuance costs of $11.9 million).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $83.7 million and used net cash of $57.8 million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $393.7 million. The Company&#8217;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#8217;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#8217;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#8217;s business opportunities, as desired, which could materially harm the Company&#8217;s business, financial
condition and results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079720656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable
Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debt
Issuance Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Receivable&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;Quoted
    prices in active markets that are identical assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices
    in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
    by observable market data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
    including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note&#160;Payable
to Related Party</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#8220;CODM&#8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commitments
and Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income, net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078822496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Reverse Recapitalization and Pre-Closing Financing</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Reverse Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">August 29,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673186750944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">377,967</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers in or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673182550800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
Cash equivalents and marketable Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,174</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,967</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,537</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 months or longer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 28%; text-align: left">Commercial papers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,199</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,199</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Corporate debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Due in one year or less</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,073</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in 1-2 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">332,142</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079440144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
Accrued Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued employee compensation and benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional and consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079389328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Note Payable with Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable with Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby Pre-Merger Oruka issued a convertible
note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0 million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $1.5 million, which includes non-cash interest
expense related to the amortization of debt issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which
was determined based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into 2,722,207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080455616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-203">no</span> expiration
date. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-204">none</span> of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These warrants
vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-205">none</span> of the warrants have been exercised and 3,054,358 warrants
remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million.
Pre-Merger Oruka incurred less than $0.1&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.&#160;In November 2024, the 2,439 shares of the Company Series A Preferred
Stock were converted to 2,439,000 shares of Company Common Stock. As of December 31, 2024, there are <span style="-sec-ix-hidden: hidden-fact-206">no</span> outstanding shares of Company
Series A Preferred Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock <br/>
Issued&#160;and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock<br/> Issuable<br/> Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series B convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">251,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">137,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,931</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,428,149</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#8220;Series A Certificate of Designation&#8221;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#8217;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#8220;Stockholder Approval&#8221;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into 1,000 shares of Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paruka
Warrant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase 596,930 shares of Company Common Stock at an exercise price of $19.39 per share. The warrant has a term of 10 years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of December
31, 2024, 37,440,510 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Shares issuable on conversion of Company Series B Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,428,149</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Shares issuable upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202,207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issuable upon exercise of warrant under the Paruka Warrant Obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">596,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding and issued stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,054,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shares available for grant under 2024 Stock Incentive Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,246,324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2024 Employee Stock Purchase Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">460,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total shares of common stock reserved</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,556,257</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080351664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although two non-employee
stock options were granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common stock
available for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388,567 shares were subject to outstanding
stock options, and as of December 31, 2024, there were 4,246,324 shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective on August 29, 2024, at which time 463,489 shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;85% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, 2,960 shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were 460,529 shares of Company Common Stock available in the pool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $0.1
million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100.21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.26</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,567,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,567,760</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">11.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,567,760</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">11.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $9.12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $0.1 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> RSAs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested balance as of February 6, 2024 (inception)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,207,553</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Unvested balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,207,553</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Agreements and the Paruka Warrant Obligation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#8220;Paruka Warrant Obligation&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $10.4 million. For the period from February 6, 2024 (inception)
to December 31, 2024, $10.4 million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued
to certain Pre-Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during
the period from February 6, 2024 (inception) to December 31, 2024, the Company issued 3,054,358 warrants at an exercise price of $7.80
per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance
and service based vesting requirements and upon completion of the Merger the performance-based requirements had been achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Employee<br/> Warrants<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,054,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">7.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">35,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,054,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">7.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">35,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#8212;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">99.02</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,919</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $12.7 million, which is expected
to be recognized over a weighted average period of approximately 3.2 years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.1
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $16.3 million, which is expected
to be recognized over a weighted average period of 3.3 years.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paruka Warrant Obligation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,357</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,626</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Employee stock purchase plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,919</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080545008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Disclosures</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
Segment disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business activities on a consolidated basis and operates in one reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#8220;CODM&#8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#8217;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development personnel-related (excluding stock-based compensation)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative personnel-related (excluding stock-based compensation)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">External research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,680</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative, excluding personnel-related and stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,082</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(88,123</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673186394240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-239">No</span>
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(83,724</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Loss before income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(83,724</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period from February 6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from
income taxes. The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory
federal income tax rate to income before income taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.18</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.41</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,994</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,501</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding
the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by
$21.3&#160;million primarily due to continuing loss from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">21,317</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $10.8&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to 80% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$3.8&#160;million and $0.4&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Changes related to tax positions taken in the current year</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,047</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,047</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078542112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option Agreements and License Agreements<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsAndLicenseAgreementsAbstract', window );"><strong>Option Agreements and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock', window );">Option Agreements and License Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
Option Agreements and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#8220;Option&#8221;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#8220;Research
Program&#8221;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#8217;s sole discretion at such time as specified in the Option Agreements (the &#8220;Option
Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with
the ORKA-001 Field, the &#8220;Fields&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon,
on material breach without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones and up
to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $1.5 million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $2.5
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Company&#8217;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $2.5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#8217;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $13.5 million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $2.8 million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $7.8 million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $42.0 million of expenses in connection
with services provided by Paragon and Paruka under the Option Agreements.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of option agreements and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080623280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.2
million, and operating lease liability, noncurrent of $0.8 million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of 33 months and a discount rate of 17.95%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $0.3 million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(275</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total discounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">968</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: current portion of lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(213</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Non-current portion of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">755</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell
Line License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company entered into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics
Ireland Limited (&#8220;WuXi Biologics&#8221;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide,
sublicensable license to certain of WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed
Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use
of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;).
Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002
programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $150,000, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon six months&#8217; prior written notice
and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for
a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails
to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other
party&#8217;s bankruptcy.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078537440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerUnitAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February 6, 2024<br/> (Inception) to <br/> December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss<br/> Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Shares<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss Per<br/> Share,<br/> Basic and<br/> Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(65,037</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,789,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3.87</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series A Preferred Stock <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,918</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,873.25</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series B Preferred Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,769</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,946</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(322.81</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(83,724</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued warrant to Paruka</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">596,930</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,426,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerUnitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerUnitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673186946032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paragon
and Paruka each beneficially own less than 5% of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fairmount
beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Board, and beneficially
owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paragon reimbursable Option Agreements&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,482</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Paragon milestone payments for Option Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paragon reimbursable other research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Paragon reimbursable patent expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,022</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080558736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of 54 months. The Company expects to pay approximately $1.6 million over the lease term.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084677936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable
Securities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debt
Issuance Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivablePolicyTextBlock', window );">Subscription Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Receivable&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;Quoted
    prices in active markets that are identical assets or liabilities.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices
    in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
    by observable market data.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
    including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock', window );">Classification of Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NotePayableToRelatedPartyPolicyTextBlock', window );">Note Payable to Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note&#160;Payable
to Related Party</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock', window );">Research and Development Contract Costs Accruals</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segment
Reporting</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#8220;CODM&#8221;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commitments
and Contingencies</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
Loss</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OtherIncomeExpenseNetPolicyTextBlock', window );">Other income, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NotePayableToRelatedPartyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Payable to Related Party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NotePayableToRelatedPartyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OtherIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OtherIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract costs accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085312256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085662240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">August 29,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085657920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets Measured</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,350</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">377,967</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079457680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Commercial papers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,174</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,967</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Commercial papers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,537</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">314,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Total marketable securities, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash equivalents and marketable securities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">384,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 months or longer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 28%; text-align: left">Commercial papers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,199</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,199</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. government agency securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Corporate debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Marketable securities, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">U.S. treasury securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">U.S. government agency securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Marketable Securities at Estimated Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Due in one year or less</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,073</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in 1-2 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">332,142</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673186916304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Accrued employee compensation and benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional and consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080247600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Stock <br/>
Issued&#160;and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock<br/> Issuable<br/> Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series B convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">251,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">137,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,931</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,428,149</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Shares issuable on conversion of Company Series B Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,428,149</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Shares issuable upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202,207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issuable upon exercise of warrant under the Paruka Warrant Obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">596,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding and issued stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,054,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shares available for grant under 2024 Stock Incentive Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,246,324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2024 Employee Stock Purchase Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">460,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total shares of common stock reserved</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,556,257</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfConvertiblePreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673182545408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100.21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.26</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">99.02</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected dividend yield</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,567,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,567,760</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">11.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,567,760</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">11.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSA Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> RSAs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested balance as of February 6, 2024 (inception)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Granted</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,207,553</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Unvested balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,207,553</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock', window );">Schedule of Employee Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Employee<br/> Warrants<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of February 6, 2024 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; width: 52%">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,054,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">7.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">35,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,054,358</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">7.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">35,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#8212;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,919</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paruka Warrant Obligation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,357</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,626</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Employee stock purchase plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,919</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079394064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Loss from Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Research and development personnel-related (excluding stock-based compensation)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative personnel-related (excluding stock-based compensation)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,992</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">External research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,680</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative, excluding personnel-related and stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,082</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Loss from operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(88,123</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079713952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Tax Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to <br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(83,724</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Loss before income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(83,724</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes</a></td>
<td class="text">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory
federal income tax rate to income before income taxes is as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.18</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.41</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,994</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,501</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text">he
Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding
the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by
$21.3&#160;million primarily due to continuing loss from operations.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">21,317</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Changes related to tax positions taken in the current year</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,047</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,047</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080574624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">369</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(275</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total discounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">968</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: current portion of lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(213</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Non-current portion of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">755</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085650976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerUnitAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period from February 6, 2024<br/> (Inception) to <br/> December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss<br/> Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Shares<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss Per<br/> Share,<br/> Basic and<br/> Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(65,037</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,789,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3.87</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series A Preferred Stock <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,918</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,873.25</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Series B Preferred Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,769</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,946</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(322.81</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(83,724</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and issued common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued warrant to Paruka</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">596,930</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,426,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerUnitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerUnitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080469248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Related Party Accounts Payable and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Paragon reimbursable Option Agreements&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,482</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Paragon milestone payments for Option Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paragon reimbursable other research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Paragon reimbursable patent expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,022</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673074793728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 03, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AdditionalPaidInCapitalTransacationCost', window );">Additional paid-in capital transaction costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PreFundedWarrantsOfCommonStockShares', window );">Pre-funded warrants of common stock shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants exchange | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash operating activities (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents, and marketable securities (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Net of issuance costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStocksConversionRatio', window );">Conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">83:3332:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_InvestorsClosingShares', window );">Investors shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,784,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,764,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares', window );">Prefunded warrants to purchase an aggregate shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (65,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember', window );">Oruka Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of convertible note (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember', window );">ARCA common stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember', window );">Oruka Series A Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NumberOfSharesPurchased', window );">Aggregate of purchased shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NumberofAggregateShares', window );">Aggregate shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AdditionalPaidInCapitalTransacationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional paid-in capital transacation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AdditionalPaidInCapitalTransacationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStocksConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStocksConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_InvestorsClosingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investors closing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_InvestorsClosingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NumberofAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NumberofAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PreFundedWarrantsOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PreFundedWarrantsOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of prefunded warrants to purchase an aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PrefundedWarrantstoPurchaseAnAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085698128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal Deposit Insurance Corporation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084383520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673184325904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Schedule of the Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080911328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 52,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">384,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">45,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">377,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">190,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">13,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">190,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">13,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">12,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">12,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">34,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">34,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">75,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">75,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_FairValueCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_FairValueCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673081051616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">$ 384,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">384,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">52,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">19,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">19,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">22,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">22,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">314,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">314,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">190,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">190,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">12,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">34,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">34,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">75,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">75,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">18,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">13,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">$ 4,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673073215552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">$ 130,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">130,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">18,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">18,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">49,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">49,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">39,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">39,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember', window );">Marketable securities, long-term [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember', window );">Marketable securities, long-term [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">4,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_USGovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_USGovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673074768816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Schedule of Marketable Securities at Estimated Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Due in one year or less</a></td>
<td class="nump">$ 314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Due in 1-2 years</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">$ 332,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080353232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673071701136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party (Details) - Convertible Note [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Fairmount Healthcare Fund II, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Aggregate proceeds</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084463776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">680,000<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Employee warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember', window );">Paruka Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_WarrantsToPurchaseCommonStock', window );">Warrant purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantsExercisable', window );">Warrants exercisable</a></td>
<td class="nump">680,000<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">83.3332:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Series A Preferred Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The class of warrant or right expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The class of Warrant or Right warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares issued of warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=orka_FairmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=orka_FairmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085636624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details) - Series B Convertible Preferred Stock [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems', window );"><strong>Schedule of Convertible Preferred Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">251,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">137,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">137,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying Value (in Dollars) | $</a></td>
<td class="nump">$ 2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">11,428,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078865472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">27,556,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Outstanding and Issued Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">1,567,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember', window );">Shares issuable on conversion of Company Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">11,428,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Outstanding and Issued Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">388,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">460,529<span></span>
</td>
<td class="nump">463,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673073633600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 22, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,556,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,919,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EstimatedFairValueOfWarrantsToBeGranted', window );">Estimated fair value of warrants to be granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window );">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">RSAs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">RSAs price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRight', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,634,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">463,489<span></span>
</td>
<td class="nump">460,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window );">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock expressed as a percentage of its fair value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contribution of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP', window );">Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>class of warrant or right to purchase percentage of outstanding diluted stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EstimatedFairValueOfWarrantsToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of warrants to be granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EstimatedFairValueOfWarrantsToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement diluted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673182545152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673081152224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years), Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Stock Options Outstanding, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Stock Options Outstanding, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673071726112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSA Activity (Details) - Restricted Stock Award [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of RSA Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested balance, Number of Granted</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in Shares)</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance, Ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079709936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) - Employee Warrants [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Employee Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in Shares)</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in Shares)</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Ending Balance (in Shares)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber', window );">Number of Employee Warrants Outstanding, Vested and expected to vest</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding', window );">Number of Employee Warrants Outstanding, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Granted</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Weighted Average,Granted</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised', window );">Number of Employee Warrants Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Employee Warrants Outstanding, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants, Exercised (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employee warrants outstanding, vested and exercisable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Exercise Price Per Share, Vested and Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673186637488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company&#8217;s Stock-Based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">11,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673081147776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember', window );">Paruka warrant obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember', window );">Employee warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673073631392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reporting segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079123408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures - Schedule of Segment Loss from Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 75,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">13,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88,123<span></span>
</td>
<td class="nump">$ 88,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (88,123)<span></span>
</td>
<td class="num">(88,123)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember', window );">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development stock-based compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative stock-based compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_ExternalMember', window );">External [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OtherMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember', window );">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,082<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_ExternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_ExternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673182503744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Change in valuation allowance due to continuing loss from operations</a></td>
<td class="nump">21,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome', window );">Operating loss carryforwards as a percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080542688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Tax Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Schedule of Loss Before Income Tax Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673085499296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit derived by applying the federal statutory rate to income before income taxes</a></td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="num">(0.18%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(3.41%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.87%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance</a></td>
<td class="nump">25.46%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax (benefit) expense</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079457680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">10,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">21,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right- of- use asset</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(21,317)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673080656560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Schedule of Net Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">21,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balance</a></td>
<td class="nump">$ 21,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084716704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Schedule of Unrecognized Tax Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Changes related to tax positions taken in the current year</a></td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 1,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079875600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option Agreements and License Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember', window );">Regulatory Milestones Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant purchase percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Regulatory Milestones Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Antibody Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RoyaltyPayableOnProductSales', window );">Royalty payable on product sales, description</a></td>
<td class="text">low single-digit percentage royalty for antibody products<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember', window );">Nomination Of A Development Candidate [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember', window );">ORKA-001 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember', window );">ORKA-002 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DevelopmentCostsPercentage', window );">Development costs, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Initiation fee</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant purchase percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OtherDevelopmentCost', window );">Development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchInitialFee', window );">Research initial fees</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>class of warrant or right to purchase percentage of outstanding diluted stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MilestoneConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The milestone consideration paid amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MilestoneConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OtherDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OtherDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchInitialFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research initial fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchInitialFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_RoyaltyPayableOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payable on product sales, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_RoyaltyPayableOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079973408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 15, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="nump">17.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseVariableLeaseIncome', window );">Variable lease expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableLicenseFee', window );">Non-refundable license fee</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseVariableLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseVariableLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673084476048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078553936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of lease liability</a></td>
<td class="num">(213)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">$ 755<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078940448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">495,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">4,328,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079702144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">11 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (83,724)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (1,918)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (16,769)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (65,037)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079252048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">7,426,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember', window );">Paruka Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">596,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673075189008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember', window );">Fairmount's Ownership Interest in Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially
owns more than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially own less than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Paruka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially own less than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially
owns more than 5%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minority interest ownership percentage by noncontrolling owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_ParukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_ParukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673078871792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember', window );">Paragon reimbursable Option Agreements&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember', window );">Paragon milestone payments for Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember', window );">Paragon reimbursable other research expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember', window );">Paragon reimbursable patent expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 6,022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45673079360928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease initial period</a></td>
<td class="text">54 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future lease payment</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M1O8N(T9Y*8J]F=:.EPIEL8776</KK!5G3AF6^"R[1AL;61ZJ2>TPAV+;!4'
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M*1 %T5HF.NG6DRKT#5 ^[4'4"#&UZ^)-P^\MR'#'.DQ!@F%/^D9/J5U0M[-
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M<+S/S07X_T((O3TP">I71-/_ 5!+ P04    "  YBF9:!_(@PYT"   4!P
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ME#:R)D0KG[GPIT^I^.67J^A--PIZYITWV@VGF9*=YT $)PD23F.V>DN?8 H
MPD3LOIVM9$EB$=C%#"9*N5:TY5Z(W50I/COHQ-S>Y]($8@=,@0^+@0\/'+2S
M+"^V--5:= C%D&V$B1\3JO=F$B#\-VES^4W@A3OH;!_6"Y0/O>4N/WT>F?[+
MWP.KZ;HAP3)59MT$[,S95U ME\@RY/MB=@1 /IK-(S]!N9+="0M4K'MAX+$"
MR$+/;^CY$(D0V,C "<^0"H"^V,JB4>*'Z60ZG8D-:0BKJ728T((_A<]7/)%;
MJN-2*YVMX$$9;8E3@6"87J2\L%Y@?A_ DZ3+&KK3L9"4"S@3YN0CA'=B4]GZ
M:$3'U#WQ3KE@VBMC@BYY_+([55>6A&49,IBBA81= ) E."F#6*WDFF/1**K,
M]S$?N"(H"7D]W*,"]UKK/Y1P@*1D35,1'O38C+W33%<5:F$B"[ (@*,&]TXV
MQ%E#OE/?5=;$A)"#(\ ^#WW/ZL NWNO!:"HR96K(+DJ4]C2%^JXMQZ4NMR"I
ME;&CP*[*P H)V1G9,J,=KY1Q.0:K'0MV??:F.W 'P+&UG03"WI4Z_L>I/($,
M:\>9(,#O3,LJ[^>@>9&9^8&Z-:+H&='G0HK RJJ.YE@=2$,[RE'!D[D0\D'8
M,TWBU=O#_T=C)N;QWIL@9$=+J@* ]](@:]6.&*.\0PFX,56F5,[2@!R9ZKM>
M.ZU^F)^]FDR3M2X*3M8N'L&_BB:']#_,\52$IQ@=9\*"6UTUMB JEBDX4>XP
MCBL&2UN0J1838" #\EZXTD(<(@?E"B3345/^[LQ1)A!!TS@_@;]8]D#;0"BB
M=QXO,C>?*UE:0S]JOQ<]+QHE0I$%]) &QFA<>=22 4A@:U[SA_ET\BI:R(E'
MY1J,4IG<41&)3WGC!I+SY\[3P.XV4N='Q*$=50N$LTO%DS$J#@Y<=^.UXX_J
MN09YOB/1=D*0;F31.N.1*.ZQ;9T=XGAO11K%;Y)D;.$][U/50?6"<=2>,8,$
M^OF[R_+B"V5+<1@\C$OW%U1 )<-AX).#4;DBC'#C .B,%_O D>1N-@Y:.MD+
M>*U:)F_@PWYDUP/Y0?)S'/0/#&I1[%"_$$IFK%=YY#; X5A36ZH#R''9JD_O
MLXMF3F6=P2P[XQ:V=F<"BCRCF4_8N$7/=2POKJL-2]_GC;LT[C8I^TTR\!MN
MLE #UY5MC#,(I[+A9 Q!'G>L5*AO#0+'SS38:0PZG9R_.GV].TO2G\6'-3GV
M(&U8XBUD1%>X5EMM.8=PZX13P[X4$CC<H0Y;/;*=/D'<*.ZH782P8B#=Q+[-
M.#D#.]N;6.*$UW&2 3'KN$JR5P?GW'T?9O3[W[>1J;@7[Q*87QYMJ]KSX&>K
MWN&E.SPTSKU7=;?;LD4Q7I,429YR-[!(Z4>YXY'@:/VL>W[RYN3D9/YF1KL?
MMK\;G-4F)(M *':=HA=R(T:G4GEWFJ<T.-3;$7D\(G=G2IZ+!F.BC4WXI&@$
M08?;0; DHPEE#V!ZDC_JMHZ1[QLYDG&HU(MT,F&*XC28,,0!>52;*[."P,#G
MA'6G?.N10V\!!AHNX0=H,U;/8<Y0[R6Q!ARMG\2%31 HL>D]W@SB?N((LV@Y
MKB<IX\,C&9S/T[/SE^GLY"EXI?E40&;BK">OT_.SD_1L>OKLC#/DK4,2"ED@
MSWQZ]F=E>9F>G;Y,IR?S9XM210H70(#7&A!@65045B$G>M*;1-);KTS5W*Z&
M4Q$C=!7 J_25UR@$P"AS&ZCS.CV%.O/I>5>)D8&NT>V?4P#[]BR1?$SC.>V>
M,Y.16*'N+_=6)^*K/ZK@ABQR9,[P&+N<N\VLY)Z+!; $IOL+%2P6^J+<;31X
MG41KV;)1F\JXO-P8%/R*M=(V,CPG+<V.I+:6*'(?^"0Y%(MB*;EM3QVV3@I,
MNMVW$"=OF+'M> 8'ZJHJH+(5?+3%A6]-)QD0<2U_I]9SK+Y=JG.ITK;%P'K!
M=-3WZM\R9=BA;)2_9F=OK2@DOH0+]=8VBFMV=T+DGD=?>VR=,:408/J6CQ42
MN:."+K53C;$G4N<%=ZSQ(<=.9:%),+XLXSREH;TJ^AX&H+OMK23<6_&=)$;9
M0=MESWH3;K$;0GDZIF3W[IQ%>-=Q^]O!17(;;L:X$H\+ +@A2(AOSNR8C?"(
M63O#!&5!Y[<\ME1@#M:J.I(@G^^T7]9Y,Q:#!\-\=-893I,8=>DT<\>F21:Q
M88=Y,L%Q''5$6EBEK5)UZ6Z9N L?MY*-U9U*VP"];3E_TAY%=%IO=-:PDYGV
M-#+IR]'NW1,=SCT$PO7L(E-,6HH84E[+1_VAT!]M'X=S<EEAE_+?&UNWA7WW
M&'E$6K?J/FKC3</'M\7#L$3S'2,F<3;M4X4(\>WA)OE?3?T*E&Z-.[%CJ<$\
M&0FKTK%/;D9XCN./PC>."24(+)-IRV?7F<*:>MDY34O'Y\/6&\6XN:<N[Q71
ML==GQ6T%<W&[U;$G!#6@A,XZDXNB:(_XN W:U3X-1NGQQ\$;'4..6BX=X5Z4
M8&7:5@^)^^PZMH4_26V#@4Z$9&AB#1LW3YVA I)-%2Q/1Z'!L=P)93PS=O&0
M['<QAUDP&,36E>O-T?T-E:?PK(+N@+"#W-/&TH)\;EGPSO'1-F4\$^2OU?>Z
M\[Y1#%+(G=>?KG].>H>&;2#/9J.1W&_YWL3]%==AS]I>"BL1[TQL"IFY[WM=
M.XBPVZY+V-%"6YK<7]>-AZ[0443R=IOG2:P+R\S3UT"(>].+*O.-OQZ;GD4Z
M?>W[8>$VR*/ZI3X[[C:*)?6_;PE7W66-5^GI=)JB?G^R:T;%9BS'.&)=1_($
M)7#W9&:XPCQ]V6/EG3V+*39V"-H2_)G=A^2Y)?@CW8>>:J*K&AFFIYXXY'IP
M.'<RF)MRU+"<%[-GF/E%NK<]V06?H8U/SWD/G^@8[%=T/GG]^C5KN;NR9REQ
M.2(/C[3X9^?GD[.VQ4]OT^%1*(_:5O9L-GD=6MDO)N(7C=!'W#QP7_ZOE3M[
MQ1 #Z>E24**9I?K;0?W87S%IA^/X4VQ/>0GG@%2T/E^-L15T][<V\JT//)K'
MGX:Y,RCW-B4=<&_74(&&MT:N;9KX\_]0NV*EY3+,$HZ*Q2+<A@.PE"77&49J
M#GY?O81MKK::<X:_H^(0)$>YH.EN(9-.VVQ(%MX%=_6DO=<S2:X(-'QS>-GP
ME;P@+%(BYS7'^XA%,Q3C94)L:;*5/Y1K=0?Z8RG*Q+&+"X<(U]WX]?BA-K"P
M9442N$93^'M.Y X(S9A&*<?'<HTJLEH7+@5SY]K3V7AR#M=VQJB',F]5V?B3
M="Q!1QS"@@ [WD")*DUZ^> [93L6P^5&Q?O:TEB^"^P0-!3 TI/9>/[M64Z%
MK&@PQGJ++>J0;_&=*U^[KDC,+2A!D/OPB/24#!VC"MY)2] L\2BH:X96?&03
MZ]\N*3*)4672KL02]:)U*W5N@%GMKB_Y^*%#?Y>%71YW[^]>UXL#7I A?U*9
MY]*C*;@K-:HUBGV2DL/]_&1R%D^N^#B TA&]PD+3*Z_.)N?Q%7+W??O%S26^
M:?B$.#E/GKHEVHK)>2UJ-G.G:KZYU;)!EN3D=4?:WO%[3%F=6C!ZVLJW_.(A
M]9]?G6-V05$/7,FT;^H1(H\FSFB=A*#&G<)"B (,&0/O54%5J[MX'<]+B2]Z
M)'F:03('=VW*_C6$GM(>7AE4DB&HT.='\,UE!-:;"*&F,.&[H8[G=[V?2N86
MF49.?.A<G8X^88\(ANJHQ:\VXD>@S.]*V5 GIJ%PCTX8-S2$;D9<WUVL8Y5@
MD!9]!V\08PL@O@.(_UL>Z 0&%VNM41RO)HNBP*\RS3O+5ZDZ@629!BQ0:+5]
MB3$?EPM=$/QQ^R"CA!:.CN^I7UR" A#-=8"']1KC"CU&Y'C*[!]OI2[(VP.!
M#8Y$4Z7^RIBKV=;4#[%^^GY(K^4#18=/:NY$ONL? H$$8H[\FJ."@KO 6'2K
M.CA652KZ:EVAVFII@4N&]&K';6,:C=7*<.N(_'"[8[#CO"JD;$J.;LB(8 GW
MM;J7<DU;^B2QK:E"0W"X&Y%55.P(3<F>G KF/I;,D<8;"TU!KHR"R+$@NFGV
MZ)QI&_U)O)SB*]'8[.GPCK%?*1QW?H#"AP[T,QOBP=A-]UN4^&W\)<^%^P%+
M^[K[&="OTMS2A:5"+3%T.CE[=>#ZE.%#76WXYRR+JJZK-?])U\&5H1?P?%F!
M"_H/M$#\?=.'_P)02P,$%     @ .8IF6OL$)9IA)0  .7@  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&ULO3U9<]M&FN_X%2C/[I1=1<FR;">97%7R
M->/:.-9:\>S#UCXT@2;9,0@P:$ R\^OW._L 04E.=O9A)A8)='_]W6?S^YNN
M_^0WU@[EYVW3^A\>;(9A]^WCQ[[:V*WQI]W.MO#-JNNW9H _^_5CO^NMJ>FE
M;?/X_.SLJ\=;X]H'/WY/GUWV/W[?C4/C6GO9EW[<;DV_?V&;[N:'!T\>Z <?
MW'HSX >/?_Q^9];VR@X?=Y<]_/4XK%*[K6V]Z]JRMZL?'EP\^?;%,WR>'OBG
MLS<^^7>))UEVW2?\XVW]PX,S!,@VMAIP!0/_N;8O;=/@0@#&;[+F@[ EOIC^
M6U=_0V>'LRR-MR^[YK]</6Q^>/#-@[*V*S,VPX?NYA]6SO,<UZNZQM/_ES?\
M[/-G#\IJ]$.WE9<!@JUK^;_FL^ A>>&;LR,OG,L+YP0W;T10OC*#^?'[OKLI
M>WP:5L-_T%'I;0#.M4B4JZ&';QV\-_QXQ<0HNU5YY=:M6[G*M$-Y457=V ZN
M79>77>,J9_WWCP?8#]]Z7,G:+WCM\R-K/WE2ONO:8>/+UVUMZWR!QP!H@/9<
MH7UQ?NN*KVQU6CY]LBC/S\Z?W;+>TW#ZI[3>TS]]^O*_+Y9^Z(&)_F<.$;S-
ML_EM4+"^]3M3V1\>@.1XVU_;!S_^]2]/OCK[[I9#/ N'>';;ZG^2A+>O?7Y:
M? &./GI;P&.O_>! 7N"#7S:V@!/O3&](!N'+86/+E]UV9]K]7__RS?F3K[_S
M9=6U'M:HX9VZ7+G6M)4S3>D'^  4P.!+U^)#J(/<L <1&3;EQ].KT_+O%Q>7
MH!M^&QW@%>2B!46";Y1#!W]]LJ556!:%\:!Y=@B'7Y2FK<M?QWK-RP\;,Y1F
MM0)500 "R%V/P)@M'M(CX/"ZA7_ABXTS2]>X <^,?^,KM?-5T_FQM_@P (NH
M04BRAX>"G@6 %!=WGUUWF /*M56WM?2(_0R*VL,F]=@C5>(K^-?.]JZK_6E*
MPR(@AQ9(\(/J%O4F;(:X!NS#:OX^P ) S5C;<CD"0@$7;8<8 *K!"T 3Y'[3
M5QO:L+;78!1V^&(1H,<O>MO0#L0ZKBZ['K1WU8_P4=7Y!"77IAD#9X&NK#Z=
MH(K&Q[:X'G]G;DQ?YROK=J?(HLJ/!;X+1X -(F;@_4]M=P,8Z&TKJW2P=P_\
MU7^RPXG?V0H1BE#R%[")O48968&ZZ'IA+S>42]LX.+-'3"R1.L9WK5DVMAQ!
M0?;,#ZZOQBU@M*T O.(]@ ^G:]<=4A$ =,"\"9];1L$4;&!PW-8"!9 *U<8
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M$:V*19I9@JI?T;5]\5[0.:!P([G:DDRWY"#"#2 9GO%6:>K^"*P46OAJ2BP
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MP*R](ZRF8?5@LY+)"H1&2#)AC%Q(3$&0R+V0&7.?$0R=&5+D0:((&8PE!K4
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MF$M.#9PK_I.5MEX&9P$IH:(MM[=J>P5]/J=.KU#<^%^R[;"G""Y:8Y7HR>A
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M3@.BNX[43:QJ?!?(E<6>XH<U-G'0#H#[E5)V-W$!AK^%["]02P,$%     @
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M&2K_D[&@K470<$->,E4Y<EOZ$+=S)RK4FKBI8B12+YUR;0#6(/-'@HNF4*F
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M!BI;DXOW:F8KM#;16:A(XKF&HFSK"Y*(<A7@VY2L6(SCP702CZ<7K6X;D6T
MNP\GY_V+C>0&4-Q*2D2D)0S8E[ <E,6ZN:FL>%32NKZXK;D @<K;9&T"+>I
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M>@#?SPVHI[Z@#=I?_%S]#U!+ P04    "  YBF9:]3X<XU$.  !@,0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6S56UMSVS86?L>OP+CN3C-#TQ)U
ML97;C),FW78F&T_<-@\[^P"1D(2&)%20M.+^^CWG .!%I&0[3:>[#TDH$C@X
MU^]<R#S?:?.IV$A9\L]9FA<O3C9EN7UZ?E[$&YF)(M1;F<.3E3:9*.&G69\7
M6R-%0INR]#P:C>;GF5#YR<OG=._:O'RNJS)5N;PVO*BR3)B[5S+5NQ<GXQ-_
MXX-:;TJ\<?[R^5:LY8TL?]E>&_AU7E-)5";S0NF<&[EZ<7(U?OIJBNMIP:]*
M[HK6-4=)EEI_PA\_)B].1LB03&5<(@4!_]S*US)-D1"P\;NC>5(?B1O;UY[Z
M6Y(=9%F*0K[6Z4>5E)L7)Y<G/)$K4:7E![W[IW3RS)!>K-."_N8[NW8R/^%Q
M590Z<YN!@TSE]E_QV>FAM>%R=&!#Y#9$Q+<]B+C\7I3BY7.C=]S@:J"&%R0J
M[0;F5(Y&N2D-/%6PKWQY4^KXT]DKD"OAKW4&MBX$JNOY>0G4<<UY["B]LI2B
M Y3&8_Y.Y^6FX&_R1"9= N? 5LU;Y'E[%1VE^+V,0SX9!SP:1=,C]":UK!.B
M-WFDK/S?5\NB-. @_QD2VQ*=#A/%H'E:;$4L7YQ 5!32W,J3E__X9CP?/3O"
M\K1F>7J,^J/,<Y32,)^+D!U4"BJ=O?F]4N4=_S&/98[APZ]3D?.?-Y+A8S[\
M^+M_?',91:-GM 3OT._QLR=\)PHN$KTMX;#E'2\WDB^U, G7*YXH Y&J38$_
MKHT\>R?-6AK^WE2?! >&WLJEJ0 X^-QZ1,B #UX?PK=&WRKP/ Y0U2=0:KXV
M(B]Y@0)SX &$+ ( %C"]BI$C^T3L@*&A!U6N2K@O<F 7.#?V]AEB0L+L+CQ%
M9MM4WTD)2_5JI6)IX*H6+N Q' N0 :PX8B*Y504\"OOJO&GS:OD'=BJ(+T/*
M:X1?RUP:D:9W[!;XYOH65JQT9?B=%'AJ42U_ PZ00=RX%:94L=H"033.^.)9
M@8R5*J]07O .8-RR)S]O@7DN5B4>*G-/4:3E1E?K#2]WFN<Z/_."LXZ&^4["
M;L_Z3I4;CARJ? W$3%;P5!:@MPW(T/ ;\BMR T  F2WA7(\" 7*/W,"?7/-B
M Q>T,M99!CY"1S-Q*U0JEJDD5U!%40E0:6A=VNITSV7?Y^RJ6@/<\BAJG605
M/+BCX^1V1=_5M^B3C:]C?(G\KM8X<;O1*9BSL'[5L+%HLS$<)"V2_#O\X5AZ
MA:MK1@R$\TH!$WOR(+<A_[E_$RP+J;I@J#O<8\,&SMN+'!<N(*.,E<4,@SGP
M2X*J%5!6'S:LW#Z&NE&U_I<ZKPI9##.O$&$@4:H"W*NK^AK:X$>FRE)*KT72
M6$>'P^N]4AFH1N26Z;@FELA"K7/1 C=+%V*N88GN-[J'NZ42J?5DOM50 .R%
M=U>V:3"?3(/+Q=CY/@,)O ^\MC% &T+^?64HR##:I5$:<-'HK(>B_#M4+-GT
M"7(Z$'*3R\M@-K_PT48!W<(3*/4*@+,$3F-[+D+P=CR2B=HTB*;S8 +<N#.:
M"%:Y%0$T8S7F5@!BE% (W?&EI AOXR+;5]Q.I2DN%!744V#3&)$2/0KJ6'0S
MT-I/(B>UC)%;*>(-(1%L6JL\1T4J2HDSBXDDK44SP5<J!PMZ:BUBC&2=3'$O
MQE6F*X@D^7L%RT%QLV^]_R4JK9J80(ND%9TP9-H ,IU<26.:Z,I1>/E9FEBA
M./#\;(7: , 5!L.W )=UBH1HE42[8Y(J)QP6'$)?&@A( _@:-$*!ZR42 1O*
MBGN"*N2O*V .,<-@4BZVDDKO5F9D369L9XYVFFS2K )!X)@$*;K,Y'-]'P<)
M*<H"_;-0B1)&H3>!B\E4K14Z%"B^SGZE9,Z_>L!HRQ_/F'M2F7B#VMBK@HZM
M:H/*FYOKZQJ7ES(6&?"U6CGU@ Y[X \^OMLH<,82.B$^G4^"Z>6BE?:<V*SM
M'S:D7(V7[*7 -UX-M3$HB+:>YQ[ICNNUL EE0?8NR8L9WB+7\099"66 M/D$
MC>6M2"NY;ZD.75$;<J5,09Y#% 5<)\"?CTGP&TFP9B$MK'5/1F:I A>4A+A8
MS1BUK*C2&#>AYN6NDW#M&'';F]&/4#$ \HUR,@V*I5+E-)H%H]&HR8H)H2U#
MP0!<P%N%+64L9I&R"(1L"('C-:64Q>5&]OJX!)<U&M^".]6!6M,!,!(F5=*P
M@P4U\< >@)LM/O\:L&1'P)(?!\OQ5P1+=A]8\B\ RR_#2O;UTG04+.:C^P*8
ML,'9'1*WTRFST?S0;#T?!;-H (;V8GHXA[_5AK6D_0)!6WU7-VBA58%KQ+Y4
M.!AHO%JT6XW343AF&3@Z; LMO^P]'<I_!;"RY#!J5AJ+8;(0B6*'5^H/BB34
M!U:\,CD3T'")-00-J#9SG4^%#(+L$$!Q!1QY.Q,T=C#1=8^^XC[@".Q!^GG*
MKUO;WWS&[(NZ '_$O19SGO!Y.&X>WFID+\7F<SP:A=&8?\L_J.+3V<I(-!^6
MTH!,!@%I&D9S>%SO311F8G"=.R73A%+=.'K6T6GQ$%6V2T<[K(/*&)X-=;OH
MJ?LUWI[R0+/[KL4ZJML8ZEX']/>OBFX A8_.O,W%U7IMY!KU\$JDF%)=Q!QU
M8Z^3T_JJ?^<'UR&/L=0.+B"23_EX'$X6H&D/5?U=$$PK22FO_ZS+8$_.@9,6
MX12O9\'T8L1_!8MC!V9' ,Z)-#7OP>.I.2'0\$.['Z(A]"$?;]S'&S6G9Y0I
M6V&UQ6:2.JK]MK6>1"1?A+NLSSH"R^DB'$?-J6'+3126(7FA8L>:D31^@RSC
MDAE6-!+MM)3E3DH+E3@AR0C#^F!! 9'>8;DQC+NY[?5]BH,LAB4S[&YU:EC:
MG\&J,]@G[^JJJ*NLD'^H^W4W-[FR2/5CSFI-D1;PT'<""I?6U,)SY])-%$2C
MBV VF[02QX>;*QJ:02]0"@"GUO!LKQ=HC<VP[!2LE@JP'$JQ<:-^>SK\R;'2
M;Y37FPEV&^:;"K@GAC;@7;[5<'G&SZR C4193])Y>D>3B6;B)FB&=4;%D/6J
MP#M:JXR'>@J,>&OCRS>\W9YZ9>.Z,G7RE+?8_^"5'9 T0R3+)Z-FM*UV '6H
MH !AH7K#'B!OWZCKQV.S-NC-:J]SBK'2RH3R.!_(X^ROR>-T?#^'\SJ'/R##
M  V?6.[NR[4#,AQ,&*R?,-@OWK[+/Y$FF$\*3>@TSPZ<T >H@<W<YF5V!2@E
M,P(CCQK7@D+CHRV%^?LEM$?6*E<%P\;9.X0KEQH2 5;-_>/;+NG!U\XZ>XMG
M@6T^[,31<2)\6<ZP<_>]D>!YK7070DVK 'CP[1[>U7%6-YJ4,]RU&W'F&, 5
M=#MGOL< YU1%X 8]>0VI#GSJ$X\VO U>U\"7MTXE/MI3@H,6\*,#Z^S-[J9P
M]'T^'NV;&5NSMU,X]'9],Z%)>O9 =0G7M1:=8C5@3=_5LX2M&=K9)ZB[RD^Y
MWN78%"%=&L3X2:YWDE;O1,UJ7?JYJF]F%6<[?GSY4$B@@UJT]P/DVK4KNH*2
M=$GO"G3CR5Y=#3%"MK:G-OTAKFV:;>3:Z<%7%&1?-A@2*#SN'X _-\QT\ZP:
M!6H\Z@S?;1_J8*PQO'-,\CYP6VL9MI1H% <.C;^WO(UV@4JVNBC/6O<]-P8<
M&[(OB@#9(8ZU03NG=S:Q.L?:=RD?V_#+>C"C5R"PNZ+[*)&@IEF)I>TU7!QX
M +-?(;B;?<T0B^ #@7\7U1J?@W[T.J?$;)FL#V'T0N"WJG"\M>HIYUO8N_@Q
M!E1GVI3-@,EI&# G7X/Z(1>W]N.A)K$]'A+"$D6G*A%V.@'_9-*^.=% C5S/
MOLK 9&?D!C]MN,6Q64&X=%\Z]*T0EH]4:2&I!.J"5&_I(+]NP&;>K3,I"B@J
M$K;G$?TJTUO9FW40VT&#I^,1U/EU&G[[R+3*ADN##E7*^\["?UB??NP(X'!6
ML[9C#[$='[;=O2\KD7V(MBH7&3H7BC#,YD!W<9#QD+_/.WC?-EH=@\&!@8-?
MZ#2;BJ*P+PG18*R)4'R?;5]*ZP$?[P;N@?JCF=&RCSXE02E!.@9;+J%PILKA
MIPK*TDG[K>=-M2QBH_9 U;Y9S21-[- B.)I 6@'.#"%R[5N#<@/N#[D 8:?N
M;NJ<:"'+-B:LU7_T6H1F3$[15K]^55DF$P7' M,UR)."P"40/YRB+;$07PJ@
MJ=P+>.4D0'E\A\ >$S8'*NJ!KFL2C&;38#*[;(3']BD?: ]/+\++$<,VRBT-
M7->"S4D#Y*+P/C&$>SC?S6-ZI>FCR.7WOA7VWR3"T?29&8A)..ES0+<%:V4G
M:Y5J"_Z!<9E*<I6.ZCT:><(.-#I$,/DOL?6&%*  4),'M1,^AOZ*EN+OG4$U
M/G/*T2?^LA%4[Z!%.(/+R2R8CAX]@3I.[&\<0-7^_N=F3S77K#M[FH?1Q?_S
M[,FKYV%!]W4&[K5)_A=&[HM%.(J.3MS'LX=.W.V7?*SSMNF-*S8>H%Y?"<2B
MC:2#WRT=J[[N*XC9O445Z0T_,"O@>?'D*6MIF'TX5 'CZ#E8+"+V@_T<SGU?
M9[^]P0.!>A0LH@OVLR[A,:R?!HOQ @N2 Q4<K:OR5OG9D3C6:*5NL=G,]KH?
MPF&PCJ/PPM>U/KU"->#QC=G"I'6:FROV<*=YS4%?F7VFD,4**HSN_X;NN%#L
MJ%#W3.(&A.)?(-0D'+,'? KX2,L,E"!DE'DX^<I&F0!%Q_\#PHX:=U[>;>7^
M!RU?+^8>T(0>B[G#'10$T0C2[D7SM4RMW2BX7"Q8]RO6<3"/YLU:&R/U7 \_
M<N"37GP.?4I]WOKJ/<-:#[_MQ\]8H4RU'\#7=^O_/G!EOYIOEMO_>_!.F#4D
M2G#I%6P=A1>S$_LMH_]1ZBU]0[_49:DSNMQ( ;D0%\#SE=:E_X$'U/^IXN5_
M 5!+ P04    "  YBF9:QB;QD3D$   E"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6R=5FU/XS@0_IY?865/*Y!"VZ0M%"B5>+N[E0Z!8/?NP^D^
MN,DDM7#LK.W0\N]OQFY#N:75ZJ0*''OFF>>9\=B>+K5YM@L QU:U5/8B7CC7
MG/7[-E] S6U/-Z!PI=2FY@X_3=6WC0%>>*=:]K/!X+A?<Z'BV=3//9C95+=.
M"@4/AMFVKKEYO0*IEQ=Q&F\F'D6U<#31GTT;7L$3N&_-@\&O?H=2B!J4%5HQ
M ^5%?)F>78W(WAO\*6!IM\:,E,RU?J:/+\5%/"!"("%WA,#QWPM<@Y0$A#2^
MKS'C+B0Y;H\WZ+]Z[:AESBU<:_F7*-SB(I[$K("2M](]ZN7OL-8S)KQ<2^O_
MLF6P'6+$O+5.UVMG_*Z%"O_Y:IV'+8?)8(=#MG;(/.\0R+.\X8[/ID8OF2%K
M1*.!E^J]D9Q05)0G9W!5H)^;/4&%*7;L1MA<:ML:L-.^0V!:[N=KD*L DNT
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MWD"7X>I_,P\/J#MN*H$1)93H.NB=C&-FPJ,D?#C=^(? 7#M\5OCA M]Q8,@
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M4G @1@OP/%.HY>:"-N@^MUW]%U!+ P04    "  YBF9:TFIE.B0/   J,@
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M>/<"G[6,)?WPFAFD+J6U.(K$J<?QK)2/JP,DC4;5^;CMP(K8$5F%]L$G'OL
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M(2&S9=JBA=;SAMV\:B\"D)]61WB&&K<6SX8Y:7!,"%*M>QK.]U;ZH)RR"<A
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M/O- '7\XW=%? Q3:.=W0UZT4P# N@/MKK5W\@1ND/P]Y]5]02P,$%     @
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M++]IR"CF]V2$Q59<#9B_Y5Q8<N>::J-=H[E0VB5ML8B.#";'U4## [!D%Y2
MFJ8;:\<]EX4GKL[^KT_N\U'M0#T%/%*%\HYE$.(5CBG\,@DONQ9R)LI'6U<^
M70UVW70,URZG(#:+< 7'TH.8Q7NJ[FUWRW<3+[=>AL<K0C1("Z97RSFFC@:G
MQ[UX]FM_>%.%JZZ9\=X4X9&O&:3E ?@^-\:W/WB![N[S^G=02P,$%     @
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M&IS7[++  1D4">!]+K$2^PT9V(_<J[\!4$L#!!0    ( #F*9EH*+['%>0,
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M5!D.[0M&FW=OTJODPP72BY'TXA+Z-S[11:SS3-/E;'(A,G0D=D9/A [7W;,
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M\30ZPK*F68V6!>B^,L8?-VQ@G/Z;OP%02P,$%     @ .8IF6JZWS9"' @
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MVVH(E 4B;O'E!"4K/K;!]?@[>V/;,E]9MSM%$E5Z-/@N7 $VB)"!][_4S0U
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M"OQJMIAZ F6;:JFP-Q[:];/L#($<IC;%-V[@*5BT*,GU;A)<"QDL&E JB&D
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M8$MHA9*%^0X788</X11&T/6P$0<7R$O/\SN=@TFX>X09.PSL=OGG$^=#^NT
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M 2,<OGWT+V8QD[-8\:=8['T-I[WF2$FL>KH-6P BB\H'T_'F8+Q&,CA'RJM
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M,B\#)(J6<X$L(X^_3S_:^XG7_Q?^F9+^CZF5XHWM[<L?-IB9?0VN"\UXJ4%
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M02#B"8G[5W'0^XHL"H=)*73OZ,(P[DVS3#7PG/9T&).SWA?H CNM)V38#X*
M'/HR_MX$5J *MV<TR60C3#N,G;=;9=-V@I_"VSUX0U7!!-8/*TP-SM\./:+:
MW=(>C*S=/*?2X'9P9HGK&)0-P/N5E&9WL 3=@D_^ E!+ P04    "  YBF9:
M3-.J+9 #  !-"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R55DUO
MVS@0O?M7$.JB: '5^K1D)[:!)-V@"VR H$F[A\4>:&ED$9%(E:3L^M_OD%(4
MVW6,YB)RR)G']X8<4O.MD$^J!-#D9UUQM7!*K9L+SU-9"3558]$ QYE"R)IJ
M-.7:4XT$FMN@NO)"WT^\FC+N+.=V[%XNYZ+5%>-P+XEJZYK*W3548KMP N=Y
MX"M;E]H,>,MY0]?P /I;<R_1\@:4G-7 %1.<2"@6SE5P<1T;?^OPG<%6[?6)
M4;(2XLD8?^4+QS>$H(),&P2*S09NH*H,$-+XT6,ZPY(F<+__C'YKM:.6%55P
M(ZI_6*[+A3-U2 X%;2O]56R_0*]G8O R42G[)=O.-XD<DK5*B[H/1@8UXUU+
M?_9YV N8^J\$A'U :'EW"UF6GZFFR[D46R*--Z*9CI5JHY$<XV93'K3$689Q
M>GE+F23?:=4"N0.J6@F8<:W(AT>ZJD!]G'L:5S&^7M8C7G>(X2N(04#N!->E
M(G_R'/)#  _I#1S#9X[7X5G$SY"-212X)/3#^ Q>-&B.+%[T1LW_7JV4EGA.
M_CNENL.,3V.:VKE0#<U@X6!Q*) ;<);OWP6)?WF&<3PPCL^A+Q^P%O.V B(*
MLL?^"P-)95;N"%8GN66<\HS1BEPI!:BG%Y>?4G-VO=-J'DL8%:+",F9\3;0]
M'\1.<TUT">1&U WEN_?OIF&07BI2&*8;R[0\8%H,3&G'M.Z9HFTDXH9#O0(Y
M;#KYP#@N(5I%>:X^7HQ^\1C]#1NH2$"Z-NS;B#P*3:O1#54E@1\M0SIFKT=X
M1&&'A22?\.(K6D0E?Y#$C28^ME9!>'G0LW.C;^.',='2TMT1!5DKF6:8AV?'
M8.8FB7]D=F%KL0')S5$C>-WQ[&1\Y,ZFTT-KA'FM0=I\-;0!^>(=AFZ0ID?F
MR$HFV9'D7ET\<:?A9 B9F)#)Z,XFPFSI'JG3HRY>2U(BXN\DPW?367ALOR$=
M0>C.DN3(/).0*':G> $=FN@O&R&I!KRO5_K4.NG$G?CQD=DGLCZ;A9>U@MCU
MT^C8?BV)E>#K3QID_1MIC-S$3X_,-R0Q=N,D/+3.2QNXO:PY=?UD=F2^=M"P
M1D\C[Y58E*:XE>E!B473V(V"E)RZ,+V])P[W?FT?<D4RT7+=O7;#Z/"O<-4]
MD2_NW8\&;LB:<44J*##4'Z<3A\CN\>X,+1K[8*Z$QN?7=DO\WP%I''"^$$(_
M&V:!X0]J^3]02P,$%     @ .8IF6JL1]RI7!0  MP\  !D   !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULK9=;;]LV%(#?]2L.W*)P "7677*:&$C2M!O0
M D'3=@_#'FB9MK1*HDI2<;U?OT-*EF5;5@UL+S9Y>*Z\?")OUHQ_%PFE$G[F
M62%N1XF4Y?5D(N*$YD1<L9(6.+)D/"<2NWPU$26G9*&-\FSB6%8PR4E:C&8W
M6O;$9S>LDEE:T"<.HLISPC?W-&/KVY$]V@H^IZM$*L%D=E.2%7VF\FOYQ+$W
M:;TLTIP6(F4%<+J\'=W9U_>!TM<*WU*Z%ITVJ$KFC'U7G=\7MR-+)40S&DOE
M@>#?"WV@6:8<81H_&I^C-J0R[+:WWM_KVK&6.1'T@65_I N9W(ZB$2SHDE29
M_,S6O]&F'E_YBUDF]"^L:]W0'4%<"<GRQA@SR-.B_B<_FWGH&$36"0.G,7!T
MWG4@G>4[(LGLAK,U<*6-WE1#EZJM,;FT4(OR+#F.IF@G9P]$)$!_5.D+R6@A
M!9!B 9\(_TXEF6<4GFE<\52F5,#XBY*(BYN)Q,#*?!(W0>[K(,Z)(+8-GU@A
M$P&/Q8(N]AU,,.,V;6>;]KTSZ/$=C:_ M4UP+,<;\.>VT^!J?^Y_GX8_[^9"
M<MQ-?_5-1!W&ZP^C3MBU*$E,;T=XA 3E+W0T>_/*#JRW T5X;1'>D/?9,Y[8
M1879LB7H@A[/*:BOBL$X_56H@,;A#.:[@*(-:,(Z2>,$"*<09T2(=)G2!1 T
M>2%IIK0OD3:7 AV9$#,$@)"H@%7)A,*294B2M%@I"Y3A5J#YG/)V.QCCM$!-
M5@E,05Q<&\<:=SGC,OT'G3XP(>$#9T+ UP*IEFGI!Z29.!9_Q#[N@/<DY?"-
M9!4U#O>-@?N<;IJZ85EA O : M/U+?Q_\RIR;.?M7DN/&5^OGJ] 8B!1\4UG
MKL">FH$?@-=:*$'0&*S8"^4%(E(" K2(]RQ=<QI%K=GV7TN-!Y;GE,<IR: D
M)>4"',>T(ZM5&[MPH65A:'QA$O7BPQ/BJU$/,].ZNN<;G_H6O%^*2UMQCJZ&
MBK?,T(O ]V&,#+FH!5/GC.IMQYP&(=@P=I2=Z@4]9;N>&5D1N+OY08%MHR8O
M&2>2(N'GLNLX]$W?#2&$L6>A9]6UO&:.3FSWID[<?IYI!18$ 8Q]-6E:$+JG
MYB=CQ>I24IX/S)!K!NZTLVRZ6A1:X1F3Y)E>Y.^,'943R@)GN)XV+[ CTW9V
M>W.,"W6AA%8P/;5M3F(!SX(;>7@:(FR%ZKC@FJM%;^1V" .,]%M&^F<S\FX/
M-\]DG_,($5(<GGYX8B)5UXD^:@Y'_I)08\>NIGI]%4+O0J/MF'_=^:D3JG8)
M92JALDG(Q/5=<;HB"I5SA:"_&=^:;T!N2JKG'E=A)1-#P10O5]JI8JQ,BPJ)
M.> >4]J"&VU4':2(J1;'G"Y2J0TPSS5RN6 2KVPQXXN:['V<-L\ ]4<JU-1@
M1-N!O+Y#[%H86NU%--";S=!@[JS8+_K']#X&Q&N]QZ=3M1U=O1G[(+ZG\S]#
MT)N:4\MK 'B(\^[@60<^M-T:B4>>VJ$!^+E3I$/4H._HT](9_"72#JV'$6>%
M#=H.8W8'SP->X#2@.YZ =JQA%ZZK:R&0W"Z+>I?_0&V 4T'+J>!L3O7?0XF$
M1X%G6!_XW96D#TR#H?JO<V?02E%#W8,K_:60V[R::QH>I9(4&SU)X5MQ@OE8
M!&V+6*HB7E01,$0&XUVEN84W+=A0PC4&%"=>MQ_41L.^=+2&V/\FH9Z+UQ7/
MZ?V@3#J/*83!2C\9!59;%;)^5[72]E5Z5S_&=NKUDQ87;J4NDAE=HJEU%>(7
M@M?/Q+HC6:F?9G,F\:&GFPF^K"E7"CB^9$QN.RI ^U:?_0M02P,$%     @
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MC<>/Y-#I 2)7(L8@P0*@%/77=P%2M!S)K*S6;2\2"&!WO\5^6"QPNA3R024
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MKV?/[@+G&Z4?S1K LN=$IN:BL[8V.QT,3+2&A)N^RB#%+TNE$V[Q4:\&)M/
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M#7<'ZA F#I9;+^94-G4GZ/F-VB-!K!/4V%6MH!X+T-3C*+=HNCY_EO&_D!E
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M94?VLX<DSY/YZL^IX&.1%F^0KS\F2;YY4!1X2=*GU2H-_P]02P,$%     @
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M )*' Y+Y-..QXA*7FFX?<,G#<8E@GT!%_8&W@5<>X)5'PBM\%F(%+"XUO0,
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MQC.(YI?JF!6QN-1T^X!8,9Y/)-@G(%)_X&VP5@RL%9/RC_CC_:P92"XUO0.
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MHU\MTN^2'CY QP7K-C4VN;,N4/ 0+Y=/ZH++C6O]<X(5[E,J];L#I?H-!O[
MG1]79?ZN9ZP4^G>52O^N1WH8%(LZ5]W^8Q?8^;HDA0<'O@B T@5<#RB0E-YV
M/U>^2+3]&M?&VE.^K<1:/C;RSKMV5WCY^L6HKR_J8G?X;M&'HJZ+S>''E<R6
MLFS?T/S]L2CJXXOVZTI/WT][\W]02P,$%     @ .8IF6CQJC\3_!@  K3P
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M65P+!3!4?;F:JL;59-*QO>4!+%0-3$VDC#2V-W$=35\2 9IZ[>U-KPM[TP-
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M2YI92%4P0UVU]/5*(<L<J!!^% 1#OV"\])*1&[M6R4A61O 2KQ7HJBB8>KY
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M3\B$1Q'.D>J[&H=H.G*#<CC7Q7#\-X9#R40D>JG(WTD(80U^] [>1N!B;*H
M^2\!NO:MC!,F6Z1-SXCO^>=U [+#;R!X"[XSG'8U7^V<KWW@?/W\A@ RUA"K
M7W7A+]C/Z]E-SKA4*0M@X&!24"!7X S__(-VO;_JI#=$MA.(\RH0YS;VX3C1
M@*R:P!.F- 5U8JT,^XHMR&BQD4QV7 UIJ]-W5S4B.I6(CE7$5,+G"<@%2/)=
M9H^LVE%U:JQ4^ZIIB&Q'=;=2W3WJ&NXV&8B&R'8"T:L"T7MG#7/-6412R9.
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M30-\_R!P 945TT%UJ37\'U!+ P04    "  YBF9:!PATZML+  #2E   &0
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M#9#_+R@53R?J36#]YG?\/U!+ P04    "  YBF9::B,UVL\)  #R5@  &0
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M:X!6><:3J"HL6A %<?F7OE:!:!2PW2,%<%4 'Q3 WI$"3E7 .;<&MRK@GEO
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ME$:@:+I"RKG;)ZQ[.3:CSS0(Z3)D1==6#!(Z90%U[16M.21SL3MVY'2GGHU
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MDOR!^/XI2?C^C:R@?LSM_']02P,$%     @ .8IF6NDL^V8[ P  G0L  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULS59M3]LP$/XKITR:-FDT<5K*
MR]I*+2\:TM 0"/@P[8-)KJV%'6>VV])_/]L):3>"-R8F[4MK.[[GGN?.9]]@
M)=6]GB,:>!"\T,-H;DQY&,<ZFZ.@NB-++.R7J52"&CM5LUB7"FGNC02/TR3I
MQX*R(AH-_-J%&@WDPG!6X(4"O1""JO4$N5P-(Q(]+ERRV=RXA7@T*.D,K]!<
MEQ?*SN(&)6<""\UD 0JGPVA,#B>DYPS\CAN&*[TU!B?E3LI[-SG+AU'B&"''
MS#@(:O^6>(2<.R3+XWL-&C4^G>'V^!']U(NW8NZHQB/);UENYL-H/X(<IW3!
MS:5<?<):T*[#RR37_A=6]=XD@FRAC12UL64@6%']TX<Z$%L&:?<9@[0V2#WO
MRI%G>4P-'0V47(%RNRV:&WBIWMJ28X7+RI51]BNS=F9T961VOS.QNG(XDL(F
M6U,?KAVXLB<@7W $.85;KP[SG?$2E<T6C+7-8^EV:KAVQJR (\JS!;?FQ0S,
M'.&4,@4WE"\\A%L9KZC*-;P[1D,9U^\'L;$:'),XJ_E.*K[I,WP)@7-9F+F&
MDR+'_&> V(IO(I ^1F"2!A&/,>M EWR -$E[ ;QN$]&NQ^N%(@I??&S@ZSF*
M.U3?VH0&85PU'NJ29CB,;+EI5$N,1F_?D'[R,4"RUY#L>?3N<R3_66Z_?K:N
MX,R@T*VJ>_] ]6ZC>C>8FI.'TEX&5I!!)>"=E;5&JMJ/81BI7UD" >%.(_0A
MIVL=H-AO*/;_C.)2NFAS9M9M["H04J&XFW<Y(ITD2<D@7K9XWVN\[P6]7S)]
MOS-5B#;E-D:H#2AJL(W!WE,&22?II?UV!OL-@_T_TY^S)<NQR&'-D.=M#()
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ME/X-4%D#VI]):383&Z#ZVXA^ E!+ P04    "  YBF9:(?57(Q<$   :$@
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M1PL-)V^MNNX'K@]0-;[)#PKMR/AE9>\HT"[!GA^5PG/@!,9;+_L#4$L#!!0
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M42S00[5 W>7"#6#5LV-BR\K;A\#[#\MB: 0ZKQ,Z(8WH:4YTNVQ&(BZ:0YE
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M96)+/V.\H47K^GHMM)D2;EF;L8S2.ICS4@B]-VR ?M!G?P!02P,$%     @
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MM5$[!SHOE+)[PQ'T_P/I;U!+ P04    "  YBF9:U(N33-$'  !20P  &0
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M%HZGZ!@7]@0.@2OX5NO64F&;QX[4>$YQN6$^[IAG'S!/4W@@MK6%+ZK"ZE^
MF&SHO<BV7HRSO8A3+$]AD'Z"+,F&\#R;PO'AR1[<0>_Q(. ./L#][R;^O)E;
M9^A"_WK/MH[,\'TROLFO;,-*'$74Q1;-"J/BZ" ]3Z[W2!WV4H?[T(N@H&&\
M N(/3.I6.4L'78J6SLB?N*L1),EH35#M/1%>%0C.YEQP1Q?O/55=W;-0U[\T
M*[H YWF\VB4;[_2!1+,,W6ZA]"RZENA7^P?EINNCO^'=:_3 S)(K2]P6E)J<
M7E!ETW5X-W&Z"5TUUXYZ- QK>A31^ #:7VCMMA-?H']FBS]02P,$%     @
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MT=6P 1OKAF_A(A"JP1H-EGA!ID3<+^^8?+.*+'X8DX2'- &,S(>-:]B?V#I
M]_@G)"N^\0P4E1FEC^KEBS]LM!0B$A%/J!18?CR1"8DBE4GB^#=/VBAJJL#-
MYW7VSYJ\)#/#G$QH]"/T13!LN W@DSE.(_&-KOXB.:&.RN?1B.N_8)7W;36
MEW)!XSQ8(HC#)/O$O_*!V AH[PI >0!Z$0#M'0%V'F!KHADR3>L&"SP:,+H"
M3/66V=2#'AL=+=F$B9K&J6#RVU#&B='?<J5\I9R#.\+ -,",@"LPE8O%3R,"
MZ!R,,0\]@!,?W(11*H@/*D*NA6#A+!5X)H,$!5-!O<> 1CYA'%S<$('#B'\
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MS;QY,WSRS+ 6<JE* (UN&>5J%)5:5\=QK/(2&%8'H@)NWLR%9%B;K5S$JI*
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M+DO^T: +"7R^L);>@]#\W:^K^ -02P,$%     @ .8IF6G+0'Z17 P  #A8
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M$:PJI@W;P3B2)!@"M>BNT3A&LA/#Q[T^V"Z)HB1Q(X"Y%401AL!NQ!%, 6C
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M+NQ?7["OO.!5+E@;7.,!1@ PZ@V0?9IR#S(&D/$'0LX<1/O@U9+=;H3V(1,
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M.[SDL^F?M>L_4$L! A0#%     @ .8IF6@=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  YBF9:$#[@
M\^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  YBF9:F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #F*9EK8!F$E900  .<+
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  YBF9:W#TR]]@&  #L)0  &               @(&I#
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ .8IF6L"+WV+)
M P  D10  !@              ("!MQ,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( #F*9EK:_#OL@@4  "X:   8              "
M@;87  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  YBF9:
M!_(@PYT"   4!P  &               @(%N'0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ .8IF6HU3;<<O"P  65P  !@
M     ("!02   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M #F*9EH2 "_]9@(  "\%   8              " @:8K  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  YBF9:5F;=\],&   F'   &
M            @(%"+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ .8IF6H/1$T2[$0  ZS0  !@              ("!2S4  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #F*9EK[!"6:824  #EX
M   9              " @3Q'  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ .8IF6LGXP:MH P  '@@  !D              ("!U&P
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  YBF9:$OR+
MCK4#  "9"0  &0              @(%S<   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( #F*9EH7O5F]<08  .D1   9
M  " @5]T  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M.8IF6IH5'I64 @  (@8  !D              ("!!WL  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  YBF9:/#<LV9H&  "'$   &0
M            @('2?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( #F*9EIUOO7/6@L  /TC   9              " @:.$  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ .8IF6O4^'.-1#@
M8#$  !D              ("!-)   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  YBF9:QB;QD3D$   E"@  &0              @(&\
MG@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #F*9EK4
M,"!<N0<  'H3   9              " @2RC  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ .8IF6M)J93HD#P  *C(  !D
M     ("!'*L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F*9EK4,TS!%B<  )B$   9              "
M@6/.  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ .8IF
M6DBE#2VY @  [P4  !D              ("!L/4  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  YBF9:)H+"5J8"  #L!0  &0
M        @(&@^   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( #F*9EI,TZHMD ,  $T)   9              " @7W[  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ .8IF6JL1]RI7!0  MP\
M !D              ("!1/\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  YBF9:Q<%=$J "   %!@  &0              @('2! $
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #F*9EK7&K<N
ML@,  #<)   9              " @:D' 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ .8IF6AF3_5T^!0  ^!(  !D
M ("!D@L! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  Y
MBF9:N?N,7_\"  !"!P  &0              @($'$0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #F*9EK)TVRHM04  $(/   9
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M970S."YX;6Q02P$"% ,4    "  YBF9:7__%OC@"  #<!   &0
M    @('2,0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M #F*9EI8W8>:Q0(  'D+   9              " @4$T 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ .8IF6E0#I1F  @  ZP4  !D
M             ("!/3<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  YBF9:O. !X90*  "K=@  &0              @('T.0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #F*9EH\:H_$_P8
M *T\   9              " @;]$ 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ .8IF6D+9(*-]!0  PB0  !D              ("!
M]4L! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  YBF9:
M,[Z0-8D"   =!P  &0              @(&I40$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( #F*9EH[(7FUL0(  !T(   9
M      " @6E4 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ .8IF6C.17ST-!   X!(  !D              ("!45<! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  YBF9:!PATZML+  #2E
M&0              @(&56P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( #F*9EIZ(:DEM0(  -X&   9              " @:=G 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ .8IF6K*Z"#BH
M!   !1X  !D              ("!DVH! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  YBF9::B,UVL\)  #R5@  &0
M@(%R;P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #F*
M9EKI+/MF.P,  )T+   9              " @7AY 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ .8IF6BJ%P(.'!   8A<  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( #F*9EHB3B+!' (   $%   9
M  " @7V/ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M.8IF6KF35?8>!0  4!\  !D              ("!T)$! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    "  YBF9:<9GMND #   '"P  &0
M            @($EEP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( #F*9EKGPEM^:P(  /4%   9              " @9R: 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ .8IF6I9_PUSU @
M)0@  !D              ("!/IT! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    "  YBF9:T7Z.B<D#  !5#P  &0              @(%J
MH $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #F*9EH&
M=#V4< (  /0%   9              " @6JD 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ .8IF6@4G"^Z& @  $P8  !D
M     ("!$:<! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F*9EI0.*J@A (  &0'   9              "
M@=^[ 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ .8IF
M6E;<- D2!0  7AD  !D              ("!FKX! 'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6Q02P$"% ,4    "  YBF9:1\5-F$4#   V#@  &0
M        @('CPP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0
M   ( #F*9EK A:<?X (  -\+   9              " @5_' 0!X;"]W;W)K
M<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ .8IF6G(!M5Z= P  M1,
M !D              ("!=LH! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q0
M2P$"% ,4    "  YBF9:)_8C3RH"  #&!   &0              @(%*S@$
M>&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( #F*9EIRT!^D
M5P,   X6   -              "  :O0 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ .8IF6I>*NQS     $P(   L              ( !+=0! %]R96QS
M+RYR96QS4$L! A0#%     @ .8IF6OG8?]6-!0  ^C$   \
M ( !%M4! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #F*9EIG_%)"3 (
M &@L   :              "  =#: 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( #F*9EJ&IF-(# (  &$K   3              "
M 53= 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !3 %, O!8  )'? 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statement of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals</Role>
      <ShortName>Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Cash equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CashequivalentsandMarketableSecurities</Role>
      <ShortName>Cash equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note Payable with Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedParty</Role>
      <ShortName>Note Payable with Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Segment Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosures</Role>
      <ShortName>Segment Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Option Agreements and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements</Role>
      <ShortName>Option Agreements and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CashequivalentsandMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Segment Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosuresTables</Role>
      <ShortName>Segment Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SegmentDisclosures</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Note Payable with Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails</Role>
      <ShortName>Note Payable with Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NotePayablewithRelatedParty</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity - Schedule of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity - Schedule of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRSAActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSA Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Stock-Based Compensation - Schedule of Company???s Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company???s Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company???s Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Award Types of Company???s Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Segment Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosuresDetails</Role>
      <ShortName>Segment Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SegmentDisclosuresTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable</Role>
      <ShortName>Segment Disclosures - Schedule of Segment Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable</Role>
      <ShortName>Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Option Agreements and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails</Role>
      <ShortName>Option Agreements and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingenciesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Commitment and Contingencies - Schedule of Company???s Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable</Role>
      <ShortName>Commitment and Contingencies - Schedule of Company???s Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Commitment and Contingencies - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable</Role>
      <ShortName>Commitment and Contingencies - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0233170-posam1_oruka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SubsequentEvents</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="ea0233170-posam1_oruka.htm">ea0233170-posam1_oruka.htm</File>
    <File>orka-20241231.xsd</File>
    <File>orka-20241231_cal.xml</File>
    <File>orka-20241231_def.xml</File>
    <File>orka-20241231_lab.xml</File>
    <File>orka-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="698">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0233170-posam1_oruka.htm": {
   "nsprefix": "orka",
   "nsuri": "http://www.orukatx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0233170-posam1_oruka.htm"
     ]
    },
    "schema": {
     "local": [
      "orka-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "orka-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "orka-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "orka-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orka-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 279,
   "keyCustom": 73,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 30,
   "memberCustom": 50,
   "hidden": {
    "total": 242,
    "http://www.orukatx.com/20241231": 54,
    "http://fasb.org/us-gaap/2024": 185,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 199,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 595,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 698,
    "http://xbrl.sec.gov/dei/2024": 7
   },
   "report": {
    "R1": {
     "role": "http://www.orukatx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
     "longName": "003 - Statement - Consolidated Statement of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statement of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
     "longName": "004 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "shortName": "Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c19",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c19",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "006 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Parentheticals)",
     "shortName": "Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.orukatx.com/role/ConsolidatedCashFlow",
     "longName": "007 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation",
     "longName": "008 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing",
     "longName": "010 - Disclosure - Reverse Recapitalization and Pre-Closing Financing",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.orukatx.com/role/FairValueMeasurements",
     "longName": "011 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.orukatx.com/role/CashequivalentsandMarketableSecurities",
     "longName": "012 - Disclosure - Cash equivalents and Marketable Securities",
     "shortName": "Cash equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "013 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedParty",
     "longName": "014 - Disclosure - Note Payable with Related Party",
     "shortName": "Note Payable with Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity",
     "longName": "015 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.orukatx.com/role/StockBasedCompensation",
     "longName": "016 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.orukatx.com/role/SegmentDisclosures",
     "longName": "017 - Disclosure - Segment Disclosures",
     "shortName": "Segment Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.orukatx.com/role/IncomeTaxes",
     "longName": "018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements",
     "longName": "019 - Disclosure - Option Agreements and License Agreements",
     "shortName": "Option Agreements and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.orukatx.com/role/CommitmentandContingencies",
     "longName": "020 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.orukatx.com/role/NetLossPerShare",
     "longName": "021 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactions",
     "longName": "022 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.orukatx.com/role/SubsequentEvents",
     "longName": "023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.orukatx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables",
     "longName": "996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.orukatx.com/role/FairValueMeasurementsTables",
     "longName": "996003 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables",
     "longName": "996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)",
     "shortName": "Cash equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables",
     "longName": "996006 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationTables",
     "longName": "996007 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.orukatx.com/role/SegmentDisclosuresTables",
     "longName": "996008 - Disclosure - Segment Disclosures (Tables)",
     "shortName": "Segment Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.orukatx.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.orukatx.com/role/CommitmentandContingenciesTables",
     "longName": "996010 - Disclosure - Commitment and Contingencies (Tables)",
     "shortName": "Commitment and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.orukatx.com/role/NetLossPerShareTables",
     "longName": "996011 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsTables",
     "longName": "996012 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
     "longName": "996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c41",
      "name": "orka:AdditionalPaidInCapitalTransacationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable",
     "longName": "996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
     "longName": "996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
     "longName": "996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
     "longName": "996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable",
     "longName": "996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
     "longName": "996022 - Disclosure - Note Payable with Related Party (Details)",
     "shortName": "Note Payable with Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c104",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c104",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
     "longName": "996023 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
     "longName": "996024 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
     "longName": "996025 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c52",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationDetails",
     "longName": "996026 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "orka:EstimatedFairValueOfWarrantsToBeGranted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
     "longName": "996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c144",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c144",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
     "longName": "996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSA Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c145",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c145",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
     "longName": "996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
     "longName": "996031 - Disclosure - Stock-Based Compensation - Schedule of Company\u2019s Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Company\u2019s Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
     "longName": "996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c151",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.orukatx.com/role/SegmentDisclosuresDetails",
     "longName": "996033 - Disclosure - Segment Disclosures (Details)",
     "shortName": "Segment Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable",
     "longName": "996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)",
     "shortName": "Segment Disclosures - Schedule of Segment Loss from Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c161",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.orukatx.com/role/IncomeTaxesDetails",
     "longName": "996035 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable",
     "longName": "996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Loss Before Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable",
     "longName": "996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable",
     "longName": "996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable",
     "longName": "996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
     "longName": "996041 - Disclosure - Option Agreements and License Agreements (Details)",
     "shortName": "Option Agreements and License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
     "longName": "996042 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable",
     "longName": "996043 - Disclosure - Commitment and Contingencies - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Commitment and Contingencies - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable",
     "longName": "996044 - Disclosure - Commitment and Contingencies - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "shortName": "Commitment and Contingencies - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.orukatx.com/role/NetLossPerShareDetails",
     "longName": "996045 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
     "longName": "996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable",
     "longName": "996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
     "longName": "996048 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c193",
      "name": "orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c193",
      "name": "orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
     "longName": "996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)",
     "shortName": "Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c194",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c194",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.orukatx.com/role/SubsequentEventsDetails",
     "longName": "996050 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c198",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c198",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233170-posam1_oruka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "orka_ARCACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ARCACommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA common stock [Member]",
        "label": "ARCACommon Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "verboseLabel": "Accounts payable and other current liabilities",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r52"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and consulting",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "orka_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r71",
      "r136",
      "r601",
      "r623",
      "r624"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r18",
      "r456",
      "r459",
      "r511",
      "r619",
      "r620",
      "r835",
      "r836",
      "r837",
      "r848",
      "r849",
      "r850",
      "r852"
     ]
    },
    "orka_AchievementOfDevelopmentCandidateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AchievementOfDevelopmentCandidateMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Development Candidate [Member]",
        "verboseLabel": "Achievement Of Development Candidate [Member]",
        "label": "Achievement Of Development Candidate Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r793",
      "r976"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r848",
      "r849",
      "r850",
      "r852",
      "r917",
      "r977"
     ]
    },
    "orka_AdditionalPaidInCapitalTransacationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AdditionalPaidInCapitalTransacationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital transaction costs (in Dollars)",
        "documentation": "The amount of additional paid-in capital transacation cost.",
        "label": "Additional Paid In Capital Transacation Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r362"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs of Pre-Closing Financing and reverse recapitalization",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of the Paruka warrant from liability to equity",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r38",
      "r91"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r404"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "orka_AntibodyProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AntibodyProductsMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibody Products [Member]",
        "label": "Antibody Products Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r131",
      "r157",
      "r194",
      "r203",
      "r217",
      "r220",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r451",
      "r453",
      "r489",
      "r595",
      "r674",
      "r757",
      "r758",
      "r793",
      "r816",
      "r876",
      "r877",
      "r933"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r137",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r451",
      "r453",
      "r489",
      "r793",
      "r876",
      "r877",
      "r933"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Preferred Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r594"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Marketable Securities at Estimated Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r269",
      "r467",
      "r588",
      "r780",
      "r783",
      "r862",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r83",
      "r84"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California [Member]",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CashAcquiredInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashAcquiredInConnectionWithTheReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Represent the amount of cash acquired in connection with the reverse recapitalization.",
        "label": "Cash Acquired In Connection With The Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r129",
      "r744"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r80",
      "r153"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80"
     ]
    },
    "orka_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r944"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents [Member]",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r134",
      "r135",
      "r157",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r261",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r336",
      "r339",
      "r347",
      "r489",
      "r628",
      "r629",
      "r630",
      "r631",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r662",
      "r683",
      "r705",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r818",
      "r843",
      "r853"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Line Items]",
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r197",
      "r331",
      "r332",
      "r334",
      "r336",
      "r339",
      "r345",
      "r347",
      "r628",
      "r629",
      "r630",
      "r631",
      "r770",
      "r818",
      "r843"
     ]
    },
    "orka_ClassOfWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRight",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights issued.",
        "label": "Class Of Warrant Or Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per warrant (in Dollars per share)",
        "verboseLabel": "Exercise price per warrant",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "orka_ClassOfWarrantOrRightExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "documentation": "The class of warrant or right expiration date.",
        "label": "Class Of Warrant Or Right Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock",
        "verboseLabel": "Warrant purchase percentage",
        "documentation": "class of warrant or right to purchase percentage of outstanding diluted stock maximum.",
        "label": "Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exchange",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "documentation": "The class of Warrant or Right warrants exercised.",
        "label": "Class Of Warrant Or Right Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantsExercisable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable",
        "documentation": "Represent the number of warrants exercisable.",
        "label": "Class Of Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassificationOfConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classification of Convertible Preferred Stock",
        "documentation": "Classification of Convertible Preferred Stock.",
        "label": "Classification Of Convertible Preferred Stock Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClinicalDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClinicalDevelopmentMilestonesMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Milestones [Member]",
        "label": "Clinical Development Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Papers [Member]",
        "verboseLabel": "Commercial papers\t[Member]",
        "netLabel": "Commercial papers [Member]",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r292",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "orka_CommitmentandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommitmentandContingenciesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r103",
      "r597",
      "r661"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r285",
      "r286",
      "r729",
      "r870",
      "r875"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r730"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "verboseLabel": "Total shares of common stock reserved",
        "netLabel": "Shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "orka_CommonStockConversionRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "documentation": "Percentage of common stock conversion ratio.",
        "label": "Common Stock Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r848",
      "r849",
      "r852",
      "r917",
      "r975",
      "r977"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r662"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r662",
      "r680",
      "r977",
      "r978"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r599",
      "r793"
     ]
    },
    "orka_CommonStocksConversionRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommonStocksConversionRatio",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "documentation": "Percentage of common stock conversion ratio.",
        "label": "Common Stocks Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r141",
      "r143",
      "r148",
      "r589",
      "r611",
      "r612"
     ]
    },
    "orka_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and office equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r118"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ConversionOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Reserved for Future Issuance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible shares",
        "verboseLabel": "Converted shares (in Shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "orka_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "label": "Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares of common stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r40",
      "r64",
      "r90",
      "r342"
     ]
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r780",
      "r794",
      "r805",
      "r972"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party amount",
        "label": "Costs and Expenses, Related Party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r306",
      "r334",
      "r518",
      "r539",
      "r593",
      "r745",
      "r747"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable with Related Party",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r155",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r291",
      "r292",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r325",
      "r326",
      "r328",
      "r497"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r53",
      "r54",
      "r100",
      "r102",
      "r164",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r844",
      "r871",
      "r872",
      "r873",
      "r927",
      "r928"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r497",
      "r498",
      "r766",
      "r767",
      "r790"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, percentage",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r321",
      "r927"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r844",
      "r927",
      "r928"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r765",
      "r922",
      "r923"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or longer, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or longer, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less than 12 months, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r271",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r272"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r764",
      "r869"
     ]
    },
    "us-gaap_DebtSecuritiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current",
        "label": "Debt Securities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesNoncurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term",
        "label": "Debt Securities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r101",
      "r428"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D expenses",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "orka_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Other Loss Carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails",
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "verboseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable",
      "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right- of- use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36"
     ]
    },
    "orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "documentation": "Description of minority interest ownership percentage by noncontrolling owners.",
        "label": "Description Of Minority Interest Ownership Percentage By Noncontrolling Owners"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DevelopmentCostsPercentage",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs, percentage",
        "documentation": "Percentage of development costs.",
        "label": "Development Costs Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r364",
      "r395",
      "r396",
      "r398",
      "r776"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization and Pre-Closing Financing [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to stockholders, basic (in Dollars per share)",
        "verboseLabel": "Loss per share \u2013 Basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r446",
      "r449",
      "r464",
      "r465",
      "r590",
      "r613",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to stockholders, diluted (in Dollars per share)",
        "verboseLabel": "Loss per share \u2013 Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r446",
      "r449",
      "r464",
      "r465",
      "r590",
      "r613",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share Attributable to Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r190"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r189",
      "r191",
      "r192"
     ]
    },
    "us-gaap_EarningsPerUnitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerUnitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax (benefit) expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit derived by applying the federal statutory rate to income before income taxes",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r415",
      "r437",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in the valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r779",
      "r847",
      "r910"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r847",
      "r910",
      "r911"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r847",
      "r910",
      "r912"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeStockPurchasePlanESPPCashContributionsToESPP",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP",
        "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).",
        "label": "Employee Stock Purchase Plan ESPPCash Contributions To ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan [Member]",
        "label": "Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Warrants [Member]",
        "verboseLabel": "Employee warrants\t[Member]",
        "label": "Employee Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r125",
      "r145",
      "r146",
      "r147",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r262",
      "r263",
      "r276",
      "r349",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r500",
      "r511",
      "r609",
      "r619",
      "r620",
      "r621",
      "r637",
      "r705"
     ]
    },
    "orka_EstimatedFairValueOfWarrantsToBeGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EstimatedFairValueOfWarrantsToBeGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of warrants to be granted",
        "documentation": "Estimated fair value of warrants to be granted.",
        "label": "Estimated Fair Value Of Warrants To Be Granted"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExternalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ExternalMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External [Member]",
        "label": "External Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r783"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets Measured",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r920"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "orka_FairValueCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairValueCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and marketable securities",
        "documentation": "Amount of cash equivalents and marketable securities.",
        "label": "Fair Value Cash Equivalents And Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r587",
      "r780",
      "r784"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r468",
      "r481",
      "r526",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r468",
      "r469",
      "r481",
      "r527",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountHealthcareFundIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountHealthcareFundIILPMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount Healthcare Fund II, L.P. [Member]",
        "verboseLabel": "Fairmount [Member]",
        "label": "Fairmount Healthcare Fund IILPMember"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount [Member]",
        "label": "Fairmount Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountsOwnershipInterestInParagonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountsOwnershipInterestInParagonMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount's Ownership Interest in Paragon [Member]",
        "label": "Fairmounts Ownership Interest In Paragon Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Deposit Insurance Corporation",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r274",
      "r275",
      "r327",
      "r345",
      "r461",
      "r488",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r610",
      "r764",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r794",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r864",
      "r865",
      "r866",
      "r867",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Dosing of Human Patient in Phase1Trial Milestone [Member]",
        "label": "First Dosing Of Human Patient In Phase One Trial Milestone Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative personnel-related expense (excluding stock-based compensation)",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r685"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative [Member]",
        "netLabel": "General and administrative stock-based compensation [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r414"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r107",
      "r109",
      "r591",
      "r607",
      "r751",
      "r757",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Before Income Tax Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r414"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r283",
      "r284",
      "r473",
      "r477",
      "r482",
      "r616",
      "r618",
      "r690",
      "r742",
      "r782",
      "r946"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r473",
      "r477",
      "r482",
      "r616",
      "r618",
      "r690",
      "r742",
      "r782",
      "r946"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r415",
      "r416",
      "r422",
      "r433",
      "r779",
      "r915"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r415",
      "r416",
      "r422",
      "r433",
      "r779",
      "r915"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r409",
      "r415",
      "r419",
      "r420",
      "r421",
      "r425",
      "r432",
      "r438",
      "r440",
      "r441",
      "r442",
      "r633",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r177",
      "r178",
      "r194",
      "r206",
      "r220",
      "r413",
      "r415",
      "r439",
      "r614",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r411",
      "r412",
      "r425",
      "r426",
      "r431",
      "r434",
      "r627"
     ]
    },
    "orka_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r322",
      "r329",
      "r768",
      "r769"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r839"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r204",
      "r220",
      "r757",
      "r838"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and marketable securities (in Dollars)",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities at Estimated Fair Value",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "orka_InvestorsClosingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "InvestorsClosingShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investors shares",
        "documentation": "Number of investors closing shares.",
        "label": "Investors Closing Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceCostOfPIPEFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceCostOfPIPEFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs of PIPE Financing",
        "documentation": "Issuance cost of PIPE financing.",
        "label": "Issuance Cost Of PIPEFinancing"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization",
        "documentation": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.",
        "label": "Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)",
        "documentation": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.",
        "label": "Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs",
        "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs.",
        "label": "Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Future lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "verboseLabel": "Lease initial period",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r62",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r452",
      "r453",
      "r454",
      "r489",
      "r660",
      "r750",
      "r816",
      "r876",
      "r933",
      "r934"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r104",
      "r603",
      "r793",
      "r845",
      "r868",
      "r926"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r128",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r452",
      "r453",
      "r454",
      "r489",
      "r793",
      "r876",
      "r933",
      "r934"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r831"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Axis]",
        "label": "Marketable Securities Axis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current",
        "verboseLabel": "Due in one year or less",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "orka_MarketableSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesCurrentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current [Member]",
        "label": "Marketable Securities Current Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesDomainDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MarketableSecuritiesDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesLongTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesLongTermMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities,Long-Term [Member]",
        "label": "Marketable Securities Long Term Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Member]",
        "label": "Marketable Securities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term",
        "verboseLabel": "Due in 1-2 years",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "orka_MarketableSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesNoncurrentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term [Member]",
        "label": "Marketable Securities Noncurrent Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r358",
      "r405",
      "r471",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r803",
      "r878",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Recapitalization and Pre-Closing Financing",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97"
     ]
    },
    "orka_MilestoneConsiderationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MilestoneConsiderationPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone consideration paid",
        "documentation": "The milestone consideration paid amount.",
        "label": "Milestone Consideration Paid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r358",
      "r405",
      "r471",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r803",
      "r878",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "orka_NatureoftheBusinessandBasisofPresentationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NatureoftheBusinessandBasisofPresentationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash operating activities (in Dollars)",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss (in Dollars)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r108",
      "r126",
      "r140",
      "r142",
      "r147",
      "r157",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r185",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r446",
      "r449",
      "r465",
      "r489",
      "r608",
      "r682",
      "r703",
      "r704",
      "r814",
      "r876"
     ]
    },
    "orka_NetLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NetLossPerShareDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "orka_NominationOfADevelopmentCandidateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NominationOfADevelopmentCandidateMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nomination Of A Development Candidate [Member]",
        "label": "Nomination Of ADevelopment Candidate Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NonRefundableLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NonRefundableLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable license fee",
        "documentation": "Amount of non refundable license fee.",
        "label": "Non Refundable License Fee"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NonRefundableMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NonRefundableMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable milestone payments",
        "documentation": "Non-refundable milestone payments.",
        "label": "Non Refundable Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash accrued interest on convertible note converted to common stock",
        "documentation": "Represent the amount of non-cash accrued interest on convertible note converted to common stock.",
        "label": "Noncash Accrued Interest On Convertible Note Converted To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock",
        "documentation": "Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.",
        "label": "Noncash Exchange Of Pre Merger Oruka Series APreferred Stock For Series BConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired in connection with the reverse capitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Assets Acquired",
        "documentation": "Amount of assets, classified as other, acquired in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other liabilities assumed in connection with the reverse recapitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NotePayableToRelatedPartyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NotePayableToRelatedPartyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable to Related Party",
        "documentation": "Note Payable to Related Party.",
        "label": "Note Payable To Related Party Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NotePayablewithRelatedPartyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NotePayablewithRelatedPartyDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r856"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r856"
     ]
    },
    "orka_NumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NumberOfSharesPurchased",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of purchased shares",
        "documentation": "Number of shares purchased.",
        "label": "Number Of Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NumberofAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NumberofAggregateShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares",
        "documentation": "Number of aggregate shares.",
        "label": "Numberof Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroOneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroOneLicenseAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-001 License Agreement [Member]",
        "label": "ORKAZero Zero One License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroOneMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-001 [Member]",
        "label": "ORKAZero Zero One Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroTwoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroTwoLicenseAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-002 License Agreement [Member]",
        "label": "ORKAZero Zero Two License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroTwoMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-002 [Member]",
        "label": "ORKAZero Zero Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]",
        "label": "Operating Expense Excluding Personnel Related And Stock Based Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OperatingExpenseExcludingStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingExpenseExcludingStockBasedCompensationMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense Excluding StockBased Compensation [Member]",
        "verboseLabel": "Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]",
        "label": "Operating Expense Excluding Stock Based Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r751",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total discounted lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "negatedLabel": "Less: current portion of lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, non-current",
        "verboseLabel": "Non-current portion of lease liability",
        "netLabel": "Operating lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseVariableLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseVariableLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Operating Lease, Variable Lease Income",
        "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r792"
     ]
    },
    "orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingLossCarryforwardsAsAPercentageOfTaxableIncome",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards as a percentage of taxable income",
        "documentation": "Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income",
        "label": "Operating Loss Carryforwards As APercentage Of Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance due to continuing loss from operations",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "orka_OptionAgreementsAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsAndLicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsAndLicenseAgreementsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Agreements and License Agreements",
        "documentation": "The entire disclosure of option agreements and license agreements.",
        "label": "Option Agreements And License Agreements Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsandLicenseAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsandLicenseAgreementsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OrukaCommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Common Stock [Member]",
        "label": "Oruka Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaSeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OrukaSeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Series A Convertible Preferred Stock [Member]",
        "label": "Oruka Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r260"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Accounts Payable and Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_OtherDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherDevelopmentCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs",
        "documentation": "Represent the amount of development costs.",
        "label": "Other Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "orka_OtherIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "documentation": "Represents of other income (expense), net.",
        "label": "Other Income Expense Net Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PIPEFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PIPEFinancingMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing [Member]",
        "label": "PIPEFinancing Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon [Member]",
        "label": "Paragon Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonMilestonePaymentsForOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonMilestonePaymentsForOptionAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon milestone payments for Option Agreement [Member]",
        "label": "Paragon Milestone Payments For Option Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOptionAgreementsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursableOptionAgreementsFeesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable Option Agreements\u2019 fees [Member]",
        "label": "Paragon Reimbursable Option Agreements Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOtherResearchExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursableOtherResearchExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable other research expenses [Member]",
        "label": "Paragon Reimbursable Other Research Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursablePatentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursablePatentExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable patent expenses\t[Member]",
        "label": "Paragon Reimbursable Patent Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka [Member]",
        "label": "Paruka Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaWarrantMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Warrant [Member]",
        "label": "Paruka Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaWarrantObligationMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Warrant Obligation [Member]",
        "verboseLabel": "Paruka warrant obligation [Member]",
        "label": "Paruka Warrant Obligation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs (in Dollars)",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initiation fee",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs (in Dollars)",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "orka_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PreFundedWarrantsOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreFundedWarrantsOfCommonStockShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants of common stock shares",
        "documentation": "Pre-funded warrants of common stock shares.",
        "label": "Pre Funded Warrants Of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PreMergerOrukaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreMergerOrukaMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Merger Oruka [Member]",
        "label": "Pre Merger Oruka Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r810",
      "r811",
      "r812",
      "r813",
      "r975",
      "r977"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock Authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r662"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares issued",
        "verboseLabel": "Preferred Stock Issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding",
        "netLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r662",
      "r680",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively",
        "verboseLabel": "Carrying Value (in Dollars)",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r598",
      "r793"
     ]
    },
    "orka_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PrefundedWarrantstoPurchaseAnAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PrefundedWarrantstoPurchaseAnAggregateShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrants to purchase an aggregate shares",
        "documentation": "Number of prefunded warrants to purchase an aggregate shares.",
        "label": "Prefunded Warrantsto Purchase An Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of convertible note (in Dollars)",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the PIPE Financing, net",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of notes payable to related party, net of issuance costs paid",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the Pre-Closing Financing, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r840"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509",
      "r592",
      "r606",
      "r793"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r119",
      "r122",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r350",
      "r358",
      "r390",
      "r391",
      "r392",
      "r405",
      "r471",
      "r529",
      "r538",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r803",
      "r808",
      "r874",
      "r878",
      "r922",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Represents of recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ReclassificationOfTheParukaWarrantFromLiabilityToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of the Paruka warrant from liability to equity",
        "documentation": "Represent the amount of reclassification of the paruka warrant from liability to equity.",
        "label": "Reclassification Of The Paruka Warrant From Liability To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Loss from Operations",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "orka_RegulatoryMilestonesMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RegulatoryMilestonesMemberMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestones Member [Member]",
        "label": "Regulatory Milestones Member Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r357",
      "r515",
      "r516",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r515",
      "r516",
      "r517",
      "r518",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r932"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]",
        "terseLabel": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r686",
      "r687",
      "r690"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r357",
      "r515",
      "r516",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712",
      "r932"
     ]
    },
    "orka_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516",
      "r519",
      "r634",
      "r635",
      "r636",
      "r688",
      "r689",
      "r690",
      "r709",
      "r711"
     ]
    },
    "orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r306",
      "r334",
      "r518",
      "r539",
      "r593",
      "r746",
      "r747"
     ]
    },
    "orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Contract Costs Accruals",
        "documentation": "Research and development contract costs accruals.",
        "label": "Research And Development Contract Costs Accruals Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development personnel-related expense (excluding stock-based compensation)",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r742",
      "r757",
      "r941"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development [Member]",
        "netLabel": "Research and development stock-based compensation [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "orka_ResearchInitialFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ResearchInitialFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research initial fees",
        "documentation": "The amount of research initial fees.",
        "label": "Research Initial Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "orka_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards\t[Member]",
        "label": "Restricted Stock Awards Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Award [Member]",
        "verboseLabel": "Restricted Stock [Member]",
        "netLabel": "RSA [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r91",
      "r602",
      "r622",
      "r624",
      "r632",
      "r663",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r262",
      "r263",
      "r276",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r457",
      "r458",
      "r460",
      "r463",
      "r499",
      "r500",
      "r619",
      "r621",
      "r637",
      "r977"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability arising from obtaining operating right-of-use asset",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r792"
     ]
    },
    "orka_RoyaltyPayableOnProductSales": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RoyaltyPayableOnProductSales",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payable on product sales, description",
        "documentation": "Royalty payable on product sales, description.",
        "label": "Royalty Payable On Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange shares",
        "verboseLabel": "Number of shares issued",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "auth_ref": [
      "r179",
      "r359",
      "r819",
      "r851"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Available For Sale Securities In An Unrealized Loss Position Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Award Types Of Company SStock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Basic And Diluted Net Loss Per Share Attributable To Stockholders Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Equivalents And Marketable Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Reserved For Future Issuance Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SStock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "orka_ScheduleOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Convertible Preferred Stock Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfConvertiblePreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfConvertiblePreferredStockTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Preferred Stock",
        "documentation": "Tabular disclosure of convertible preferred stock.",
        "label": "Schedule Of Convertible Preferred Stock Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of the Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r779",
      "r910"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "orka_ScheduleOfEmployeeWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfEmployeeWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Income Tax Expense",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSA Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "orka_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Assets and Liabilities",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfRsaActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfRsaActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsa Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfSegmentLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfSegmentLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "orka_ScheduleOfStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r778"
     ]
    },
    "orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Assumptions Used In Calculating The Fair Value Of The Awards Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r649",
      "r650",
      "r651",
      "r714",
      "r716",
      "r719",
      "r721",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r771",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r808",
      "r880",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r973",
      "r974"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Disclosures",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r194",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r228",
      "r752",
      "r755",
      "r756",
      "r757",
      "r759",
      "r761",
      "r762"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r223",
      "r226",
      "r753",
      "r754",
      "r760"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Loss from Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "orka_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series A Non-Voting",
        "netLabel": "Series A Non-Voting Convertible Preferred Stock [Member]",
        "label": "Series ANon Voting Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesANonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stockholders",
        "label": "Series ANon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "verboseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r879"
     ]
    },
    "orka_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "verboseLabel": "Shares issuable on conversion of Company Series B Preferred Stock [Member]",
        "label": "Series BConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBNonVotingConvertiblePreferredStockAmountMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series B Non-Voting",
        "label": "Series BNon Voting Convertible Preferred Stock Amount Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBNonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stockholders",
        "label": "Series BNon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock [Member]",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r879"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Exercised",
        "documentation": "Number of Warrants, Exercised (in Shares).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "documentation": "Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested balance, Number of Granted",
        "verboseLabel": "Number of Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in Shares)",
        "periodEndLabel": "Ending Balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested balance, Beginning",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested balance, Ending",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ending Balance (in Shares)",
        "documentation": "Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Vested and expected to vest",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Expected To Vest Outstanding Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Schedule of RSA Activity [Line Items]",
        "verboseLabel": "Schedule of Employee Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contribution of employee's eligible compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options Outstanding, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable,",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant-date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Stock Options Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options Outstanding, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average,Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in Shares)",
        "periodEndLabel": "Ending Balance (in Shares)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Vested and exercisable",
        "documentation": "Number of employee warrants outstanding, vested and exercisable shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and exercisable",
        "documentation": "Weighted-Average Exercise Price Per Share, Vested and Exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Expected To Vest Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSAs issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in shares available for issuance as a percentage of outstanding diluted stock",
        "documentation": "Share based compensation arrangement diluted stock.",
        "label": "Share Based Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Diluted Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r368",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r399",
      "r400",
      "r401",
      "r402"
     ]
    },
    "orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Warrant Activity",
        "documentation": "Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.",
        "label": "Share Based Payment Arrangement Warrant Activitiy Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock",
        "documentation": "Represent the amount of conversion of non-voting convertible preferred stock to common stock.",
        "label": "Share Issued During Period Value Conversion Of Nonvoting Convertible Preferred Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "documentation": "Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of warrant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock expressed as a percentage of its fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "verboseLabel": "RSAs price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balances (in Shares)",
        "periodEndLabel": "Balances (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)",
        "documentation": "Number of shares conversion of non-voting convertible preferred stock to common stock.",
        "label": "Shock Issued During Period Shares Conversion Of Nonvoting Convertible Preferred Stock To Common Stockin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r154"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r134",
      "r135",
      "r157",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r261",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r336",
      "r339",
      "r347",
      "r489",
      "r628",
      "r629",
      "r630",
      "r631",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r662",
      "r683",
      "r705",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r818",
      "r843",
      "r853"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r125",
      "r145",
      "r146",
      "r147",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r262",
      "r263",
      "r276",
      "r349",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r500",
      "r511",
      "r609",
      "r619",
      "r620",
      "r621",
      "r637",
      "r705"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r649",
      "r650",
      "r651",
      "r714",
      "r716",
      "r719",
      "r721",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r771",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r808",
      "r880",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r973",
      "r974"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r500",
      "r556",
      "r626",
      "r648",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r809"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "auth_ref": [
      "r179",
      "r359",
      "r819",
      "r820",
      "r851"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r229",
      "r500",
      "r556",
      "r626",
      "r648",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r809"
     ]
    },
    "orka_StockBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofRSAActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofRSAActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of RSA Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofStockOptionActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r628",
      "r705",
      "r723"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r374"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r637",
      "r705",
      "r723",
      "r815"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and Issued Stock Options [Member]",
        "verboseLabel": "Stock Option [Member]",
        "netLabel": "Stock options [Member]",
        "label": "Stock Options [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "orka_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r85",
      "r664",
      "r680",
      "r706",
      "r707",
      "r793",
      "r816",
      "r845",
      "r868",
      "r926",
      "r977"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r156",
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r346",
      "r349",
      "r462",
      "r708",
      "r710",
      "r727"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "orka_SubscriptionReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubscriptionReceivablePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Receivable",
        "documentation": "Subscription receivable.",
        "label": "Subscription Receivable Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubscriptionReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubscriptionReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Subscription Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r522"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "orka_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash operating and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, value",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r403",
      "r600"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in Dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)",
        "documentation": "Number of shares classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)",
        "documentation": "Number of shares classified as temporary equity issued conversion of convertible securities.",
        "label": "Temporory Equity Issued During Period Shares Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization",
        "documentation": "Value of stock classified as temporary equity conversion of convertible securities during the period.",
        "label": "Temporory Equity Issued During Period Value Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r327",
      "r345",
      "r461",
      "r488",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r610",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r794",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r864",
      "r865",
      "r866",
      "r867",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TwoThousandTwentyFourEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Twenty Four Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TwoThousandTwentyFourStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TwoThousandTwentyFourStockIncentivePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stock Incentive Plan [Member]",
        "verboseLabel": "Two Thousand Twenty Four Stock Incentive Plan [Member]",
        "label": "Two Thousand Twenty Four Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Agency Securities [Member]",
        "verboseLabel": "U.S. government agency securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r772",
      "r942"
     ]
    },
    "orka_USGovernmentAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "USGovernmentAgencySecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities [Member]",
        "label": "USGovernment Agency Securities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury Securities [Member]",
        "verboseLabel": "Treasury Securities [Member]",
        "netLabel": "U.S. treasury securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r772",
      "r774",
      "r780",
      "r942"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r423",
      "r778"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes related to tax positions taken in the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r778"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r116",
      "r117",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "orka_WarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "WarrantsToPurchaseCommonStock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant purchase",
        "documentation": "The shares issued of warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "documentation": "Weighted average exercise price per share exercised.",
        "label": "Weighted Aver Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Per Share Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)",
        "verboseLabel": "Weighted average shares outstanding \u2013 Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesContingentlyIssuable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of as-converted",
        "label": "Weighted Average Number of Shares, Contingently Issuable",
        "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)",
        "verboseLabel": "Weighted average shares outstanding \u2013 Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r188"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001213900-25-021251-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-021251-xbrl.zip
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MY-91&&FW,U!?$H4^HJ$REUR\;AGJL!D2DZX#'\GB<] C!V.A7.;NLAZZK/\
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M./8MD9^=9X/M%IWS1F=HXXHB31JJ7KJM<%*?>#519:ZKQS1V-(*CP0OP!GZ
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MV;X+YL WIIT/RP$; ]^6@&&=%R%[%-Y3Y; !T6@D.&Z:+#*2%% +HD=(-,I
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M/JOK"0Y ,-*4LY$8FJM (U$@D6==^@^/'(\-%XAN;2S <NFGSKLHHT]CAZ6
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M]]IBLCN\&^WUE:I>E-P.'D[@>L-DA1P2%2HU0D2#XH;!'8.X]WNN2=I+S6B
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MMFK3 KC[7I:7FP@?J**#<^\8HLT#6_'!J4I,$0HDPB5<:9]PL"QQ.>(3P!O
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M8_.FX4#8'^.&#5AQJZ;[B.%0-J?,!>?/D-K7&<@1/_,T$CBTDX,C*/F*>4$
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M$M9*DJSN#?QZ0'J3 M5XO-$!VW,7P>R(4J)NB=:P-]( B*<BJ"I\Z*\0IE=
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M3D%7*,AIO!_F]S@[R]J.ANQ"J;MV(8M"6*F.NT:S1+\DCK11E/L,R5H_#-_
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MM4O0*V?!/WW%KAY]T#5[]G;O!N5Z? _EFD.Y?G\/Y?K7+NYW8&'[1O!9J^]
MN!\O]QUU 9#9^4O77@^L5O<29G*1PNT_Y9C]E!C;7E#:")P ;8YMJ7U3.3IS
M.#6>>G=3GX>6?BXZ<9-ZX&$XW=!V%]&7T.:[!,GQ=#@3F,)!YHWR2#VN.ES>
M=<!"@LBX@?%!-P^#8F=2C^<,FL@SX 40/$$CW, XUF!]E;.W)(>#BS4IAY7E
MKJ@T,F6XCNXB?1;\U1-XPOW1U]9VN[+N!$'I?.)BU9=[>7S#\<<(0JG_9_E
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M<HMU)3SIX5C6W0W4)%GA0JH_@?/S\7[/WXI'G=X4IR(# TROR(V32!)ENUY
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M".KH_=>\9B^IK;#B/$\YS[?H?DL*=S"<DS4>O?(+R5[FV/6$\:<*$84SRB/
MDXIJC&*Z[^[1/"?02W5:'7*;(LV_[(BDJ.6^S&UUP&'.QP7W8Z-5EU).S:"S
MM ASF63:BI1FXQD3,-%$-$5WV,/P0P(<G5D@DR9.PT71GM4ZKQDC2][ET9B$
M:@EX.5VR#\/3QJGHL"AX.QZGXCK8%)Q2G%[#J(!&YK%HJIMZO0E9R9Y"7.8(
MLXY'JD(&93C"-\ &$Q_@YY$L.H6BTA&2[@6(:MEM]Q*A<_@;+TK,4JFE7%.E
MDF/%)D;I=E<)L1A_5X/4/:^4F\/ Q)ZTB0;[-%]MJURY:Z$GMQ!"P\1BJ'0
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M\ 66]G-L SVP[\T%'N2M4R\]<!P.V]/,:F5L5&UGZ3T>KEYS(6HO/>=Q'[=
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M#7OGI!<^:!5F .4)9<K'^+Z@!A ),>_@>T%"Z3.$ZD&:PP^ZI#]L*RSW$Q#
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MH/33],?/ZL^1.8_+I+[B)TA*$>@NKF!L5>9!J:*JRW*_*^+/Y??R(]+.[$3
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MQ\I.I3:&J$.8HEC>?2PMD#BQQ9Z$]72C?DY']J:S25U:ARFG1K*=H?"[&J;
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MY%N^%(K:V$[&>0L=.95WT-R"1V[!(Y\-'KE^E I7C2 9R-H'A+?;LO;?+-5
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M#.<GJ\O-3M,"W>(M"=]*#C.A]4'WDDW>!FW'J5V)-*Q&5V$Y4W9\LXH^[E=
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M,[I+SGIB!;0FKF\W Q'>0U9XBJ=N9.B E*@WBV>L4.D7L463JO/C0 -A-@G
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MI$LXT5&BOHEAIMC,CG1&6[E-GP0EP#[M:._G*^O4!Q'FC*,'#465<6AF#EK
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M=*BNEA5.@[! WB1@D$.6C4\'E@6I:Q/G"*+$.<DD4LL!J@QT+-:NYZ2CK++
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M_%5\7L;#T+QIA:N!YL^#Y1^=A=)@P;QH4!E!E'3 W>3]GO7<!L[^,'9V&V!
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M+X'7L@.[Q6OU\%KW;O%:W^CA[B)'*<?K:F4[9"Y0O4!US4PVJ91F"E)(Z5J
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MC=!*&%AAJHQN"*B;2J4(:$U:J-_4R;<HIAB%-4D1U)_D8<%,P"*"J.-P;1N
MACFCQ-GS\W7VDBI&5,P.'%V%BD8;P%/3>OH"9<!G60$>M)H+[>PZLJ''<2F?
MQTWI(\87M9!BV)#+8X]!RW4T02^5>1AUZ.Y)AF+A-HA,...:<R^=DJZ!4L5
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M;KP$KJ]>_.13-3#6>*[Q21>55S6(H.0(KX@38CQFOB>;!N).2U?%>82OV[I
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M$TMY:A=\STF8L;4;2MLPI0&]=C8=4ZK*KPK>.%(^@?W;XWD9$;LJZS5!0^@
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M3N&9B6L#?L*@O"&VF'58O2\0DT\.U38=OV5;]2CMHC9QV29YKPP)LEHE@\G
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M^M&;A7AD#*[P/4,S?4CL"0A2\ HD9=)"H8NP[)%D:&(.P?PJQ;_0 )[F#T/
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M_3.CL4EWU/2EE]>(*"3_X'I(93Q_4=Q;O/)PM9E2[WCRPQY:U00?B<KAX?N
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M>;QF1M>,4#1+S,T6[\?'7FNT/JAHCM>S;*O:,C7'@HQZ6(?C8Q/6M)217U0
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MSP^Z8^RP0G\BHW/@@61;*N>$&5IS:3S""L(2HEI(/X2@NI R_26SYVG5)-H
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M$SM^PKYTZP%\"/R">Y,?7A5FJQ)*R+."! $N%M).V ?\18$$%"+GJJ=_,KE
M9)@%(N/MBS:,PBP>)AE]>0&F?#SEWX%10[B-,L%.,M3,17M2PCN'C:HJ0>-C
MHI+:O<M-5B"M7SPF8HU*!J8W@U4)@L$I&(MGV[LH)75/,;#'+RXU2S$/1E&4
MV/54O[+ HE;S!UCC%.%O,@BOGYZ#F .]]%1JTNT(0'E4\!V,/Y0QIA:Q^:1J
M74<&FCP%=X*!"$JW%B ?. -[4B;P-L!_OE<DEDLU!WJW??O:954?> DH@1['
M (#ED_SUV<!NHE3,"8$D'C;*Q\A7:X4K5VF=F!])N8W+2^G5!'?1U'AA,"^@
MH$7GZ DJ/JF-JRW*P(IQH86,P@N0"^C#;F!XHATW;&/RJ_0I6Y!N@W/NW^RT
M,^6 #=6=5):8P1^GYI%(D\VI>WSZ@2_6%Z^?73UCPBVWY[T=?F$)^0J8* _[
M+K<\K;[%\/!ZY619=X7#-;*]A['5SE$U!S72_K7*$>P<-F2PRMM5LJS.7+47
MN.]J:UFC7[EO:AF[1"^^/3;1W!'S'8^LCFP3>=RH N!UH2EN@5%SFAN^(C6I
M;CD:1H\-HIK3YAAQM$W%'-7NB+:%0II"!PJG!ZO/OP#C99"X[X)PMV_0?;_@
MO(4[P]#.T#*]4C@5"^]I'E-!A!KR3O<Q[D%FH];5>.0%C-H:@V/,;@&;%Z?E
M'#7B<YR"#YZ9[B+'"@)3>XS%]@3! 3F?8.VT[HBN %CD8)WG5!:B3-;VC6GE
MK7?<IVV1AP7VJ.+PL4&"@_0$2IFBCV 2"$N$:_([9+G/L;L<@]--.UQC"=AZ
M10*$3M#MP=QYFFMSZK6Y2<$F'O[BF.4*T_?+:O[Y:'@W]OC03.R.7I#^8J9"
M?2=?8H7P>KD7I&R*+)->@J@^) 5E>OM(^HRZ3V" 0(QDKT65+=!(]6ZRB!<?
MZ.I)B#1ZY.4]LST-':':.'V_B;GMHT='CX]-C=;S9V=O39,RR4F.8@IO(5:S
MD+Z+DA=_HM%$!I=J(PVW@R)W]3#A"YC)*TX!:GTVKA2^57MJ>5A>MI>]-EM]
M'3QP[DYZ5)2Z>T?K7I#S!<N[_(]>>12EFB0E>U"=#F$.Y!)AP"Z>N!U9=C>4
M+Y*60<F<6=CP.J%^J+6][-UUT&2=9U=PU)?:A%$>D#L/$06W8YM*"Y-P0VNB
M,<(GQEX]<SNO5TR\+LQ1_K2E+]>F=FMWFY *+;B,P@.DJJ7IC*/VNXSATZ.>
M%YKNYI90BZFR"Z[)HH9A8[5B364?_C9PY*T=-J-GB[,F5ZO)4O.CV4ZA]&:2
M3\D;UN$3O[Q>^U[/]E&W]2ZAU=TI;7<DG>OEJ /VE=UNVXW:6*HBJK2JA6L;
M_%0N3I>NS#;1G9:!61XGY/SMWXF?)3UZ]) >[:1'G^P\I$?OJ7!W(+3>/6DJ
M;MW;,)#;4&\US^)@95&L#E 8^^$4=%PQAV</8'-M ?>I:6!JRT>X;;SI$"A.
MF7F2TW+9/.;$/L6V$T ?4/DD#<M(RZ+8#@>.FX@.\[1AU(WA<-&<$N)JN>>&
M+@56,%/8E:R%_N>PQ\@^+-?"X)=I%!SQ) =J2;:<5 D2[H?CJQB()6<?@XF5
MF>_YR4FE,]X._IQ)VPF**N4A_C7R7\'SH;O"G92)*]C=Y<Z#V&BTTN8=R"DV
M64KK$8HMJQ4)YIAV1C/A5X4#<F="]7R%T3*E:GOIUM(N)\</<>P];1L] 8RI
M <T'IIC!8558,%5H(]"EK4G@G!/=@E3\8:YJ(VI*#4^WMT$G&FEQ3 $9!4N\
M6GC6A(#+V6P=?!7[3])U'N!R@U><4!N(/PD+G!?] ^-6H&EMR7%\.:EFY-3&
M%P5VY*H:INLC."!WYDB\A8+7L3V)C5\"&:=[C*U=23,X'>AD6D5U"(ULP$?&
MJCZ+6SL],?#5E$A@\:B-EI9C5V%CI^^WWI^KX\!MD TBC7!Q5*3CVIW$QMA^
M7MN4QD,UH3KWU@R(X-+A6B+[.EVPL:M80C. P%FD\/I%>M]:H]_AH6/XHQ[-
M][_;CLS^>/$(3,J$PEX]PR;K]_WO3A$-_"/%[#V("8V,P[N.4NMX1RBVV^%O
MQ66BR//N,IJ>LG#J";AZ]'/5Y @B9RTC8%;QU%! 4V6$((DTCV&F :WFH2 *
M2"H23$PP%T(<<1(A8J.=:>2LVQ=I74L)*N R&:^M2;FZB:=OIXOTXYT<J)^@
MGK#GHG1<8KUM^SP$VPO3+66'>RLAW3/!)#:=U;S(G9Z:\,AF@5H#!&+_Z.#G
MO9UP#CM.JK ,#_ZA[^2BS7":%4/R.T"?-Y;?P7EFK60:$J)#&>58(34;CB2G
MYZ)VJ7&QT&MQBRG'DS>].+&R)J]D$EX_+;DAG+ H0L4UC\8\($HX5V"&D_IV
M.QE";OX)HY=0 !R1=%X%='1=3_62,C?^>;\D5@]I1;S-^F^%:VE4 ?>?PGNW
M=RNIB-8"?0*=%@:)8^D@)G V:]T1]>N5TF/>FBFR&U.[A*9P7$KS##<QC5?M
MM,%@/HJ1!E_A5TX;.1SN1^U ;SWY%7&I]=4"#%O'<A8M"J+4KS6Z>X(S@1_]
MN"X@Y"&U$"CN-GSW.O":N(L-")[HL]YQ<,F&]H+7Q79XN'_T:&]G]\!<=2?O
M;&#/&OJOA'1PP(!O8Z*_LI:^,R2''((D[Z+(&K:),#J?2A?.H:F=7VX'5[9$
M=J?(X!WMZ>O $EW$IZ:T6L0!;H-?S,E4-5CH$8.VL)BO*8,R632U0@=L'"XS
MU.TN2(A5#.. **="X*"UE76?4Y\Y@-2X9@N)ZF5PX\9E?(E%_XZ%I7<?&$:1
M8\@Y#>^Z%ZGSU%X=M^$RCY!M1<H1RS['R41:MP65_&1_8W=GD_YH#75V1?4;
M>SN'&P>;FWK/M</B6%**X>QPH[;%[L_.!O2A'@0)A^K'7N@[6!7ZYM%O6MI?
M>WOP5>YZG.S9F_@^3CG2^2-,<,Z%B:UH-SX'+G\U2N6"QJFB&.W_O/MX^[!K
M#(@%@"UA\:AMHZ.N.^=#7(S*LUYG@_E)6SMCAB<W2C LBWB,D,RT+,6MH/VC
M'Y(384JK]B)A7I8'G6._$%(I7%:#T0#DMA!6._G665S"-<\N+X6AI63,"7/(
M8 ,JZ:5OJG)[\>R=U6XJO5<\ B](<-V:N?$>3XST7AD 8,H&Y[F!]UP0\X$\
MF<<1A^-BU'#/5NDL630U?U_O=9OT$<8&F S]6!_52=<4ANB%*^7VI$4LT4'P
MY)%2EWQYTSBC*3G(I,@5W>%MO&>D,ZF=AY%I^)ZN$6J#'I>*?2GTJP+K.Z%/
M]0G.$U.KK1[J-;ZBCB[PG48[AY9C+7]TB5@1EJ9%H?D53G7ODXR?_;1,Q]-D
M5;JML!SENWQ:]GGK.T\@^!Y<BO\1X%"+H*OBJG9.?%T?; L,][)=M91K3UVG
M?=GOLG?#"$YAFQXZ6,U39#RI'E(4FJ)X_)"BZ*8H=A]2%%];N E(\4PQ_D^U
M9\$SBU-&@XJP5.N%Y.#[+I.HM\-'+XR&&)(G2JPL"]H)?[=DPL&R\3WK@/=<
MB)\Q4QP7S'#,*I^JK4HZ??\(;T]"AAG"GV 4ER5FS-%\P'>/$-9-@2(RP<%J
M=\("4I<Q3YBL .W1UCS,-%MO[3/OX=GZ\X !JF[IDVF%?<U[-#%US<N2>B9X
M<5CJ=(%FJ8G@"],;V 8!QDME*8QMXG <C6="/U6TS,!I43B-K35I8JZO9PE8
M>D)-!++Q6Y*!2?,A%:BA9&L<[&A@Q.(*5 _XZ1J8(;U*B^X: \I[L"_F'+\.
M?N;;=.WXP#.*GR$#Q-[.SNZCO9U'IR>1C0ZL^K9G*)M(TY@@G$1*G!#SR2QN
M,K7 3$]!*V,]\&K;\\#G4U[_T-)[XS@AL(;JS1SGB2/U')L/." ?.RZ TU6&
MN28D<E\)"041@*.1#>M(S2#'">8$(G6@.O!Q]3TYM$/IH0ZG. *?J$L[B*S'
M 6W4(:?#$,V.^-W:Z:37>EVJT!MSUEE^;=6&O-OT:&?#_+(PS?X"S-5AL.<G
M>H%A9#BAMC!X\ >*3#7R_?K$=_F0[@#E#Y?D%)5(Q9GJNDX4E 8_61FI5W*?
MH&>&6B]GE1G#=K7ECF9+53NP@9TB'[AU1L<)9@LIM-P:'3^-(+N(TRU0+)#6
M99'F@A5UT4,][VIOB)97@!\0<RC;VV+'\6Z7#YB1;X<#\ ,<"E'#LFO<KI3/
M>%V,BLQ66KK8,MM>PX2)5E<Z5$9.[,\PTE>Z<.7 FQCN)RYPSW;;$ZD <0FW
MQ-B3K2&$'W%B<25X0@UHD<;"P/D0P,;CDAG;MK\8'4*[B6X\ZESF,'FUIZBS
M8F"@35CKX-6[;L_!D=3^ [KD5Z^M4AWP66YRA@K:MIY.-TD;L<J3RP!N3.2T
M)\(@[!W0:O7'<D4J+9]FB5>+,#%R1@FMKE)51%Y,SE$9,V^.8QJIQ4,%SUFP
MT7=COW .Q[EPXY>A">>_.#>@DO!-GG0R/AY$GR.;M@2N+2>FPX18(3+;O-[D
MA2$$!X,M8K("8>;(,J\H6N$K2BV\QBR60"8IK<G_76#\B*13#[H6>B/Y"^C\
MH L3?C&1*A'SW!3S+DI(:[M=*"V@X(2M=G#8@%9NA/,>+NC 7GM5U2@22(6%
MTWO(?-6O46.FK.'9](">3=(_]K_6:;  SQ*BX6"4EJ-FCAIV1*QM:'M2D$PD
MHEC46V #*#,K79O.5*1$B'''/:.F[RL'H&/N2RLD.Z[M0.U-,N0QQ4KG!=OJ
MSM$"D>P,YI$G+$T<,$8=WZEQ\LQ*A_C6(P_PDFT";0YL[R1;(,>'L6KF<XD@
M]TQ42[TM% BC5,A@;"UIO/*JA,#H9&5M$55IQPI#E&_@6P9T6BC(!6N'AS1,
MYVCE2K<H!5AHLPN,($[1&,G@$E>ZXY:%OQ^U9LBV6KNJ+/"NQXLTEM=73I<I
M(DC&3[%7.<<$:3"LXACR09R9VJ[5>:O_MBV%.KA7..:7&?W\=-F>Q2&YR" $
MTX*#QPR)U]NZ:1O%*ST27N(\45"<GUDBN81A./AQNVW\$UP 2D(P3.JX!9.R
ME%U3I>22,ZK:#>G[? 0Y]S:OG%>Q4QV81VC'F_[:;[(--M)-DP#@];2L[0YO
M%L/]R$S"=2C$7M"/P:=+X4$@7(M,^)OC.KA,R!6@8(VAAAP7I9-NZLDIGX*Y
M SKN.6C.A8O5=( GWL)+%Q'=&P11+IB3 U\(XTHW ^,LY(7Y8IG4PK+ O U$
M[)RH.\$@.\YWH7 8W *Q05 S7L4%$C &B27II..OUS=KRT8K\>]W?$GC2>!B
M4$3!I* P,QFYX1_K=CB,M,]/SNCCYR_/3(ZK\NL/I?(%ZWX<<[;'KVDUDDB8
M]LX,Z 1Y_E).YOP6EUBU_Q\3-" J/1+)M^UFTF<>APE_]AL%R=XC&;^!N>"]
M\QP#.4:ZS]J!' DC!4X825K]7"0"/P(K:IJ:4KQ5D9]UE;5G=H<=9@J^;3LQ
M'-*DP>FK@0]FLO19I#1L$,QIKQD6U+D7K'@^Z]CS/2NF#6^54::"27:'HC3O
MX8"M&WP]9;:B@#0S4@M6#>$>QWC?*K(4J2NQT&R4$AP9"VS&%^G(1&,P0H>H
M9Q.>,WXX#N^5F?N9VP_,BJ&)K_WVZDS-=<7H8[8.'>JQD2/\]-R.9$ C"?\$
M:P)7'YE6E^BR3)*$FT!+%VP.A6)\IC,-ZPAQYPJ_14ZV#+09)2TVL3(QZVBY
MF+GAYFT=C$5^O**<;;U<")S48)1,,PBB;A=PCUZ@$;W)<.P*/TFP,9HE<\01
M+END)NH^"*4M$Y]L1@15- :)\*O25_7#JF[&J?)-"=\1#'":9GP?$Y$N.0EI
M]6$+WAES8ZW TA7)E.FNJKGB#GDK4R:KN_2SRT[_VU<FLC_P(OL#QWNQ47X;
MF/(Y)@+C&:RM6KE=:O3)0VJTFQK=>TB-?FWAMJG150=_O3*B+YPL&CNT?G_*
M.#,5K6,G]Z6<5:NXYS#<0>;\D+3SR'!?&\H*>A?G!;CKRZN!VW 3_\TF"<5;
MV:.TJ4Z*%'";MRBPL:2<X7<:[LOA(0,-%HFSAD1$Z+90NR8WH$=WION!N6W7
M5F6_*[0V#F=/S=@-S#'R>M(*ABLPE6.T/9K5(3(1=^G<T)[&ZM#&(&(H8T0Z
MW]JVF1\O\H%N83NI2@99\,HDS]\ZH/B-\Q<(Z-Q[M'N\>[2Y[=[2_+!Y#,9I
M@O0!99&+L>-&$^UCT9SXS2/:8=%^:R60@=:!N?Y_>VOO_W,3;ZG",XE'OIN9
MPGX)Z;GK5/C8@<KIQXF!B8IQH>'>[DXXCI?48,HX8K#U@>'IL5682[>*P WN
MH+ S.X!I2L[3ARFLK;B_ :NMF:(X[WOE=#AI)U+$2=9D'+@N2EH[340LGSVZ
MY)X'#.(AP90SD[4P6-6W9QX*!)23 C_?GK$L8"FP%S;<C;"EP8&2WG'7+Y.4
M)X4H[_,Y0CE)0KD-7ZA([K#U2-["1S@NW4:R/=T6X0]/P)H>QU%P?@GBS.<C
M0O:C"$^T%P&K-IW9(.Z\ZL,$F"CA"F9%;N>38%6<E@Z5*3'V(2J:+H(IPA8G
M<55O(4SW SR+ME ;D=A+A MD.6[%5XK1;VLKY0.]"BOW+M0P,\J<1LMQG\"/
M#.J9(SWT(PT+T=4@ZI'0RY@T2N$*6(ZR%IT5P7<['&>N5-JX$246$@6+PO1L
M%97@F>%<K1-['5EW)\X%Z9N45E6LEW%)T*D^B\I$T VHFC 03(DH"8Q7 U8%
M)FMG8MLGK;(6-U!BR^>U2-*Y8O4!SJ,I]<EZ,G,8C0*+L]:"1-$<#-1QKE6$
ML_EIHXW717D9+Z/PQ2C)N+OF.'R9)B/L.04V:YJ+HNQ?&Z)5GB\:.(/EDI!5
MIFJCJT[=<*P#PJ*DHB8(ADO! V+B1W2JVQY537>JEZR<WN(VAA0@)LD+(WEC
MB+%+DH#5J ]2C][76W#PSD;/P@VT<?17$=*HQLB+,\(UUV>AA) $(*T/3 UA
M=(&9)T. >MY'(1UN)BD,[H)I&3'5T<CT4.7@=A+7ACQ4*=+3BCH<A1N_O?CC
MT>#%L_,(U>,(D[UYTL";$K;1"+4#WZ88!-&OQ\.$N^(V=;&5SN>-I%(O4J3R
MT@=O<I>JGM$[+:I7S '#6,O$P2*I\1Z@1 K2A[F]T-C9.3#LXU?,G"]D'5[4
M-S(A8C0=<]S2O=JV?HH"YU@248(&_U/3+HD(P7$<%F'&6"C2 Z\&GF7>?UB8
M;'!H8L"FC036A% 99B"5FS'!H3B,''HN(U%C2O5CFBT=][&#$[G1H-;6M'"@
M57WS9FL:H^,A[$ L]G00FR!^Q#@/ EX0WR/W4:(LDRIS-51\3<Z^J.3T\05I
MI9PJ_M.TJ5X/W2HW.4 !H8[7?*((>Q@I#H%O#._-\V),TFWDU=HM'"FVUCA&
M,*Y;(C*VT%TC&@QS"!5R(T$7#ES8Z\J4J,G<J;+>)+@BXQ,JB?(H21>R;GS!
MP>,\=HJT"G 08H@)1]TH*T8?D#]\0>7D2>Y><Y<E9DK(<RS*EC=I<* V;=!"
M'C&4T?9S,]D$N%@^.'AIF![> IP^HIVTM*XV.\'N<,P-CP7Y:2@MVI<^#$Y[
M</(9)@A]DJ':QE"%V>WM8.!\[NS('/M>X?2$6]4=+76-_3A*%DH.S'J35Z^K
M/FDTBCOD->.\6_P7E;^Y"DM56>3P%"IQ+YGLA.V GY/7P^:.:;QGE2S()"P[
M>?KT,#-R-/2=S@W$ALM2"0/;/=P)2*+226LGC>E6-<C;0)U(_@*GVIR2:U;9
MGF'"/)A@A8&_A@I_+;4Z,6CO*846860I>XJ5N;$E!64(F D;(03Z'O)(ZB0,
MTI;D)F?,AX6@LKFIE;!:KVMZ7%A$'DZ9I(/U@"9%CQ[SL>1HIW,NS2;( -;V
MRKA=5NCX(2O4S0KM/V2%OK9P<U;(RPY\'QZ\#8>3V3\AU)]3SN7@-D?@:RH#
M7;^M+@@<])_!@JXE4.FNXT^$FR.$NY2R.-Y-<[5I)3?54O$)0;S2-0FO=TTB
M_ ,_,6W%4&_@<PA;S,\$WPNNG$^\*NLD<'_/4]$8,5FZZ1PNHCA/J'3!&Z"6
M"]7HKR- QJ"1 T+]_HR3(P3?JK6FX&D'Q-Q3?4AB07\U-JJ)*#NQ/P%GM5X3
MF! P@K@-D26EDUKK(":7_9*%6A,I!",/I6*>ODJ&KZ7T%= 75N:8 <)%O3%O
MD.8AD-_Z,<O-M;V6WQ'B:D5LCCI65P[]2UT$$^P$RS2/(UZY3@ULG[GK,%%Q
M-5>KJP,&?E%^.T59KG2SK8<N6M!] QIE& HAXPK3"DXIKFF+P#V.6R^1&(E8
M@E[\+;Z(TRQ6CV%%DIL:(J!&5 !1FO?IQ/ JG:CEI>WE689N*+0U\$@09\0<
M-DH"]XQ&TN4!?0/%XYKV[.U*#I>NU3J]#.A?-;+4UB>9H^O%3"/%CLKQ=$>'
M 3$FI*G(C,%DFLN*JI5P(%[B&:=$L5E2[Z?$\,,[E)4X7=^Y",@[,$X9RR"C
M!BT+QJHESSM2HGRXEHE1Z,-DBC2.15$SZ:@I)D,D&E&(N1>"4(NFU:*AYH:X
M2QV.GEB_@!YSD37L@R98A9=6<^G5N&32>09!#D4:RK;70BW;A;\$RU\4[M:)
M=VLQRS>O[\A0>HM,NJ\,"C \R^)UP^T,J&SBDO-Y!-&PW*)]TS<@A;=.]'U,
M+1^'IADM_LZ")[6LQ1"0*D<,^^U<@D\9:2;HEVH'?)K+S*]E2ABG 5]W#@HP
MT+?1V2U&7*MLJ@]$P6Z',-9*CQKVY^76H!20DS($+4GHR5%2/$,TE68+,,2'
MJ^8$KZ3EJZ/SL0#6/!B&T*U.93-55D4"*_BJ+L2E1\U$8GQM4I"(J#@Q:-]"
MKNKB8\6/3#@*$^EW3(4C\G(JQ8-WMZ8EU5_F5N2L.J@-)>7SK6,N\57:L2&,
M:Y+66R00V&$*+W^<6$5-@_25<*BDRVM>]Z!RBU+@N+SK&DO+8+'0)M4!8K,(
MJ1NWX*[ O6[:S19,.LQK)5)Q_9VT@92-QY LUV$I[=*>@7Z@ B0)HR@TW\[9
MTK6"S4U/ " #$+%QV<CH;;IS8%FEP \#:U)$O"8Z%43[#[6HSYBV8+TTZJM!
M9:C*- D!)IH)RD\P-$D$#: @,)Z'1Z5*G,^%]MESQ:BXU#5WZ*XFTN6.,8-G
MRT\$J)[<DA,)WZ6SA15O(_,@3BHPA-_)9^<8$1=Q%*())T1^>A)*[N$J9476
MPUB8R"7*B\5TH&WSL=?(IJL (L.@JLJ=#@F>?2>O@,O'%9F"^FB!]G J\A>C
MB G$IX8.NB((Z(_A;SGJ^#F(Q:QRN X"^PY9!V;D^)I'\P;1T..=AVAH-QIZ
M\! -[5&97QICEB_;,3$ML"*GF. Y3AJ0J#0#M!6=]JN$+BY,Y9@ PS>$*YQQ
M&#TN\R:E(#TPN4)]9$1L@;K$&>J<@WX-7'9\?PXC!GMP6HX4Z;=_=Z]BQ%8N
MR]]-"Z\>(B*I!;7L.+1E&G&A!IZ\ QPQ?(Y($J2OI%2<<G!@9#0F^A/+M8Z;
M@OM;Y,BXHNCGU@/0=CNQWR /M])F&C9< S)& XR8%--!SJ*=!_^+%[MF;KM7
M[HI8LA%+4YC,-RO\X75!;.)Y\*)D>!?6XN&"M)<@XGA#S'U9"PJ5M-"X;'#0
M0B5YJZ4#KTZMG&'O?Z>96 2^OB[0!<-AKJW$2K,2CCG-J+N [7(2F<8UL33S
M04D-3)M95TH]L5>-I!^K1G&(DJC1R\0])23/?# 2\\,LF=0J,SZQ&P*X=[1*
M7]Z&N2124$*HL..Q53\MD;4_?&<I*MCB-HZ[GBTE+,#3,Z+8.)*>1 XUA1U]
ML.JID=7&HK]MQ0ZZ^[SDOJHMD[F@T]HAI,BB)#V3BX9,*Q>434X_-?H@0]MM
MK$UT:"3$D^ 5#EVW.:NF]^V?"/*(!@JQ?">PR)YRY?5RR+0T[7T?#-'%O2*B
ME.)$@1-%%9@6]C$IDRT.=R,F3&3(H3,<+E>UG0=5;B@9A!S?:<AXD2!"G5^.
MKA,X:@G5[ 2U;)$=;"^PU99$8':L#7%U?FTI,O#Q\ $^IK+ 6)?A0 HD<EH,
MI7##J%ZZT ES,D[Z<&G3ET2"QTQ-2L$9RM"0RT#D+(3P&Z?Q-,<@##4>X\B>
M@<F2JR:(V 1Y*19Q6@;TJ<0)Y?$\[.WPK"FK)LY-GLAK:7NRB;W(=_>/#Q[M
M[>P\%N225[+?.A2X9Z9(?_#.J$L?=1A0D^[\KR9G^G'+>H* G'Y$'NVR UTB
M[IW!.[>WFX]#Y-0*2J=/7F$?5"5.^Q:;BK&><9LA@5MR.PVA3@EHQ.Q4E*+H
M(PQT>15<<B]G7@$#@RE\O(K2AHY1NQ[?[V@'_C^,,"%:1)GF((/#A%A9PE<Z
MT]5F@ZTZ_"CH8:.A("@W/_>:QDVEQ(=!G7'JT&/)#E""< 1?07:S=<AN7-];
M4K?=)B'?(J02/YH5V9C(\@.38(M9(#FPTHGHVW4UJ0#LQDC=8T@(B:;":0BM
M2T[R5%?64**BGO@R1-1<FT4F8%[&H9*A@00P]3QW2:RQGXLED6PK/N&*$[A\
MI% &K MK\<1515..J&C9XZ1 =.7H W4+CH(*5@P\]$@8R\#0Y]1&@HQ>+'5L
M_0@-Y<S6AZ8"B&=G6-.,#NP3:ZF^?0GDCN\.X/7$9;)[=*(!>&Q#)*=QO:R2
M\W2>8L-P-KDMP%55C]NB2^HQ6@TC1LX:H4<G(JLNJD,HW8(6NRN-U#'^@]K/
MZ:=DYD80F/P0S4R62S(36\EH>*D.EE[J*OA]J%H_Q>8A,RX2&RB@;CZ4Q=).
M<@%WDN/23CQ"DR:;P'6F^34G$_6(,E$2_&Y1J^#94NBP\*6E]&&6?DBHNENN
M2PNC4O<)55O ORV\RFG-=JY8F$C 4TT^3VJ>><PL=I5YMIF,!L%,98L$ZYE%
M[<*;9P<P8'J]*^^@IBF90:TW#-;="0O&*)KZ,DFGL\HF?--\QGWO4FMF!&P>
M6EN$Q(%P"M0'3^]]R4/$;5$TCK<(8Z23ECN([AM>H?YL'D?L NT/I;4*?6+O
M)3TPN4!>)]U?AG^7\RW<+Q';8A%[DFG5U JTQ+81$.9S$6'CCYX'SDOH#EI;
M/BD3F2%5YZ:IV&F^=-+IFI0VP#D1@DK3W0GW.^,=PPN5DL1K8,8PG)9$"I:*
MB5;"4RQ#J; B9WEGCNR7#I/;MF'^%6 9;D%BV&DP5>M@G=EHK+*EP#(],J0-
MB;-2]K8@N6)HJE+=2;"0 4I5#0Z*0CT2VQ#6*A"V_#@J2JE 1%VI= ;DUR%X
M=K8<EBDQA@Q3T)U\':JJV6!F ='0O< Y[K24E4D\7EJ  MJDFXI*FZ7#5 Q'
M:4VJNCN0"B?3<ML[FN8H:3)2JENQ2?7'U/S3)Q?3)IAX0Z'%1\@&?JW%H7FM
MJ00(0L:K5R08.8PVC 71"*-[87E:>SM\(:#CBQ[53>R.%MD5LT">(+\:#OU4
MR/,#2XU_6EEN?(=I082$ZF,F7*^24%D31_JU8Y0K6KA(NSOV"Q98Z7SKVU=&
MGZ-PY7CW(57;3=4>/J1J[ZEP#[S2SKS(M\"S(+<%R^]R/W)?3(+>HR^&-U]?
MH/$=YMB.+I%'49(#K""PRUK:!_^PN\/O[7\;/V(S:AECK' KPC![V5PU![4S
M2,X@:*="<FQ )B8::KL6#IFPTD?)Z96AYCHA(D4WFS+@6F.1=Z ;OTZAP(K=
M'"937'DE<.6D;N#<=.8ZYBVW]#NG[P5#Y8H!>H9B9-A(DH-8%XO)=@$@&EGY
M@2U6X,;KV3)8:1PPJ[E#V]]^ZP@)GNHPBYM\- ,O#WP>:EK#TII12]8- GK6
M1<U=(\Q%:5-O-.G G;3QYOC&MT'*S8C!6#;UWO^2W?Z7A#=[29!.PO[#H^%
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M8C=S&D).RI@,76H'7U=N((V:>FZ'?\ZP6L:;J-/A7CJ,!ZEAPL3AFQR$Z2;
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MYK@(PJOQ$:^TD5]KN"@I?9=7W_T?#I"//D;=HWT8;2!X46+'@!Z)"EI7OY^
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M8&LWHVOQ_]E[T^;&C6MA^#M^!<K7KI*>@FCN2W+C*HUFL>Q9]$J3./ET"R)
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M"0I?MR[H6\7]"KZ%54B#L6Q2-0-NB?OFJKQS/$6J^#WQPYB/:!JDGH^GCZM
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M3VK_&M_YFSZ.WLCI#1]X'-\'H/3;3J>]4WKQFSN.K^U/[LD?OGNW\9JS+;0
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MV'S]*O!15NML27\ %>S"^+"\F4'YE+!H9=JPC7YJBD]9>AC8GAX-_,2]*^?
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M_/3XV)L5$/+^TV5^X^VMEI#N.;T^W&1S7PK8M[J-X1HE21]\%]NH#%Z+Z/_
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M[.\#^/N; 7[.BM\)2.\#M_\^8&>P.<+9&K7J@$>%%G&R]V[(Y@'&M@1CP\W
MV %VO@/8&6V./HW:"G:D590UU'@,6NA7]#0[N6.?K+)<0J%@\B6/M.]K)*TU
MJ(S[^?T56B;.X-78"V"!&*HE:S.(455,T_GE::,P'0Y]>GEV:D^S>49F7'*;
M>EPKF+>D?Z!&XCYH9/?Q)Q/V=-BGLR0([0Z5!=\+M?K[ &0NP?!LD/PI$04>
M4&Z'KP : ,!J&BC8[ESK&&>?A7$J [60I(4ND#X@>&3@ST$&F\9=^;,YMWAL
M,<!(GQ875V<3)KZH%1=G,QZ2TCB;2ZLFA>9)0VGBAS*4T+4!":(;7[1 0P<]
M(8>H IY*\Y>VKCQB@FRLB!D',-X:&#]O)@*",9>U.,#Q 8ZW"<?/&X58LA@Y
M[4ZM+4BW_7/E#_L]QS@)D0/!AH$3L4.\D@=^?V6!PY'9)^U^>^=FIX[3'-:E
M#FW7ZG1 H&TAT/,&7RD$XKHF!ZWNI0+/.EG4HH#'\P,/5^HX ,]+!9[U*,_S
M.GNN?&X-!+R[A7&8/?RCCW\,\(\A_@'2 O[9$6F? +Z<4; /[&;K7NG6P2MM
M\$KW#E[I!P M_9$W2>YNITFR;(=,38[/OWS&-LE7V/O8EFV/OUZ>?KXZ/:.'
MK[[?\1<*5*,D1,[9GF)?>I'+*I53BNZT..&%0HIOQ*\IX"G&EH6<7,4I&4)-
MSE.&SK11':DX4R\R^QXCO])Q$HBHKSF,GF*#>V+#L5""[BF5^"+Q3UCMM[@;
MV3VV0L/L+>R(1@&W"SL-$.5^<R-N?4B:?H>BXH2RC]%+G%<81'=Q>$=&AK'O
M>VS0Q:1,CA7[L=5N.LUF$V>((]5Y3L4N UL#C+%B;L986!]W2U,V6&[EZ*;4
M2!HDBX7O)B<^<!'9/H^L%O-[:OLV"WW4A"9PM/ 1OBIS"<4.:F:S5-$EQU"6
MR;%E;E)<;2A,C3\+ 0V8HU;(Q0D2.YA.?0]CP&4^SJT+]VY(D[.F\%*"L6\R
M3.TU=)XDZD$F^*\ZC&Z*0M!T_QNH#06_;'JFPK;^D.8H!<3OXV0*F'>!-CK/
M%^GU-<F!FUSNEJ_=.!V!P2SQ[X(X2[$]IY[JET6:00.3#MUD?&O=<"8&F?D"
M[B>/"61K':>Z W?L>OXT&*MA@7* Y.0"UB^D8?3O44 %%^9D SW#"GVN%S<H
M%!-$=$MD!QA7:<M5LA44#324E8BZ4@$8)IBF2>&M\)I'4;*.J#*!2284SRM*
M'"")$P96Y!/SPD 6<I#$YV2/K]3:$N>.8B!AR#+\/,LO]8N\1]).I)!P 9BN
M\]8?$]%B:.@(,R\,3/1WU8B6&)&_7C5LAQ;ZX]&HA3SBN&&?1Z47F?&PTPZN
MC3@46WV9N?2(N<AMT,DCCPEBS_HM"Q=JD+;*PJR.7[L96@^Y^=3+70XQ7POB
ME"7^U5#N,KLL4/'70\0ODN .6?0%*% "42CE5T:N;W@-Q:UN:(K*57)&,\]\
MFE=7L:Y4H-&9*'Z#MI'/H.CSN^^9BD4WFUKN/O"J+YCQDF"&"D[;EZXO/KE2
MCKIV3!8>DWV1P9<NT);3HJ-J6?4L9\WR6:*7\?5"K 5-<S[GQZ181$4O,F/)
MRB!'P3%O!"L4J"0B3#\B69U(:F[ZJX$4^[1:]FF.]%GN%NCFF$;]L=EH]9 J
M\Z"6C/ 0:U!%E1"NT(!D'VE9/%6@$^F"=(2P@0#3BS!54.5M",T$9V[W&DT;
MY.R05+$YO\_BM)6(3;?:/]'BW"C*INPUR@_E)HG3%-M'LW)#8PYYX6)84P$@
M<EP&UYDHAZ.-5UZE55VE*(W@CL=)QE#%62IYJG[Y3.RC+)JY@5?]AIADHZ<&
MITHJ>5/RO*Z4E=]6O]_HM^VC'WN-7@_7&R<RD2:8SMRQTMTN??S6%W=_-0N#
M^7%^R\<B496=N1.#KE5LZ8W;KNBFIBQB]@M'_IA=S;)"@S:Z=&<KRF0?N=C'
M?D)-[$EEQA0OJ8F%B^(NA?J(AR)VRN.6+[I0>JR^[%BP+'6L CJ-0DT>!W5F
MJ1QKJBF5')G*U"Q6,@O#O1*)P\"FEMWS*^= FB3:D1RH!AM4Z9 B".<<R*FB
M8X&-X3=7V34:E<B=H_$N#I9+LRE:*%;B7@/97YH!ZEI+AV6Y.D=9$4&8I(JA
M>'9GY P''6?0["]C3Y4 Z9'3[W>==G.X'H%!6E4E^^X,?OHSF#+!^+$]T&GV
M$1N5 ND^*U+T>)*/I.F[@,T^: N>154(B$:@7RT:JVH,%3I/O*%"XR-.Z436
M*:-Q!$OED)JN,X#]-SOMU:=FT:DMHXZ&D"&VM3/<473D$@Z!"BK<N'PC4+?,
M&ER0:%42+#)-:EF@2ZQOM6;#L:C&(&QR,O>2/7QL/B6+(FQ!X$ZY H.U%I!5
MWC"!5@[*P(#ITN26A-UA+(Y5'$\5L:P<L5XKI7N@%ZU]\*(9O&C]@Q?MJ>#]
M3$$ 2_S^IOB !P4!\,E7XP!6@;!HSZQW;,9^E3@XZ";1O-Q*P=#?69Q)?ODX
M>J'<H5H4;!B=^W_[H?/#$Q9H]O==28[VO]?)S[]H!)-_)E+,_V1M@_]-#.GE
M;/)"L1)>_A^2GRS?]HO9'YF6Q4X$AY3[ J5T&ZUU!";VNS^9NI37=J97^E;Y
MK"5F_V0^S/);IDG-S4_$)Z/2)[(EO-,"&7DPJO3R??Q,V]["R&D/6DZ[V]J/
M+?SXL-4/1LZH.7#:PTJG\#*J$0-=.G6Y;=KSMRBJA>LUJIIMN*-/SVFV6DYK
ML$;']:UT&.J,VLZHO^$>V15@,[4Z @@;]9WF0]>R[=9D]323:X!N^+ZZ6$7"
MZ7;WI4/55KJGK04_78 ?@*'! SLCFIMF'2)QGR>,>S-1W \R0Z%)HF+$>%[3
ME+1.)O[4#<B;(<N.%GU&Y,M RZ:;WFXO,ECX?R4D;M#%+.LKOT[O>9XBB"9J
MN^),MU][8-.72$^35'F2C#9\\[JMW7*UT *3LUAWAUY=G!8]H+*B?>IS06ZR
M2$JK8M%4CS9)OHN9N@M];'%3EKJIO'"BM.%+*S LPQ'E_ S3YF9.S.(K.YE[
M3K_B8]9=@0XY:H5#4OD3V?7::6!G!TK8J_BNG6Y'+]A4YZ5VA)O:.#PNBZ90
M.7F6R8X+IZ!(5GD=_>&RS=7ZR-OM!O!E6E!U1L=BL[XJP"]J+ZK55P=D\W$9
M]>121(,'[IWBHX>^V6QIXZE\'AX/72)8E=!P&,)AKA]"=3%EYPD<LO))ESP"
M1H!ZHG- P[QG] OD5VL)P*H/C(#1G\<?4+K0S3D!=MZ_]& WW:+=] 4;1R72
M*4LH8]Z+W O*W^\-AMZ7LX.],>7VV@\TY1;-$CNV@K:=5I-"F_?#"OJ8+0P[
M+WCQ->::%V&#[@^<WA.!Y[LQ,[=Z3=-![:J-_=ZLI-/<PKFL8ZYL=9U1=^0,
M'KJ6_3%WEUV$FX*=@1'E=P0_\-J>K&1O#.\MQ*A'W-%&#>^[L ]^R1+[$@M^
MH=D36SH0G@#!=V]$^#O\F^(77K>9\ _NH\D9UY0YDEL8M*QQ_72L_'0:AA.S
MO9BZY58:-!MSE74#B%WL4?CO.(CF9(N@KF3B"]V.U;#RT/7R=.FR^2BDO1"K
M7JJRZ<.YBB)=Z+2 +]_$;N(YI7ZV^J26<5)Q/GK8OCN;X<Y\3SY4<U_C'/B5
MBK+G:GBBRPDE=+ACK!K*^$P7AE:M.PY\%2/CE<GDT&K^N+8JQ[[.YAC'C_=5
MUZFEO$B]:8NX<<P$B+AGU(+38=F1(^$%$P7N_-M@S+VTJ;&R_Y\,WPXB>:MD
MDL8?$X][N0BC8A)/ @F!TLZ<7Y)VQ*\51<\+:5]LQE\:-V_A57XIA;:G=12N
M8?]=Y?1@>J^JBE09P5%?4]9I, FHX_*=&V;43XZ:[?AW?AC/\(=Y<!U[\(HH
M9X )83=P>>E<76.E NZMG[@S'^!U;,_A9'S.><Q;Y,1VEG*#G.KV1-P[%5](
M_9!G%*,X]OG'DW;'.OIR^?OI2;/9XM(_\,O6X/3G][;\??M8GH;>_L9P$/<^
M=X;E- >8."44XQ?G,=(7@'F5C U ?).XTY/KQ8E*(Q>_ ]$O#6#$:Y$X3'ES
M^9@P59R$'BA-OAT"_F+:,V(]=RDNXR91!<<&/!05_=31B=;:,H<*?AWB$<'Q
MXT)F/I)_;BB(EE[E<=7:^I4W0^V6^+8=3 /*)DB:$E]FCV-75:0DP7\%<5(
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MVMFF2I/N2R7G>]_0+/'BM!@(+X)3?>[#6[YW+(QL*H1<M3-3L>-R<6-\K;;
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M%OO$&_K &T;]]FX <C1P>H/=S-WM#9W.R$R.=\,;6N:#>*F\ 6L'V!=Q,I^
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MK'_-EM/<$2W=Y=RO$HI?!ATG&5Z@P?ZXPD8M9]39#47=X=2O$@TV#^MG[BS
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MD[TTWE%'8,R+_7!1,X2)VGF4P:FBE2B.0$1I8] V!6FK,#**'61"PB$:%;O
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M<@^Q)3Z'9IDN7>&2H(J,7R?S8%]<TOW\B(OX.@[Z</]0H72OP1X63*HO(9D
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M"M@_55=8YK2@35UFA8B&Q*UCC %L# I/,6J'@CE<O42%-#([MP0B#'9I*=>
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M7("@J49G[JJ0>I9[X$R_0AWJW7[3TCE9#"&B\L5<>* '#<DR)Y,]..H5U.[
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ML.!<"AL/=2JA(:* 70K_R5($_&HMEV?-OCPQ#0OJQ8%LL*I=ZR(<1?Q)W@@
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MM["U#Y>!!1/$8VY60_W(3X@FT;!M6;@B?N+.A/NQ[MLMT0=90<#2XG;Q2="
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M9'3-QDS*C=1T2N;]D%F BH#CI2%"&X0))"MP(*CM\=<]1A@%BQ*(W')'.&9
MEZCTT%D:>($;]#RTNO@OL'-G6\.H=^4Z%YMP?6@F7!=,N.Z8"==5XY:)&==M
M,^.Z&OO*S+B^N^?_^?/BZMZ^_FI?W_"]WE_RO]O=JR_V^?6?-[<7_[BXNKO\
M[PO[V_6=F8%=FPGT9@+VC$]68C[P#3^[D)M04?CT^T/TZYF> Z=?8 ,%_HO3
M+5 JM[D_VDE(O\LDTK4OK+S[TO[\JAU:*5Z*Q$J<F>"H^&C<&3F(R4"&8(N3
MD\(YI>L3 [?<9'>C'@W:[;-GYH<XT,3^/1Z/SCXTN8B#?R@!D:6=BDW>;2SD
M!9/W^L_&/R%,/IG#H'/A'O&7]%3$U+NI'O'9\:'3."HJ/)IR;MN,G*T'PVA]
MI/<'"QBXCT!Y;O_)"[PX 79_9H+X6K.);[<BODO1;K.0=L7!<M+M9HYU+O4"
M;MC1AB9;;%>VZIFA%8B=XL3A5#5D2'$J1)<@ME)@/\< 'G!RXC1;;TY\Z^]>
MA#H0-.(D'87!V]:]K.5ZTQJ7Q7+Y@/Q0\J:G)NVKW:U*HY@\/!_[@Y 8FZ[,
MV79OZ$JVQ=[9);@9+$[$,;UE_=\JW' 9//--@&%([""W54[FM??.#IV3$OJV
M2HIUP8M>G[6H2$9PE+ 1V\4V8@T$JS#A6H4FG-RMT*)78:",D!GFF],Y6J8(
M=V&QNBU?0Q>EF;FAQNXJ'&>GDPE)I'*2Z'#O;(VE=;MB]1OB*TM\DW0WS]7,
MD-\1)S^G?;IXG4?E;?\KEKQ]G?M*-\N2I2W]X])5NQ6Q]->CM+X'$>.? _@'
MN'J;7\=3T2CWVHN3#7J94UHJTJ/]1^C#8?WA>@%0YG60SI+O1E[,__2%_Q@\
M4@YEN38,0-4JT8:Q:,EYY8HASZ>VY=2M1&YS%%E C$L2U2E)Q:/%\>=;:R.L
MS2/N[B0@UD:X3YH(6FF!FR21]S FA9&$T#>G0#A$9:;#[S#V>I2U\_QQPOKO
M@&E;"_&L;#^2P!M?Z)STWO9"?BT&XD#8Q"VM]#/<[;+K;.Z=M0].BOK#=U;>
MK)/9%D2%?6_\V.Q4AB%;\UH8UKC4E3BR#2 9_+_<P:@25U:.Y\I"1;X[GCNL
M#,]UYO'<&I>Z$L]!XV&K=7!2 NYR=_2@L;O+BZ6_L+J1]?==OA"HKQ?81..8
MBQF =.$>WQ@E45!C"WV!<,\J[6>-58"HY$UTZ2*NQE"T>CT0DFII;*KV/+2R
M32QZ8K430FSFDH_WSII'SO')J=,NG,V^N?:ZMQ=>;\.Y=3;WM\3<63NZ*MP]
M#QMO(ZM>D;U/]\XZIVOP =;*US7FVEHZ#-OBVL,*<FUG7A!M(ZM>C6L[S;VS
MPZ9SVCG:*N-NI-]]B^V=:^H<*]$37*J';(8@Y,\NNA1KLE]C.MC=^HZ56FZ*
M^AT*WLK);Q"&";3E:^TLXC=[]L\G_Y/OPM&S8/_[W7K+\7K^N,]B*V($BP8@
M *^V^\0-1 0#F(,5OAIJ:IP 5(4L,;^E)=S "DI5G'1:7!&WG*-. 2 S7P<
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ME>% G ?B/ZS_91QYP>,-@T&&5)W#%XA_BDO7YISNG;6<5N/8.3Q<?U5!Q6G
M,$Z=&6>9B/HDW^#PP$FVF15D/VQLHF*@XM=N>*5RO#*GJ.9DF\PRO\[FL%DS
MKEFQM,8PS/;=A6ITJU3\C UA;I\PJ]& 4O$S-H2Y?<*L1K%A[6M*E@?5J6O5
M"7R$?[<+1J><K&>/U% ]K$9Q[( E\&%/?K$7Q@D@\MA_FVF[+E,/'D8_W$]R
MA=<#6E]7F_NG)OZA<7O%DNN!_/@Y+*N<[]?:.SLZ7;,9:P1?Y7RKV:Y59YD
M'A+H/7L:A9$;O5)1WWJ#>8=M[F(UG$8#_[].OI8Q']X[%RT8H"C'1\L$]SH0
M$#]MK[^*MN*48-AG^]9W-9HD*G[&AC"W3Y@;K4HVI4R&<C=&N:9LV1!F%0GS
MR)0M&\*L)&%6 U^VXF=L"'/[A&FJD@UA5I(P356R(<Q*$J:I?S&$64G"-/4O
MAC K29BF_F4M]2^[4-UR\;,W=(/'J=4MN,-<A0ND+.6'/]M!&.P_APG?S:RJ
M&'L\"@,[&3*[YX<Q?)B_$'Z,&/]*S']-LS.]_[B0=S0RI8(R9945SBG;7[6V
M))0Y\6EE)502%?,W7P^T\J@[UN,?3;QLN<ED77]1W<EA7>M.3(W_>^:N12H+
MYS(7UIJ4YZUR/3-'-2Q&,3Q519Z::06;.A1#F)4D3%.'8BBWLI2[R@IG6RE'
ME?(!9IK^QWMGS?:QTVR?U,E&,5SUWKGJC6W_Z2;_20U-?L-.E66GF>:5*98T
MA%E%PCPVQ9*&,"M)F*98TA!F)0G3%$L:PJPD89IB24.8.Q=+6!J@9*NAA-/=
M""48O)XESS(E(YH3E98D!6'"8MS@!R_H^6-8K^WV>A&G1MOCA!ZQ./D(_PHS
M\Z7FUBY%S%0O55XLSM37IH;<$&8E"=/4D!O"K"1AOL<:<D.8-2#,C99UF>H9
M0[D;HUPS%=409B4)TV3,#6'N7#1S@P.I]$CF]\!+2A<6'L&0'>>XA<.I:A[
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MD6 5E&"S=:MI(S6464W*--U\AC*K29FF2\E09C4I<Z-=2K4H[#&D6U/2-8T
MAC*K29FF$<!0YLZ%'Y>K[AG'^X^N._J$$<-I!3X7(D*$'[H1\:$;WPW*U^V<
M0MW.Z9&IV3%<M'GY;NJ*#67NGGQ?IN1ECGC'%--4Z5XJ@73:V#L[--.C#/-L
M7JR;HGQ#F=6D3%-I92ASYPR.9>I9MF!O-'? WC  0TN>Y2WK^6X<>P-^!(F
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M*9*LJ;<#:PNXZ0X47BZX< QM#;/X,X-PIH+Q6I&ATL5#T:BE *@6/R*T:A[
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M%%.L8SDPF&D?T,Q%=#&D.CAM+?R!?5L;K +IFEA6H$N[9M^#6T8+!TF/AK^
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MR_P@^/]$2*6_(K\4R:>5Q1/][P&_U;F":K^>DJJSM*1J&TEE)%5-)14=::M
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MV0)9D!8FZIKQ)#.3WMXI1Z^/]VJ*^',96$5-XS>7-Q>RDIHS9)H\:G[,$)=
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M]J&D0=J/M]??4_>,&J] F*9=N_PG',A$/UOT;(4/Z* Z Y.C1_#07A'(O2<
M^?&[0U2 &$[.#+.1@V .;*0D_ 0@%+[*Z2C"Q@:598'U 7949)/:EYC2] J\
M%1J^",.APX"O[5558*!&U \9%2_["0-3(1(-"@S?](Y4Q8J2H+V )*BI!SE/
M$J2<F&41&4VB;G1 WV'Q**2R',Y\"G\R,UTC*1YB.!A#"LE"E,OQDWB1LC15
MJD8-.(S8DTLFL:]8*FMC*^L_+GYC[A5I#L5[ I[W$BO"W7N#E-_Z,+Q8/IBD
M@DBV15[\8W\ .)@RU023)PGQR!4&.;H'W.2&W)*H-',3-=)#VP9, U6'3G*)
M7Q]]0F:5!CBL/K.%;,<J>,6Y9E4Q[E$>9OZ5&2&;?Z$E1%6<G06EQI30+M2U
M+[L2FBV2'X*B35@5I6Y9A:"$-I9\04L7U=5+N:B/M!(Z*5TIR&%]3"V"5"6,
M2V@)E27.&1P;.FH'3@."$<],&ST WPL\#&+V^9-ZU'R\B)> \*HY;B,UE;N<
M]RJ_2XOBFI:C3IUTH=-"L*]$-07@,WGR'/V(&90@W7Q-QM,7LQ(3*)#1P%@+
M15-Q1D$\=N@^HQT8***7>?1F2P[NPX7'$_,M%TAY6U-2W@O+%(E$IS31W)KT
M&#"=N7\.J>NL[,T*6BUE(M, ,8SXU>;=\RW!2$X,HX$YY_X$(A@G"NA.BYQ1
M#RETG#-UK>4\?%,0^B8%H1U3$%I4$-HV!:$[71!ZN%Q!:&?!42%W#./BMS*X
MO=*8D%(/RP3U3HXJ&=03&['43MYU?(_H<$%"61LW;\<:)),H9\Y1RD=-2DA-
MOY@.@[M#W XY'WIL8%_\9+TQ%OY=HXD!U7Z0<\%8'GDB^+EK]1#NL'A8R_>G
M^X-%EJI<N/[R9YJ5#;&G&7*,:9EBB),UW,?'B#T*NPI,,T@I^OP6P 3B[ETX
MCB##J0H2?>&]P5QRY8SG\C!6.EE-Y(C 7A..%%\7?^[CV'=AH$?$GCWV F]-
M &M8[2J#PY>Q_F!\NIDI7"R&B^LK+N@L<_/*YPCA$H_*B.#3:N959I0#OO?Q
MP\N3CLR[+$9NM71M,O2CIW/3>CL]79Y6Y=U.RP.K><B84HBY+QO)$.U#&(PQ
MIH>MB_M490%N-7\^WIECL:>1'[XR[D>S@ V\1'BEJAB"GLX]V6<6],,HE9]C
M/\')2"QXY$:SZ)/$PKOI*>NT2,_)U-\(]="WAF-^ADI+T,LA!4-H0VK*$@ 2
MO\J_(AJ7V\- X+YTG=4W97D?Y'H<&Z+'"0M(>^0<\0PXX/O1!9,FU6*<6TLN
MO J#B W&09_P>O/5,A!Z>PRQ4DLKRJ+6%GWD+(:D,86!7QE3VT<)\I^8/2[*
M9RQEIHB -T0#T102):I3@E84T5,U.+)R*IJLO9$,0MN#3_29S_<3421;+U[*
MUN1@SD/+0ZHQX&EV1N4AZ>&R_$>]P,F_ ;@2>XRP:"G0+T66,%GJ4B(FDSDN
M1,SWL9$%<3[A[,.'1&2&)BY.UAL'-,X-#T\(.W&G* G^(R*=D#C O"U(/4KA
M6'R9F2HH. !ULMX3/QX/VYO>D=Q8P)7W?7XO?_ CCUR?"Y5N'_)]$,4%^U_(
ME67+=)9[NFYIMIOK@%U?OZ4IMH2&0G93MMS5NS8WA?N_(G'54GWII.%F24,I
M$)&/R*8C%K0.[0+K4&8D\^\. 5(%C2X0L:+0!JPM'W)+4,DX$EB0TCCC/P_
MY\?&T@&;9A3:2QB%UNI&X7NV"4O+=FC%]"C#SGGO'/_VR *( 2\IS\L_,2/#
M6\>5E.':;I D,_LQTGLI\JFEQ-9CNAZ4F#S\"VO.0\%0CRP[$,31JE >27;V
M& .A)3QPW_6>8D<."?+(\P +%8>DN!%(PG%$)3H/4.5$6/C2 3FP]!( O8$(
M\^P]_2K(ZH??,ZA4QVYVOIX'%8 F9T:5)5*I/O\C6O7D=(@_IG7\HG3(PM=Y
M6,V) Z1%W0NY,'JG//T9/_G $BBRE(\BRUS6D(EOBLHD]:ULMT(Z9IK\+*O
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M\45L 2S"RBN1A42(TUE#R$B+#ZY?BO2EB :R8N5P)< GUZ;!$+'P=5@\3/#
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MP;=I*?!VBSWJT?5,W;9^F+ W K&E53X80>S-SQ:\!NC@(8H;D2SSU? 5'%1
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M,]+OC'O%<Q7V)\^ETYW)X](T[[_\"O<HT!D,\G,$KY17*DZUB!\$*:<2,RR
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MDJ#^3J"O<L8&'SU#K'S9/4%GN(T[1Y.UPR0$\9[]:7C+![;!:/J+N)4<.JY
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MOZZ_G88)ZSV]>E/)F):'JV];/"DL!=47SUU;P1]P<S]Z[J/0E-_==\JA9YO
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MOHA%XI9Q?73^<8?2 P#'%0< -C *4#K:%(4!<K7N908$7E@Z?/@9> 9LPG)
M7]P%YJ/_R75P01[H7@HL,"C\BM)C7EIZU!Q6N!RCZ@RW 2)9RW/3] (/+5Z
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MZ#GL=D$$E*_8[/6HWRZI?:4_GTUTVWI$SL!SQK0O?%RHX8!A>,1.]ZV V3'
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MK]YX[KUG/&)N3'RF\<]8GJR#RA#^ZA!)G>B9'?W9]>S5,QP/J"(F '#CH(B
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M3$@BLG)Q&=52Y(Y3"KC,A#N\BNJ)*'LD4Q[H-\JR]\0Y6(Q#-,8O[W>SGUX
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MD"+-4=1\D+WT&%;*$\U2E.A2:SV])IQ_]L-QG[L/[G.' O/P4X3Z6/!O&=&
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ME6'(;^@?,>V8MO&/J2SA'&[8$7PEL5W!NF,\CW:'.^:+6P(D.-AD0[;0X*.
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M6X-&IP4&DUO.9J<:..KU7 ]Z76_H.:Y2[60]Y=57V-C?/&*[U :>)YVNWY9
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MH_R_\;%3R_#&;&><:% RDT**QP*^8:Z%A&IX&<I6IFC^E_S@V?(,C1TOZ,N
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ML/+=LTEM9Z1/LD?\\O"<,=AFF0=_>0%:4L:4ET +E$>:JUP'8!4!+.G"H,N
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M,T![/Q4_%I."=&07#MB7&UG#^,6GK;Y^Y6G<K#W-."JES\+E<JYP'S06F;G
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M:P.$+P9AD5Y^K=FN1+5&='Z#QOYZ[3-AE4OXUF'-?&\*G#-:EIIOI9<^8F=
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M;H,&LX<ELY1\\9,#0F^ZF)W=4M;^(=89N;I2^B>6U+,YMSCO1<NMQFH_2<:
M=G5[&;R6KU]E$(J4"P"F,!P=GK3%54]BZAU5"A'^K&/82[EAG;K$[T/?19WX
MS^OZF\FN +6F2Z*XT,S5$ZRN9HV1.8?=(5A2/'Z+]\RPUC%-C1OA4=_Z1:9^
M]8[>\M)C[[R64=FDY>S YU&;J[0SL]5&?U)WRU;L!$C#_.#S>_G=A9;!TS)^
M?@F)E=H3R^/8-DNEA39U5ZY7M#DY#$!$M6- ?C?2,<ZM*/H17*YW?BV%8VXW
MB#F'A]%SW^)'G/O3I/[;?8$25=]URE3ZQ677R6^_1J_S@6U5LG94V&7W1U\^
MPWS,+$O1=$S4>O)EC$/-:E5!O,G=:2IXFGVRXWN<&L]8=;MJ:5DV2K7W ]YQ
M^/SN@1TE0;USM>%":]F2MH]QRQI9O\"@-D;VS$N5^A=A6AAMH14':R3.>E]F
M25P!&H@C_&%"G\\_AOYT&\W^ ?-K38(LZ+HNM[4\27?*@5,MDK&C06Q,5%L"
MK'KC!L@#T7Y]EWGP3VN@BC);UV;;I*#Z!<64^MEKJ.5!<LF,TW=J1PQR .6>
MV<V[&YP2E'K@^A;7;249(Y'0CFP/XOOPR,3(0<QQ<4H^I<OO9!14]8N)MBT?
MO&BNQ;[_17^F>Y5+%NK$E.Z!T,]9.\8(W7*:*2JF\$G,Z+-BF$!;<V.#XBQ$
MYJ'2@0R<B@#P.N3!U'@5[[A,FYL:T)L"ZWH-Q&!.5J9K'Q S[+;,C?B9\J"^
M#S.X4?_9;/+E7ENYBF_5?.[#!1<BO8YYSPW$)EQD0/*LEPF2^7P7FMBQRSY7
MY]:G/&\8W,L#F6C7+?F8'P8*R(P0Y>OA9]@-AN"K="2CL^RC(M\Y?;/<U>@_
MYW$!#?"TZ2U!OYV-X1F&>3A:)U?;VE]LSLDROY6PDMV85J2YHQH\K5.V,^;L
M!W.(,G_%*=B$@#Z8A>U+";$=3/H\&?>: EFQX_(R5D1=8V3P<K,+RM@#4"(0
ML*T F9Q63R.;,9%<;JN,2R)U/F517M ;:QFN<W@*JDL)_%T51M>%JMCQ4SKY
MZP!0P&*Q@B&*K8QK:K].>$P6!W#+\>/.'^:?9,$%$N/ZU-@FT";.%#4%]3^C
M$%+7..8ZU\@=*2,>8^DY?O3,&2E95C4,HAC\ K^VO&'-<22+'<''<YXJN6$?
M<_*!%\K3(=C+W!K;KB^NO!N(L)Y&^:X,OZ/9)7--[@N#.0LN3-1AF&HQFNSY
M'T4+IJ#38JM'$_EN>F4%K8TO#N>T)6P2G2QLBGT_VQR(!#'* C$9>S"&=C44
MNE+5QF=GP=T\\*UT_JF7^L"JJRB1/;@0B&#:V8$XS/]U.+4&WWW$H58-<D&Y
M.?ZWFQ1LAO(?!44<UPI/JU&/<)=\^Y6B?:C=U,;%/Z/ !8NIJ?"]/C8T(&[:
M6&7K.5I 8-4<=B$*<[K#-A(:&!!CTF%(C"\>]F#LJ6L8U;94)P+BTF*%^$@I
MA/_K=IOR&=O-[#8@ZLWH,#9E.PAAIZ)\N99-NU,R^H0E9(7_S[1!I'Q5J7>4
ML<@^UTQM%2'5%$\>>:*KX1J>$S/8ZWJLWV=/,O!$M&.<R!R0=QG>&G6=J@T[
M[H[J,H'5B$Y<B.,^W<4=O_(5:;S</13,#36"_<2HGRC*&M3J96'A43S56H%@
MQY[\J%0+!$-C3==&]]O@8"WPYV!H8D\S]_GY.3*>[A'3K66#Z6R#XNPV5:11
MFL(LA;132H!=E)%)HJ;(4 ]O1!<P7]/!11.%XJYN]\/UU_5=>WE/_7D%)< 8
M]3.;S\W[F3C?H41F5L!O/!^JW7PR[R0HEN(I$!M>E9!]+VIA8.///72;9[SM
M!-B8'M:#5$OS_!W'+3$^YU;JW\=%2=GHJJ_W4RSVATW$_HNCP:3]&U"F#,CM
MAUON(=+"C>\;ZQO.Q1O;/;J.G@KWL]FM+X? *V4,FLW8PNJ?A37 &M0&*&?D
M L,<9^3<COO@WC8H?Q?Q&MY$4S7#C>:A"PS_(6^HL4NL!(>&<+^WF0GQVEBC
M>;CG.^?T)N@^[2:<2SQ\7K9:D]/IVL.HZT[5^RQSPLE\]ZCJWOTQOM,)>5",
M(03#QVOLFM]/B(N7O;8IB>4MB=\"'8^Z3!;ESI@Q6<[._T"J5D_>DF$ !*Q;
M5'KG:3[D)&/#&H H<G,[(NO-D5W@VS?]M+@Z+7)P(G$!KIINAN=P;#8TL,T_
M[^GUIK!@M8^7KH]C)?KL#"9]VL0?DU!<EG ^BF@6>,=%MJO*V"&17X9T?MP]
MU__]NA.)@!;+/D@5,;U4HZ_9/>Q1%"O,I:_)!GBCKRE-411[B^U%K'"!C2;;
M(Y+_15)>S?X;4$L#!!0    ( #F*9EKYZ6*\YEX  -]D   -    :6UA9V5?
M,# R+FIP9[1Z!5A<V[+F)FB 0' (&B#!78)W",%"</?@%CRX-)  P1T2K-%@
M 8*[N[N[NSLT]'3..??<^V;>?3/SYIO-5]^W=Z]:?U?5JE7KK][ IF'+P--W
M$M(2  (" O !_@? Y@ Q  T%!14%&0T5%?7Q8S1T3/PGF!@8F"2X>-CXY,\H
M*<B?D9%1T;+245$STY"1T;]B8&;GX.;FIJ3C%^;C%&+EXN;\#8* ]O@Q)@8F
M\9,GQ)S/R9YS_E]?L&8 !PT!XY$=(@(U\ @' 1$' =8.4 (  C+"'Q?PUX7P
M"!$)&045[3$Z!ERAXBGP" $1\1$2(C(R$A)\U L^#B#A(.,^YQ!%P5,T0*6V
MQ^?TC4I'HWE3TD*@-'),RV7HX/<8G9"(F.39BY=T] R,W#R\K_CX!<3>BDM(
M2DF_4U9155/7T-0R,C8Q-3.WL'3\Y.3LXNKF_OF+?T#@UZ#@Z)C8N/B$;]\3
M,S*SLG_DY.;EEY:55U165=?4MK:U=W1V=??TCHZ-3TQ.3<_,KJRNK6]L;FWO
M[)Z<GIU?7%Y=W]S^]@L!0$3XQ_6?^H4#]^L1$A(B$NIOOQ >N?Q6P$%"?LZ!
M@BNJB&I@CT?-Z8N&_R8JO:3E,0V7TC&!H<,(.B$M]\J+D]^N_>'9_YEC?O\M
MS_YV[)]^S0*8B CPQ4/$ 4# Q1*^ZYCT<;!68ZX-QZ?^$C<.(MI<I"UR@4DR
M"!&4[NG]^I1YQRM_=C*(38-70?+U=HRT;9J8[4.IINEK 3/&ACOU, RIPLS(
M^3JWYEB<3OSS76D8@+Z(/QXWTZ56G\Y$LXU_/;'RF%S1N+&/#/O<Z(&[^"2G
M%4V*4]_.'@90_&ATEHR4Z'PY"_Z*,"A2/FU@\56A6="N8+SDO."2@_UV'!J1
MD;"F_H5X6?CJX5%BE#?'M>PT8\,)7<XM1W$*;;"YJ94;:G\@LNC@$VF\UNQG
MKEEQ1/D%UO<6=V@A>ZI"$5DP8,7<]6,7;4G%?$FG[TQ&%3- !W@YSA;.>+XY
MWDS'K2<*9(%B A^\T 8=]45<W4\VZ-X[)>R7E5C[60=+D=D,H1*,]I!1D/BK
M?OJ6.BI-H/6@KK2A30[L,^H2)TKBT14(9^@36SP%C*-5R=W"TY.ZM,@8LV28
MDV(YOZ[-2PGO=55X2<C*K2C+1ELE>7A[3BB?X4!IR-41&PP6%W5%R68CWP9H
MDAI$&;*%-3P]\TW>C# .=@WP^ C"YR99QRELS,46JD@".%2M1=BOU6Y7##[?
MO2YCUUTRMLZ7[J*K<"L**Z@85YR19Y1T8GXIC7XNWJ5.XR-UH++/HTW*H/Y^
M='AION>E4+<A.O%5#UU,^#V#!ZU2(<T24?NM8R[5P&<8\'ZGK;W6OFN ;C6N
M57-Q1O11NKJ''V>;]X;R4I0R^1M^&P(DCR'97"[E[K":P14A40.J%YK'PDIY
M>JY]TB4P0/<RV?TG;7"SK'??^WFA;*7/S!KGA4P>!USMO#8?V 5]QPU\\S9D
M[,_T354:KDM6ZLA3+2U9ZG[T25@JGQBU[J;55RF&^0]>HS53U$^1K($P9?$9
M/*PW6WU6WXIVC>/H:>=-[RC(X$(6I+I>5)&@-JXDKQ8JAW Z&:=$.(+(A8B2
M']OV7%;0W4XV-'5@/UE Y1">0U(U!9D)HW470_;K94V0;/$+4!1P2,5M?:\3
MY:]EU]4H3<M>'_C24$A30 8CS' \+"@.0)T@-&U"35:;*C95PBV>1U#K8X]/
MT3  !B#(>MX4+U6FY][DR[3B(WG;34@(V8DK9>/Q&[Z,^)%^7;=BT4P_E<,O
M-(<S&@()><"KL(O@&;-/SD(*OFDE= ,4;EJ:]=QRYII?1J(PIW]C/?Q,MP@I
M"8),YLQ0BM-U4C[NKON2T!164C"YA L5=A%2:)\RV:!B_4!3_/Y6?5 KOP\K
MH^=7EM@CRD]DB%%3V2Z+. $HYAO/*3:2K/!?!-]>' W0O:,?)0ZJ,C.:RYYB
MIHGI=?-)(*UO?&4T11'7OTM)(,3S8ZDAKD\O2+$RI;+]\[GPWJ"004B/L3;1
MDAL>(B?#C=]:DR?VGD[;;F)J^B/MA7;6#)]0H:Q#>>MS1L8I_!-.N1[*UYK7
M>V\;2SRZ:9-;OP2^I.;U\F+\#%4\'C?5Z?GTWKK"QV<J[EH/!LCYW75'V3S'
MA69K?L[R"7WJ"FV,VR&BP!^]>,)3=*!A<JR9T?FBZ_VM2JU]^&9D(7]!9^?^
MPZN1@S@](X>2R)S^4[EA; </1;<U:XI!-!,C>\9^NPSBD*C4+[[#ZDE6WG@R
M7U-8BK/#-<8<9KO;@U!++M;2BVREPF& K,/DJ=2WE4!#X3.5W(["Q_'4BNZ9
M"X50Y1^Z;T;;3PF41'L_A*JI99_0B8Y:T]36:4\$S:<9V,BA79P7<4F.;TBM
M2H;SE]IUHZ#I&\W?J>:,EN]=Q!\^G*YB\!@^O(ZE4MMV<;]<S9G)NF!1LS:W
MDCR!M#HDB]]G/A]DK_R2: 2U/,Z2H9%*S$>K=IAD?@01TU/U6"DTW#PT,C[5
M;^[?L[*WH+]!VR8])RDX,%O5)G]:%?2\G"/FE^@G;S<4+BC_T"K#W8MA&BVU
M\7,KVS ]O'JZ_;V\;J)XD[*/]!=T%<^O%Y:'I<YLK\\K>+HU.IP<5]RFY$9_
M$NC1K+MQ;F!XV#'UK)>/+\<5VF8Z11.=MG*:!%W:RL4V))+E]S!E[A1@!U.0
MC%MKK9(<$K+?@=P>*\EQ-1=P>HJ.&-3><0>YEWX\XZ_BF]O3 ZV0LRG(X#WI
M2.W.BN1\3+0EY.ZN+NN1/F2 T""S$4K?[!;P;HN$(@?TKM@$E\!B=LN,KKT0
MA2Y*EZTK_A7''4>GL&4B5/>X+5FB-B9Y;:/,:,">\$S2!9&T>U-[3YP&;4,4
M-1VQ:4UAT1+E28F,K:V=\?LOINQ;<\(@+>]>VCLWVUL*/QA  .5YDE7%A7&=
M&>9'R3GNIW&)V"!N>Q+8FO!\YMDU8Y[AP,?7?/O">WU9E7Z7#*POAU\R'YS>
MIQ[U]^PDXRG*9 ]A19+*!RPR_1+5_;9U-Q\E6?+5PRTU"_),B.KTI[?):3S?
M3:%4UV0M6KUU9J]OY/P'&#!&HR\LDVGIP&!U4/8::SD?!M0K;V/Q%VV]"5<?
M^>!ZQ>SQNCV0+D)?67HT2*&8=W](+:)]]F.WKIYLFG'TMY_FWB]=;3QZ#I2L
M(GCQ E&8O55[=71G+1(-+$A$NZBJQ*ZG$BS=4^,H2JN>>96G]XC89IKEXL?1
M=@D<TE_E>=-=.Q#:';B=%DD3;J'NJ)*NH?JK#=A,+WW]7NEG+:]U\KAX7@[D
MV#@-[:':0G)"\O!0=M*UM"A<K3IEF9:F$$63DQR.F"R8;A_:XQ1>]U0]'ODE
M,V$UZ5L78FA_D0M:L775Z(QF:+);]\$=C\:N+GXT4LQ#3!"643^<P_G&C?C6
MJ2A\[4U%3161LT=&PA%QF\NA<!A%)_5M_ZW&15XCV[4: N6WJ=Y!3OPY,M_4
MM0I<3[WC>L6?X3Q J%WAI43+K7KHG+B]EQ5[]-,[']6HP;6X?2Z5"XW*G1$F
MFC?;,RK <JC+5<X^-5UPZE8U72?H<;4AQ3G!OG6X_*C_=<>*&HE:D\&!I9S5
M5BQZA]&=?#1'O&F/WL-GD3A#F:IX$R>(*=!#D1G.,21L?LF!VR&W@)VQ=IVR
M<L.[K/^HK^[)1U%*Q=DT2@(HKTWCH+J"Q."KACS5H?&I(;M='"VO#/'JJ")=
MWL_ER0^T)XNE-K:L-@#N$*VONXVAO<S,VQ%#XZ'<E]>0E6Z:8(GHG7B)#^BO
MY3C&DS\1:,"=S-MA67I 3+QI82U:\[=.5=<8Q(Y+%2X%/9L;*>^HUW2T>SM"
M88"1?.LXZB_QTK%#19O6B\!B;8#PM._ GJ<KKL[F_5NR>R8)RJ?3[Q&4Z;N[
M>PWKQ]Z41 OC:W._XWL2NKQU.YG2,.X_+@BH&-EP?%;8*0HX*61567?)U"ZC
M WI@@*=*FV(5#8TS:*'HS>,J=MJG'G>3![\T\;T$U&P82"4R3:/&"[NNFHX2
M#2:LFW9R[L]4%Y&;^3J4J^E#HK%7W@0S]&3<[<5+C_^&4I9K,@9M%=_?%3E(
MHR79 3\$C!+MVGR_#$T6SV02J4F<G! $V-\=W5U:D+;7NE^<-1TM&$CMID5S
MG1,HF:GI0'K#WV(5",2>L"9# V(>KK.2VF<_T6Q:R-^5Q.BY.[T(WDF/1A%?
MJK(7\K*4+J*NKF0A6WJ^QM3%H]?SM(3./95^3,?D_30,*'(R<)JC0_I,1[FO
M'C,M?2E3@F,A973V6%]8F*FHPM"ZJI@N&RM:_$U=_)8T*.B\SV6.-AS[KCRP
M_=:<9.&EP'WOV1-9/>UX0S=R@&=(?WZ7]_!Q7"_[C50GLE+:]]@3I0BQ><F@
M\DF2Q6L8X/!C[**/1<G-H,+,[.NC&1TLJZWU"2>42.I!B37?9 0]_^/\54VV
M"OKU#W-&8I$S/?,6*AF9I/YD9N6)8<&4Y OQ0V]4@<-$/6QPG%5[_7>3;U0*
M&I#:+/5RJ"=?R7##1A(,$-4ZT8CLOA:-[Y+7JM5_'$YW';IX#/&KD"=>DL:"
M5#*9?STK,AYL'[)5\BJ8W/=&-F=O1I[,! OE%.2I4/JT/#C-NC*]K1H6>I$S
MW9SFO6,<%7@BB%ER#WZW;?58Q7K;>2R=@%QUB L&^).OA-L[Y87>OF^"RC)Z
MXAR/LH.LQH>$/C,NPX"UBIU/*F=]-=ZM$*-!.-=]?_T1+^BH=>NYYT3KV;!G
MQ2\12@N0*>\!SURGAY!OR:VZICC9Z:%2-G(IW_=&HNW2'4DY[:1KZRN;1R1O
M(KVKMTY^EAW+MQ5#..]4[>SKN(JIG.\J=E24MA+L+A7V[4''!4("E=96Z+*8
M[QT6M0'MZ61'S:;C;$_>< J,% D4<J&\6",80%XLE1'NYH)M@M6%D0-E&3UO
M7IU3'N\\E;&)(J6% <U6"M>LPYSX30UABL[^D@H@ROA:2_I-H_4(HY#QQF<6
M[OD?JYO&>5U4G4@;F]AH9C-&&@DMGA&TR9J!\S;"-;5,&+TSK5VX%0=85_;7
M/*9[(]YJ1/2YV7^>D%;"WM%IK#H.;-.:6$^@.>!E8^,,H=-H#ZRA0:F;9= -
MZ^#J[6IF0\>^\9B0GS2& :L6DLWR&-@WGA/@HU/P"<_N)^5-PTO[?;=2*-[Q
MZ,Z!R67AV_8NY_<%D5Z-6D4BB-<ZG^HG0$>G, "NRZTXQ+H*CXI;K#YB_2O,
M$%J7V?S:4[044<KK ]V::_'T!>*0Q5VJ]BS6*=&IO+L&JV'ZG-\SV/?=YL$H
M]7Q?%;<:X]Q]:8.=[T7T&#<CCNLD1E@35R?/%,QL,J15(HH7]G0[\&LVYBUC
M"2OYMA](S4\LC_*"CI[TA>+JVD,+WK A[SP59<:1Z"'+<<SMHIO*_O3;I#6%
MX&W[5Q ,3Y ;1Y+3."=>]' W$7S0>MN;I&K8>MV/M*YFU3&EK-HZ9PY06\#G
M[]F>CN.C^Q1*4D_S0T>7I]U/J=^AF1<A?TH$>;3(U )#GF+M2M$'\;PH-9@?
M8E]K[X4EZDV^([7;X^3.F^S;8 _I+8I L>AD2$^4"5K^=NB:]4%=)#,T>#LW
M,U6W13EXVT!^1>8Q]\W'Y6@/J74DPLKGQ&9%6$QLLM=6&1:E76PI7I].M@QJ
MDWNJA.T$T/?-,[]__J(O%C7V0+$S:^P@CGQQX]\CHMR=K1(#B;5>+>I8/A#
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M?Z'.QMUY)W'Q/RX"Y?D_#-2]Q/X>QQ8PN2YV67>S::YN_)$ #]'AE<$>,72
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M5>&(!_!Y^G_.^_NK#0=(BLG@ 4DO!COWP0/RP!CS0!C0<#_'=G<.OLX7*50
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M^PYA@)^'Z#5D!;X_0) _%'ZW66)M3><W?\*O=FK!T2/RQ>HH+^/ ;'4/CP_
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MXVT]O7ZR&"Z!GF&F*HZODD@A>X)\>9WG SIM 14ZR#)<@%(^->%2VH;H/S3
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M^,[T[G#0>T#:;+A":@GO_YHBX"83.92%H0)8*UQ])_L3LX+[#J-SB/P@F7;
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MB18_X)][8?@M>$SKH: 72@-T##!LHS">&<[NOF%H#C[R#X7XGCBIB!_O>\0
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MJK%&M>;_+;A_[S^#^<U;U6X[5B'+*N"6O,_6I4G5?10D4#IO"6\!+1;^=\9
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M_>NSK=JMVMVJK;VO;M6K[GY=?>X][Y[;KW.O:X!W<F (&  '!P<P>GL KXL
M*0 J,C(*,A(J"@H*&AHJ.B8!%B8&!B8)'CX. 04I%24%*3DY-8B=@9J6%4A.
MSLC/Q,K!R</#0\4@*"K )<+.S</UGTW@4-'0,#$PB;&PB+EHR&FX_A_;:SL
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ML[>/%6JMWIHC@6?KY9QJY+=/!SDT7@'U: 0(U.0Y#--O[WK\'_/IL?ZLA](
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M4T1T]$WAT6:Y%<&/L3!A6W[[JBW^0]5!.^!CM9DW96T'*'KM>(Y9F>U?8A"
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M]/PL[):@;<'/+SZF5?3=A3W?X19$Q;2*&SP'%_RP4\_.MM%<#T732'(*Z^@
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MJICO9MQ&1]_G=FUMB$Z2T<%']E+[G7>R@1=S!\YU5- 3,<5M_Y9@[4H5L1:
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MLUTBLY&6SFUM_ELG+&-]N83Z"AZ>5?/*W2:!T1_Y,"UYWN_EFM8$,O B3_/
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M$2:THZC+UXT3V_,9X(XWR.G, Z24QT@@*DJ95];[>%U[[[5[%U),$A6VU@&
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MI1!%0,.*WY644,Z4G-KA2_VM_@QH)9SWEVV3((+[@=Y]AQ#+JVW/WM4W<C$
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M9UH%LI GJL<#2$?5?HA[M5JSWE 7V0J -? J,"8G_ZFSE@O3"3@"FGRK_3N
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M8W)=8GD&_/Q\KWSD !TRL=D1;0Y4@6\ 1%E0N$RKU)#^]O,GW'5\+%>Y8OH
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M1S^KX2Y<OJ%:F5-]/O,6A;]C3=!G/DZS]VRPMRQ;N@L&;S=#.]CA.WVJ%*^
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M688\IXIS23%-MXS)QK@'U$2CRF3RY.]OUK#Q:_*6O&^WKOM]@WD;S<7A=2F
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MJ<]L")B:0NDG_Z^$L+"<)0)D&MS]=\$_\U_\M\?C_P>A_S'U'U!+ P04
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M18\=EY:1E5-5.ZVNH:EU_H*>OL%%0R.+*Y96UC:V=C=N.M^Z[>+JYN/KYQ^
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M$UDMOY<:)[K])]J3_V.T?RJ>_*\A$BB$Y>< BSY.B_\.]D\9(?]-P7\ B]@
MV_Y[J(P#1'/1XM:3=*2;N9N.4HX/_&<0V']EG&O%?C 'A_G976UV1G+'WUAS
M 'X,_R('2&Y=S/I-\#:$]AK486/(!VCIL&7-_Q:<FX\5#I [SAIIQ\:)/N4
M*8+T4;]I,I9_I9D-A[+0:ALF^@?X;?^^ZI^B+/\O16G[3R[_#U'_&L%MC#2#
MB/\[J#^A&E,&H NL^?4RK?G_;,N_-![F:NS58;VAL<!O7$T8\GE6T'0,INXD
M68<#3/FT_^.$JK;_EI0_Y#G+^,-Q2^CT _^2X:\=&CC[QP[E  .+:S_1&E-G
M.,"7?WO[G_G]X:1"'.,R5V$TCA:#A,/64[LW8&S@KO\#QOAO&$Q,Q^+\.L2(
M>P"Y.7" Q@C&8A-FS(:&TUCB %'C"[\-(@:*A/^A3.M?!AE>4L7]<QK_A?__
MCQ.&R^>?7/T'<O#NOV_;OV53;".;S2P;#):;F8Y",A1*I#NT_X]B_^&R80[0
M'87XQW.)N]51X_GH-@@-Z[)>0LQ'[6',YDST2;[$O'?K7F#8U\WOCWN1U=<2
MC D\<I[J>@LYFW\HZ9;-]7AKFZ^-8N66L+,V@XUO;>T0_4DGG/K/!O XRS6)
M/4]RB9;]9=,T90N7,[3XC%=AT)L_S<<T@[GP!CC[@EK47-5)#G"D.X(XPY?)
M 2:W5 .>9GK[@(W'^AND.)D5 7.>9VIR@&U<*U8Q,A#P[G\:/@.!M_TY[7_S
M7+EW^N>INX;4@Z."KU;%KR2^Q*@G?]BZW12NT7Q@/)VU-!6T].Y18-:! N*;
MRE/Y9N8Y<EB7?KHK^DYA=0@&QS"KXJ8 EK- *:SI"$HROQOX>;P@)%AR4-9J
M(BX,[C0]FQXZZ0BS"LE:-6;%B;PP1[C! C=FG@?W>2$0/[E9OQ&2@ZTJ:UU-
MQO^:-5QYRO[% 6J263+KI<]JQL%S8'O.$"SH="D6,:Z_O,P69%BI]P7=JQ+'
M/K^'7%E'^^)<(4,(YB2F#IL';6?BU@291LE(]E@7?9HU,:0UCG-R/S"PU*(L
M'O)K&3J,^(HM7M!TB,'LGHWQSYAJ+?YCA2Q6&[.M:(.(ECIW'1O*Q/V[UGRA
MGZE+J_,7E0)'<CG  ^7K@CD$R 8/V(+@K);=M(1.&Z$*@P2+7W9WK_U!H\0Z
M=TXW7"M$1EU3.K%5<RVB!M-:VO4W8(L&\_H_N,@X0*O/6MOO!9M$G*:'&1'>
MK9-GRI><IP0M6=KH?2&V*\D#'. SHN]*9?,?4T!B:XHZ'L^] K8W,>'P%TC(
MD-,+Z%#.OI <=M8D^]=DG':0CT$GSC6DE17*-,(AV1-]0[ JC)W)]/0ZA/;>
MJY@*.\5<J(GH_YD"+\;.*[.7B.1_O<_5;+J0\$=>*IM7L=,V1%=Q5 L)^R($
M3M@T/GCQ\YP6R#L,P;;_28=O)1%*9W['G]B0P LR!,.OS<#D&IEPQ(N@G2SN
M1$^6.?OMXM<%G\Z@40@\"_*'!;A+):4OH9?9*K>1()WM^EOOIO'.Y!S(J:4?
M2.KT]&\+S+.,08F*MF4OV;_3T0UA+B]G()=!OQA/Y"C>W"=Q*FBEV0U*FJOF
M )&8^E(.4/ O>,ICV*'8-&IW/Q%NY$AE-B^O<P"HN\BL)GAL0R]L3M;6<5W;
M0.F*9=U@L^7;?0@?#G#H3S/\F=EF/!%=0XA=>1J7MSP )1H)_ C&FP?A+;I+
M[_SGC-_V@>$7QY(W>&&X^>V2J9@,=TK/F\;!$;17#B,/#V+46']?Z;>Q [@"
M@,$IOP'.DA;>6_BD+E3AS.:;X8M1 C]\OBYKCMXU'"\E<P^QL;^XI2G1F6UU
M*/^[:#[6K5$<@P 1PF+6]R[C$-><PLC8->$J;L5Q59=[.E]4G/X":@Z,CV";
MKMKXT' 4 ^"A(52@"_D)@B4$$<-^H-3(PTP>5S[(JF#I>SD+W[ZVWH+2X8))
MV,^I^NO7'IM[NRX4IQ&&O3H&WT3)J[R5>?,J96RH_ROS JUV_.+AB!])&E6]
MS_<4&HR=6HL_824OZGE]WY,3 @ <<0+=CE@09R<39\994AS@W2(E-D1E?\->
MU>B=A5]_?O[Y3>KIT1-?7ZGHR>@?UP2N7O(B?#J4N*GF%CN3.*K)5,;TMC(,
M.(#E>*,HL(Z.DGFUZ>_/D]0; P_6<)/&)FC<^?2R9N(2RU47]TI@D>_\_:&(
M0PD#NW1Y.,"RCZE #XUK*I+X(AAD_0LQFT8K6FFB)S=QKYB4X5K,GB\B#XO9
MIB3FH<D Z4LEM-,U4:9Y!<B^O;*B8\D!MXX:^R^,G>5/,&8>:=%(J\E@9^EX
M4[#;4,=+:4T)(QQ@/\J*44ZIEBWF ((NN%WDY(L5'C[PCU$F!HWWAE]^/DP;
MB\P>T"@7] FL(&=&F#RX'6^U8U%3???UHDOCC^^]Z]WED63VF:YQ!PI1:2)E
MB>_R$67XV7:UC/-_M0B3SC W]W?]<65*]B>V.N5F&:I2_K./J.V0]0O+'W=[
M8O2EE&JOY"G<@LL=B#2+W5FGDK--/\LF2V.A4AK9>"7GBQ/&TB#85;'Q^WOK
M$U]\;ET3N6MPI*JDB;SS W^;H4M,6^C1:Y^4<*=&?:S<%Z+-.M!:2+X&Z $2
M*.)"W*NDD$'3#Z,H2_8XNJ@'].&B=:[E33@=JNX:[_2+A>O5W#?,'.R;J)$4
M/N'NOUJB32YKGU4[NC@*3?:@5ZYD_30_Z(<)+]5*C\CIKR8T^*-WT8]G47K;
M2:9TYRKK'X?CQ=RG6RIQNR;M4FLL,X5^#$D1BN,T N2[2>G\ZT<NBB?$=1#6
MB'[TT!5\EU.+<0=*3"3\_77XIBE17"37K%[[6S'>[F]-;KR?)KD&>>;E>#"/
M);YSDQ3O].W_<K4S]INK6G7UQT&]4VP$3;D1MA_E3A:#[T5=_JDZS#?5C7];
MZTW>IN GYL[>,]9L%M\NI#NXU&Z $?B5*HN6+H%+A?3$];F./#8:D:3J[;O,
M\W]Z'+PBYQX)W#+>KSQV-1<8Y6D^M'#*N_EL5Z4<G5MUB=XGC;9%0*I$=*C,
MUX$S(8::K?A-U>+9T0VW#KC)GAX;BS>:[4M]R1):8#D_-Y C?VN&R,K(";T:
M2)LIIZM>Q7O<&<A?A+ S8>/ORSF 'X:!-9413=(REF8OP.JJ7H)[MJPT^_S0
M.%"[YK.T3NU+Y@[,\)7PC\=Y-SN$:$<Q<3/<:J&5.W7D)&RSTV&SZ<<9JZ6,
M=/SOB+C5K\S@8+,__U_' >AJOR"T)[D2/,N\ <N2'9BZ<VGWEPX,=O^4J)X
MZ[EW()1;:=YO9D5P *'M81Q@2(8#..&Z?;I@Q<3)8N+J5VX(:/U")M@.6>R"
M,\D81LH"EG%1)$9&JH2_"7,81,ZXPLB'G=!F\]UXST%3Y'=(CQ]LG'O/T0YP
M@">8AG,9'.#L/J\)[L6WC)T]S %TN>51C37W:,_Z'=,4U@LAIW?^XG4:K"N
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MK%\,E61=85.&V543P[W/%[#QOF3?TRW,!4=_=NP_%>M B(Z6X*OI;GK6FRA
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M,>\RL=<+ AJ[3KJA#W0OK;V_UGFDIMW+XRC)TR.CJK3:D.S2UV=OF_@F[;A
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M.D/JE.0 =MUJ.SR4C3\:2MPPJ*RI0N;G=V8ZZYWZ_.!%XMD6(&C[&GREG6%
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M^7J]GW673):MK.Z^Q&+8V>D&5 #=PHY6\\HW3:I.!'VHHL+KN&SQ> I[20:
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MRMN1.?56-=(8$0<'W;$LRG?/U0O%(?>H]E@X+;_>[DM&C[&/@K="<LGSLJA
M?Y&$%SMCCGY:V?[O']?XVR/?#,IP;SI/+>A6?[%X'["K_C.P$+3+@+1_9G\3
M\EWK[*TOWB#^.^^"10))?&=WUC/K]9(;X>_34L7[0O"FW.8U<E'<.;E9E?RM
MF5=C4;_*Y7A^\%N*+-R+Z;LV#PHMMGZ%'0;%P7V8JQ X23(]8Q+4"VI>.;L$
MR6'\5 T==F%55X/$Y!KY.0Y0ZLP!8# IFC(C NE4=K/Z>MOH, W+ ;@77MPZ
M>A^F#@:V@MH<H MO"WZ&S:PLL8)7. "T&-<K,$%\GL'T1RPNTL]RNZEY?@YP
MAL[$K4F:L>_#O4@<('\>#,Q@ LO]W% @%#?*['Z/N2E)QIPT9#\9BEZ+@OVQ
M]CX(?1<-MR0(J01Y?D%HV+N?[ENVQ5]P5HC7KQ<4?YHH>]1SEZ2ZE<'!@6UX
M' O.% 9;G$YWCM+Y8F"W!1\,R71+)_S 67>!(@PC#G YQ4GPA>*W/JO5ZX''
M(K7+F9_&9[$SH5RHW.H?]E'P%1O6],RG[P/J9[Z<Q\2@%D&VA-!69BJ0[^7>
M__$8(R LF/QJN:+*R_U.)W55DH^,"!L2HBDE"(>.8+8C?6HKQ.7R))^2/01-
M?JHNZ?VRF*EP)A2;YC7]G&HT]7[HGLGMTE$<(""'"07+.("N>Q=WR=))4!77
MR]>&.0FJ8CQ-9RM*/09+C_>']"=X$$_WRX.'QP[.GX/YL/8_W6"/FUO'5<#J
M\5,NX"<H+H<#V+.6YYT*V4]"1);^H%"*@=<3@S#]'SD #O>$2)$@8R8D83XZ
MJ4C4"H+E*XB!+VS,3:-OI( TG!7TJ5WP;L8"K(NK ]@Z.;T\'1>B?0L[VXN!
MC6Y(3^1*7YX.9]_'5'(3Q0XAPNG<K'%9<  )EJ[\GQ1@X^W<^;/K&.S2WY.^
MX[^2;JK*VX-^OLR]C=%+N![(##-DV(&)P355WV8>8J)Q%"USS$V('JN9T<:N
M5!YG7<8T:-=Q@)\ZZ''0X!GFJB04D=/"=1D%.\/+W1EQS!!=F%+B% ?X;;,L
M\#,T]#?]_[!,.0=X.DH]HWMF93*458%^)BB8?A=V!I:C-@WYK?CL_#*KFK&1
M]Q4N!:K!R@QQ?)P2"AX>$@$?<!/,91VXAB8J$TGIF*8$)B\;Q^+2SG<JVM![
M$<*=<'8)\2T8L\P!E(/^:W$8=ZO U_E^?QQV </%._\3$T%<7,T$/W& VUS5
M.,"T]7L.<!-R=AT3*[UR/DAY3 8<3&:Q6)?_2A<'D/H*^R"XBJ$/FRTM3:^)
M;GP3@HE8G!U>QEMS^4:O8>G<92%N"*Y]J]FP7>R)/V/\7;H$#K"QQVD2Q,_C
M67QG=)LQ<^.XEF6\#3?"< Y7[/_B\1?QO1O$5;YP .YZ:!R7.78AB+MCD6MH
MG))N"->U4,*_R0Z)6&A=_C/EYSG XP!N/_D*R6YE8:7!3SHL(B*9MC2.7^1:
M9CU@:;4U!Z_Y>_'!:I@D^^W?\L;B /\R*]2!07J5R%"G^]&_HA09X4&[AG9W
M">9HZ@3[;:T9H>6PHJ%B$MZO7-C<6E["G;'"]IE&:+(\V_U9^QD-#;N@^U#Z
MM50=I+J=%!'?W8V7FIC?3B<3=\6=\)40CPNDPDL.KOLPN,E*I"C<*4RH*YF?
MZ=3C  \T8.S2!9@5K3]B<E2UR,8B._>]R26%%*,O%7??)9NV!SAJIQ]C6B-7
MILFKGX;%IH2=1!EM%.TTC'$5[8X*:A--M[D!_AC<D]QH%[*2*!C'9;:]=\AV
M>*B'813XIM/KUP?7><7X??$[;%_.@?+<8N" JI=@'\J"$7$M _P)X_6+QFUF
MP!NZU&&;P .XF KE!NOHIB&EGW[]. CK)@W>5/F8=?ZUFW#07/*[6*6+"LNR
M+ZWIV,B1*KK$X!O7I#;P*:;6S'=>T!WV,2G_-2/Y4C?!!.9(;WZH^CCA+#LC
MDYTH^0-<M8C7ECAOQ6B(5+"S"G4_(?#.I=2_VS_]4&2W:7J77\*U-6F0OW-$
MP&?E"MVA#].$Z]NQHIE43\D4A8?6"+&D&?!,I+P#HU'ZL2<!,@ND2S/Z7T]"
MA>GP1F>7HR<N5B0_RB04/C5G+Q-*A(ZAR.N!S 3$=G3;<.'^Y&9B-&P'>*J7
MY<2]K>%[4=IT;"W;<<D#8O:AG!:70<:$@;!*.AN,=,YT<HT?<*EHCEG>$6WL
M&.SXL0.H(OQD09/]U6&]PEGHJ<U/^ ] T],'<UUX1Y1[U5>TZ9A/D'VN%?.Q
MX!$&IFEE>!=TIRNN"%L[H:--=A_>.6"/DFMGV:I'Q^'I//-JU=<%;E"VY@1(
MQMX(]GFE]P;I/T32MU582BSO\!SPQQ1'/$1I$/=BN/L9$I+"8N! 4>DZNT,5
M6EQ_8XJLX3!!M&P\D18G< 7I6G!W[@U[*9S(4U:^93>^UW*1;_88!SC<VAL,
M_N#>CNMXJ,Q//A+UU:L8FLN;^[N!K7R >9L>$"C='"+2#)5BG*7O/<>X_99[
M'""9EK2"W-MDCPL.(8DCG<<>;[8I*&,J+-:/]=L/"B.*X*KWYDTJNQ?Q(#^!
M%KSRG'$C'V58Q6CTHICPUFG%AH75O'C%[6NULK[/1QVI#*CLFKGJWL+M@'I5
M[!T<(Z4<SQGHGSUQ5HY-95[B'J$'EY4?21XK9O#[7;M-%]4K 5O3%ZU,MI(5
MK)P]SBZ%W!H;6KSTH>OZH\ 2Y7Q;QXG%._%#ZQ+Q[R/7JIG'6?[L;+0VRI*6
M77F#;E _I,$PH2W6VGFFT>/GQ@24ZZRT_/'>[KG?5MN1&./T56LZ(MH+4Y09
MXR[<71'P8"8CW/W9Q_*RIU>QU"*GG;6W!JSK!^RM3WZ?N*'A'Z<4#N$);_J:
M9!T=KFB<8C,@U_Z>W"JO.FLN]\Q-R<Z,V.$\8!W3@KP-)0?9['Q7LO>Q_#5Y
MRLFR5'&W,1O;JP,.4@\;=5V:4$_'F)<],W-[.UXPM8B^F/2E*;J$.I4#U'^Y
MH[BL&+1 _51Q*^>.FO(N!++-8\D>L6=BC_V.SSIGLXP\;^_(;N65>M6!KO?7
MZ=F?GS@>:=<Y/LM/@\/#*<&MD36"#Q1O1-F&3M$#HQ+L!IRRC^P8J]QA;#N>
M*,3M+EO3I8X%A$3U.[8FZ\8_69IOU@EH]FJJ>M=,]:J7<*HWJ6[3<<R8WNMN
M5>@P46&2."IEWWFI>[CW:;^=J[6BE[_7KHR*+[.9%W]%433-+<_NBZG)*2N^
M]L'ZL*$5LU[C:XG@9M\[>S]+#=T'B_>=A-49C 4N33:CB5EJF1>L ZZ^??"B
MM]?2S/K8B^=/]E_99!M9]R#^S'Y6Y\:'@*H@3#MN94B Q\Z#^UVXQE;6$3D>
M03Y&\M3A"Z!>1&EX7O_I8;5VA]J&?_7!MFM":_  92?)\]2>7K7U".9EAC:5
M6U!=$]"NAVY[V>A?HYI06\,C>2+B8D5E:%.IJ&+22S=0YB/AF3 QP9)Y[KS2
M:Y[;Z5/;E*\^U_IRI+3ZQ>B3EH\S>1#Q9O[HP#1U,_);U>FK?3D'%ZR-WO<E
MC/WJVMT)TUMKY:?/>DI3T$KDOE25U)LT\AVC^GJUYER%7?>R(O,B5LJ#D_8\
M?+8G\UVI:$_8%W/)A0#BQ",+/2W^P_&:-S3K&R:/B/OQM+VX=TKCNS$BDEB(
MQM%)3;#M:+G)FM.E=//^24,R$[9E2J6@B*QXWIZ^?5 AP,>^0;HPS&^'KN[Q
MT,ONAQ25A6V&+EJY1./*U+@'=)]Z_7KXBXR)8-A'981EA'[<.+S]MCWLPW1%
M?&W&4&"2>E]B%TK*W?V=:_)J2MJSY.3%2Z76UIO42^";V0>81B\)2"J+N:)&
MQ\04(^*ZOV2[5.3$^LGC=TY!U=H]=,X&I4B'%1MR^TW7?(8398Q<\-Y\R$+@
M5VK%C/H'WA>*^8F7I3P7W>JIF#X5&RV_[@B/5^5M=ZJ, \F%F&R7H%M9.<AW
M]?5]7;@L-U%J54RRG412H8=W'F(RH5'S_OG7C=NE!J:D7/CZCVUMWP<@QUGC
MI>.S':C5]ZR]W7[:Y7;]E%V%.3T_;J:[',%=">R;,M&R/]$BV]&E6BJRYV5W
MR8+ML1<W!BR/7("=T]^FMSGIT WOJ1ZJ-R^P-^8) *3NDEWB61Q+HR'LB@GA
M==1FK;3OF6;VYV:*IDH6OY4(M4ADQHY.N8H:@5>#NR+-/ _N]K#DT9L6?)0R
MF!_66#RDUG$[W3 +=R3$1%'I>-+0V/_5W)>&-=5L:T9141&",@D(<4!1$7$
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M>4+G/S$2A)G.$;Y?_5.N'#67(R!\Y'[\W:401HV^><<GB4 :(^(?9EN'$+2
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M-D%N.".V4[+N>;TOY*L>7-*1&UH,N5^T%3<\/7L?_P55@[<+2LSCG0+&8W9
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M!U&2D+]QQ]4N TT/OT*LAWEUY\)TF-Z()2 @!1OV]*0ENZVM"EKVS6]J_#G
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MX(' 8#Q\, $!/O[-;-C-/(!/14#-(:9">-OH/H33AT8\(J68B$NUH8O6>.*
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M$-D,"QKM+&60]QL(OB^\&!;6[EN%6(V'-7>49#XAKA\7\CV_BO\\YMEJ<%Q
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M4O=P/=)TF*,^@5Q,UOJR?EEH&S3@TN*H=OH0>X>VE%G=//^E!<&'F8=P_#_
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M2"]Y.^"*]O6%6+<[(Q]5=*TM<OPSZFW9,#;]%\?Q__%SBN+/_+\!4$L#!!0
M   ( #F*9EK!I^;LRRL  .,Q   -    :6UA9V5?,# V+FIP9[UY95A=2[;M
MVMC&@KL'""[!W9+@(;A+@LL.P=TAN 4([A;<V6PT! _!8>,2)+@[! */G+[W
MW;[G]>U[NG^\6M_XLU:MJCEJ5LT:L^I^YGX9P%&0D9<!0" 0\.;A >[G@><
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MUM2<4]"6]1F@^I+G!0-.*O$0:R.#1U\E\\,;:8('T#9_=JT6%!04VP)9Y44
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MP7E[D-]*E-MY:1;;A+=Y\<)VG>&,WH(TQ F_5._EL\/% 1R95^!U0^"XSF"
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MSER:J3Q2#-YP[Z'Z@V(('!*6ZBI:T<S?KDSMN-JQZ/2_]9X_#?1;1 HP-"<
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M1\:O/&;:MS0JB!]> 3^UE:4!TQTRXGF\R9P6+TBDU=R31 U^37\D'-_ .NR
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MV)RQG'[_[WO\/SC&S3G+0<U8K]E6RJ\@Q"S0"KJ3X/ MNRW!5ZV/O]Z+=Q%
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MMH.8Q!$B?MH'W:!ZT PM-UQD.M_$(@-5@^HF,HD8LPYYA>?!9H4H]*M=,Z1
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MC>0-=7N\P2+5Z^^XI$U=+U1?VFR+N"BT'&^5,P1[,P_AR=4^Q]](DJ7W^X"
M[$]3RZ&O+5$I/]+B?!MEOU4TG*_3!::;MB:)?^,>*[9=^N835N8I [EM:8>8
M^DJ5^_;HNZ^NO VA=O3S&9:+"$@KC9>+HM5P%OAUO(X2=4\"<V@A#O*5ESB(
M/:7$628QE!HC9=A*G9F);X(OF-*R%;\57COUBIW?J(]LSP_@'BHQ\1(DI?I[
M*Z/D^M H3%=.'AZJ/544+&&5YJI^.GLY[*7H21EPI^A48#WM)=(SWI+7]8W.
M7.9P<2.<4@*2YC4KD(F4'<8$_)<%KO27OMW,1U>K;3W;.;WOEO5#+RV58V@J
MWN1L"35>]LD?,*?U)IJ_:[*L#M0X0VPR?-GEL;-X=96)9='5HV7GXCQ#6.J$
M'7V%(VZ) \[!>)%8$7[WW>_*/B1C16_D .U.[AU;F5WSL'H&\Q:(7>K^NX%6
MS;M1;=T%!>Y1O1ZR*O+Q1BIDR;UNUY(7Z+"SEU8/Z!*V),[C**-(G])9?=\G
M4#>+=02*II^E)13@*9@[D?47V."+/&'(R=/9B[[6BO$,@\,80'+FB-%)X7O_
M[H#X*,(0'&2/V^]I9!(&C+5-KE3$+@O@ZM#5OZW,E:N/15;:>5Y[\R-#^.5@
M'4?1#[@H3W0]6F&$']9/'+H2GCT"<Y]5/BHA8FX/F$0OQ)6OAA]+64(Z28AM
M+"(?/):17N'2!/L6X0.HNYV1W=[*R*/3[SJ;0K)L(A:XMLJ7SW\I?M*NC'\5
MN/8R> [- @%,\L-E89,GV&9%S^K%LRV%!GH74FFX<(#S"Z?(R1M1U# >AV][
M> L-R07+3SEP.1L)M^\3>T4",K%">4A)GC8:ZGU[H:FC'C#3ZANU84U=LAM>
MHJ5<0RV]16.^8DG1VJP)=\P-<.;-Q&/T?CR1@B]**]I#W9/!);M)28 @+0BX
MA:RN6#381,7R]-&CJ8*:;BLG4-*KX2KM2G=GM,;GQ-WQ%J7QXQ8Y.Q(=6?8X
M=G6IMAKL7G0X[KHGG-%OQ-)18R>,?:6/04=H*I?P*,O$Q%2&_S_G-U7E-RQQ
M,\*FA)_*Q L4Z!L\$[TD$)*UO;!7$<_"8\93M&85\QJFB(QTAR<O#K@4YNL2
M*V5H'2L1&A9V<NBFX:76L/$&Z;RK<G=?I<K8RV0PW[:9G-_;N"L>7R9FA]B0
M\J_']XUP7.=&/P+5VY^E8@D69K>:,=893T0+2_1J,^@KZA*]JBQ33X)V/(;=
M):KV35*>V^O*TH8K4$=SMKJTDQV+L$CB\WX9I4G1_22%K\KTOVU9.%)>8\OK
M,L'Q1LF_1+'6#3ST."A=]C10H57M25W!Q#H'%IJ&]$C![/;YLED1[D*5[8 6
M48&/^MB1KB1;RV:S6 Q9B,C:&U\424-+7U^G<H/[*C5W[]Y-]<JYIP<U7DXI
MW6-("S4]=?/X70[4J.V^1Z=6",OFT(#553O6BI^A9A$8J&XO+6BAGN0V'5WZ
M-HUY/0=G6YL&>>UTL<,C._RE7TQH>H=9,P\%=L>_L1Z54DTY;)SA4RVD7NS.
M^W.<WX:R'=F_NZ8WQ_K^RF.#HBW"VKI.N>=)%7>^@L0O4NK5JDB4&KE<;-[3
MK5-9KH;!G)A1;'F&;XK.8(:D_9J(CU((B7T^HTC)2Z7O+8WG%_.QY"$?MTKR
M(B[SW MZ\"2I/>/5!,@JVQEG+4'!IA&\4AY]"^E:0!RP;;4/BK??U3H!>T7&
MF<6$XPS&#K%SJK.8'3,A3 H+'$\HCO%HNX(/V5_PX"-N]N.PX(07K8->IQSZ
M]YCOM%)-U-R:BF9P.!9@A>?IB' ^L?Z_V1W-W-8SEN,#>UL^:N6&.T?FY.\Y
MANE^[.\M1G]L8/QZ02+0O_]$:G78[TBKI3%PMU155A+! 9^SN%O2V-[B6HDB
MO35^3-'<P;F(G2K,N("93FQ6-(<;[GO7.III^N9A%I<>*^Z;3Y9X<LSO$X<Z
M5(;P4L/A>OVJ?\)9<^R->T3>$)?11!JH1R>^3,JE;/CH7!!CH,X;+4X7*X,H
M1_>!?<^?\"9FND*8[1&@-L)_!&:U'@$K*3%R'GP5,:3_4'"&G0@:0U+4(WSU
M5U1S0VF0I3$+LE""-&K$OZ Y<[4_O"W\I9L#'LO5/+Z^FGGR;1ESA>/PNS?3
MGA)T L^-I-3&R)C%QCY;80Z_,= QANH7;?H@B&M4BS =O7FR6<VTW*#WBII8
M2$&(N6H]:^Z.9:=%K"Q1<IS0$KP9OZW$]3W6G6QI$/2)/,:+:== EDQ-M;;[
M],R>2ED 0'?%5T\@QE>1 OYS2=4"K4'P=#V<AW.CD^TWI'DO^SG'7U*D)_<J
M K9+2Y+F8+;A[D)\CN>6[OSH*%XGY10>WT0<-+XIF,57UT<?6EYK+'WLLCM'
MF)ENN&[6*?O%=+RLZ,+DTJK@;HPGL(]B[*WI5R[\3>\CYNN(Z$WMJ&3Q#6PO
MH,9C4UQVD\QW&X$.6[[<U)0]_9LB@M_!CW52]:9<WOU7*EWVR*<1'?P/&FAM
M+=(?WN$D'?)+/1D\B4D!="@.#]?W7X?:X1=N<3Q)H.5O/R^YUY(/%$#HP$.J
M,SA]ZOQ#Z.Q@NF1N@*&XJ'_B+6,0N@;:BI?E63%GSY,U!=LZ)=S^;G9DV8N.
MAS@X-9G S?.Z\"I/YQ".SQW U;VU_S0)]<-0"A?^1Y_FR/(H^;' XUG"D/O:
MI4 )#A13ID.1(M(A/9L#"1[/YOY(.G?Q3C_:3&XXZDG;<_UL"5U-!&+;U'MK
M%G([>]G/S[?M3<@HDO>T+\G!A7:(SO?9"TJOL5Y-D#>U'R)YY7\^_J#0&C*D
MT=K00(27/>2$Z:'^UG.AOW\=.!L&+'QXB)ZOR:K^$ I"2?@)3C1%G7-T&E@7
MV#6<4(SD">.)P&=FZOQ*#'BAN_Y_Y/=?A8#@>^?RTI:9)2J?G7BLTZ[JE,&K
M;NZ%#%&S$$JVY@$SH(A=@%'8E*(:K@-*09QS(G+;O5C]XNRCFV^N9_(9G=VV
M"^8!"D*@7U#>"7*+:+R[J1VB_+#C-]GO@]K,TG#"\ +;,U&2^@Y=-BW/[Z1\
ML9()$\E4]9)-"&G(.SD8%A4J)9_OB-%%*N5YB6Q]L?PJ';.LV^/X<752/J"V
M8D<*<!F%=N2DKY:57BW ;)QA+ATK5O@B05QE@%%@!8OK]3%%%F'QBX]'QG*Q
M JZJ$B,X$;W4?SS,5A.<5]I]]51/BFPBVCQ&&3DZ,EGD%T*7&JMN>>@0LL#4
MQVOUC&L3G(/S3*RBL**ZL0H)0H<,>RX,"-'KD[XW+A,MR#<OOUPJAB,$X%E^
MCDQZ!&C3X^"LPXH<<E2EYT+A0KM?>Y%1_$PL5U&XG+QNE?-@;=O[4C'01W;K
M=9F)P:UAXA%<>_!9 "$I"4O::WWB8KT4S2.RJ,.<-# :\S7V\,37NWNA4:04
MYAQK'-2A_0PKDD= ]?I77;X(Y(V76LHICR8]/;6[)0[';8NWR\&O>7_6,8W6
M!6*[)H8?3@^%+5R[NS<GTU&UU,R\ PD+44MU3C$+D1G!@$YVT7TCUQWN.<J]
MFCO_^2-P@65%-!;M)U>/^ @4V?>AU&W^FE1&*F*N; GG(#7G9^4/C1+_O/ (
MS(S'.^!\L=+ABA:(^*"2H73JD8F!KZ'1&E'Y/A&JQ/%RSU'(SR]MM\T^O%?/
M-M,X_:WML:-'WS79*#)15,UUL]!J77-(3]F0;&6\9N]B>D%;'46-VNN07QI)
MBP8)89>G]#9Q1V"X31.CRRBZC(<:"X\"0\[.QL">;>T>OD0+8O+80<'A]+T6
MHLF-&RVMK"6)=\6>K]18$TEB)<9X%6+J8YTF1N^1-,XK4[3BYZK(;)XABM>H
M&\/-JNV5+Y@B2<\Y]\C<Y!]-U-6)INWH[2QDR_.C)"4YOA$1A$W:PW)9L*S-
MC-$:ES1T4="87KW!=AB:J7FQ8#I :K;R[?>P9)I=WK5X*\.R4=$27COZS9+*
M<M#6F6N&(J.<'$QXR1>A3]?V4A4N-."ZT5%F>W?9GTU%%@ML];]NOY_X/ (G
M8GN"1I%F]?$+KN/8E9_/6*0!),@<U?99>:9-"#1G]5>:=Q?"K>@H[*#&.8(U
MRK?BN]*FLM#*A-!G"U?U1&0R.-=LT5$0US,W0[,JJ3""+CX(*2(PE?!\6-#H
MP*&V PS)'RF0/R'2J']-0I0O,UYDS26>/R<%II_6T2=0;'@+-X(/E^>62#1M
MGZZ4&!3;<+L\):GJOU3R%H?;.<NPV4YTRIK->=Z$NNXGK66AFK_OWB0?O8*4
M4]UW!">JNUR*.+@1O;GO*<TG99DF+DN5B93K>G9@.DU9:F-=4!(O5X:NW5)P
MR[X=^RBJ/O(A<RZ7D<$.9D+9JR+YZ]+1K]QP2EHI=D;]D=]#*>@X>;&7+N\<
MK9>"IR+2XVCJ?"?Z,SC3947.-++D"$R]4771)/R.^^M515QT&U$^-(L4[<XT
M)I26M$1LO&Y5%6L*#VKKEQD9Z$-TS\2:674+SM_K/320_WG -=O(UCC(&?;>
MC%<H-6@FL\?KIFPL?*NYN(."?KR:RM:>T"IE3UEQ,<_/94R2Z3;H[(IGSZG>
M_,>*Y[X5O#Q3MC_Z?UN*"[E9\O5KA@3%:$UIJ>@#UU,!-,8=YBE)=[ZY4OI4
M*=9EW<33-8,?4)+.R"U_X;/5^XEEFYD9A@WBC=!DMM=X.:_XPLT:@X5-\UPI
MF$Z8H7X=.HAV+HPW-7'13>*DH;2C%"@N85L^"';>1!]YT,JJP6RO*JLPD@_H
M(G6<K[NJ9 ?[*/S?E8NG+&,D/2-9DZ-U"I$A0?87^.BC:W=X.'QG<\D=(K=F
MX[$L!Y_;JH*90Q_*3PN?<TQ_WUH.FQ9+?488#-3CS]Y:+7Q\2U8,R&P:\-2F
MF8-=G%P<[/!=%LF&:-@Q,KRZCRL?@=#R,,@^"VQK3I.)]=FR(7?N$'RNC.#F
M/8H7V18A& 98C'@9I)_O,<&E:Z]8!BA4+:=) 5R6Q,/L/UQ27/&!X?3S)I'=
MR=\UQJI@-P,8[T4-,4S#SX<!4A07_:TJCYD97##O&:ORJZ8+TH!IIA'9OMLW
M(.H+_#K=Z>R^?<)*O;0W!ITOB;])9$:;?2Z@"&I8GXY@5 PTDUU;O,21-<CU
MJ_MLF4PZ:>;'.*LVFW9)G=(_5% ]@J_\086@&9O$!)\J_$E.#IG9 WRCK*B'
M2JBJ[ -!^QU<H3]\(GY(],B+Y:@7RQE2""15Z6UY%$8B?P67HO3[3X"*&+_Z
M/^_GB T9CFL2PUC7 T\V(U9]3Q0Q3$;/0<J^+-])5VI+70H795R*YVJ"&E@<
M3=CX#;L<EBCU9VHU%*4?V+B4ZEO3*C%QJB-=(H&1;3%*/H\JZ2:HYQKBQ$&9
MKHT<#1[MP%/E[=2H"0))V?K/JK6$*QCN1FD;T?:L+JG8UG,G(V'E=RI X!JQ
M68RVOB1\YB,@H^QU]"N67V#E1@N$9\2S<<PJ+]Q>DH/"$BWX#-BAY\,:(6TL
MQN^W&AGT:RCI2=H5I*HU7SR*?D_1/,'*?LAJ;Z34I/2R?C$B]>1-PNX+5QNK
MU_3"%>J6^8?9_FPD%RP%=K6_$+D"LW)MXZ^HU+^RK_MW5DH_(Z0V'T$73=L;
M'M[0/-@4_D@_=UKF-262?Z YKU*C"_J\U9<$N9D$=FQCT4*;ZA4*ZJ_ES!$H
MQ6>UG%:>Z+Q3=-CGJOJDUZ.]1GN8F[Q.6^L2?L_"MSH3Z,-7LK"G;*W W1AG
M+X'#H48FDY-Y\</YC4WE^ .QGK8U[Q67]8P[AUX_722#E'Y,_Z*,T;B_".*[
M[(#Q__8#=AC 7%;@<BG"N;7MH<3 Z_L]S[]]A,K9>HH:"(=-=7U04^7I&A'=
MK</CB@GS*-[!(N&J0+CMKU0A*S=7/3:_=(-[T^ 5[!/V,>P66'BW33N+F,AB
M(>PUY9OE9.^*="-#\_=&,'[.]PF)]62SI6:).,K( YU*Q&PE=9Q&"W$ULG1I
MK^'RHA$3!ZGC,&/E1@B(_%V%[,R;9;[J>K:^FB]DV>H>JWO:+: )A.V6OFLB
M90D]9"O-";,)Q/S&O-) 4?-IU>$:_5]?;ET4U.W-&_4^XE(RVH:K'Z'0 NE]
M\V7/Z5S$/JC(S5<=7!"F7%IQ=%L^>+X\V//(M(C@E1A\7Q1"F\F(G[F5S/)Q
MS<+>WXTD$[$N/B_4X+/]:C17.K-N8<$B?4^J$BFR00XFW%;I*)R46DO;[5,)
MNZTX(:3OQF2XCD)3N6_[T8@9*P_$T+TT).B(WGN6;^XOU2&0C(R7DL48NCBM
MX8%/<!7<:^5H-/B?'L9*']4C,::>A*O);S1HGQMWV1G;I!PE5,V"5Q1\*KGZ
MEU3G.*X6;VY>J)UO%2Y9"X;D-#)R@J,K2$W>A[[0]T5^!2F\T?BB^/0^P"Z%
MH*Y:/\8BTH66XA2DZC)"&6FEB[:TX]3V9/_HQ=LIFL9)"A.Z-;D-6ES!L^"E
M281(7T&LFCVGWLKL;"8-%?],8S@=0?:X%%5%,LVQ]K+-_DA-8SG1%<UA7'=W
M,EISX^RPY_C_W5Y96W DG#L"^51(;R[W+,F>A<S\\L75%W(DP$&5$*'%Z6:[
MVP[O]=B3^[1)K2H.#()&#LSNFW S[,Z&XI^?@KGETJKUDEY\?XU_I/:LDHPL
MW9>_!W!=9C]1\+#', ^9U=?73\#Y8/>UGH0N_1&0/[5SZ/;::K$=M9XO;9QM
M_I*"FH7.O\,UN59A.>G0+'99H-K8]C*+WE!.CK1_FV07JO%^[(" GIHD]W5J
M$UX84"X27*VIJHA1>VDN2>MRNGVML1V*'H0_6%6&?'*DV!3EET9FE;.%X(&0
MUK*7-$X]1R9G4[&]'4?1^@CH A\T)^!B2>A2I.W]OPZ,U KDU\9S]V>8:<I.
M(.D,8#<U06YV)0W!V+3?2+_.!+!4TA/6J.[A&2>^1M\PLST2PX=4$M22S//5
MFR98DH#2M)\:"!?B[9M]C$K%;CI03'G80_W^"+S];NR,=AT@VE"D^G,I)Y&(
MY(?P5#!?D66!B-Q:BF(3M0!=V8@JU";78,BO\>APO1*GF8.SCHMLY606'L1A
MF$LBUBOE\>+#G8YH4%:[G?TA/-TV;SG*H )%[CJ=L=NNWK,/86P7"RB?M:9Q
M,=[%E2AW/J,WG4D]E;U:*XY]Q5SAS34;5,@_PKVW<8=3R)!GREU;U7S)W$'M
M2>G43_D2I0R%8-HB<TQH'U]%+@7091IFL(*SRATFR43*#A^#K0;).=Q M4K*
MO__^FGF>'1T>KHQ"3_FI)_<JUMJJ4D<&\W,?G?R/O= 7<9), W3ITBA*><XW
M1-U':+-&'H$VQ=?9D>LJ9Z:FX!<LF]+-=\W.V"@IYY\,:'H']];VYN?Y"QJ$
M\F.D,3+.,GXT'!!V+J@WGACD[3\7:;)NK[;GQ*)^'S6)/>@O0 Y9ZU8JG(5T
M\A"W!1*QN5$PRB 0+X0@D)%MU=!"6PJJ4&<DI](E?_2\8CQ]HN91U7EYNO?I
MJY0-G5.L>4L\[X$M/!^NDC[ /%P6M )MELS=:W3NL?'('*",;G[][3E&\WKX
M7?>[$1[%8C94%7?[34UH.7R@4DA->Z99PGL I-M= :T%U1Z]3L ;1HC'Z<*$
M-*-D;J1#?K!,M$Z B]B6T_O-Q;XP:%*R%$?VU=/R? ;G[7#N<78F\-Z6;@2L
MW?_@34I$%7\$+&O0BFT9\EP+1R@_:>[)/@+OW36(J669,P.]$$9T"PI]%&NG
MJIN^($[48%@T?,Q,9I R'R%!;H$WPMY5&^8>G^T<5^1VZ>_Q!.,=<EP1$Y?Y
M_>HR1*V-GE_<3<"@T]R2))R(^X@W,L$*$=22<O[IYDR!?Q)U1^-'43>^]:V^
MP>J*(U:G'8$Q^]B1Q1X4-GTJVEM7'5R9*C*!%Z7/:C8CF2F7Y^'=>9RKI<I3
MXOR20<R]6#CC7;B921)6?,-]ALU]IBL..D874:Q%WW %V<&-98K=HCROYNM3
M; (?]?I;;EKYI@FRO,[D]V 6_'F7H :QFZO"C+6+P$JYB^VE.XF9UV:H,LJZ
M$EZ^+'DG&1_,>8<H(C"5\Z9FYE\0 ,@ZSDT&58<"I0/"+[*&'5A3(M,L60;+
M9C@Y5P1<56@IOZID9.9\$6>R7AH1A'RD()XB8^MM<V<Y2\H%]]/>]\>(W\GE
MSPVMZ#UQ:I9P<&52[M9)P7B^\I'B@W\#$-F\UB3D2]O).W\87P;>$O)\Y2R#
M(=9&5[1-8AJ)?/@A4M&^AR*QO,^MY-OK7&+&2-5V F-24KE>5*H'[N?<?(@W
M9#UMW8\ O'8O(E%L9YD,R"2)2*1AX>Q9TIW1L2P=^1ME<73QJB]!L[[+K5,S
MP_FZ^E)V^*,Y>54ET2&43HF',8?,:,*@/ 76V %3##GZ3@,NG(%X:8*'3$SU
M!.>(D\3VXJN:!#+++V OK_OY>%%V*.<K;(H<QQTOSMGOXG<2&DV/ *8'C[UI
M==-$B>CH,?G']:W3T9>,.PA\VYH^K-REM&(5X^]^%5K4!;2.X F2SU'5+[7W
MD06-ABLC&]VQC2!?IQM=1O3>65K.6OP0<:K+XWL@? 0"*YMN56V1%S(JAR.6
M,]S+:]PP"G3+,F\".P-/UIY60Z_#X&6-\N5 $9H.6+M*MM-'YGBO9D"VS#+(
MMH=GH.7^8<#Y$3BN;\89N5/,78F&C-&ODT,^U&"<?.K NL73C/F2$6]'SQC9
M;%<6Z("Y@X-6D*A42SHO1^=&_A-9&F20F9%G,K^;CA]E.'YAP/NJ+HFU2KKB
M^1Q?VNF1'_\ "DIXZB@\7\\(<G:"K\2FNK-.B07@*R<O#6U:Z5YH4JDWZ,/X
M0A*R?G!Z9B!W2]%2H*^[*&9>^_D=GB0G3OT[JBCY!%_VP0W=T-*QGIQ0M@[*
MO5E,>)%V.F44&K\74"9<K$(FZMIHVZW5%M$C(VM3'[-CSJ]L)?PHT8HEF91W
M;HW)PD)Y"G2Q(N&LX_JE"[$M%AC5H!DR38:LU4< R3^!:)J7Y1NA:VC?8@01
MV,&8*#P%V'WWZY>ODE)=:S6$<WZ-@TXIW%ZMG[]88V0GT<LP/GNWT35W0@'1
MVX[&70)KI0&NGIC.SW7T__V]^'5<?&BR.!VFO]"MVAY+\EIM;:SGAO9:A )7
M0[NRT&<Q"O8V_&:Q<06A 3"94*OL:[)M_N>IV_.5/,6W$99J4SP6L6MX'-]5
M6CF_$L$I31 H?$_4JF^--5=PX1YV3M==M]=.1\FS3%/5TX.6NA)*VL\M<!ZC
MG7/#90YA2F 4AX;'^)/@(5!_O/>Z^GIH7UK.EA>YY43<=]/:]MJTE*.ZV#Q0
M.G2 /D"*T]QI)D#S-?V6=)WV>K*:C9FYTB-@Z,^R.YJQ7UW3K-(^:%Z;UM)&
M$?^RSH'-C'.X80$7_GKP1IW044\?V7L.%_Q-_5"8 =2DNI1L*,"6TZ@=2&6W
MA[QU3G8B1M2J;I O4KEMX3),Y6*'D27AEI$H<L]"J+ P9"9K:0[6PXXW&(=[
M.!!=7KOTGDQ+'*E#0.>77H+%P+/4'C#<W#UHC_Q*]J6"9<&Z[@W1^ZSF0(6!
M0_K >4Z?C]K^&)$-VS$I7[K<GI?OU4&LZE3(BS(-?IVQ/'7F%"EV5PTDM3,<
M?#XEVH%IEM3V87:Z]-2NX4?.@6M"GP H>/M4]U3H3*30=HC8L3WCC9?*2D!>
MCZLKP52E]T!#Q(9AS@0YBL!=L>+*!X/)36].MNJOR!2&XS'['LPBUBPL>DS"
M4ABSA(T2(&\ZI[LP%+'G@K&F$:A]WR=GHO4]@N3'[;;#,%^=#MY*RR("*'LV
MS HUXZ[Z;X:<$?.1.P^QVT4?:O2T3/DB<E/G$H*&E%LM5"H_)Q LS.GJ=2#R
M'MOZ\"5I8_H_H><-5*=:FH[J+U[%QE/"_F0VP>"J2*%@2O_UG?I3@LT T6L1
M7R0O+\%&%$W,7+.G'CS;?%Y2Z?E7',//A#F9!OHD1]>RCMDFGQF%'=X)F#B)
M+!7$;,./VRM8H"")':0^Q*O*>V6_W5;\.J3^H_.LQXW7W:6/V<"3\+2$:[%$
M)XS1UD3N!^2C,QP"]VRS@0G;VL*UN\I1@JQIS#HI^820/]4V5$F9N>;J?7Y+
M^BE'(;>7W?FNDY/=1F!/R&*PSS&IU0C*_!>[%6\%$3D>4C A2R5=KPZBYYFJ
MQ)MQKE[.ES(%+3)-D[5[1A*77]9:A#0M"6-E=_$QA,<).E^A]FL*W,YNDS=-
M19 :5LU43_B:C7O*]Y"8*X;GNO:+\%/=/S'N.+XD)1?48Q-2COW!\DFCKO%T
MG;*5ZA$H^75:B10@^C#E-M3AIBE]0+AV4'I(0L=!LD ]:?=CQ5F<F'BWA_#C
M1(9Q5-\S_3'N&(P$ 25V#J+AES[!9B0;Y*77&E^4",'N,[6:"1/"5882EN&H
M/PB<,I+.4<HIIB(<5I!K(G39%/AXUYCV-ZP\POBO3&1'AJ,W\/K$]9Y!0MY.
MK(_%"GTPR:?-'(Q:/M3']16Q\LDB4BO,XBTW<7"VRV\)% H@B>X=!SIDU*+D
MRY9I)C!IK,JS4M@>](3?$%//ZZ7[PI60>W>P03Q]?9^T6R:33!.^\?G)FMEE
M&3"2QZ=PS-6#Z6QH&"3:3Y# )%'T<=T,H9QQ2_@6Z_D\+U[<9>6HKL=GN=:0
M'[(O5D!VBI<[/Q!D10*V<A6]Y9T$#*0GKS%:;>5%Q2<8)U*VLJ ^;PF_SB?L
MK.NY)OFFVD.HZQ@F,C[_)/>MTF!]H%Q<W,UG^=43(L7IJ4!FNK$$^G+VU,\O
M:*(P>PS+.BWR9GZ+M,GJD&U++CO:7@?G&['WLY1OYVQT5HWZ;F_%J3%_?">R
MHD^J;-\FMU'-G++[JB*%C_E_GG59,J::Q:8C=\WL\F,9<;Y'T2)C_G3"!^0L
M[@53=IB##V,LOPYCSBA_B(5__88\+M^#GRIR$BZ4\M,TVN&3.V06JY585YC;
M;E6-F$*4.=\X>HR0?!5&^[I@/>$1>SF6EIFH08_1.U9WD_2!N1T'&K9SP%TL
MQ))<QG:P'@F.-'/=\WX$1#V.AG5/C^4 LXOU4H UIKAW<!#5)!"UO\R"$IW8
MH71+H7(3,=C^:<_GYY_<.K'\5,[(PLE.QAM3F.#C$^(M37BZIT>O'1PEY4+>
MHB$@ *E8(AR:G64NU7[J>TQ B:*-?.3%,_?Z6WYM"I$%/N/87(Z+#I4>NS$Q
MXF=ODAU<\S@-F[6^#5''6N+$D7XC!2RIGA3_K'$8DP(8D&AIOL6;(U)DAKDZ
M+[--&KUI&3?73(XW!&,^K7PBH*T3_U+T4I9,&:&L^>7$-5.==470I_<<&_V!
M1CP2J7>Y%$(G>@F"OF7IL6PE$ARTR:2Q<J:'OA4<LP"2YVNO#^'G4]5UK8HJ
M9D1R[G0/6O,RB72*C9QX125! 3.(7IH7Z:6%L-VM1QG8_%UC&(L[!_+2I:4'
M02[&;J!<GZTR2M98RIF(Q55/XN7,I6:K7;425X<=3S,KO90<#0;#7>JAILL$
MU+HMY.(%GF)Y36]^W6B?JS=\CYW@73:(79P*82^K#4>,(J@0#(8X(>9=>MK0
MI+(KH$BT^%:E%.=8*1:0F#4FV]OGQ?P_E7QE6%O=UFTHM!1I*1"*:[ 6:8N[
ME.*%H($"A>(.A> 0M$B1X.YNQ=TI%MR+:W%WMPL]YWW/.?<Y][O/]R?9:ZVY
MQYISS#'7VOO)WB'-4.VFG_# 1Z8[%^<[H:T<U38>_?/;_SB@\&GG+D-T<$N8
MB)7%T)P'?E2H!F4 K5 86T#YV@HWW\GOVCSZ1UG)V6H;42USPQP252^G/B>'
M63OJ@-6J[@'((H-_K)>8K.N&B06IH6G#O%8IQRV@.^I N2>TB2D7P@:CANIU
M[?']1]B8$L]_"7MW]3^ZWVN2&"S^RTW4CV2<C3<%YZY'LG!MC%YWAM"0IQ2!
MP;(,:G%W #MW/JPV5^RQ8R7UGA-A,P$M@:$S"NZ%MQ38R=TU^5NAT.Q6;@\.
MBPM4E[5K_RT^T0-4#9\C99^MSD/[>+L1"XK''.'N8+&-?NA<]30_190IX6XL
M^2/1PPL-PV*^0)C1HY.(MS??#?6-LF75Z8[S.5D8*RWV<^TFP-U.),J$%&%C
M'RKJZEFF.JTU:+F/!=5L*T.MK&SQ"KV^8LQU@K"Q8C!/+'B09@:1TPZ72@)Z
M5).Q@Z8[D,G5PJ:ZI^@)I\.\G+FX%5PC?"7'?X#J*N/%DAS-1E<5"=$(2 R3
MTF=LLQS<6@0H#TA&:)._ZGE4QYD]AK,XZYV<-*>@VQW).%!/6V3WA7B .'N3
M?2NDK;+B(?[2CBZY^$&SJLE6PPU-MWC)OM$B7F!I>9+]G/9M79S=)::D"X1(
MNY[)/+J96HM!Y:@E*.1#>U6D%<A=@I]K9Z3BD2'[0H$V5;A":5VD_!F#6!M
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M@);#L>#K%IL[P-7.INHMFX._:ISJ,8/X=VBTUEL/C_"!D3_V?YQG_9>>1NX
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M0L_'P,S.P<W-34XG(,+/*<S*Q<WY6PD,,@H*.AHZP8L7!)RO25YS_A\_SQT
M+&08'%A'.!A* "P6#!P6S',/@!P @$& ^?, _CTPL'#P"(A(R"BH:%"!VI<
M6!@X.%AX. 0$>'CHK"]T'@"/A8#]FD,"\96J,1*E$PZG?VPV,M6;JDY<M<D3
M:BX3YP 45#Q\ D(B&EHZ>@9&;AY>/GX!04DI:1E9.7D%]?<:FEK:.KJF9N86
MEE9 :Y>/KF[N'IY>@4'!(:&?P\+CXK\F)"9]2T[)R<W++R@L*BZIK@'7UM4W
M-#9U=??T]O4/# Y-3<_,SLTO_("LK6]L;FWO[.[MGYZ=7UQ>7=_<WOW&!0.
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M[?0'SZLZQYXIX1QL^4XXM#189QL9$%)K>?F@=]ER7XTBB9ZH5C@G'(?MB><
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M!C=,$S:$^?&HD.R;B<TT?2_ LZ>)M@J88UW/.TU** V&&]*>,^0:B@Q*AJ-
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M/('$C%M+HE,P2"1D%TDKE!ZVOX[L6*X?:TF-=#ZI[X!@Z[C\/,<_)'QZ!DB
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M*\:%_ <FRC>Q3!6KA F;)K\PG)63!R['WS$N%P:Y$K@RV%=4V+'BKI_]0+S
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ML[^U8R@]2S1RGA*UYA:WA79E61V_XH %\]Q23N3V/'KQ=B?.D**3W*K90/J
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MA0JV* R#HKULI4U0YK4Q'D]"NRS:+#)\GA16#"M/6F ^Y.DW:;0!8L1@VJI
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M>QWKWL2\9I5>*'21*+1_9KI\ 3:8ST-N8WF6=AGP<Y_6!#K+J\5?!Q1@+48
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M^3CY%/O;,<&R:]VW%[!_YM+;:UW:7\SZA:DRH?37$P>VBYO6].H+)%DRDD!
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MJ;,G@%P==#4'/H&T*44U93>W%9!9AX1X2&Z.N$V?2X6]>ZK16.@!PG=4"_#
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MO7S)!<%7TU--V\ D6U7RMGH8&$+R<,NA-<)2[ %K-<RX&%ZD^7@CG@M8[PR
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M+/0R5YH+(V?_S5D@NS$-S_[!5@8M G#JJ&T<+8HLCJ,(]3\<T,JCX@".DCB
M&[ ZQ'[!C+H:"L.U1V-/%##R45E!R 6^K@ 1UEF4S*MP6SMGN:4J:.CJ(?=P
MP^X9E!Y-6*"B\\0Z"_H;'\;<D<RDQ=VZ2AUI6]R)WE%Q.JCCBL(845I"BD>U
MAFI/11RT":AXV^?K F>S0RXO I<Y,F]>RI N&U.7P=<4,4%6,!/I%^M+MP0E
M,@!=9NC_]Y#8MH[R03N=NK3^;*UJL3:)=4B'.2G;38&9:@Z0Q#@XCC6AF,5:
MG&>@(<L?+Q99X"U*4=,[NMJ_H\E4"G;C-WOC2IL!Z]BWHR=?G8B<,S^OLRAG
M3X,I5&B,] XCV_<=3 ]N0;4:J0VX\Z/2$U"F!3['%L5;?IX1_KE 46%#6=4-
M I #_+N &]4X0$D<Y]\8E'P9<)FQ7&9^>LCB+RR&H%R8<9*SN.!&JI7-?)U%
M=;7I,OT"<91$X7"4L4,!;<:4QI/P+SD7"\WE,G@ST@U^Q"'B*._U,S!$4=Q?
MU'"U2"UQ#W+,";<,57U(X#&8Z0^"Q9R ++\%  @\HPM >WVMY^S:\7%2(@QO
MP,.?P-M&-19 9BC=_\+HFZZQW_?2S*7[(,OPO5%C)EC>PSC KUO E<J7NS "
M4N@I2"4?6R MW8B<H8Y[3>D;+&8_':>I'79+$?=%^R:_, P.#B>!J=H65U@!
MU.,4BS5F6SJ]??BUZF/.B1'X\-9[+_''Y4>UY^(VX-',)\ !S)#PCT3*%J:#
MLBCV\K$>LOS4D<E7AS>[D00XIAJ@OZ\!74Z6F\*]0&S7[%794.P,I+E;]>6R
M*/Y>JL, SR[_C-J"WO_E#^+8\0"%1,W:0+UDDPX\!.2'D6>/+E!?Q14_:M:F
M7.W["LC5/=>%BN",:''4V/X/EN>;^V2K3HK=1^U$OM* >V=,=+:>^Y/VRY'D
MER.MN\@2XL@2^_UAWKTW(V<MVV=%(,>++"_/T?T1'\L4LG<MD*_YH;TV+V\)
MV1#"5/+7+:^)\K[Z=*N!^4F[MIBC])=*?%JZLX'OZ+/?9H8RPHS]-E8"-H+>
M(@--_:R]SXM[.MFE@S!-2T3S"7 G$I]]:7.:E:_K1A9?EK-3^5/VG:.S VU#
M8[2^I.8EW>Q741C:\HM=:_E0#(*HGW/:U^4U+<U*7 DV/Y2 >>_VOA[]W-J]
M?S<CH\XSX'HOLGLOBA^,/ ZJKQ*6'BQ,D82=VHS*UR>Y";0TFSB[JXB3Q")C
M";H7^6'XR3(KXM7PS<*IY?KT2,TD2PC):OIS"]Q,PFK&D2,7$ ^\*T+B N=_
M]C3LM'6A%NA^LD[&NEC<44RH90<H*7UA^-8B=;=*%.KT0B_?[%8*6_1>E!K6
M($?AVAT13=S\J$,K1/P(PY 1/7*;$GFG?T'E&J-<)1-R:;BQW/LN2HK@D,U1
M88[2BYY47[*$N BORTXBS[MR<9C)(1XQ @=-P@MMTFOXJF3G;G=+6(O!;BB1
M5ZFQT./QW./Q(H^:_7*[KC%\4F7X*@ORC?Y8)]XR85>8!FXA [>0A DW,A_B
MU&C3\WX3+NS-M^H>B8EIA'@IVO 79+5NTU)89W].J0=Y60K-F*JAUM3&\R/X
MLW57TV6@F2UUX-6.B5'6U^NX6&3'8/L_=_^A%M(M*2RZYJ>MO8\IF[&4;"3)
M:$L)%T="FI<R42BP=._K2GY[D?@$O.2",EMZ%/XS#[(@V15IT3I/WI^= 1U*
M]^?(*]AEWW&S=:;B]!4+U,].<4OW(<LR)QVT4GLK1)81$ H$[R0H,076?;!)
M4$^N/75RI\751P4I)*RP8'[O5O102N CEMXB7#>YV@FMR]<FKE=3B\)Q6!8X
M5(GH5#=R=R^.QFNXJ[ 1?$D@=+Z5)TP'/9B0HBRJ5!\^_-S$.,TQ+&"<-D_>
M2G*\NF-,:@7A&'0D!>/+'K9, J76'7:G<E5>H#_:5>VJLC>]\6!%N;):\2;3
MQ.P=2O&N/+_0FK!'!JI)9:U.;L/KSF(V*>. :Y<B;A(ZXT#,SXYJ0"U[>D<J
M"3L%AF-[^XXH6N;7A%U$]QA5E6V=E,B#WJ7=S)2WKF((FXZB>/F%WVSG(F,0
MQQ>E.6^A'BQ.2Y>.=#.]),DO:$;@"L7:):0!KRF\DGR='>77B1QZ@R9]E&\M
M8*;#U+/=> +5.AE^$@[<]UQD(+0<5)J[=HK>VN&F^WA@-]HLWH-1;!]Q\Z.I
M4!@*(PW@5%J5]=BWK67 F,,AC]B<0IL@MT65B[9'LT3OK6PDT&+L/9Q"^:U2
M10MC_DG-OD97^Q.0QGB3PB/O^2/K80;2/TV&A^](=)]G]G+O:YSJ7M0G'@-@
MF;=5!7=C@^"#K^3]>3.+<3;V,ESH[F67F@IJM+N=3X!V:^XK$OL7G<A1G!$7
M\-WG16Y T3=)J]"$#0&V^<5)W59Q' W*_4#*'5FI)9<1>+*RDH6=&.A&%UL;
M1!7AKE71[+2!U/4'1^VIL>KC[$CLSL$&]@;8LG6I4D:-H,6M3@W%I:6=2_5M
M/'$M.] 4#SRO1*=Y>%MT!!N'1^G8E$5>;80FJ3:M4D6<@V1=#: 0G:J(YJF1
MMNMY6&1S&[_TA<HF87,6<?0[5 4'850$&Y3MSV%J(0V%C"'6.6X=3M?G$WA5
M5%TTX0WEHT48.JVT%QG("(\2V9"2^@)2(;JLU$E;IF>%-"5CA=[K?68Q#<NW
M7T23++&#I!1>X^K@\W<ARGQ^S+5R@P!?'\'R>^XRK;(\3>V.36E22I"'OMO/
MOA]L\@(CT$^ S>R1&B-# 9)LW(TJCV/L'%^VP$*^HLP;9 SHN':*<_L\7.W9
M:;F8%3.M &J)$I(WZX8:0E$*U&D/],/VV1[$,/@18OS26I6<U2B0>";8$<4S
MFV(V5&>B$=1*A')RJA\^P]F#K"PV#TH4RY,E9,I[)GPDK)IF+=:;CV@,[&9[
M?G0$K5&70BVKS13;9C9ZY8]C25]%K 4<1<1!F?V=J+_'$$"0W7:.4XV%H!(*
ML G3M9WGI^PNB)R?1!:%!N_B-;1]T7E8!,<#6FW"HEDP(VKV=:_?[PXN2>G<
MT]WID#?9.H"7 3"G*'8O._8RR@%WY_819!EL.73Y\ 28M]_-=#MWS^Z9I#EC
MK_Z0_W@D$+FG1;G5@T%WV_<$3!6&LWC0ZQ6]%\ECH:JKDN>1WRM3$//IF1BM
MOYW@;WA<IWZ$53C/[AJ^^DKN!YIJ0J<:;A!9VY-8VU.TK0>=SK*?1T+<)IG(
MZQ79S_Y&Q.2/HO=J0\IS7OJ: =+/4_BN?0YI97_$"3QCU<*R0Q .MT+J'5_]
MZ8*>3.W@;M9;XJ@[^9YZN@., JDLO7M(13[<G3PW-4'\>4:X6-)"-<,-[0_P
M5I.&UQ4T/M!*Q&+UIDQCW3^ X;=Q6"+U:Q?9;68!Q?I6G,.X'3.M,5W:LM)?
M_-/%2%_N>Q"2$"W2P(1N>C.^2 K2=-E;JDGLC*E\[59DG/J-OV_[V8OBZX35
M2]#^GC5G]<+\C3(H>>- +VS)'5I")B* JVUAGN%WWX+Z5]_BF*"]</&]R_GR
MSM<H[0=<J%S6#RTTDG(8V#0'R2OG'NY)]Z!5"Q?!%=+B\:"Z.&Q"I6H;H2^=
MCN=#@!5DV==3_?80'=(BJO]J$<E_M8C5?[6!4"3'XL[8XES6-+:3FB9$FID1
MB E\T4HX!@QA4 I97("2EO9BQ4.\#1&WUG,F^ Y/=!7-@U)T3-%+//S:D24X
MM.-G"LE^$RYK%QEHF=;!S./>I]E6\AQ;,-SX<UFQP5C2#Z/OWPZ>:!ZMU+6,
M,Z\V-\0>L*\G(CCTY(E,&JN-T3:,?:VJ2LJ+]SMC)_8E6 \%OL&MMZQ] "_9
M/L"9[KPGX>'%QY)S,-,2H'ON_,-I_DQ["D/:UAB%4\HD&@/>>7XR!0AEM(!T
MF1I8M'=%H0E_-$;0R)\$O3*#W*EC#?L/";L4():J<KXX9;!"'.+:?Y,U6*QV
M*IE#)G5>1..HI2%",5;"_7K<CC4KXN#R(-SOD25U#4:XTJHA^5,.;H-S'UF<
M!_58:IWZ87^1(Z89#1W:,[Z]4!M>!WE520YV TT6!RD$PAY=LP@SD"G&'V)S
MOTCTF89ROH._44O&'R1G>]LL67XD[9S_4[NM2M852Z(-U[;M$-87L4=?BCR<
M9%"_G_H^>D=9[#/!A*]9(D'V^D_'[-CZ:B5QZ7QE7AEMB1U1$K.FXET'J]-V
MO'A[ 5'5N1[F[,J6'Z*T)J$\N>@DMR8G>E&$0-JS WW'56+$(V\U+^BYI0'.
M;"="O$ZID5+V)!H.EM$HY_;V(4^QA]'I/$]9@UT-'KP2P1^VJV=?W(0^PV^^
M%?.*M'*M^=(2)R)7C/D2@_\9%ASA+5):J(%I^@U1[&,S9"W]"K= R_R?H%2$
M4K,O'EJWR)2+)/ZHSD!@GD=QL:>>GX'"=3PA\]/ZHX'QC'L/7[<DWSV[RA-@
MG-@>LXS7!EO\\N5-@ OY&_42'*C@-#+-@S2Z0[:N=@TZ:47.B >/O5OU?I;>
M25D\"JC8B;&4S:.+N^A\7<NIA.LX^F>4=M<_',<),M#\5S>)I<*J>BNZ!:I(
MD#3-I->TJ Q.ROLK4P-T)QL5BK9;S29>C[VAF2_!( 1<^NZ^U929FCM:FY-6
MO^ S?NDKO;@TH@@?+_Y\D.T)*(['W^THZ&567F$^M-?:C#WL'CL87F977ZWS
M9[UPR'S 3P$B#T;K;NLW$Q]Z?X XN\@M&NP;+/WV:'S!3).%=-"E<]U"?= ^
M.'47.,B6D4O-L=NA10\,DSA0.OOLZ:TT1Q?QK3DP"M6D!A)/@-?FHZM9*!!B
MNZ+0A&.\G:'J:V"@/ I98BF)HB0FI3^,:Q$3C]7JQ%//%D'"KB:/12426WJH
MB/".> Q2I[7)%,^S^B$==@V_2.'@0_B.9,)B_-<-=!FAKSN2U>B%5: !>QD>
MWAP+#_T)CU=CD1;D:J9>W%3+YB-34?E4D=:;>;@?%A:&Q3[P4QIDAC*@=E1Z
MB[N"3;.E15*#QQE95MM(0]*3?9^_PA T4:]Q?N3445GI,VF6S0NBE5;X::Q%
M@&OPDF&>(V""C%W:=QC)2CLAQUXHL;BRC039*Y+9V!)>Q";?# ;AF\=YR=QG
M*;M5=MW7,=T+RN(HZ,O6:<?A_MK,ZQV+E_3FKAS$2=0?>.#A)R+]>E0FIA7>
M2!4\?+8PBW"VA4JAK.5'D6U R! .E"Q!L2"*?/#\]=H)4:NJ:^L-L NZV&-]
M]+<@M/J[!8WYKRTH([':],'YE6: 773$,QA*!">?]W%0><*#;LOV0G5(63$]
M,^KOOWHPM\0EJGP,PNTY7*,>M#GIVVX-U*NM>TUFMT83P1_?&'VP+1PHQR3-
M94L27!K&IA;T,@/E@6QU]DX!6^?[1A8[2C&'D[""9_]X,WKN3AKM9]T@K<$Q
M?-/PX-G ;R>D#];9000'JYJKX<;BVX5L<$(7.%!]+T_09>)?O*MK"J%N'X"U
M[3?!W-HPDGA&0D(N:JTFI)'9I.WGG=2H/%(A@=1F+A3MZRY$0L;03$8P=G!>
M,[Y""3T84YV/(;4?V6Q'X3R\HQ89L \WKT$^B^]EE#B,28B3>SKXLYW$YU3X
M>D\4O^>3BT1-70/^-F6],\F;WN^.I.[4>=1IJ1<%I1<SQ1=><B*R.IEV$1-?
M5-B#VBFP4[> <P32DY2VV#:!UZ-B50NZ;T9DQA&<"0EL3-T.9@O=(GS)WUL;
MG8G7?ILL*4O;7?&.*68>>[G11"DH3?!#0D&,<XD+<0Z!FJOZTY4X,\P_MYF(
MMI!UFQ]Q0G>? )4).QK6=PX_ZP8C-[H^( 7&\AFAR3N>E^8T:GSNR["6IXT1
M9E^;Q#7'?OO9]_UT,T=F_O "L=]WJ/!F-8FKQ6Y7818%K^7I\E.[ZHD@)5L<
M2JH(RJV;Z"TRG1CH(%HF!1JT\U?'-]^ECGR(FF8]Z%9TO)4).N)[;6SN>@B&
M!ZURZORY&7EUB+6&ZN]D^%O\:5[/1-=.86X='=E@#XM:69>0=^+SW&K/[2C.
M?<]-VK"0ZR:3OO(_K.^UC^-=I#["UM;;3PYOK$^PNX=Y/LB^<MY+HTDHTVZE
M!).HWM;^8PS?^AT_;4,F.M",/\7A<1EN;S?2VV]HNZM8A1L6X_:5!DNX4,Y>
M<KI&6'UI6--,G+^NWO?&TJ)#=.ZG+-90M2VL9QJ<TL>.V>);[MT!U,F2H8DH
MIM#$5YQLQIO]ZR2XE!$(NG1K-30+=?0Y/E2>')=Y*HIPB@@ "I*KB0O%K]V
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MKGU8B.$9/&Q V/V'Y<C^@OE(HM(O0FY!]XV+YC\^FR?M!(3GHR,1VWFL>ZK
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ML#?;^,#0SM7",M;!&5<;:(1 \ .>4SIG-(*Y9=09.B&40>YW?:FL.1#3$U3
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M]C%*Z^+9A;A &L&Q>=LX2BC_U+.!B'J2=$]O$:8Q\\;*<?&2=NMLE:I^=:D
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MUE&'G)^-L'\X^@P[(/54U3GL3FD$E92Z8U8]/ ^9SQ";->FY)2W2CT.T97F
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M#(O^9/K!39RCD+V*N- >3MO8'W,%6U,*4[>L=67FY T*O.]G#(#]X#IA+UO
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MK#<*OV[S3>Y$9+E@-?Z#TVQ"RDI"_YDW9E.TX/]Y]/__@_?OS/\ 4$L#!!0
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M^34F9?.\D7Y6^MAZ=H, T2JH;'R.HP#"+E+6O!#:J9%AR2H#+ (Q4K3P*A4
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M=#$>(R.\6!IV9"(34C,W7H@98F'7!-OG*.:,-V8KBS"5O.-1RCV@0I"S5/,
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MJQ@I929KW3!8^X.)@]ASL?NL3SQ%YGT%3'E3Y]+R@_"<OIKX(7)TW _[2BX
M "O2=]'0Q[OXM<57A/*::%>Z59C6YZM!<3F"_)G(ZGOEN1,X/ZXN=3D,J^Y(
MU"6L?%5F]8)]J.H*6<!16-KI6*X>;\2[ZNY49-$4J6?_]K?NG\CWX#]LF?*Y
M)C4(E4.2FP[,]E:2I'*=3'<8+CSU!<5'4D90N+>2)$D(*DEFTT/ %TO#CLSX
MW<\ WF"T:;BS2ZN-"X5@BA"^*SKX:7K. $^2*V4LX&D+O.JG7&R/@Q57DJFW
M';G%]0I1)HFJ0&J0)%6$H!0JHK-RZ7>OU<"<A9+(55%J?UO8PI8@G2]AN?3\
M7*F/6G1)XUM*^BVRG%'DQS<CY:J;+I$JFZ%JR'+WZBPP,$&3P@.Z:BA,M !;
MD7DI0KK!OH$;*D\P$\T2,X27$&7HV>#"/:J:?CE8);RS*)7S/*E7'MG61"&7
M4(R<D*S\R7!%".*@)3#UF5>^E:&BB!/?<.</2"M#!!,M4>W/!%YG\?Q5/A.J
M!D6E^ D>.0Y]RTB.H,1/S:A"$Q\U[I6#3V*[M/5.B0+XY+E?O#"^(O8)T"N-
M;HETR^'0H^9/C/HLUL**,P+R]$F(O13+,C4_+>=<5Z&T<SVD=\ $!96^,M:E
M=V72&TX5(;*($5^.PX4WG'H1G#T:+O#GU:47^8K7&=7"F6>]F< (D)X+Q;?6
M7'7*N<AR'>"[P7L/Z[T+G[IP9F"E6KY: D/A80ZIQYV[E)#'/P%:$5_9PY!=
MQH%"=8BNA"U7E\\]@UPW#1=(XPD 5?1CSW?B6Q:4H54*2Q#KFS:F,#"FR-&)
MS?Y_4$L#!!0    ( #F*9EI@QV.W!@\  -"T   5    ;W)K82TR,#(T,3(S
M,5]C86PN>&UL[5U;<^*X$G[?7\')>3FG4@P)R>16R=DBD&2890+#96Y;6UO"
M%J#$MAC)YI)??R3;7 R6L8T40W:>9N(XZM;WM5HMJ=6^_GUB&KD1)!1AZ^;@
M^-W100Y:&M:1U;\YZ+3RI5:Y6CWX_7^YW&_7_\KG<P_0@@384,]UI[DR-H<M
M#>7:!%BTAXF9^X]M_C>7SPUL>WA5*(S'XW<:>X=JB$"*':)!RA_D\GG6X*S)
M,H&\P:M<>^#D/@&2.SK+%8^O3M]?G5SF.NURKGA4?._]R6_7!K*>NX#"'-/;
MHC<'2Y(F76*\PZ1?*!X=G11F+QYX;UY-^(/ ^^,3]^WCR\O+@OO;^:L4A;W(
MFCTN?/M4:VD#:((\LJ@-+(T+H.B*N@]K6 .VB^1&O7+"-_A/^=EK>?XH?US,
MGQR_FU#]P,,ME[LFV(!-V,NYFE_9TR&\.:#('!I<(??9@,#>S0$FSX U4CP]
M+GI-_)L_^9O\7<86Q0;2.?:WP.!=:0T@M ]RO.E.LQKH!";.,[ GG+T"_WU!
M^.<%-2IR6R-P "V*1K#*3-2$*30-:\556+Z^@ [N#3Q.H^3L3YEF4O3B%JL[
M!L0]>P!+E$*; DNO(=!%!K(1I&W0->+"&;,QCJIDY9EO>(8V;[T%-8>XPH!]
M1VUD<MCN 2)?@.' =+U)UKI\:DJ:1ARHWTV&S#HAQ[3. "9EAQ!HV5N3E;!Y
M>8-BH4(-4WH+V3SAC[PVF/CJI.O2IO94]*%E ]NQ,9G>0YU-A,9<<I,9B8V]
M'U>42DO9-K(D>N&%0MQ[8HN9"W4'?P7V(+,>G8F5YU32R%!!--<#6%-:'_)X
MAX5#-<BFXR71K0$>L\?<"?;[!/89)^XK#3 UN?KINR]!K.^>-&!HCN&&)#76
M>Q\#+C+EY!Y %DYL:.G0"TI^X_9V;6 M\(K! R),9G]G@"XT;@X<FN\#,/S;
M8]1W04&&N':4J>>&1CU NVY\Y/]A@5-7@(9-9T]<,ETBP]OVAD,J)?EL7++<
M2?GNIX-&P. PE^PR(&3*F' G!<G*QY-96."^1'2)!'L'B#;3COUWC?M@[.F_
M4:".:;JMY9$-S=G?]P@V-[!GX\3(8<*\&UM['.3&$/4'-O^O9[^)N0J;P]68
M5Y2D7><E$B6?C>(6;+B^M.5TJ4;0D"O;A!ID]#.!-)8?%OUM8!3O%+317?8Q
M/5G!-*5#:A X!&@6R97\0$ZE+XTC<;D_.T5-(MA\ID[E,.4UKF1B6XS)[, .
M0SD<SU7?GA;0,,_UB"WMU5S\DK#=,/BX_GT9)8&+3^F,,(M4[6F#!8DV&U1\
MHA_R0/01RO="$:)V9&H(=SQ1$(GGAE1\!-<-3=YBO=>AWD:-9$*B92TL:K?H
MV("08 9(Q<5B@E'FI,)E[.CD( #$A_S]VA!( _K24EE-,!0B8(OQ6M(T[+!5
M$5N^<X?=)D"'BA;$$9(R7K&(.0N$%E%025Q$^CNE2TK-@L6E1_+)B2%S7VB*
M Y^$=6:X1Y])F:H91AN$91T5QN-H$V)R%ZPK W?YW$&MCPM(VI?!(X9*8FBB
MSI.M^*N= #P,Z3 ^)*]6!:-,72RX45[FJZ0-I,1 3+1X3<E1R\;:\P ;K%'*
M%V;V5#(I(0*V4+=!_/,PMUD51P]A$K)=RHDI6MG>6T=&.*!3'01AT\26,N#7
MFL_4>\8#?1T2R<.SI.N(:PJ,!D!ZU2J#(;*!(3ML$$C)W%W&8T$(DBB,2QG$
M.2;O/_031]8SJ7@^QB.TZ[TVF,@/[!))SSC8B\E;4D@E!H!-: -D0?T.$(O-
MMW1)EPKL(0W)#DYB"-R':28.;JKVL]@Z6GFXLE'<[BRC(N$0A/I1,7[:F #9
M;N(-SW3 %@]>H:7)7U=%2=I#3B*!DQQ$M*$YQ 20J:?.+/VD9/*E=LFV">HZ
M[G%9&S> @G59<OG9>L(T?*; .#HZV9>.A[TEGJ>O"RLI>?+R]$(3Y)=A"Z3K
M;;FC,4LC5K6#,6\_];S9A!0R[GD"6@6.H('=(U>_7>FQ392L;&U:2%DPJHD$
M2S1GIN'%NT!D,$DEW406HC97;P35,+-)6J9K[%C4;,1+/%EN-<(7ZP]58WQ)
MPHX,D?4^AVY.+NA:'QCY+4+]1VSAH"IJ!H583GJ[J5HC2-UXSFNQ:MF0L">2
M51>*R=:"-C*W;$=BJ&2?/_!-A7755&2@A$C)?/,L$2E"K.2ZUQG7OB;+ J6/
M%+&DC->+"4=+!&+K2XC\-NP\0EO9M!=L._O!$=;5T-EN^;4-YRD[V9$(:Y,[
MMD,68(IVPZ,D94Q'#! "Y 39DYC%)=I1[U@$ @.]0/T#6[0SFW@ R.+2Z]8B
M6[I$$&6_JK ?K7X#$H1U150J4S-S#Y/0$M3Q)<XT4[D;,[_^+]Z"23E%\:8;
M!(\0:^AVVJ%0KUIS;UW2V.)015Y/ L'I%T#_J/DW(8^OXS9; T#@+:#>?B(;
MB&Y'9.?$A O)/I+8@A(1<)+/,F;K%(U?JE6R.Q F(>/5]5;$A"(F,S,BF+2F
MB)10&9GN7F[)2CAH<N]?5B"+)C2DPH4%FMYKQQ4$29B[D':_0R.<X KT_F5:
MN7> @FG.TK<^8@G=\Q@@+K0^HV<2@H-UD>++'HL!KBS5?&MU]GE:VYX+WS#.
M9<R!(<88GLJM?J@+Y.[Q7)D 7)_3"UF[U2$VMNQ=FM#-?&L \EK#.T+Z7L_"
MB:'VF;Z4E6C-G =T\3(QD_#B]K;>JR#J:<%<28- $SDF79Q?J;@%F4*)PKPZ
MZ9]?/WTY^^O/;]K0F7RWWE_J+^>C_O>IU:DXXX=S<GG^1_&ITYY2XWRDO1P9
M'^V"W8(?7\Y/GB?'6LT^^G%_7VS]41A-;LO?CT9ZBX!+4'SJC1_LT],G@@^-
MSO3GR^?:66%R7+]$'TGO4/]P,C5'Y$?SL7MQ5J@>G4W.2Y?&TVVK!6L?QITO
M]8N75J<X;E>T[@A??ODT?@#@\O-S^WDX^'KZU+0&T^,"/)R<%6_+'ZN%]J-V
MB''5_H@_:*>5VK?/6K.KD\.[^F&K?%@9&_K9I_ZXV>KAH79B'=<N>O6AV1V7
M1GK7>#COE4?=4_/P_.>/%NH]DI]3Q_ST_N2+]KG_HWZ!3CZ.+@ZK1GG\]>+X
M>?#Y6^UKI3]P:L/VS]&H5Y[J9GUX_^UY6+@K/U6.JK=P7&L,G!^=F[]RY5;3
MJ]>ZKV,KK6W/ME6.)!TOK8]QOR;-K,A=:&T:Y5XUEA)O*U2*A_N,_Y#T#IF+
MH<7MME<B/%SJVV)8@.R,TJ*\$^,PM3TWDL%V?)C@U-OQ\Y*2N*3]=!"!PDHV
MDCN70/!N!GT1_ ?N+"8 6)1J)H78L(I1JCD-E?FVZ R'=?U$(#V3 H7OD04L
M+0/_$R8XO?\A6(-0I_>,HRJE#B]#6^^5,6.#A7$,U>"=7]D&FU#Z;IINA"6L
MU"A+!K7D5,5E^8_8AHIVAH5B=C+X2<%=$#O)A?[F4F:.[AX3-\Y2[VZ22G\S
M@S$6U))K"(8[@P9!(V!#%IIH4$7,%T_HKA[:;.5GUZ&5<-/;+4GLEN#V@A%>
M& !;%M1X![\B>] >P";DG_YA_VA>R0!_;R1(K:!(<\JF]]'3;@6E^$159DPT
MK\/Q2E'00MZ;')$!0"6>H')%5^KA-]G2@B#-SQEDB[[@@Z4WO<3&U;V.NXEF
M.+I[+4D; *L/^==![GH]9IVRTXY?5_FL2^EEP]5*FE_L3;$=3,W?60!#U_/"
M1+U? ,;SK<(H5'ZF==P/FBVSM)Q[G<9UWSH469!2-C5T6?>YSFRRQWV+YZ97
M=08YZB$NUM-G%BJ4 GJQWSDFU.471Y>M7=IEHDP]? M?LND=!BU$V6Q#747V
MNNP=5),MMU:/5&V7CY7<A?DNF^:ZLK],<TNRY5X=5*"MNK1+Q<K^,LTMR8ZX
M%*TT%$OX>591;";ORT"2[5Y\8"E-XW_<M^JB:$OZR3HY57Y_?6)*#CLQ:G:K
M=$9)OZ8L]D9O]QLBJ;IT9PX-/(7P%EJPAY1]O35:6-8#(Q&](1]'$8(HU97Y
MPAH$]UBX@7B!Z'NH:I+9(&S?&1."N&';,,%9G2\IO!9?K".YZ!8R_B!;4@+B
M8!+YG1IE<\O&[]A+GDP65_WY(957*]=!5M\_!\#6JC:0WDUL A@Z;'U!IE5&
MBCL?L[]D73'<0CB*RK.ITS3]G<6D*E78?]BJ1<L>G+DFV8[=5S# E6SN])1)
MK(610H][]B/JR[YLOH4BF9_.[[[MS#F++M6A;#IIV<!VF!5.[Z'.2[W.5>-'
M<S;V?ES3>M-4D\;@O7/ >>DE7X4P$"4;> +!J:/A<!E\Y\W26/CAC0K;YV#.
M2>#E5^EU,HTRWK]);C'+@U4*)9(SD>/HY-T2TY\<-==@4ZGPY@UA'73)I95B
M*S%_Q*8B/CLU(-'D+ZBW5B?;F/&5#$+(A<P*3W&T*;O9-%5K=J>4O>2=W_ S
M#P]ZP\!CGEZ8@:$DT>ZMVTTBID0%J529$7M89CHA-]/+W?/(P%I"E'CK1A&&
M^WKF=OX5,MIX^4!L\1G.S6Y;L])$B6XII\(UH0]$?D5.@9#4 ?Y:>XLJ.:Q=
M]XM$; TU!D17WI,(R9DOR*.Y#5:&2P"HQ'V7-;GSP1F0J<A!)I6><>"]!9V;
M8)4<7X?)7ZG L5PZM63IL^.Q\-JJ92Q]_UJ)BME.G=O9Q_;\R(S#8VC(K9>,
MW,,E]^P(&$K2,[?1Y W9@QAM&7&S>P*XID6@Y-U:%H7@9'1S*WLP+\?%0^KW
M9]?5PE@?(X-_D:QJV6PIA>:IBLH#Q C1>SNJ(O$47#V4PR2O@X4U2&F<E /Y
M;&X2OP<C,CVT@N*KV_ Z7]VJ2S&+%)4B-%SU:$O--3DJ]5Z'>F,AJ9>/:&E'
M O8HNL*\?10V4M/&UF>8A63Y%]<V2<NT;F],**+].XG^=-9^=B_<>F66MGK]
MC?2XF^-[2EF<?>Z02R.J]SJ!-:7A]:Q9EUH#/&:/^2W??I_ /K"A^\J\U)J*
MNR0U-F]#**BQ/9-<<62;7VRQZ>^<1(KH6+I?$9>O[WCPXGV]_36[*=0A\V P
MJ5$LC\"4L,N]_OHZ!?DCRN_O+W^;RNW+_O9V4(R:?/T-PK*>YS98:PQV-M^I
MD$F2LBMBF^5E/K2VYRK&93%1'')=X$*ZK#7^SO\!4$L#!!0    ( #F*9EJ8
M?8Z_\%<  , 8!@ 5    ;W)K82TR,#(T,3(S,5]D968N>&UL[7UK<]M&LNCW
M\RM\<[_<6RFO8^>]M;FGJ)>C/;*HE>1X=T^=2D'@D$0" LP H,3\^CN#!PF0
M&,P#W1B QH=4;%F8[NGNZ>GIY]_^\V7EO]H0&GEA\-,7;__RU1>O2."&,R]8
M_/3%QX?7DX?SZ^LO_O/_O7KU'W_[7Z]?OWI/ D*=F,Q>/6U?G8>K]8/KO7JD
M3A#-0[IZ]7_BU?]]]?K5,H[7?WWSYOGY^2\N^YW(]2B)PH2Z).(_>/7Z-5NP
M6/*<$K[@7U\]+I-7'QSZZJOO7KU[^]=OOOWKUS^^^OAX_NK=5^^^S3[YC[_Y
M7O#[DQ.15PSO(/KIBQ*DER?J_R6DBS?OOOKJZS?%+WZ1_>9?7_@/*K___'7Z
MVV]__/''-^F_[GXU\NI^D2W[]LT_/]P\N$NR<EY[010[@<L!1-Y?H_2'-Z'K
MQ"DEI7B]$OX&_]OKXM=>\Q^]?OON]==O__(2S78HLM^9Q3LPY06^?9/]XQ><
M7J]>_8V&/KDG\U?I%O\:;]?DIR\B;[7V.>;ISY:4S'_Z(J2_.PS:NV_>OLM@
M_6_^DU_IK^=A$(6^-^-,.G-\ON>')2'Q%Z_XTA_OKRN[#6GRNQ._<#:_X?_^
M1OCYFTP&,%'\]<ZA)(B7)/9<QX]:8GRX&M(&^*FB9$F"R-N0:W885\0 \;I5
M4H2[P+<]W146A=O-PY*MO S]&=.#EW\D7KQ]9(N\"^G7BI@W+- %EF;D5E\/
M26Z<:'GEA\\FTE%\RC #P>O6B1-*PCG;\UD2>0&)(B=@AS_RHG!^QRXO1HY4
MLRLBJ[X>H'PDJY5#M^'\P5L$WIRQ+H@GKALF0<QN\SM&.]<CRL*AMM@;J$OF
MGG CA*WA.FLO=GSOSY0\C&B,6N=^R&BXN/+8WUWV!\4]Z*T))4I7CD=_<?R$
M?"!.Q(1@Q5BM2O7Z;P&/'SLWA!WUC>/SE1DEF+WU.XF=)Y\\$#>A7JPN(HJ+
M@8D($S^:D-GERYK="H3#F[+C1<\3RI75C><\>;X._NKKP3'@-HS)G;/E)'KV
MXN4]\;DZ8^HVWJIJEH85,H,$3%.STQ-[# X[+7/"B#)[B$/W=T:G]/^5FT-=
MA^LL"J@;^>),_6:&!>.WCC(7? Q)[0>RX&?]PHM<II?8R5?6T\<?@AVXS.QZ
M=%Z4L2E_ <>\Z9K3>[*@)%.(3%AN/)<?VOW/%!%46@K2W%FMO)BOR@ QX>=W
M)WM>:^A8\0* 2HG$-V$4W1&:FH2JBNC@*ZC[LZS14L>"XW*>J5),^#G@:^TA
M>8K8S<>X<KG1$+ZCS^!8>&R:G6W3/ZEJYH8%NK90'_G=!FNGYDL"BH"6;:FU
M(Y.5X5A4:X%JX=^T JB!HF1^:J&NM22@,"E;HEJ[T5W5GO6HQR23I4%MM5IS
M4$]K-2T!9K\=VX9Z2(H^!Y3\DL&HA=OQ=[#2*[*Z-"55L@PDS@?FF!:B]=_"
M72HBFTSS7FQ<!,K\Y-&=6>(3[J8+UTS1;!GSN"Y9<T:FP%3/C\)*\%@S%3^)
M(I(_;:HZ7AOQQL7@]-0.WLYV^-DCU*'N<CL/:6[L.'Z&2FY6S,QVI \!\MVP
M0X-;&I=JEH;V%G761N#A9.-X/E^<$?;!*8/D5/X84,)M6C)+-0ZS9G<WG_9&
MS2&!F@,[?.K([,274>RMN.;:B9[9;O56AU<L>N:D/C/UE@=\E.X/CLBR-#R'
MS<O!<XC;&V&0@K@G$:$;,N/*+>&AJ.LH2G@@VW0KJBMC\.43\19+)N(31DYG
MP6^D9)7Z\:*/S(+V@G/'=Q-F'##SBHG,[B!DU]>S0V>&(@D%%X,F*2]R;R:S
M@S;%4T=[D\*%4.Z]^X=).W2/%L @[B7[*MP2\LFA-/4GM<&X<3&$^Y>_*)U@
M&]6_,7/]:JP&5)?&N6'34\6S%"+4?1J"03DQ^2N<VS!S&JZF:YY^MWOWZ!_W
MYN7@+R4.Z8Q;:&3W9F_%&]EZ.,K6B9,XI-LK,F/T\G>0[YGE%8?97P^0,K6#
MVL#">:HP<0\#_I)(+[:+W))A8.'>F28P,!A]2^(CV&8[$J\$?\3X2\<-%P%_
MZS!@9R0@<\\4\<;%,*^K9,T^3YUE?I'>=1WPI.)4/^7>GSB\88_S-F)F"@OM
M;'&$<C4<+%*()5%_6(;/F7DY62PH63"\TE^Y<[;[N(HQ'5J"A9=DGB#GLL-^
MX?D)X\"!7W(2Q]1[2M(W<!R6??UF9&@'#4/_3(+82['Q-N1R/B=N?/GB^LF,
M/;?897T7QHSX'I-9QK\DRQ\,Y_78&QH^P/!QWA E1W >ZHWRC"AHIT0+4&"J
M4CF5](+$CJ><_:N]+)SN5PK9Z^U&;TVPK&%Q+IXF,^0+P18;:$10]79BMC:<
M;-6^TC1EJ7$-2)5V%&#51%3X/92 EUX8>JC5? C&8Y4</CUL=58$VX8X.JQ[
MXF3KP%U%U3M>4\?5?PSI*!*%B/40E:T"F0]730C4O?/JOR[8[5!7%4-!+6)1
M2LB+$+]-$9]Y*UZ2%0:O9V3N)'[\Q:L<3!G=W1I>$+]AG[S)?^?-\>>YID+&
M-5PY7F",:O;U7O%C(+MD2U W>2*O=X#U\*U;H'2V4 B<$N;UBJR>"-6D;N73
MW8G"P-+Q?3W<^ <[C)B<>D$:.;YAL',,^*\9%KU6]D5>V(.*/:[R4ET&S@_=
MRF_XO* XI,5GOO-$_)^^2*+7"\=9_\I]A>GMQ' CU^R/T3&-HF*K<R=Z2O>;
M?_V&:Z0WQ(^CXB>ICDIIU@!@+U/FZ.:/,1Q4*\^O"@<GM(HM8WB!1,Y[->'(
MO^%/8A5>Q*&8!"%EQO!/7WS%?C<5V[^Z[ )G8G&9N:>8Z&<VWO[?F:5'9C]]
M$=.DO$E#1IS[3A1-LQC@Y,5#$Y\C.#ME"LZ@6D7:R+"*--8RZYA,.=_>?B5F
MC!EKRJ N\FL+E"<U "I'&I8;QW=P(RM$\ECF2AV%CH\1%C=^_:H;?B SHS#>
M$+C!*50<#UBU)3+,S[85/QV\'M, 7!@.?=9K.G0L."EF95M.HFBY&@#6M9R^
M^(J8IJSV8'@#KO,$W+&H\Z!YHZ8$]=1@ZC1X(-0CT43H9OV0/\84_ ^*2V&>
MF^H#LHXQ8GN(,T"+)*"GI0SY-@Q^";G;#9 KRFNB73B@S%$GD<JI,>74F1R-
MR8K'C+3YI;OR0 Z5-L%R[KU#NY'J. -Z'_6"06+[2'3M*"LYTY>0$RTGP>R@
MMF02GSN4;IE\I)G/T$\C)9@V%:":TT>1=@JL,^%<7=U(GK0 S*\F2/WG4B.=
M%&XE_3LI>8I<ZJVSE#.7,,'(RB%5;AW!MW;55C.AFS>-<G.PJVKM>$51T21/
MV<FR,7'.@ I$/.<GV&%0(ES.LJ]!68;)G#HV])L/]13_!OIVK]-]S/1S.[LF
M2L &<#IDY,K9]"VP+LN*R.]\GMM6JB2_)?!*K '4$(Y-,ZUR]GP'?8JJZ=3W
MO'AP.O\8927TP"QJAH7F38-BD(14.8>^!W,"[.#NKS$T_58/8W?J^\J1>LKD
MG/@!-I*3P4&YW7M/Z&+O.65_!*9L-4O]D3HS@F1,-4#J_VNOD4YHT?V\R4&I
M6* PK2OM:Z'YI !S$!Q3H9T\8 ERNQ<PMSB'2P)L #:RC%P%G\0/?@C]5R[1
MP=5_%4B#.$UB.A6\$;_L#<]0Z:3B,*4&P!#>*W5T*9C0^-B'U&1X!K$4WA!X
MI$"U@F7BAS_ P<$[,;TWG6LO^J9GO%&D:U=/PPV,@Z;=L/&M!DC]OT$:Z50P
MI_$%;\*=1[):A]2AVZR L BA95'H<LGV8Y@-L0'FF3[\WOMB#$A:L%?L%C",
MUI02"S BRG40>L^?6K(4'!"[#TQU7][G#26@?[A\WR^<8WH484KH*/UD-DNW
M[_AWCC>[#LZSYN_0;Q8!E"'87T(*%2R!2QDK/9*259(FV60/I..A=+RD]9;$
MT_FC\P+_P-2"WG^309N>!6L;G 2FI00QVQ*973HT8'==5,+L@M'.]:#M!@6
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MUY,*JVM\HR8$56K%B=L>W8F65W[XW'!P6IZ; D*$?UR.08U7@8[<"UDEOQ3
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M'A&O,E:0DF:X]  T:RO**93S@%H]@F(]-#OGH$"O]\S4H!]>=8[ ;L:_+C4
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M2ERKHB'<,R,$,QA#4DPHE;EO1LV@V<WF;R>S<!V360E9&@;LC]GXP!;74"L
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M(U6:UTI1A:#%?H%=$P?K__H5 D61R4GF3N+'9O3D^T7)L!8>F;/M(_M<55E
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M,+/AR6_"R\S)ES;$8\>78P/,LQH  SE-=:0I@HB2]SY\G_)DM7+H-IP_>(O
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M9!4D3$(NR(;XX9J+1UZ4B36C6@K1:E<BI<3 @^G3<AKBAS21N'4$P&Z75Z6
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M<QRARN%:&FL"N(B2XN<HW<#NU'1E!)"2<A"R(CM79+P(P(J; -*&U<+Y-_\
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ML*8)+NH>V^W775)(*2F;ST[?4^ADY)U@?J>*(!Y?ZC@29!H,B2>93'FH$DZ
M<?3#'EZ9GNT7I1RBYML@,<"/ %MG^[O3 <A@-154#<A2NEUQ)L#B.>>NU+"4
ME.<,73)>%'0R7)*4IX5-YBE/1:Q2D'$*\'IV(Q]BB>=KP%GV@<N36Y;#D<VE
MCA_]J>$B3?./V 7#]8KG4 P6#:W W*#S\/V>Y\H4,":6JQ1J@O$'B1969$[B
M3KLOFD]/-D<6M^6^OF]!-KSPFS>P+,%C\SF(FN^G=7.T*J-C<\6_;UV^6KS/
MBK8&.*):&ZC+\Z<XW6#,SU:TP <LJBC!^]-=?OX4K9*,?'X#JTV1E3=YFE[D
M!?83L[S;.V?7HRG/]5@4=$R6)-$Q&Z+3T3)] 91==EXD8ZYD"=BQO-1$5)SY
M'0]J4P*.M#6H "@>$!D+/MDH'873#2A*$HYTE*-G.^TF%R(2741=H6?+ A)?
M:OJ*$..W0.9W.F6\M3KTX6V@S95@L=(N0/=]_=A$>F%_'?C-R5BL;<29]F29
MGQ.G^6J55 T5^E2[A.A@@Z5SSV<]VIYK+.CP)JP TO1!:SFSG4Q'>3)"P,ZC
MJ.94F19JN-VLURF!?Y3B>M(7Z'YSF2WR8N72N4N5JM=P#S6>%)_UHVQ;5Z I
M =LS+3^.^P9,YVWYI"H';V!43LHW2Q,BO5 2C3EUH. .YS-1YX^G<O4$.V?B
M?A (LCP[C+&L<^JA@U0SO&,MD@RI9^0G[-9#GGI^"*JL^1&O<<3953-]9%TP
M#V1-,O^SC:O#5(NTSZU*AS&#_:KMGNY%/>>CVX?\(_X+=E;JPC_I=PWUT-KB
M&.BP\-:>YA&.H=A\"B&?XI:A9QGBRF0#U!E7Y4WJ@[+)\+Z,[43H=$T)3-=U
MT[!/.[H"9X&I-3/>DX3I<,<[52\VN,9=7U@AC4B^)#4BBZJ @)?S<.M$<QO:
M' 2\R/W1%':"Z9Q36_4C:3O."^T\*K#!%AO2WV>)*Q\A$17/[D$"-D1U@6!%
MHTW732&1J2@W T+KQ1!(AFP,FEE6)?,DW>#8A%L8;PJB&=&W&3BG86ZK]::J
MWW(8'FAFIRV_ Q?U(AURZO'=TN$P1&F*F :@:[%;X#!$04OWX.N5QW0\]>:V
MYMIN1*INWQ515F*K DX#XV8/'R3G-;O&$#<"6/=+E;,-IV-!5I5K__E<83I,
M\_YL[DOXZP8I2^>/XN<S"W9A 1F_AF ^$R)+2OLYH-]/14,8DEG?DB<9LX%9
M8PZ3?Y[E,<E1A>L*2W!2POC+9?[X C6A$$'_Z)"QUY'M( 71;7:7L"@:H?Z$
ME'L.<22*9AI+ESL&;8T/]W*.#K!J>P.7"<9%5N':P:-DRNW0FZE"Q(% R/13
MT'U+"CV'L1\-2:.1NW!X^LI&UQV.@"K6.8TXQMD'X"F^4!?;TWQN P_R_@/
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M!WP=J^5QD62H&?H'N9-=+9 J@'Y =S)-"X MJE[O1M;9UWV;P &;2/\ZI-3
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M:Q%M8U&?G5%TG_,)QA[;&]U8K843=/Q)6:Z$0/9CO.++:YSYRA&/.%0ZG&7
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M7A?Y(JG>Y&5Y@<91LU'>Y:?HOIRGR1R?GZ[@:(FI (BUP[G"R=  '/<(,-)
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M3$#HW'EO!+T_F#'.8YO[$OZZP:;$1_1_6,]V9/'C4?%LQA&P(3+WM5\#\CG
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M;X@W)5J,L.[F]]$Z+W\L 4R3)<DL&C-<36&-.H2G%9U<12QF.GG;)5GNS4:
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M%/A_-C3%.35UZAW"W_EJG>9;".NW'6?;FPH=?R[Z%K@=M^LU!-KGP6>X!6I
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M.L:S72I4S0[VYK+8@JOQ4# U2UV.U\7Z 3SS@!_+#I76NIA6MMJM=CM:\?Q
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M?<_>T5I"NG:1(ZQ3*<6M4/+0JW44:R+ZMZ<FZPYZ*31(VW715'G!]B1_ [#
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MAQ@(K9@R-VG\&+Z@1_-H/L=-8#X2;- P)HGJ8^L2?F6DFL\)EU(:)#F.L*I
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MSWG3 8)2WO2@9%31T8+_6_35A=1:Z(B$M$_@2-J#X@]"V!=-TT= YCL0(4=
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M:0Z3AWK> YD2,PTYJQ\ F.8YVX.<XW]H>):*\?4\T&]1$C#V>VB-?#IZQU5
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MUJNMX#  0KCA7PDYEHGG]LH52,M(%9&)H^10>G7GDL")O%#6/TZ_7.$^_>W
M>?&Z8_6-2YYYQN8.HE48J,>+8K4O04QO&&_IT3M&VO?<QP_AVCC60*_L[6DM
M)HJ@RG*:<@6IOQ'+A;71SZE4;3=WG=IPQ8/CA]GX#^ZR!Q%!,0_U?7I;0@__
MXCQ8X/GUVMMJ1 S.GTGD>C&YB3SP3.2AL,:N9QR]*'?S7-]XXPCXH(&8WIW>
M$G;=TK^S:<7,ZDT=G[GJ/XPE0F.P ^30C46A'UH4T%O6P)WT2[HW+X@]UT9_
M67MXHD9H1J^^FTS5]]?Q+!(,B?V9Q.QD!HM]_#1D?QJ[!2V-]E&>#5@.V*]W
MG+(](1/<<#/'!R:T=.@7M=8/!X:=KKQWD<TVF@0K^(V]X+?L. A<GJ#O<)+Y
M+>F/0DLPS^QLM8K(RDG(J-\"^OLXWBF ,E$<AN_1KA.#;5?V-\K70AN_H^A*
M\+ 0R1\F+I(3,O)EL7[!MLD0/"\$^R.BX6%@@HFW.14K76<'1R<[E"B442;C
MV@ADX:];4".6\2:B1U%69&PIL<85#AB6R*>L@/TRN,D\_I^B,!Y-<F0'AD<+
M0YJ7I71"1"V'+53G[FI,YC(@YKCU"DCB#,GY4LR1.AKG<XNRL<%G*:OAR''.
MMA=74B3+BP1\2K,& B_SHM=@1"D[QI%$%/U8;F22*E(-^9<IL0,+0"GM>*%!
M Q/G(HR6Q&.-6^/<C^U%V0K[O8_,>.W']U7>_.9<+J5XK.&YOD-;V>(4];8J
M^J]2RL%EH!1ZXS"<]1+<V[N97.FM7MWM;>P8UMOR5H!N_UPA GAYK6AMA'RV
MUB'!OGNO1E)5VR&E,M6T0O'!:G-\;##9<Z+[.T6:53YK<>V64-'S6+J'<+2F
M,??X,##3&'K[_PG( M>9:\K""W$73+,C3CY\YC*@PI%F-MP\69/H?NT$A=%V
MS>:0L#RJ<>42*>/].GTI<&PW+?>]2YPHP?&ER&^V\1S)'/)G3G)H$#H]\>_?
MTJM\JPXB*Z85Q/4S,[:;H1ZNFLS):*!]+$DS8#E@A?"X9%O^E/_ZS60D7_5.
M.!X,2_("-XUXK,<FMQJG>#:.)0D07->O56Z7XH]4Q/M/NI4DV./-,-'#(24O
M^F7,@A86-H->C;%0LKUG]4)@ F":X;"^U1353I\K4@ ./$HF V?XE^0Q8"8(
MF$G*M$SP3$K"("9$:@C.<5RHN5H8;@;H<1ZBZ3S$EQA,TQ15W, :?TS9Z%X2
MQ\C:JWP0X$?6]/-6&WO2:N(ELG&'1NHEQ;^&YRATC&O@*O[>XRIH$5.ASUA*
MG2&V\E*C86BBH6^\@!^/H\?_Z/&W[O$':;X[9ANF*>&CLF)>C/+&X"IDS$I5
M4=L[JNJ](.W*MPV$7]0+=%24!>NK.SFKWHXE@VG7OY@3,@:*5BX,C9+<,5\8
M>==4I0$$@]\1<C@>'3N _(;JB#N4G/.WV6H&/!YWI0Z"+\A=@\MHC.:ZMH]T
M'PE&:O\;(G]4^D-("%S/WG$?F7&>A:.SQY2K*%UW;5QQ^S:MPH#4@'8+%YFC
MC:+!0+ >N^,1T%%:VM(-_H\2;,IAK,:\@WN)>*21%W!T3%^@;8%.4[AVO>.*
M_A]+P$<F[F@EX#K-A)OIN3BV2K:A5GD6HGDB@] +5-*#\1*E(;"] RGHL#ZX
MKZ+>:/VU2Z8*V^!Z^ZI(9/60#+!-F8ZO-P4F:B(]B8V\H#,Q"7H#]@X>E\E=
M-%$^T&4R5G<;\Y<4JT'A?"GDQG'+L81A*BW"\0QR,"Q?D-+')^9>V,V#CI;[
M8C *.<$NYM?4LE!4$).>+AEZ33(*R'>=D#5;9JBM;="=JM4>X8Y$CU0"!"+H
M9\O1G^;+6^*&J\#[@TI@IB!/PSCA==<POR2MX*A/L[/B, C.YB]>LKX,%MZC
MMT@=OW5.X]:)!R(3&%I(-?%FYZIF%=@1:J2&'I<!U7KDCC(AX^-5@:N%EAY=
MD)"M1YMJJBHZG<0>EP"<A2Q?:!@1*&"AFE@2YT""DR75*GT =)^=MY0$%/WU
M+%B<D4?BAUL&J-!/MB8A]$)$+CY0Y)(4#?7/72OHH<7H3R2@)K)/<9PM-E[@
ML9LG\1Z)35;+P<35RHJ\EB0C7 <:W*#-4%<6G#FJ3WFC^ZW8.EGP*5.(!_#Y
MD@2*+470;XW:$"%)NL,UVK+M"]C/Y8EA_ *ZGH$#'G:]!/IPU+V0/2W+E$D/
MWH[3# .=JD!+" D<! .393S^ ./3)-/2TU!^!V\%>?0.#*23CMZ!HW= A2\W
M#K-/RI:F#[ZWRE96:-7:O<(4J-Q# \CW_*ONGRO)CIX.NA O;:W8$U/%>5S2
MB@NEO?XDN-5!'HVV7Q]SA@5$KVGIWG?!D+E)(W=-K\X;WU'19WUK8!;\*)X@
M(1GTVUD)RFU>HADUP(,)P(6E.;[ZZ,0:3+"0O5K<H()-M]8=6>7**8X98>=;
M$F7+Q;WN*TW_507@10V@II^J?SV#=JO,6QZXGN\5WO-B]6!U$X5+;P^TP"&^
M#T\IX-#W%DQ(;.2K ""D6WN6+WE+MF'$ .XQ"5;LO%R$43<N=50$?BASN\P2
MEMA^*NE34P^ FDLOB//IZ'[2M2'A%-"0OJ:CL^D%.)OVHE:8->?/KI^RIA9\
M,TKAT::W,G:X5)(QFF3#SD,Y)AR9GT65A".55R3'SW+,-II.MM&0+C7Z0HL"
MQU?QH-6_,H6[K[E+, >9TO7(JE]4+KW*YR?@E:QM#ZQW.) %<D-7#8. ^+?$
M=_(F+?:,$E5@D]!D<*35[YW=DHV7]LRRYC*!\$2#&XE#FH?(!9EV76'2)B6H
MH]F".3FL(8G;W&\XD>@E.EH*1(EA\W*!=M>UUT>N(!N.^1S2ZE\&)IT#6@CE
MA@?;F2UN5R"\%O7/I:[^@#:NQ64SNL@0/B'+,"+Y!NZ=9ZGL>'W_<4EKUNC<
M"U)*ND.LI($)B>E#,G(H.;W B789$ZXI)UF+]-#/V!E0BI$XX8<F@;S0=C$V
M\\8KX79&?X@3S\6GTAZ3$7@S!A'(=D1 DW-@]3@#R1Q5ML1;V0D/:2&"_9*=
MCM#M6:=OKYIWU+5(+GR9E,84WQ]I<N@-Y5">GP;*,4P<?\"D+OKME K][H(L
MV%MQO]M;:G$F8?YKBQ"@!8MUAASLOA/Z>J4F,8\S!RQKWCBKQA<(8KKWW?ER
M25SV=*_QIP$D*7BXYVGMP\!$@<!H#/YO2'FKJA<0CFFHD7U8<)4]&8VL+)D]
M9-&?V>(_:9QD#F\$,6NA\-KEJLT3#<-I:$&B?SRE2'E)7'JR$42)@\0('H:8
MLL1C"Y@?T:I2:CC;XAL2N93<6 I*A,XKEZ]N5IGDQ33TECUI.UVS1BB70=DE
MA7YH%L<DB=EPF)Q(OA\^.4&SB>T@PJ>"W2N7125&:J02#2&:/'(-(G5<P*_/
M$N/3WR MJN$/&*23<1@PLS%<4MW<.@M.L+CRG =*H<3K\P3HB/4!_GS9 CZK
M ;?TWM?!0-.IV%K^FM@*(76"PO9%&S"=UX2.3TZX#F(@K-Y';)D/\M2)HMTR
MC%@MJJV6S#*0L05!YD!T<KR+JH MY&!$8/^XJB%JZ?VK"AWW[C86A#[:0L62
M &6A_%MAKE1S:*D.+*R7F%]1SKIS#B PQBBB/C$@A,J<25#N$TMBQXY(]$C8
MM3MSW2AU_'Q^Q_#2)<3DI0F1F.10&5PJLM)"^(I00:Z88%)5$OVK3,76D* '
M2EV1<!^?PG#QY/DL\?>2DC18>?21EO^3[4/<!7K:I[:3J%!E3R#LOPQNHM E
M\=[8J9<$V!:!/O!3.?;Z](4O=#)5"!%\LK4 R,1?#06E"@[J#))L^NL,&5BY
M9@;Q#0G@81]:> >1B+!P[T)-FZN"V"V;C3=??HGSBT;5[NI8:33'M%N^&^97
M%VD <V6,SNP^&B TF,&.*Q<4]DE5XJT<\8RS5^[K2AGD3K4>W)4-V+XHK=P;
M;]7JA@*0PM1^!-:$VS;O&] PT[!M,;U)4 /71^VX6XZ74EPY'A[(CIBC#A8>
MM2C^HZ5#76K$NK;9M*^[Q(D20Y.HC5<3]3+C9K8)4W#/A#+X$9E.4H*@3E_
MH)>M\__K-S@:8#)<EZ2A?I0I5P#G0>-%9/,2_1)$^VF#=%]E%*WO'H5HU"P
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MMO?I9N-$NW!YYZT";\EFT2=%FS'FY M]SSVTFONJ1N_ZK$^31G 52)9:;74
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MM$(8D\>0N27;LKOD*B+YFZF!G[SNZ^&F/"RL]TB?*)<L5*":D8=FG\:O4\.
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M_6Z%7?2W ZN$RTY/!8HII-^J53L$PY"Y)=NBS= >^29^\CJPAX?RL+!.8)\
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MOH(@."A+,WU7*:]P:7J/!MBZ&?V1*-J.9XKD+5FFP8+M<*]0BS:O<CV+>I9
MOH]L5#;E\?%NPH&U@U,R)\.=XR<[B@7#:AX4&OC.\25'_W8N@!V,L\7*;JIA
M.82.HT'&)27PHT$T'BN"6U/-;50J*38.G305@[$[J+GZ"]7_0F)BC2RNFFEA
MG%1F@TLI@(ZO8Q9,V&)?%[5PWBE[&^*4XNPMLEX2(7WY>G+3>CJ^_A+YUT4M
MN%&[6KV06 >7S@QT8(4K 1 W*F=9 \L0'&X.KUYEM>NR%(RX-#$9QJ=IQ"@'
M+ Q=D)#CWY;%H)/&^C&Z]GP_M>)%AD;CLI'2Y]POOE!;BD\DJ &QB@&97(]<
MLOD&CD]-.LD03.MK+_4=Q*,0V.!4DSNW4/;0[YGZVB^5JP)*&@Q&':8?_L&Y
M3=_;U!9D_==(X'JVVN,?X#&*UP':;IBO!EO]KNJEI7SO*LFE3(]\A2(MJ88\
M_EPXZ)>QAB1FCBQ)-L-T(E+-@M\7^7XBX2IRMFN6MP%4N2!>&\<T5CMP9<9[
M!X40FD=E&.7C4ZKX@%4JB-?&X9F4C.Y9)2:,21)OG&RC7T]G'=2-B?NG5?CX
MCGTRIR[[J4+98@7,J@0Y*I9;!>_1-.IS+G'+@;1IUTL[)7%,R*'=+7%BPA(.
MYDNV-PN&CP1 5 ]7KRU22Q:5H![N++$Z;EF<:[[\$I.LERVT>=4):SI<[:$9
MG/8R9^B5YSQXOI?L['@@>X A6\T&3&W3#:D570]ZS TP)&<K\+"](Q#<K9)/
M(Y;[,6=P0!)SKU8-P<;\[%O"[,CJ!0(]EE<9_(2Y+T-<L+ PE,W%GODLY'%+
M[>@!+*X:.-Q8DK'!52<=5,#8_)#_[$0>>PMDO_#&:0"?:AZ\"1]C+OG 8K_:
M>;5%6K%L,$GTW4DP1KAQ_1#L,)&$:WICAS%+!,I&IO>&#W0.^[D3L5N% ?D2
M>(FE.($(BDYZ.)<H\G& KN]K/V<J^RNGVWNN+?]_#S#DYTR/0&4'LHN%2$TP
M]ZZ_(JDV2X^U4,8NAH/$-XGSU)I2R:<3B*M?BW<D\D@\NREAYJG-5B:-=D#"
MM3][Y;?&Q"Z"Z7OZVHE)^MP\&8R;?$B3XZ: 8+ EY./52WTW,-H(V<8[_CIE
M?*$<94C&^\A+XN\NXSAM6S'&0JX.']7%+6=)53FO06#08 :\W2]JC]OW (!L
M_FWI(= +3OF<]1!+_F$@M1!L UE;+X1><+BWFZS,Y;F=,NP=/C'HU;\;5,[=
M@ \(@UZ &28V6P!6 6![SI0L3!Z!C%J75C,&P\">A=]>?T)V/8<X<)V;U5/J
MYD\!-7[6WA8H];&^WD2T&(<0 T]+FG+77ZX(B=O]#IQLE+?A5.X[BJI8^JA:
MV1#*5(P+QXLV+*SY(W'\9.W2C5RDP>+R\NI&I?%8[RJCE&J)S0/V75"4]CUR
M\1[_2]:2F\2LJ9FRDE%8;H0G18488-T41G_9R;]> 3M,J#68B-W(V^8C@3Y[
M01AYR:YDW)Z3AT8*)UDJ%<MI#7V?]?++/B(EWT"@D(-SLGZ(O!\%#'%'[FR[
M2Q]B\GM*OWO^2 []U<11=CTW00.*)?>:$(SJO2V@BKPWK7,!@PS$QKJV/&A"
M,*C.\3XI8L>VFW-X,=HZ6O?T*S:\9 (H6.:AS#&J.<=$5,)RC340LA.&Y<+
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M:V$N:'1M4$L! A0#%     @ .8IF6O=YD$4)"0  4"$  !H
M ( !:/(# &5A,#(S,S$W,# Q97@U+3%?;W)U:V$N:'1M4$L! A0#%     @
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M2P$"% ,4    "  YBF9:!OL1WF\8  "P&0  #0              @ %%=04
M:6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( #F*9EK!I^;LRRL  .,Q   -
M          "  =^-!0!I;6%G95\P,#8N:G!G4$L! A0#%     @ .8IF6G7/
MCQD:8@  \V@   T              ( !U;D% &EM86=E7S P-RYJ<&=02P$"
M% ,4    "  YBF9:-E98+LMP  "1=@  #0              @ $:' 8 :6UA
M9V5?,# X+FIP9U!+ 0(4 Q0    ( #F*9EK@"E8\*5P  -5C   -
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M !4              ( !ND ( &]R:V$M,C R-#$R,S%?<')E+GAM;%!+!08
1    $0 1 #<$  !UG @    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>ea0233170-posam1_oruka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:orka="http://www.orukatx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="orka-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-03</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-22</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ExternalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:NominationOfADevelopmentCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AntibodyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-15</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParukaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountsOwnershipInterestInParagonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMilestonePaymentsForOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-69">Oruka Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-87">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-231">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0" id="ixv-269">Oruka Therapeutics, Inc., a Delaware corporation, filed a Registration
Statement on Form S-1 on November 14,2024, which was declared effective on November 26, 2024 (the &#x201c;registration statement&#x201d;).
This Post-Effective Amendment No. 1 to Form S-1 (the &#x201c;Post-Effective Amendment&#x201d;) is being provided to include the fiscal year
ended December 31, 2024 financial statements, contained in the Form 10-K for the year-ended December 31, 2024 filed on March 6, 2025,
as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K and updated selling stockholder
information.The information included in this filing amends the registration statement
and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective
Amendment. All applicable registration fees were paid at the time of the original filing of the registration statement.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-18672" unitRef="usd">61575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c1" decimals="-3" id="ixv-18673" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <orka:SubscriptionReceivables contextRef="c2" decimals="-3" id="ixv-18674" unitRef="usd">1000</orka:SubscriptionReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-18675" unitRef="usd">1221000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-18676" unitRef="usd">376869000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-18677" unitRef="usd">1000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c1" decimals="-3" id="ixv-18678" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-18679" unitRef="usd">162000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-18680" unitRef="usd">876000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-18681" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-18682" unitRef="usd">396019000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-18683" unitRef="usd">1000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c1" decimals="-3" id="ixv-18684" unitRef="usd">3462000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c1" decimals="-3" id="ixv-18685" unitRef="usd">3346000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-18686" unitRef="usd">213000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="-3" id="ixv-18687" unitRef="usd">6022000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-18688" unitRef="usd">13043000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-18689" unitRef="usd">755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-18690" unitRef="usd">13798000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c5"
      decimals="4"
      id="ixv-18691"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c6"
      decimals="4"
      id="ixv-18692"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c6"
      decimals="INF"
      id="ixv-18693"
      unitRef="shares">20000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c7"
      decimals="3"
      id="ixv-18694"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c8"
      decimals="3"
      id="ixv-18695"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c9"
      decimals="3"
      id="ixv-18696"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c10"
      decimals="3"
      id="ixv-18697"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c9"
      decimals="INF"
      id="ixv-18698"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c9"
      decimals="INF"
      id="ixv-18699"
      unitRef="shares">137138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-18700"
      unitRef="shares">137138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c9" decimals="-3" id="ixv-18701" unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ixv-18702"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-18703"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-18704"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-18705"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-18706"
      unitRef="shares">37440510</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-18707"
      unitRef="shares">37440510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-18708"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-18709"
      unitRef="shares">3197975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-18710" unitRef="usd">37000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="-3" id="ixv-18711" unitRef="usd">463018000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-18712" unitRef="usd">1000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="-3" id="ixv-18713" unitRef="usd">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-18714" unitRef="usd">-83724000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-18715" unitRef="usd">382221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-18716" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-18717" unitRef="usd">396019000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-18718" unitRef="usd">1000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ix_0_fact" unitRef="usd">75060000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ix_1_fact" unitRef="usd">13063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-18721" unitRef="usd">88123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-18722" unitRef="usd">-88123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-18723" unitRef="usd">5863000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="-3" id="ix_2_fact" unitRef="usd">1468000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome contextRef="c0" decimals="-3" id="ixv-18725" unitRef="usd">4000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-18726" unitRef="usd">4399000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18727" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-18728" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-18729" unitRef="usd">-83765000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-18730"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-18731"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ixv-18732"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ixv-18733"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c15"
      decimals="2"
      id="ixv-18734"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c15"
      decimals="2"
      id="ixv-18735"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-18736"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-18737"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-18738"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="INF"
      id="ixv-18739"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-18740"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c15"
      decimals="INF"
      id="ixv-18741"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c11" decimals="-3" id="ixv-18742" unitRef="usd">42640000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c12" decimals="-3" id="ixv-18743" unitRef="usd">1364000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c13" decimals="-3" id="ixv-18744" unitRef="usd">1468000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:SharesOutstanding
      contextRef="c19"
      decimals="INF"
      id="ixv-18745"
      unitRef="shares">3197975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-18746" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-18747" unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-18748" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c27"
      decimals="INF"
      id="ixv-18749"
      unitRef="shares">2207553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c27" decimals="-3" id="ixv-18750" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="-3" id="ixv-18751" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts contextRef="c0" decimals="-3" id="ixv-18752" unitRef="usd">69000</orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c24"
      decimals="INF"
      id="ixv-18753"
      unitRef="shares">20000000</orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="-3" id="ixv-18754" unitRef="usd">2931000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c24"
      decimals="INF"
      id="ixv-18755"
      unitRef="shares">-20000000</orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c24" decimals="-3" id="ixv-18756" unitRef="usd">-2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c26"
      decimals="INF"
      id="ixv-18757"
      unitRef="shares">137138</orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c26" decimals="-3" id="ixv-18758" unitRef="usd">2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="-3" id="ixv-18759" unitRef="usd">2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c27"
      decimals="INF"
      id="ixv-18760"
      unitRef="shares">2722207</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c27" decimals="-3" id="ixv-18761" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c28" decimals="-3" id="ixv-18762" unitRef="usd">26445000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="-3" id="ixv-18763" unitRef="usd">26448000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c27"
      decimals="INF"
      id="ixv-18764"
      unitRef="shares">20061932</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c27" decimals="-3" id="ixv-18765" unitRef="usd">20000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c28" decimals="-3" id="ixv-18766" unitRef="usd">248437000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c0" decimals="-3" id="ixv-18767" unitRef="usd">248457000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c28" decimals="-3" id="ixv-18768" unitRef="usd">20504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c0" decimals="-3" id="ixv-18769" unitRef="usd">20504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c27"
      decimals="INF"
      id="ixv-18770"
      unitRef="shares">1208883</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c27" decimals="-3" id="ixv-18771" unitRef="usd">1000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c28" decimals="-3" id="ixv-18772" unitRef="usd">4999000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c0" decimals="-3" id="ixv-18773" unitRef="usd">5000000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c25"
      decimals="INF"
      id="ixv-18774"
      unitRef="shares">2439</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c25" decimals="-3" id="ixv-18775" unitRef="usd">56097000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c27"
      decimals="INF"
      id="ixv-18776"
      unitRef="shares">5600000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c27" decimals="-3" id="ixv-18777" unitRef="usd">6000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c28" decimals="-3" id="ixv-18778" unitRef="usd">144433000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c0" decimals="-3" id="ixv-18779" unitRef="usd">144439000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c25" decimals="-3" id="ixv-18780" unitRef="usd">-3263000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c28" decimals="-3" id="ixv-18781" unitRef="usd">-8592000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c0" decimals="-3" id="ixv-18782" unitRef="usd">-8592000</orka:IssuanceCostOfPIPEFinancing>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c25"
      decimals="INF"
      id="ixv-18783"
      unitRef="shares">-2439</orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c25" decimals="-3" id="ixv-18784" unitRef="usd">-52834000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c27"
      decimals="INF"
      id="ixv-18785"
      unitRef="shares">2439000</orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c27" decimals="-3" id="ixv-18786" unitRef="usd">2000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c28" decimals="-3" id="ixv-18787" unitRef="usd">52832000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c0" decimals="-3" id="ixv-18788" unitRef="usd">52834000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c27"
      decimals="INF"
      id="ixv-18789"
      unitRef="shares">2960</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c28" decimals="-3" id="ixv-18790" unitRef="usd">53000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c0" decimals="-3" id="ixv-18791" unitRef="usd">53000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c28" decimals="-3" id="ixv-18792" unitRef="usd">10357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c0" decimals="-3" id="ixv-18793" unitRef="usd">10357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c28" decimals="-3" id="ixv-18794" unitRef="usd">4562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-18795" unitRef="usd">4562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c29" decimals="-3" id="ixv-18796" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-18797" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" id="ixv-18798" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18799" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c33"
      decimals="INF"
      id="ixv-18800"
      unitRef="shares">137138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-18801" unitRef="usd">2931000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-18802"
      unitRef="shares">37440510</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-18803" unitRef="usd">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-18804" unitRef="usd">463018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="-3" id="ixv-18805" unitRef="usd">-41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" id="ixv-18806" unitRef="usd">-83724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-18807" unitRef="usd">382221000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18808" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-18809" unitRef="usd">14919000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c0" decimals="-3" id="ixv-18810" unitRef="usd">2245000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" id="ixv-18811" unitRef="usd">1468000</us-gaap:OtherNoncashExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-18812" unitRef="usd">127000</us-gaap:OperatingLeaseExpense>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-18813" unitRef="usd">27000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-18814" unitRef="usd">1128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-18815" unitRef="usd">43000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-18816" unitRef="usd">3462000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-18817" unitRef="usd">3292000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-18818" unitRef="usd">-14000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c0" decimals="-3" id="ixv-18819" unitRef="usd">6022000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-18820" unitRef="usd">-57837000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-18821" unitRef="usd">189000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c0" decimals="-3" id="ixv-18822" unitRef="usd">329938000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-18823" unitRef="usd">-330127000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c0" decimals="-3" id="ixv-18824" unitRef="usd">2931000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c0" decimals="-3" id="ixv-18825" unitRef="usd">24980000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c0" decimals="-3" id="ixv-18826" unitRef="usd">227953000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-3" id="ixv-18827" unitRef="usd">188681000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <orka:CashAcquiredInConnectionWithTheReverseRecapitalization contextRef="c0" decimals="-3" id="ixv-18828" unitRef="usd">4940000</orka:CashAcquiredInConnectionWithTheReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-18829" unitRef="usd">54000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-18830" unitRef="usd">449539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-18831" unitRef="usd">61575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-18832" unitRef="usd">61575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-18833" unitRef="usd">982000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 contextRef="c0" decimals="-3" id="ixv-18834" unitRef="usd">114000</us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c0" decimals="-3" id="ixv-18835" unitRef="usd">54000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock contextRef="c0" decimals="-3" id="ixv-18836" unitRef="usd">1468000</orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock>
    <orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock contextRef="c0" decimals="-3" id="ixv-18837" unitRef="usd">2931000</orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c0" decimals="-3" id="ixv-18838" unitRef="usd">52834000</us-gaap:ConversionOfStockAmountConverted1>
    <orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity contextRef="c0" decimals="-3" id="ixv-18839" unitRef="usd">10357000</orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-13839">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
Nature of the Business and Basis of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Background
and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#x201c;Company&#x201d;), formerly known as ARCA biopharma, Inc.
(&#x201c;ARCA&#x201d;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#x201c;Pre-Merger Oruka&#x201d;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#x201c;PsO&#x201d;) and other inflammatory and immunology (&#x201c;I&amp;amp;I&#x201d;) indications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Recapitalization and Pre-Closing&#160;Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 29, 2024 (the &#x201c;Merger Closing&#x201d;), the Company completed the acquisition (the &#x201c;Merger&#x201d;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#x201c;Merger Agreement&#x201d;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#x201c;Second Merger Sub&#x201d;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#x201c;Oruka Therapeutics Operating Company,
LLC.&#x201d; On August 29, 2024, the Company changed its name from &#x201c;ARCA biopharma, Inc.&#x201d; to &#x201c;Oruka Therapeutics, Inc.&#x201d;
and its Nasdaq ticker symbol from &#x201c;ABIO&#x201d; to &#x201c;ORKA&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of the common
stock, par value $0.001 per share, of the Company (&#x201c;Company Common Stock&#x201d;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#x201c;Subscription Agreement&#x201d;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#x201c;Pre-Merger Oruka Common Stock&#x201d;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#x201c;Pre-Closing Financing&#x201d;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#x201c;First
Effective Time&#x201d;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $0.0001 (&#x201c;Pre-Merger Oruka Series A Preferred Stock&#x201d;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $0.001 per share (&#x201c;Company Series B Preferred Stock&#x201d;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company
Common Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#x2019;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#x2019;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;PIPE
Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#x201c;PIPE Financing&#x201d;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase
price of $23.00 per share, an aggregate of 2,439 shares of the Company&#x2019;s Series A non-voting convertible preferred stock, par value
$0.001 per share (&#x201c;Company Series A Preferred Stock&#x201d;), at a purchase price of $23,000.00 per share (each Company Series A
Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000
shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7
million (net of issuance costs of $11.9 million).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $83.7 million and used net cash of $57.8 million for its operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $393.7 million. The Company&#x2019;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#x2019;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#x2019;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#x2019;s business opportunities, as desired, which could materially harm the Company&#x2019;s business, financial
condition and results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c38" id="ixv-18840">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c39"
      decimals="3"
      id="ixv-18841"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c40" decimals="-5" id="ixv-18842" unitRef="usd">275000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c40" decimals="-5" id="ixv-18843" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <orka:AdditionalPaidInCapitalTransacationCost contextRef="c41" decimals="-5" id="ixv-18844" unitRef="usd">20500000</orka:AdditionalPaidInCapitalTransacationCost>
    <orka:ExchangeRatio contextRef="c42" decimals="4" id="ixv-18845" unitRef="pure">6.8569</orka:ExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c43"
      decimals="4"
      id="ixv-18846"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c44"
      decimals="3"
      id="ixv-18847"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <orka:CommonStocksConversionRatio contextRef="c45" id="ixv-18848">83:3332:1</orka:CommonStocksConversionRatio>
    <orka:InvestorsClosingShares
      contextRef="c46"
      decimals="0"
      id="ixv-18849"
      unitRef="shares">22784139</orka:InvestorsClosingShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c47"
      decimals="INF"
      id="ixv-18850"
      unitRef="shares">39873706</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c46"
      decimals="0"
      id="ixv-18851"
      unitRef="shares">2722207</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c46"
      decimals="0"
      id="ixv-18852"
      unitRef="shares">4764032</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <orka:PreFundedWarrantsOfCommonStockShares
      contextRef="c0"
      decimals="0"
      id="ixv-18853"
      unitRef="shares">5522207</orka:PreFundedWarrantsOfCommonStockShares>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c1"
      decimals="0"
      id="ixv-18854"
      unitRef="shares">9664208</us-gaap:ClassOfWarrantOrRightUnissued>
    <orka:NumberOfSharesPurchased
      contextRef="c48"
      decimals="0"
      id="ixv-18855"
      unitRef="shares">5600000</orka:NumberOfSharesPurchased>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c48"
      decimals="2"
      id="ixv-18856"
      unitRef="usdPershares">23</us-gaap:SaleOfStockPricePerShare>
    <orka:NumberofAggregateShares
      contextRef="c49"
      decimals="0"
      id="ixv-18857"
      unitRef="shares">2439</orka:NumberofAggregateShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c50"
      decimals="3"
      id="ixv-18858"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c7"
      decimals="2"
      id="ixv-18859"
      unitRef="usdPershares">23000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c51"
      decimals="0"
      id="ixv-18860"
      unitRef="shares">1000</us-gaap:ConversionOfStockSharesConverted1>
    <orka:PrefundedWarrantstoPurchaseAnAggregateShares
      contextRef="c46"
      decimals="0"
      id="ixv-18861"
      unitRef="shares">680000</orka:PrefundedWarrantstoPurchaseAnAggregateShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c52"
      decimals="3"
      id="ixv-18862"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c53" decimals="-5" id="ixv-18863" unitRef="usd">188700000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c53" decimals="-5" id="ixv-18864" unitRef="usd">11900000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-18865" unitRef="usd">-83700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-5" id="ixv-18866" unitRef="usd">-57800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:InvestmentsAndCash contextRef="c1" decimals="-5" id="ixv-18867" unitRef="usd">393700000</us-gaap:InvestmentsAndCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-13967">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#x2019;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#x2019;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Marketable
Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#x2019;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;Quoted
    prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices
    in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
    by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
    including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019;
equity on the Company&#x2019;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#x2019; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable
to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the
Company&#x2019;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#x201c;CODM&#x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#x2019;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#x2019;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified,
as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and events other than those
with stockholders. The Company&#x2019;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Net
Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
income, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income, net, consists of interest earned on the Company&#x2019;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#x201c;ASU&#160;2023-07&#x201d;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#x2019;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-13975">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-13987">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#x2019;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#x2019;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c0" decimals="0" id="ixv-18868" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-14020">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c0" id="ixv-14032">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Marketable
Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#x2019;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-14059">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <orka:SubscriptionReceivablePolicyTextBlock contextRef="c0" id="ixv-14071">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;</orka:SubscriptionReceivablePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-14099">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;Quoted
    prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices
    in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
    by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
    including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-14149">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-14156">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c54" id="ixv-18869">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c55" id="ixv-18870">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c56" id="ixv-18871">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c57" id="ixv-18872">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock contextRef="c0" id="ixv-14181">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019;
equity on the Company&#x2019;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#x2019; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;</orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock>
    <orka:NotePayableToRelatedPartyPolicyTextBlock contextRef="c0" id="ixv-14219">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable
to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).&lt;/span&gt;&lt;/p&gt;</orka:NotePayableToRelatedPartyPolicyTextBlock>
    <orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock contextRef="c0" id="ixv-14231">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the
Company&#x2019;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.&lt;/span&gt;&lt;/p&gt;</orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-14248">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-14286">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#x201c;CODM&#x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#x2019;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-14298">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0" id="ixv-14315">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-14327">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-14339">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#x2019;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified,
as applicable.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <orka:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-14392">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and events other than those
with stockholders. The Company&#x2019;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.&lt;/span&gt;&lt;/p&gt;</orka:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-14404">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Net
Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <orka:OtherIncomeExpenseNetPolicyTextBlock contextRef="c0" id="ixv-14431">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
income, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income, net, consists of interest earned on the Company&#x2019;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.&lt;/span&gt;&lt;/p&gt;</orka:OtherIncomeExpenseNetPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-14459">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-14476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#x201c;ASU&#160;2023-07&#x201d;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#x2019;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.&lt;/span&gt;&lt;/p&gt;</orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-14488">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c0" id="ixv-14522">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
Reverse Recapitalization and Pre-Closing Financing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;August 29,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0in; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0" id="ixv-14532">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;August 29,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0in; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c58" decimals="-3" id="ixv-18873" unitRef="usd">4940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c58" decimals="-3" id="ixv-18874" unitRef="usd">114000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c58" decimals="-3" id="ixv-18875" unitRef="usd">54000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c58" decimals="-3" id="ixv-18876" unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-14573">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Commercial papers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,825&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents and marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;377,967&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers in or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c0" id="ixv-14579">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Commercial papers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,825&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents and marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;377,967&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c59" decimals="-3" id="ixv-18877" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c62" decimals="-3" id="ixv-18878" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c63" decimals="-3" id="ixv-18879" unitRef="usd">19660000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c65" decimals="-3" id="ixv-18880" unitRef="usd">19660000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c67" decimals="-3" id="ixv-18881" unitRef="usd">3988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c69" decimals="-3" id="ixv-18882" unitRef="usd">3988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c71" decimals="-3" id="ixv-18883" unitRef="usd">22177000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c73" decimals="-3" id="ixv-18884" unitRef="usd">22177000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c74" decimals="-3" id="ixv-18885" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c75" decimals="-3" id="ixv-18886" unitRef="usd">45825000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-18887" unitRef="usd">52175000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c63" decimals="-3" id="ixv-18888" unitRef="usd">190792000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c65" decimals="-3" id="ixv-18889" unitRef="usd">190792000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c67" decimals="-3" id="ixv-18890" unitRef="usd">12966000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c69" decimals="-3" id="ixv-18891" unitRef="usd">12966000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c71" decimals="-3" id="ixv-18892" unitRef="usd">34811000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c73" decimals="-3" id="ixv-18893" unitRef="usd">34811000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c78" decimals="-3" id="ixv-18894" unitRef="usd">75504000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c80" decimals="-3" id="ixv-18895" unitRef="usd">75504000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c75" decimals="-3" id="ixv-18896" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c1" decimals="-3" id="ixv-18897" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c63" decimals="-3" id="ixv-18898" unitRef="usd">13607000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c65" decimals="-3" id="ixv-18899" unitRef="usd">13607000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c67" decimals="-3" id="ixv-18900" unitRef="usd">4462000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c69" decimals="-3" id="ixv-18901" unitRef="usd">4462000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c75" decimals="-3" id="ixv-18902" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c1" decimals="-3" id="ixv-18903" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c74" decimals="-3" id="ixv-18904" unitRef="usd">6350000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c75" decimals="-3" id="ixv-18905" unitRef="usd">377967000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c1" decimals="-3" id="ixv-18906" unitRef="usd">384317000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c0" id="ixv-14970">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
Cash equivalents and marketable Securities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Commercial papers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,180&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,485&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents and marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12 months or longer&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; width: 28%; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,199&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,199&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;Corporate debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.5in; text-indent: -0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#x2019;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Due in one year or less&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due in 1-2 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;332,142&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c0" id="ixv-14976">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Commercial papers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,180&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;Corporate debt securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,485&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"&gt;Total marketable securities, long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents and marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;384,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c81" decimals="-3" id="ixv-18907" unitRef="usd">6350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c81" decimals="-3" id="ixv-18908" unitRef="usd">6350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c82" decimals="-3" id="ixv-18909" unitRef="usd">19656000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c82" decimals="-3" id="ixv-18910" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c82" decimals="-3" id="ixv-18911" unitRef="usd">19660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c83" decimals="-3" id="ixv-18912" unitRef="usd">3988000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c83" decimals="-3" id="ixv-18913" unitRef="usd">3988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c84" decimals="-3" id="ixv-18914" unitRef="usd">22180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c84" decimals="-3" id="ixv-18915" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c84" decimals="-3" id="ixv-18916" unitRef="usd">22177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c85" decimals="-3" id="ixv-18917" unitRef="usd">52174000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c85" decimals="-3" id="ixv-18918" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c85" decimals="-3" id="ixv-18919" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c85" decimals="-3" id="ixv-18920" unitRef="usd">52175000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c86" decimals="-3" id="ixv-18921" unitRef="usd">190748000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c86" decimals="-3" id="ixv-18922" unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c86" decimals="-3" id="ixv-18923" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c86" decimals="-3" id="ixv-18924" unitRef="usd">190792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c87" decimals="-3" id="ixv-18925" unitRef="usd">12967000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c87" decimals="-3" id="ixv-18926" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c87" decimals="-3" id="ixv-18927" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c87" decimals="-3" id="ixv-18928" unitRef="usd">12966000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c88" decimals="-3" id="ixv-18929" unitRef="usd">34808000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c88" decimals="-3" id="ixv-18930" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c88" decimals="-3" id="ixv-18931" unitRef="usd">34811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c89" decimals="-3" id="ixv-18932" unitRef="usd">75537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c89" decimals="-3" id="ixv-18933" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c89" decimals="-3" id="ixv-18934" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c89" decimals="-3" id="ixv-18935" unitRef="usd">75504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c90" decimals="-3" id="ixv-18936" unitRef="usd">314060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c90" decimals="-3" id="ixv-18937" unitRef="usd">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c90" decimals="-3" id="ixv-18938" unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c90" decimals="-3" id="ixv-18939" unitRef="usd">314073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c91" decimals="-3" id="ixv-18940" unitRef="usd">13639000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c91" decimals="-3" id="ixv-18941" unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c91" decimals="-3" id="ixv-18942" unitRef="usd">13607000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c92" decimals="-3" id="ixv-18943" unitRef="usd">4485000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c92" decimals="-3" id="ixv-18944" unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c92" decimals="-3" id="ixv-18945" unitRef="usd">4462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c93" decimals="-3" id="ixv-18946" unitRef="usd">18124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c93" decimals="-3" id="ixv-18947" unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c93" decimals="-3" id="ixv-18948" unitRef="usd">18069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c1" decimals="-3" id="ixv-18949" unitRef="usd">384358000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c1" decimals="-3" id="ixv-18950" unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c1" decimals="-3" id="ixv-18951" unitRef="usd">111000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c1" decimals="-3" id="ixv-18952" unitRef="usd">384317000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c0" id="ixv-15333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12 months or longer&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; width: 28%; text-align: left"&gt;Commercial papers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,199&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,199&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;Marketable securities, current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. government agency securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;Corporate debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;Marketable securities, long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"&gt;U.S. treasury securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;U.S. government agency securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.5in; text-indent: -0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c94" decimals="-3" id="ixv-18953" unitRef="usd">18199000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c94" decimals="-3" id="ixv-18954" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c94" decimals="-3" id="ixv-18955" unitRef="usd">18199000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c94" decimals="-3" id="ixv-18956" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c95" decimals="-3" id="ixv-18957" unitRef="usd">49904000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c95" decimals="-3" id="ixv-18958" unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c95" decimals="-3" id="ixv-18959" unitRef="usd">49904000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c95" decimals="-3" id="ixv-18960" unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c96" decimals="-3" id="ixv-18961" unitRef="usd">4713000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c96" decimals="-3" id="ixv-18962" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c96" decimals="-3" id="ixv-18963" unitRef="usd">4713000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c96" decimals="-3" id="ixv-18964" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c97" decimals="-3" id="ixv-18965" unitRef="usd">39468000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c97" decimals="-3" id="ixv-18966" unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c97" decimals="-3" id="ixv-18967" unitRef="usd">39468000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c97" decimals="-3" id="ixv-18968" unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c98" decimals="-3" id="ixv-18969" unitRef="usd">13607000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c98" decimals="-3" id="ixv-18970" unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c98" decimals="-3" id="ixv-18971" unitRef="usd">13607000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c98" decimals="-3" id="ixv-18972" unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c99" decimals="-3" id="ixv-18973" unitRef="usd">4462000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c99" decimals="-3" id="ixv-18974" unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c99" decimals="-3" id="ixv-18975" unitRef="usd">4462000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c99" decimals="-3" id="ixv-18976" unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c1" decimals="-3" id="ixv-18977" unitRef="usd">130353000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c1" decimals="-3" id="ixv-18978" unitRef="usd">111000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c1" decimals="-3" id="ixv-18979" unitRef="usd">130353000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c1" decimals="-3" id="ixv-18980" unitRef="usd">111000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c0" id="ixv-15696">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Due in one year or less&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;314,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due in 1-2 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;332,142&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c1" decimals="-3" id="ixv-18981" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c1" decimals="-3" id="ixv-18982" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecurities contextRef="c1" decimals="-3" id="ixv-18983" unitRef="usd">332142000</us-gaap:MarketableSecurities>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-15732">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Accrued employee compensation and benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued professional and consulting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-15738">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Accrued employee compensation and benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued professional and consulting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c1" decimals="-3" id="ixv-18984" unitRef="usd">2041000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c1" decimals="-3" id="ixv-18985" unitRef="usd">221000</us-gaap:AccruedProfessionalFeesCurrent>
    <orka:AccruedResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-18986" unitRef="usd">1084000</orka:AccruedResearchAndDevelopment>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c1" decimals="-3" id="ixv-18987" unitRef="usd">3346000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-15779">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
Note&#160;Payable with Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#x201c;Purchase
Agreement&#x201d;) with Fairmount Healthcare Fund&#160;II, L.P. (&#x201c;Fairmount&#x201d;), whereby Pre-Merger Oruka issued a convertible
note (the &#x201c;Convertible Note&#x201d;), with an initial principal amount of $25.0 million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#x201c;Maturity Date&#x201d;) and prepayment was not
permitted without prior written consent of Fairmount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $1.5 million, which includes non-cash interest
expense related to the amortization of debt issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which
was determined based upon the Company&#x2019;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into 2,722,207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c100"
      decimals="-5"
      id="ixv-18988"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c101"
      decimals="-5"
      id="ixv-18989"
      unitRef="usd">25000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c102"
      decimals="3"
      id="ixv-18990"
      unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c102" id="ixv-18991">2025-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c103"
      decimals="-5"
      id="ixv-18992"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="c104"
      decimals="-5"
      id="ixv-18993"
      unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c105"
      decimals="-5"
      id="ixv-18994"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="c103"
      decimals="-5"
      id="ixv-18995"
      unitRef="usd">1500000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c106"
      decimals="INF"
      id="ixv-18996"
      unitRef="shares">2722207</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-15818">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Pre-Funded
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
pre-funded warrants were recorded as a component of stockholders&#x2019; equity within additional paid-in-capital and have &lt;span style="-sec-ix-hidden: hidden-fact-203"&gt;no&lt;/span&gt; expiration
date. As of December 31, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-204"&gt;none&lt;/span&gt; of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#x2019;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These warrants
vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#x2019;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-205"&gt;none&lt;/span&gt; of the warrants have been exercised and 3,054,358 warrants
remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million.
Pre-Merger Oruka incurred less than $0.1&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.&#160;In November 2024, the 2,439 shares of the Company Series A Preferred
Stock were converted to 2,439,000 shares of Company Common Stock. As of December 31, 2024, there are &lt;span style="-sec-ix-hidden: hidden-fact-206"&gt;no&lt;/span&gt; outstanding shares of Company
Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred&lt;br/&gt; Stock&lt;br/&gt; Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred&lt;br/&gt; Stock &lt;br/&gt;
Issued&#160;and&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;br/&gt; Issuable&lt;br/&gt; Upon&lt;br/&gt; Conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series B convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;251,504&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#x201c;Series A Certificate of Designation&#x201d;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#x2019;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#x201c;Stockholder Approval&#x201d;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into 1,000 shares of Company Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#x201c;Series B Certificate of Designation&#x201d;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Paruka
Warrant&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase 596,930 shares of Company Common Stock at an exercise price of $19.39 per share. The warrant has a term of 10 years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of December
31, 2024, 37,440,510 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Shares issuable on conversion of Company Series B Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Shares issuable upon exercise of pre-funded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,202,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shares issuable upon exercise of warrant under the Paruka Warrant Obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued employee warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Shares available for grant under 2024 Stock Incentive Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,246,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares available for grant under 2024 Employee Stock Purchase Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;460,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total shares of common stock reserved&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,556,257&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c107"
      decimals="INF"
      id="ixv-18997"
      unitRef="shares">5522207</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c108"
      decimals="2"
      id="ixv-18998"
      unitRef="usdPershares">9.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c108"
      decimals="INF"
      id="ixv-18999"
      unitRef="shares">5522207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <orka:ClassOfWarrantsExercisable
      contextRef="c109"
      decimals="0"
      id="ixv-19000"
      unitRef="shares">5522207</orka:ClassOfWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c110"
      decimals="2"
      id="ixv-19001"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c111"
      decimals="INF"
      id="ixv-19002"
      unitRef="shares">680000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c112"
      decimals="3"
      id="ixv-19003"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <orka:ClassOfWarrantsExercisable
      contextRef="c113"
      decimals="INF"
      id="ixv-19004"
      unitRef="shares">680000</orka:ClassOfWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c114"
      decimals="3"
      id="ixv-19005"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c116"
      decimals="INF"
      id="ixv-19006"
      unitRef="shares">6202207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c117"
      decimals="INF"
      id="ixv-19007"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c117"
      decimals="2"
      id="ixv-19008"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c118" id="ixv-19009">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c117"
      decimals="INF"
      id="ixv-19010"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c119"
      decimals="INF"
      id="ixv-19011"
      unitRef="shares">20000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c120"
      decimals="2"
      id="ixv-19012"
      unitRef="usdPershares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c121"
      decimals="-5"
      id="ixv-19013"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c122"
      decimals="-5"
      id="ixv-19014"
      unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c123"
      decimals="INF"
      id="ixv-19015"
      unitRef="shares">137138</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c124"
      decimals="INF"
      id="ixv-19016"
      unitRef="shares">2439</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c125"
      decimals="2"
      id="ixv-19017"
      unitRef="usdPershares">23000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c126"
      decimals="INF"
      id="ixv-19018"
      unitRef="shares">2439</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c127"
      decimals="INF"
      id="ixv-19019"
      unitRef="shares">2439000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <orka:ScheduleOfConvertiblePreferredStockTableTextBlock contextRef="c0" id="ixv-15892">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred&lt;br/&gt; Stock&lt;br/&gt; Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred&lt;br/&gt; Stock &lt;br/&gt;
Issued&#160;and&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;br/&gt; Issuable&lt;br/&gt; Upon&lt;br/&gt; Conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series B convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;251,504&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</orka:ScheduleOfConvertiblePreferredStockTableTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c132"
      decimals="INF"
      id="ixv-19020"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c132"
      decimals="INF"
      id="ixv-19021"
      unitRef="shares">137138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c132"
      decimals="INF"
      id="ixv-19022"
      unitRef="shares">137138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="c132"
      decimals="-3"
      id="ixv-19023"
      unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c132"
      decimals="INF"
      id="ixv-19024"
      unitRef="shares">11428149</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c127"
      decimals="INF"
      id="ixv-19025"
      unitRef="shares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <orka:CommonStockConversionRatio contextRef="c45" id="ixv-19026">83.3332:1</orka:CommonStockConversionRatio>
    <orka:WarrantsToPurchaseCommonStock
      contextRef="c129"
      decimals="INF"
      id="ixv-19027"
      unitRef="shares">596930</orka:WarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c129"
      decimals="2"
      id="ixv-19028"
      unitRef="usdPershares">19.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c130" id="ixv-19029">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c34"
      decimals="INF"
      id="ixv-19030"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c34"
      decimals="INF"
      id="ixv-19031"
      unitRef="shares">37440510</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-19032"
      unitRef="shares">37440510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c131"
      decimals="INF"
      id="ixv-19033"
      unitRef="shares">2207553</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c131"
      decimals="INF"
      id="ixv-19034"
      unitRef="shares">2207553</us-gaap:CommonStockSharesIssued>
    <orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c0" id="ixv-15989">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Shares issuable on conversion of Company Series B Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Shares issuable upon exercise of pre-funded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,202,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shares issuable upon exercise of warrant under the Paruka Warrant Obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued employee warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Shares available for grant under 2024 Stock Incentive Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,246,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares available for grant under 2024 Employee Stock Purchase Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;460,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total shares of common stock reserved&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,556,257&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c132"
      decimals="INF"
      id="ixv-19035"
      unitRef="shares">11428149</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c52"
      decimals="INF"
      id="ixv-19036"
      unitRef="shares">6202207</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c133"
      decimals="INF"
      id="ixv-19037"
      unitRef="shares">596930</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c134"
      decimals="INF"
      id="ixv-19038"
      unitRef="shares">1567760</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c117"
      decimals="INF"
      id="ixv-19039"
      unitRef="shares">3054358</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c135"
      decimals="INF"
      id="ixv-19040"
      unitRef="shares">4246324</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c136"
      decimals="INF"
      id="ixv-19041"
      unitRef="shares">460529</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c1"
      decimals="INF"
      id="ixv-19042"
      unitRef="shares">27556257</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-16055">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2024 Equity Incentive Plan (&#x201c;2024 Plan&#x201d;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#x2019;s continued service, and expire after ten&#160;years, although two non-employee
stock options were granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common stock
available for issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 22, 2024, the 2024 Stock Incentive Plan (&#x201c;2024 Stock Plan&#x201d;) was approved by the Company&#x2019;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#x201c;Board&#x201d;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388,567 shares were subject to outstanding
stock options, and as of December 31, 2024, there were 4,246,324 shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2024 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) became effective on August 29, 2024, at which time 463,489 shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;85% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, 2,960 shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were 460,529 shares of Company Common Stock available in the pool.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $0.1
million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Option Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $9.12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#x2019;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $0.1 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; RSAs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Unvested balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Option
Agreements and the Paruka Warrant Obligation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#x201c;Paruka Warrant Obligation&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $10.4 million. For the period from February 6, 2024 (inception)
to December 31, 2024, $10.4 million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued
to certain Pre-Merger Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during
the period from February 6, 2024 (inception) to December 31, 2024, the Company issued 3,054,358 warrants at an exercise price of $7.80
per warrant, which are accounted as equity in the consolidated financial statements. The employee warrants were subject to performance
and service based vesting requirements and upon completion of the Merger the performance-based requirements had been achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Employee&lt;br/&gt; Warrants&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;35,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;35,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,919&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $12.7 million, which is expected
to be recognized over a weighted average period of approximately 3.2 years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.1
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $16.3 million, which is expected
to be recognized over a weighted average period of 3.3 years.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Paruka Warrant Obligation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Employee stock purchase plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,919&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c137"
      decimals="INF"
      id="ixv-19043"
      unitRef="shares">4634891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c138"
      decimals="INF"
      id="ixv-19044"
      unitRef="shares">388567</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c139"
      decimals="INF"
      id="ixv-19045"
      unitRef="shares">4246324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares
      contextRef="c140"
      decimals="2"
      id="ixv-19046"
      unitRef="pure">0.05</orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c141"
      decimals="INF"
      id="ixv-19047"
      unitRef="shares">463489</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c142"
      decimals="2"
      id="ixv-19048"
      unitRef="pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c141"
      decimals="2"
      id="ixv-19049"
      unitRef="pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP contextRef="c142" decimals="0" id="ixv-19050" unitRef="usd">25000</orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP>
    <orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares
      contextRef="c143"
      decimals="2"
      id="ixv-19051"
      unitRef="pure">0.01</orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="c136"
      decimals="INF"
      id="ixv-19052"
      unitRef="shares">2960</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c136"
      decimals="INF"
      id="ixv-19053"
      unitRef="shares">460529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c143"
      decimals="-5"
      id="ixv-19054"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-16123">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c144" id="ixv-19055">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c144"
      decimals="4"
      id="ixv-19056"
      unitRef="pure">1.0021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c144"
      decimals="4"
      id="ixv-19057"
      unitRef="pure">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-16174">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.39&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-19058"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-19059"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-19060"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-19061"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-19062">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c1" decimals="-3" id="ixv-19063" unitRef="usd">15470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-19064"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-19065"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-19066">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c1" decimals="-3" id="ixv-19067" unitRef="usd">15470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c144"
      decimals="2"
      id="ixv-19068"
      unitRef="usdPershares">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c145"
      decimals="INF"
      id="ixv-19069"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c131"
      decimals="4"
      id="ixv-19070"
      unitRef="usdPershares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c145"
      decimals="-5"
      id="ixv-19071"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c0" id="ixv-16379">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; RSAs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Unvested balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c145"
      decimals="INF"
      id="ixv-19072"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c131"
      decimals="INF"
      id="ixv-19073"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
      contextRef="c146"
      decimals="4"
      id="ixv-19074"
      unitRef="pure">0.01</orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum>
    <orka:EstimatedFairValueOfWarrantsToBeGranted contextRef="c1" decimals="-5" id="ixv-19075" unitRef="usd">10400000</orka:EstimatedFairValueOfWarrantsToBeGranted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c146"
      decimals="-5"
      id="ixv-19076"
      unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <orka:ClassOfWarrantOrRight
      contextRef="c118"
      decimals="INF"
      id="ixv-19077"
      unitRef="shares">3054358</orka:ClassOfWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c117"
      decimals="2"
      id="ixv-19078"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock contextRef="c0" id="ixv-16459">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Employee&lt;br/&gt; Warrants&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance as of February 6, 2024 (inception)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;35,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;35,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c150"
      decimals="INF"
      id="ixv-19079"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice
      contextRef="c150"
      decimals="2"
      id="ixv-19080"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c117"
      decimals="INF"
      id="ixv-19081"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c117"
      decimals="2"
      id="ixv-19082"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="c150" id="ixv-19083">P9Y6M</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c117"
      decimals="-3"
      id="ixv-19084"
      unitRef="usd">35400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber
      contextRef="c117"
      decimals="INF"
      id="ixv-19085"
      unitRef="shares">3054358</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice
      contextRef="c117"
      decimals="2"
      id="ixv-19086"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm contextRef="c150" id="ixv-19087">P9Y6M</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest
      contextRef="c117"
      decimals="-3"
      id="ixv-19088"
      unitRef="usd">35400000</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c118"
      decimals="2"
      id="ixv-19089"
      unitRef="usdPershares">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c118" id="ixv-19090">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c118"
      decimals="4"
      id="ixv-19091"
      unitRef="pure">0.9902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c118"
      decimals="4"
      id="ixv-19092"
      unitRef="pure">0.0415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-16703">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,919&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c11" decimals="-3" id="ixv-19093" unitRef="usd">11992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c12" decimals="-3" id="ixv-19094" unitRef="usd">2927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-19095" unitRef="usd">14919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c134"
      decimals="-5"
      id="ixv-19096"
      unitRef="usd">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c144" id="ixv-19097">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c131"
      decimals="-5"
      id="ixv-19098"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c145" id="ixv-19099">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c117"
      decimals="-5"
      id="ixv-19100"
      unitRef="usd">16300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c118" id="ixv-19101">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0" id="ixv-16743">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Paruka Warrant Obligation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Employee stock purchase plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,919&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c151"
      decimals="-3"
      id="ixv-19102"
      unitRef="usd">10357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c152"
      decimals="-3"
      id="ixv-19103"
      unitRef="usd">2899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c153"
      decimals="-3"
      id="ixv-19104"
      unitRef="usd">1626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c154"
      decimals="-3"
      id="ixv-19105"
      unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-19106" unitRef="usd">14919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-16808">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
Segment disclosures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business activities on a consolidated basis and operates in one reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as a single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker
(&#x201c;CODM&#x201d;), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#x2019;s
financial performance, the CODM regularly reviews total operating expenses and consolidated net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#x2019;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Research and development personnel-related (excluding stock-based compensation)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative personnel-related (excluding stock-based compensation)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;External research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative, excluding personnel-related and stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Total operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(88,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-19107" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-19108" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c0" id="ixv-16826">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Research and development personnel-related (excluding stock-based compensation)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative personnel-related (excluding stock-based compensation)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;External research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative, excluding personnel-related and stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Total operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(88,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c155"
      decimals="-3"
      id="ixv-19109"
      unitRef="usd">3959000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c155"
      decimals="-3"
      id="ixv-19110"
      unitRef="usd">5054000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c156"
      decimals="-3"
      id="ixv-19111"
      unitRef="usd">11992000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c157"
      decimals="-3"
      id="ixv-19112"
      unitRef="usd">2927000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c158"
      decimals="-3"
      id="ixv-19113"
      unitRef="usd">57680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c159"
      decimals="-3"
      id="ixv-19114"
      unitRef="usd">1429000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c160"
      decimals="-3"
      id="ixv-19115"
      unitRef="usd">5082000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c161"
      decimals="-3"
      id="ixv-19116"
      unitRef="usd">88123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c161"
      decimals="-3"
      id="ixv-19117"
      unitRef="usd">-88123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-16899">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-239"&gt;No&lt;/span&gt;
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Loss before income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the period from February 6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from
income taxes. The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory
federal income tax rate to income before income taxes is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Tax benefit derived by applying the federal statutory rate to income before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Income tax (benefit) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Capitalized R&amp;amp;D expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Right- of- use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(184&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding
the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by
$21.3&#160;million primarily due to continuing loss from operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#x201c;NOL&#x201d;) of $10.8&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to 80% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$3.8&#160;million and $0.4&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Changes related to tax positions taken in the current year&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0" id="ixv-16910">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Loss before income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="-3" id="ixv-19118" unitRef="usd">-83724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-19119" unitRef="usd">-83724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-19120">The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory
federal income tax rate to income before income taxes is as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Tax benefit derived by applying the federal statutory rate to income before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Income tax (benefit) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="4" id="ixv-19121" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="4" id="ixv-19122" unitRef="pure">0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c0" decimals="4" id="ixv-19123" unitRef="pure">-0.0341</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="4" id="ixv-19124" unitRef="pure">0.0087</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="4" id="ixv-19125" unitRef="pure">-0.2546</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="4" id="ixv-19126" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-17017">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Capitalized R&amp;amp;D expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Right- of- use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(184&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="-3" id="ixv-19127" unitRef="usd">2260000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="-3" id="ixv-19128" unitRef="usd">3080000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="-3" id="ixv-19129" unitRef="usd">3063000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c1" decimals="-3" id="ixv-19130" unitRef="usd">424000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <orka:DeferredTaxAssetsLeaseLiabilities contextRef="c1" decimals="-3" id="ixv-19131" unitRef="usd">203000</orka:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="-3" id="ixv-19132" unitRef="usd">1477000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-19133" unitRef="usd">10994000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="-3" id="ixv-19134" unitRef="usd">21501000</us-gaap:DeferredTaxAssetsGross>
    <orka:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-19135" unitRef="usd">184000</orka:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c1" decimals="-3" id="ixv-19136" unitRef="usd">184000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-19137" unitRef="usd">21317000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-19138">he
Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding
the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by
$21.3&#160;million primarily due to continuing loss from operations.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c1" decimals="-5" id="ixv-19139" unitRef="usd">21300000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" id="ixv-19140" unitRef="usd">21317000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-19141" unitRef="usd">21317000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="c1" decimals="-5" id="ixv-19142" unitRef="usd">10800000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome contextRef="c1" decimals="2" id="ixv-19143" unitRef="pure">0.80</orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c162"
      decimals="-5"
      id="ixv-19144"
      unitRef="usd">3800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c163"
      decimals="-5"
      id="ixv-19145"
      unitRef="usd">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c0" id="ixv-17156">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Changes related to tax positions taken in the current year&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c0" decimals="-3" id="ixv-19146" unitRef="usd">1047000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c1" decimals="-3" id="ixv-19147" unitRef="usd">1047000</us-gaap:UnrecognizedTaxBenefits>
    <orka:OptionAgreementsAndLicenseAgreementsTextBlock contextRef="c0" id="ixv-17219">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
Option Agreements and License Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#x201c;Option Agreements&#x201d;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#x2019;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#x201c;Option&#x201d;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#x201c;Research
Program&#x201d;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#x2019;s sole discretion at such time as specified in the Option Agreements (the &#x201c;Option
Period&#x201d;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#x2019; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#x2019;s bankruptcy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Paragon
Therapeutics &#x2013; License Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#x201c;ORKA-001 License Agreement&#x201d;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#x201c;ORKA-001 Field&#x201d;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#x201c;ORKA-002 License Agreement&#x201d; and together with the ORKA-001 License Agreement, the &#x201c;License Agreements&#x201d;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#x201c;ORKA-002 Field&#x201d; and together with
the ORKA-001 Field, the &#x201c;Fields&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#x2019;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#x2019; notice to Paragon,
on material breach without cure, and on a party&#x2019;s insolvency or bankruptcy to the extent permitted by law.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones and up
to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $1.5 million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $2.5
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Company&#x2019;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $2.5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#x2019;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $13.5 million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $2.8 million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $7.8 million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $42.0 million of expenses in connection
with services provided by Paragon and Paruka under the Option Agreements.&#160;&lt;/span&gt;&lt;/p&gt;</orka:OptionAgreementsAndLicenseAgreementsTextBlock>
    <orka:NonRefundableMilestonePayments
      contextRef="c164"
      decimals="-5"
      id="ixv-19148"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c165"
      decimals="-5"
      id="ixv-19149"
      unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c166"
      decimals="-5"
      id="ixv-19150"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c167"
      decimals="-5"
      id="ixv-19151"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c168"
      decimals="-5"
      id="ixv-19152"
      unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c169"
      decimals="-5"
      id="ixv-19153"
      unitRef="usd">1500000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c170"
      decimals="-5"
      id="ixv-19154"
      unitRef="usd">2500000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c171"
      decimals="-5"
      id="ixv-19155"
      unitRef="usd">2500000</orka:NonRefundableMilestonePayments>
    <orka:RoyaltyPayableOnProductSales contextRef="c172" id="ixv-19156">low single-digit percentage royalty for antibody products</orka:RoyaltyPayableOnProductSales>
    <orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
      contextRef="c173"
      decimals="4"
      id="ixv-19157"
      unitRef="pure">0.01</orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum>
    <us-gaap:PaymentsForFees
      contextRef="c174"
      decimals="-5"
      id="ixv-19158"
      unitRef="usd">800000</us-gaap:PaymentsForFees>
    <orka:DevelopmentCostsPercentage
      contextRef="c175"
      decimals="2"
      id="ixv-19159"
      unitRef="pure">0.50</orka:DevelopmentCostsPercentage>
    <orka:MilestoneConsiderationPaid
      contextRef="c176"
      decimals="-5"
      id="ixv-19160"
      unitRef="usd">1500000</orka:MilestoneConsiderationPaid>
    <orka:MilestoneConsiderationPaid
      contextRef="c177"
      decimals="-5"
      id="ixv-19161"
      unitRef="usd">2500000</orka:MilestoneConsiderationPaid>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c175"
      decimals="-5"
      id="ixv-19162"
      unitRef="usd">13500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c178"
      decimals="-5"
      id="ixv-19163"
      unitRef="usd">2800000</us-gaap:AccountsPayableOtherCurrent>
    <orka:OtherDevelopmentCost
      contextRef="c179"
      decimals="-5"
      id="ixv-19164"
      unitRef="usd">3300000</orka:OtherDevelopmentCost>
    <orka:ResearchInitialFee
      contextRef="c180"
      decimals="-5"
      id="ixv-19165"
      unitRef="usd">800000</orka:ResearchInitialFee>
    <orka:MilestoneConsiderationPaid
      contextRef="c181"
      decimals="-5"
      id="ixv-19166"
      unitRef="usd">1500000</orka:MilestoneConsiderationPaid>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c180"
      decimals="-5"
      id="ixv-19167"
      unitRef="usd">7800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c182"
      decimals="-5"
      id="ixv-19168"
      unitRef="usd">2700000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-5" id="ixv-19169" unitRef="usd">42000000</us-gaap:OtherExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-17305">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
Commitment and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2024, the Company entered into an operating lease agreement for the Company&#x2019;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.2
million, and operating lease liability, noncurrent of $0.8 million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of 33 months and a discount rate of 17.95%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $0.3 million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total discounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;Non-current portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;755&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell
Line License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the Company entered into the Cell Line License Agreement (the &#x201c;Cell Line License Agreement&#x201d;) with WuXi Biologics
Ireland Limited (&#x201c;WuXi Biologics&#x201d;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide,
sublicensable license to certain of WuXi Biologics&#x2019; know-how, cell line, biological materials (the &#x201c;WuXi Biologics Licensed
Technology&#x201d;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use
of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#x201c;WuXi Biologics Licensed Products&#x201d;).
Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002
programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $150,000, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon six months&#x2019; prior written notice
and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for
a material breach by the Company that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if the Company fails
to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other
party&#x2019;s bankruptcy.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c183" id="ixv-19170">P39M15D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-5" id="ixv-19171" unitRef="usd">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-5" id="ixv-19172" unitRef="usd">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-5" id="ixv-19173" unitRef="usd">800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c184" id="ixv-19174">P33M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c1" decimals="4" id="ixv-19175" unitRef="pure">0.1795</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c0" decimals="-5" id="ixv-19176" unitRef="usd">300000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0" id="ixv-17326">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-19177" unitRef="usd">116000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-17350">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total discounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;Non-current portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;755&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="-3" id="ixv-19178" unitRef="usd">369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="-3" id="ixv-19179" unitRef="usd">494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="-3" id="ixv-19180" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="-3" id="ixv-19181" unitRef="usd">1243000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="-3" id="ixv-19182" unitRef="usd">275000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="-3" id="ixv-19183" unitRef="usd">968000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-19184" unitRef="usd">213000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-19185" unitRef="usd">755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <orka:NonRefundableLicenseFee contextRef="c0" decimals="0" id="ixv-19186" unitRef="usd">150000</orka:NonRefundableLicenseFee>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-17445">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
Net Loss per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from February 6, 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;br/&gt; Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Shares&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss Per&lt;br/&gt; Share,&lt;br/&gt; Basic and&lt;br/&gt; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(65,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,789,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company Series A Preferred Stock &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,918&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,873.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company Series B Preferred Stock &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,769&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;51,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(322.81&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding employee warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding unvested restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and issued warrant to Paruka&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;596,930&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,426,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-17451">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Period from February 6, 2024&lt;br/&gt; (Inception) to &lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;br/&gt; Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Shares&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss Per&lt;br/&gt; Share,&lt;br/&gt; Basic and&lt;br/&gt; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(65,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,789,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company Series A Preferred Stock &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,918&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,873.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company Series B Preferred Stock &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,769&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;51,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(322.81&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(83,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="-3" id="ixv-19187" unitRef="usd">-65037000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c27"
      decimals="INF"
      id="ixv-19188"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c27"
      decimals="INF"
      id="ixv-19189"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c27"
      decimals="2"
      id="ixv-19190"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c27"
      decimals="2"
      id="ixv-19191"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="c185"
      decimals="-3"
      id="ix_3_fact"
      unitRef="usd">-1918000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c185"
      decimals="INF"
      id="ix_4_fact"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c185"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c185"
      decimals="2"
      id="ixv-19195"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c185"
      decimals="2"
      id="ixv-19196"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c45" decimals="-3" id="ix_6_fact" unitRef="usd">-16769000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c45"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c45"
      decimals="2"
      id="ixv-19200"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c45"
      decimals="2"
      id="ixv-19201"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-19202" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c185"
      decimals="INF"
      id="ixv-19203"
      unitRef="shares">495191</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c45"
      decimals="INF"
      id="ixv-19204"
      unitRef="shares">4328844</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-17567">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding employee warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding unvested restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and issued warrant to Paruka&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;596,930&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,426,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c186"
      decimals="INF"
      id="ixv-19205"
      unitRef="shares">3054358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c187"
      decimals="INF"
      id="ixv-19206"
      unitRef="shares">2207553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c188"
      decimals="INF"
      id="ixv-19207"
      unitRef="shares">1567760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c189"
      decimals="INF"
      id="ixv-19208"
      unitRef="shares">596930</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-19209"
      unitRef="shares">7426601</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-17614">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.
Related Party Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Paragon
and Paruka each beneficially own less than 5% of the Company&#x2019;s capital stock through their respective holdings of Company Common
Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fairmount
beneficially owns more than 5% of the Company&#x2019;s capital, currently has one representative appointed to the Board, and beneficially
owns more than 5% of Paragon. Fairmount appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Paragon reimbursable Option Agreements&#x2019; fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,482&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Paragon milestone payments for Option Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Paragon reimbursable other research expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Paragon reimbursable patent expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,022&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c191" id="ixv-19210">beneficially own less than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c190" id="ixv-19211">beneficially own less than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c193" id="ixv-19212">beneficially
owns more than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c192" id="ixv-19213">beneficially
owns more than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c0" id="ixv-17628">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Paragon reimbursable Option Agreements&#x2019; fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,482&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Paragon milestone payments for Option Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Paragon reimbursable other research expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Paragon reimbursable patent expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,022&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c194"
      decimals="-3"
      id="ixv-19214"
      unitRef="usd">1482000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c195"
      decimals="-3"
      id="ixv-19215"
      unitRef="usd">4000000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c196"
      decimals="-3"
      id="ixv-19216"
      unitRef="usd">515000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c197"
      decimals="-3"
      id="ixv-19217"
      unitRef="usd">25000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="-3" id="ixv-19218" unitRef="usd">6022000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-17675">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of 54 months. The Company expects to pay approximately $1.6 million over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c198" id="ixv-19219">P54M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c198"
      decimals="-5"
      id="ixv-19220"
      unitRef="usd">1600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">POS AM</dei:DocumentType>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:SubscriptionReceivables
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c2"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c4"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesCurrent
      contextRef="c2"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c2"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c5"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c6"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c5"
      id="hidden-fact-20"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c6"
      id="hidden-fact-21"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c5"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c6"
      id="hidden-fact-23"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c5"
      id="hidden-fact-24"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c7"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c8"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c7"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c8"
      id="hidden-fact-28"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c7"
      id="hidden-fact-29"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c8"
      id="hidden-fact-30"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c7"
      id="hidden-fact-31"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c8"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c10"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c10"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c10"
      id="hidden-fact-35"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c10"
      id="hidden-fact-36"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c2"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c2"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c16"
      id="hidden-fact-40"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c16"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c17"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      id="hidden-fact-44"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c18"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c21"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c22"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c24"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c25"
      id="hidden-fact-50"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c26"
      id="hidden-fact-52"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c29"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c25"
      id="hidden-fact-57"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c26"
      id="hidden-fact-59"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c27"
      id="hidden-fact-61"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c28"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c29"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c25"
      id="hidden-fact-67"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c25"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c27"
      id="hidden-fact-69"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c27"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c28"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c29"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c30"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c24"
      id="hidden-fact-74"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c24"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c25"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c25"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c26"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c26"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c29"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c30"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c24"
      id="hidden-fact-82"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c24"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c25"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c25"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c26"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c26"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c29"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c30"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c24"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c25"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c26"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c27"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c29"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c30"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c24"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c24"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c25"
      id="hidden-fact-98"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c25"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c26"
      id="hidden-fact-100"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c26"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c29"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c30"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c24"
      id="hidden-fact-104"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c24"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c26"
      id="hidden-fact-106"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c26"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c29"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c30"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c24"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c26"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c27"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c29"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c30"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c24"
      id="hidden-fact-115"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c24"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c26"
      id="hidden-fact-117"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c26"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c29"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c30"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c24"
      id="hidden-fact-121"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c24"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c25"
      id="hidden-fact-123"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c25"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c26"
      id="hidden-fact-125"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c26"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c27"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c29"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c30"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c24"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c25"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c26"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c27"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c29"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c30"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c24"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c26"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c27"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c30"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c24"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c25"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c26"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c27"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c28"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c30"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c31"
      id="hidden-fact-153"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c31"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c32"
      id="hidden-fact-155"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c32"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c23"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c60"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c61"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c64"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c66"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c68"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c70"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c72"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c76"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c64"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c66"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c68"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c70"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c72"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c77"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c79"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c76"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c64"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c66"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c68"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c76"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:FairValueCashEquivalentsAndMarketableSecurities
      contextRef="c76"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c81"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c81"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c82"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c83"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c83"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c84"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c88"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c91"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c92"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c93"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c94"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c94"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c95"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c95"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c96"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c96"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c97"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c97"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c98"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c98"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c99"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c99"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c1"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c1"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ClassOfWarrantOrRightExpirationDate contextRef="c115" id="hidden-fact-203" xsi:nil="true"/>
    <orka:ClassOfWarrantOrRightWarrantsExercised
      contextRef="c115"
      id="hidden-fact-204"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c118"
      id="hidden-fact-205"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c128"
      id="hidden-fact-206"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c144"
      id="hidden-fact-207"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c118"
      id="hidden-fact-208"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      id="hidden-fact-209"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      id="hidden-fact-210"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c147" id="hidden-fact-211" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c2"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-213"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-214"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      id="hidden-fact-215"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-216"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      id="hidden-fact-217"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      id="hidden-fact-218"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-219" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c148"
      id="hidden-fact-221"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c148"
      id="hidden-fact-222"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c131"
      id="hidden-fact-223"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c131"
      id="hidden-fact-224"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c149"
      id="hidden-fact-225"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c149"
      id="hidden-fact-226"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c149"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised
      contextRef="c150"
      id="hidden-fact-228"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised
      contextRef="c150"
      id="hidden-fact-229"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c150"
      id="hidden-fact-230"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice
      contextRef="c150"
      id="hidden-fact-231"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding
      contextRef="c117"
      id="hidden-fact-232"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="c117"
      id="hidden-fact-233"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable
      contextRef="c117"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c0"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c23"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c23"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-19463">0000907654</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-19464">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
related party amount of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period
from February 6, 2024 (inception) to December 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the
period from February 6, 2024 (inception) to December 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
